{"layout": 0, "type": "image", "page_idx": 1, "img_path": "layout_images/roche-holdings_2021_0.jpg", "bbox": [0, 0, 596, 794], "page_size": [595.2760009765625, 793.7009887695312], "ocr_text": "", "vlm_text": "The image is a collage of historical black-and-white photographs depicting various scenes related to scientific and industrial activities. These include:\n\n1. Laboratory scenes with people working with scientific equipment.\n2. A storefront with people standing outside, possibly related to pharmaceuticals or trade.\n3. Industrial equipment and facilities, including production lines and machinery.\n4. People in professional attire, indicating a mixture of scientific, medical, and business activities.\n5. Various modes of transportation visible in some images.\n6. Office spaces with technological equipment.\n\nOverall, the images suggest themes of scientific research, pharmaceuticals, industry, and historical progress."}
{"layout": 1, "type": "image", "page_idx": 2, "img_path": "layout_images/roche-holdings_2021_1.jpg", "bbox": [0, 0, 596, 794], "page_size": [595.2760009765625, 793.7009887695312], "ocr_text": "", "vlm_text": "The image is a collage depicting various laboratory and research-related activities. It includes images of scientific equipment such as test tubes, pipettes, and lab vials. There are scenes of laboratory settings with researchers conducting experiments, analyzing data on computers, and handling samples with protective gloves. The montage captures different aspects of scientific research, from data recording and analysis to the handling of biological materials."}
{"layout": 2, "type": "text", "text": "1896  Roche is founded 1904  Digalen, first standardised heart medication 1912  Roche present in nine countries on three continents 1929  Alice Keller, manager of Roche Japan, first female executive 1934  First company to mass-produce vitamins 1952  Rimifon, first treatment for tuberculosis 1968  First leap into diagnostics 1979  Cobas Bio, first automated lab device 1986  Roferon-A, genetically engineered cancer therapeutic 1991  Roche acquires PCR technology 1994  Roche launches Phelophepa, mobile health clinics in South Africa 1995  First protease inhibitor against AIDS 1997  MabThera/Rituxan, world’s first targeted antibody cancer drug 1998  Roche acquires Boehringer Mannheim 2002  Alliance with Chugai Pharmaceutical in Japan 2003  First Children’s Walk for global children’s charities 2009  Full integration of biotech pioneer Genentech 2011  Cobas 4800 HPV test to detect cervical cancer 2013  Kadcyla, antibody-drug conjugate for HER2-positive breast cancer 2015  Acquisition of Foundation Medicine 2017  Ocrevus, monoclonal antibody for multiple sclerosis 2018  Acquisition of Flatiron Health 2021  16 COVID-19 tests  ", "page_idx": 3, "bbox": [68, 90.1607666015625, 477.9898681640625, 683.7607421875], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 3, "type": "text", "text": "125 years of making  a difference in the  lives of millions ", "text_level": 1, "page_idx": 4, "bbox": [65, 174, 270, 277], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 4, "type": "text", "text": "Each day, our breakthrough medicines and innovative  diagnostic solutions improve the lives of countless  people worldwide. This is our 125-year legacy. It is  also our promise for the future. ", "page_idx": 4, "bbox": [65, 310.2001953125, 362.0231628417969, 394.7842102050781], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 5, "type": "text", "text": "On our 125-year anniversary, we see every reason to  celebrate. Because life is about celebration – whether  creating new memories that resonate for years or  pausing to reflect on the precious moments of our past. ", "page_idx": 4, "bbox": [65, 415.1842041015625, 371.8074951171875, 499.7602233886719], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 6, "type": "text", "text": "In 2021, we celebrated our history, our culture and  the enduring purpose that guides Roche’s next  125 years towards a sustainable, healthy future. \n In 2021, we Celebrated Life. ", "page_idx": 4, "bbox": [65, 520.1602172851562, 346, 604.8001708984375], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 7, "type": "text", "text": "", "page_idx": 4, "bbox": [388, 646, 513, 697], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 8, "type": "image", "page_idx": 5, "img_path": "layout_images/roche-holdings_2021_2.jpg", "bbox": [0, 0, 592, 794], "page_size": [595.2760009765625, 793.7009887695312], "ocr_text": "", "vlm_text": "The image shows two people in formal attire standing in an indoor setting with a minimalist design. The top image features a person in a blue suit and a colorful tie, while the bottom image features a person in a dark suit with a white shirt and dark tie. Both are smiling and appear to be in a professional environment. The setting includes benches along the walls and several doorways."}
{"layout": 9, "type": "text", "text": "Stability and long-term thinking ", "text_level": 1, "page_idx": 6, "bbox": [67, 97, 426, 124], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 10, "type": "text", "text": "André Hoffmann and Jörg Duschmalé are members of Roche’s founding  families and Board of Directors. On the occasion of our 125-year anniversary,  they share their thoughts on the past, present and future of the company. ", "page_idx": 6, "bbox": [67, 138.2001953125, 490.4435119628906, 207.80020141601562], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 11, "type": "text", "text": "Your ancestor Fritz Hoffmann founded Roche  125 years ago. What does this milestone  anniversary mean to you?   ", "page_idx": 6, "bbox": [67, 241.2001953125, 262, 277.3471984863281], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 12, "type": "text", "text": "A. Hoffmann:   I feel extremely proud. My great- grandfather Fritz Hoffmann and so many other  family members would be very pleased to see how  Roche has evolved over the years. This anniversary  is an important milestone, but a company that  thinks sustainably and long-term will exist forever. ", "page_idx": 6, "bbox": [67, 277.1942138671875, 262, 349.3292541503906], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 13, "type": "text", "text": "J. Duschmalé:   Looking back on the rich history of  125 years and being able to shape the next chapter  of Roche as a new member of the Board of Directors  is of course a great privilege and something I am  very much looking forward to. Roche has always  played an important part in my life. ", "page_idx": 6, "bbox": [67, 361.1822509765625, 262, 433.3172912597656], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 14, "type": "text", "text": "What does that mean exactly? ", "text_level": 1, "page_idx": 6, "bbox": [67, 446, 193, 456.75], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 15, "type": "text", "text": "J. Duschmalé:   Since my early childhood, Roche  was present in my life. There was always a feeling  of being strongly connected to it and I was taught  about the lasting bond of our family with the  company and the corresponding responsibility.  Since I grew up in Basel, Roche was of course also  visually present in the city. ", "page_idx": 6, "bbox": [67, 457.16729736328125, 262, 541.2993774414062], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 16, "type": "text", "text": "André, you grew up in the Camargue in France.  Did Roche also play such a big role in your  upbringing? ", "page_idx": 6, "bbox": [67, 553.15234375, 262, 589.29638671875], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 17, "type": "text", "text": "A. Hoffmann:   For me it was a bit different. I  remember my father always spoke very proudly of  Roche, but because I didn’t grow up in Switzerland,  I didn’t have a constant connection to the company  back then. I started realising the actual importance  and impact of the company in my teenage years. ", "page_idx": 6, "bbox": [67, 589.143310546875, 262, 661.2783203125], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 18, "type": "text", "text": "You are representing the fourth and fifth  generation of the founding families. How  do you describe the role of the family in the  company structure? ", "page_idx": 6, "bbox": [277, 241.13128662109375, 467, 289.2723083496094], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 19, "type": "text", "text": "A. Hoffmann:   The long-term family ownership  helps provide stability to the company by  establishing an active partnership with management  and the board for the company’s long-term success.  You can think of the structure as a triangle that  unites the family, the Board of Directors and the  Corporate Executive Committee. The Corporate  Executive Committee leads the company, the  Board of Directors sets the strategy and monitors  its implementation while the owner ensures the  long-term direction. The separation of control and  execution is very important. I see my role as a family  representative not only as a privilege, but also as  a major responsibility. ", "page_idx": 6, "bbox": [277, 289.11932373046875, 474, 457.2304382324219], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 20, "type": "text", "text": "J. Duschmalé:   The fact that the family has been  a part of the success story of Roche from the  beginning fills me with pride. Roche can continue  to count and rely on us as committed and loyal  majority shareholders. We want to pass on a healthy  and sustainable company to the next generation  and I think it really is this long-term vision that we  bring to the company. Being able now to boldly  invest in areas that only will pay off in 10, 20 or  even 30 years is certainly a big advantage, and  that is what our stable family ownership can bring. ", "page_idx": 6, "bbox": [277, 469.08343505859375, 474, 601.2034912109375], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 21, "type": "text", "text": "What are some of the ways the family is  involved in decision-making?   A. Hoffmann:   The family is engaged in the  selection of the members of the Board of Directors.  ", "page_idx": 6, "bbox": [277, 613.0564575195312, 474, 661.1974487304688], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 22, "type": "text", "text": "It is part of the governance of the company. It is  important to us that the values and goals of the  company are represented by the individuals on  the board. This is something we pay attention to  in the selection process. ", "page_idx": 7, "bbox": [120, 97.2001953125, 309, 157.33822631835938], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 23, "type": "text", "text": "How does the family deal with internal  differences that affect important, forward- looking business decisions?  A. Hoffmann:   For us, the well-being of the  company has always been the common driver. We  share the same values, and this joint responsibility  also keeps us together as a family. With that we  can bring stability over the years. ", "page_idx": 7, "bbox": [120, 169.19122314453125, 309, 265.3202819824219], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 24, "type": "text", "text": "J. Duschmalé:   As a family, we make it a priority  to listen to one another and to always focus on  the most important thing: the long-term success  of Roche. That helps in finding a common ground  which – as André says – benefits the company. ", "page_idx": 7, "bbox": [120, 277.2001953125, 309, 337.3382263183594], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 25, "type": "text", "text": "What is at the core of Roche’s success? J. Duschmalé:   Roche has managed to reinvent  itself again and again. The original idea was  to produce medicines of the highest quality.  Today, Roche is one of the largest biotech and  diagnostics companies in the world. We owe this  success to innovative research and the many  partnerships that we have entered into with  foresight and courage and we will continue to  do so in the future. ", "page_idx": 7, "bbox": [120, 349.19122314453125, 309, 469.3143005371094], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 26, "type": "text", "text": "A. Hoffmann:   This is a success that many teams  and great talents around the world contribute to  everyday. And we have done it in a sustainable  way as we have kept societal and patient needs  in our focus. ", "page_idx": 7, "bbox": [120, 481.16729736328125, 309, 541.3053588867188], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 27, "type": "text", "text": "Talking about sustainable ways – you are known  for being a sustainability ambassador, André.  Why do you believe this is such an important  topic? ", "page_idx": 7, "bbox": [120, 553.1583251953125, 316, 601.29931640625], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 28, "type": "text", "text": "A. Hoffmann:   To start with, let me state the  obvious: The future is sustainable or there is  no future. If humanity is to continue to thrive,  it will have to think and behave sustainably.  ", "page_idx": 7, "bbox": [120, 601.1463012695312, 309, 649.2872924804688], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 29, "type": "text", "text": "Sustainability is not something you do alongside  other business activities like marketing or sales.  To be truly sustainable, every action in which we  engage must be defined in terms of durability.  Traditionally, success is defined as positive cash  flows. This is too simple. Just measuring the  financial consequence of a business activity fails  to measure the social, human and environmental  impact that action is having. We should use the  natural, social and human capital in ways that  create sustainable, long-term value. This starts  with constantly acting with an eye on the greater  value and impact on society. When I connect this  to Roche, thinking about tomorrow is part of our  history and legacy, and it’s equally important for  our future.  ", "page_idx": 7, "bbox": [330, 97.13726806640625, 528, 289.2424011230469], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 30, "type": "text", "text": "Jörg, what is your perspective on sustainability? J. Duschmalé:   I agree with André’s points.  Additionally, as a scientist, I associate sustainability  with Roche’s strength as an innovation powerhouse. In order to be successful for the long term, we  have to innovate at the frontier of scientific  knowledge for the benefit of patients. It is often a  matter of taking certain risks today that might not  appear lucrative in the short term, but can create  sustainable value in the long term. ", "page_idx": 7, "bbox": [330, 301.09539794921875, 528, 421.2184753417969], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 31, "type": "text", "text": "You have been a researcher at Roche. How was  that time for you? ", "text_level": 1, "page_idx": 7, "bbox": [330, 433, 523, 456], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 32, "type": "text", "text": "J. Duschmalé:  It was a wonderful time for me. The  experience was an eye-opener on the importance  of science and what great things can be achieved  with it. I was able to experience first-hand what the  culture and values of the company mean in everyday  work. And what great personal commitment and  perseverance it takes to advance a research idea  into a therapy that can save lives. ", "page_idx": 7, "bbox": [330, 457.06549072265625, 528, 553.194580078125], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 33, "type": "text", "text": "What makes the Roche culture special for you? A. Hoffmann:   It’s about the special people at  Roche and how we interact with each other. All of  us are driven by our passion to make a difference  for patients. It’s also about how we shape our  external partnerships. It’s not by coincidence that  we are a partner of choice for many. ", "page_idx": 7, "bbox": [330, 565.0475463867188, 528, 649.1795043945312], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 34, "type": "text", "text": "J. Duschmalé:   I am convinced and have  experienced that Roche’s values are lived every  day. In addition, there is a company commitment  that every employee knows: Follow the science.  That is what shapes us and I am very proud to be  a part of this company. ", "page_idx": 8, "bbox": [67, 97.2001953125, 252, 169.33523559570312], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 35, "type": "text", "text": "A look into the future – how do you see  Roche in 20 years? ", "text_level": 1, "page_idx": 8, "bbox": [67, 182, 226, 204], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 36, "type": "text", "text": "J. Duschmalé:   I expect that we will focus  even more on prevention and personalised  therapies. It is also likely that there will be great  advances in therapeutic areas with great medical  need, such as neurological diseases. In the  future, I think the industry, in collaboration with  all healthcare stakeholders, must succeed in  improving access to healthcare. I also believe  that better availability of data will positively  change research and make it more impactful. ", "page_idx": 8, "bbox": [67, 205.1822509765625, 252, 325.3053283691406], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 37, "type": "text", "text": "A. Hoffmann:   Hopefully, Roche will be just  as successful as today. That is also our task:  to hand over a healthy company to the next  generation of our family.  ", "page_idx": 8, "bbox": [67, 337.1583251953125, 236, 385.2993469238281], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 38, "type": "text", "text": "", "text_level": 1, "page_idx": 8, "bbox": [67, 398, 208, 404.75], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 39, "type": "text", "text": "A. Hoffmann:   Roche is creating a better  future for millions of people. That is the greatest success of all. Driving medical innovation  requires us to take bold risks. This requires  room to manoeuvre. If there are not enough  profits, you cannot invest them sustainably.  But to focus only on profit maximisation is  not right. Society does not only value profit- generating activities. I am delighted to witness  everyday acts of generosity and kindness that  do not lead to an invoice being sent! Acting  graciously and in an altruistic way is one of the  things that makes us human. Let’s try not to  forget it. This kind of thinking is how we will  continue to be a sustainable organisation in  the years to come.  ", "page_idx": 8, "bbox": [67, 409.14935302734375, 252, 601.25439453125], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 40, "type": "text", "text": "You are both part of a very wealthy and  successful family. What significance does  this have for you? ", "page_idx": 8, "bbox": [67, 613.107421875, 252, 649.2514038085938], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 41, "type": "text", "text": "A. Hoffmann:   We are in this position  because we as a family have invested in the  company for the long term. Our assets essentially  consist of Roche shares and this gives us the  privilege and responsibilities of ownership. This  is why I see ownership not as a passive role  but as an active one. We commit ourselves to  Roche’s success in a very real way alongside  the 100,000 employees who work at Roche. I  don’t feel like an investor for myself. I see myself  as someone who prepares the company for the  next generation. ", "page_idx": 8, "bbox": [277, 97.10137939453125, 471, 241.21847534179688], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 42, "type": "text", "text": "J. Duschmalé:   I see it very similarly – the  shares give us the opportunity to influence  the company. The value of the share package  would only be relevant for us if we were to sell.  But we are committed to the long-term success  of Roche. ", "page_idx": 8, "bbox": [277, 253.07147216796875, 459, 325.2065124511719], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 43, "type": "text", "text": "The company still has its headquarters in  Basel. Did you ever discuss moving it to  another location? ", "page_idx": 8, "bbox": [277, 337.05950927734375, 459, 373.2035217285156], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 44, "type": "text", "text": "A. Hoffmann:   Even though we are active in  more than 100 countries today, our roots are here  in Switzerland. We are very happy with Basel as  our location, but also with the research that can  be conducted here. At the end of 2023 we will  open a new innovation centre with state-of-the-art  lab facilities and I am looking forward to visiting it  once it is finished. ", "page_idx": 8, "bbox": [277, 373.050537109375, 471, 469.1795959472656], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 45, "type": "text", "text": "J. Duschmalé:   We do research in Basel and  have a great network of partners to support us in  this. As long as our headquarters location supports  us in bringing breakthrough innovations to patients,  we are in the right place. ", "page_idx": 8, "bbox": [277, 481.0325927734375, 471, 541.170654296875], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 46, "type": "text", "text": "The theme of Roche’s 125-year anniversary  is Celebrate Life. How do you celebrate life? J. Duschmalé:    Probably by enjoying a nice dinner  with family and friends.  ", "page_idx": 8, "bbox": [277, 553.0236206054688, 471, 601.1646118164062], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 47, "type": "text", "text": "A. Hoffmann:   I celebrate life when I am in harmony with nature. And I wish the same to all \n of us. ", "page_idx": 8, "bbox": [277, 613.017578125, 459, 649.3502197265625], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 48, "type": "image", "page_idx": 9, "img_path": "layout_images/roche-holdings_2021_3.jpg", "bbox": [0, 3, 596, 793], "page_size": [595.2760009765625, 793.7009887695312], "ocr_text": "“4\n4 a ee eee\n\n= TH]\n\n", "vlm_text": "The image shows a night-time cityscape featuring two prominent buildings. One has a tall, rectangular shape, while the other has a more unusual, triangular form with an illuminated surface featuring a pattern of circular lights. Both buildings are reflecting vibrant colors onto the water below, creating a striking visual effect. There are also cranes and other buildings in the background, indicating an urban environment."}
{"layout": 49, "type": "text", "text": "Doing now what patients need next ", "text_level": 1, "page_idx": 10, "bbox": [136, 172, 484, 197], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 50, "type": "text", "text": "We believe it is urgent to deliver medical solutions right now –  even as we develop innovations for the future. We are  passionate about transforming patients’ lives. We are  courageous in both decision and action. And we believe  that good business means a better world.\n ", "page_idx": 10, "bbox": [136, 230.3150634765625, 479, 328.715087890625], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 51, "type": "text", "text": "That is why we come to work each day. We commit ourselves  to scientific rigour, unassailable ethics, and access to  medical innovations for all. We do this today to build a  better tomorrow.\n ", "page_idx": 10, "bbox": [136, 345.51507568359375, 464.7272033691406, 424.715087890625], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 52, "type": "text", "text": "We are proud of who we are, what we do, and how we do it. We  are many, working as one across functions, across companies,  and across the world. ", "page_idx": 10, "bbox": [136, 441.51507568359375, 479, 501.5151062011719], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 53, "type": "text", "text": "We are Roche. ", "text_level": 1, "page_idx": 10, "bbox": [135, 539, 267, 560], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 54, "type": "image", "page_idx": 11, "img_path": "layout_images/roche-holdings_2021_4.jpg", "bbox": [0, 0, 596, 794], "page_size": [595.2760009765625, 793.7009887695312], "ocr_text": "==\n~\n\n", "vlm_text": "The image shows a close-up of several glass pipettes or tubes with yellow markings, including the number \"20\" and other smaller numbers like \"01.\" The tubes are aligned in parallel and appear to be part of laboratory equipment."}
{"layout": 55, "type": "text", "text": "Contents ", "text_level": 1, "page_idx": 12, "bbox": [108, 171, 209, 194], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 56, "type": "text", "text": "Shareholder letters \b 10\n Reporting and strategy\b 20\n Diagnostics\b 28\n Pharmaceuticals\b 42\n Personalised healthcare\b 58\n Access to healthcare\b72\nPeople and culture\b 84\n Environment\b 96\n Community engagement\b 108\n Business ethics\b 118\n Business performance\b 130\n Corporate Governance\b 140\n Remuneration Report\b 162 ", "page_idx": 12, "bbox": [110, 246.2001953125, 339, 555.8001708984375], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 57, "type": "image", "page_idx": 13, "img_path": "layout_images/roche-holdings_2021_5.jpg", "bbox": [0, 1, 596, 794], "page_size": [595.2760009765625, 793.7009887695312], "ocr_text": "", "vlm_text": "The image is abstract and consists of blurred shapes and colors. It features purple and white tones with a section of blue that has black polka dots. The shapes appear to be out of focus and the overall composition is artistic and abstract."}
{"layout": 58, "type": "text", "text": "Shareholder letters ", "text_level": 1, "page_idx": 14, "bbox": [132, 469, 531, 525], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 59, "type": "image", "page_idx": 15, "img_path": "layout_images/roche-holdings_2021_6.jpg", "bbox": [0, 3, 596, 794], "page_size": [595.2760009765625, 793.7009887695312], "ocr_text": "", "vlm_text": "The image shows a man sitting in a chair. He is wearing glasses and is dressed in a suit with a light-colored shirt."}
{"layout": 60, "type": "text", "text": "Dear Shareholders ", "text_level": 1, "page_idx": 16, "bbox": [67, 122, 272, 145], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 61, "type": "text", "text": "Since its founding 125 years ago, Roche has  worked to improve the health and lives of countless  people all over the world. Our anniversary  year was no exception: In 2021 our more than  100,000 employees and our partners developed,  manufactured and provided global access to  state-of-the-art diagnostics and treatments  for serious diseases including COVID-19. These  efforts were guided by the pioneering spirit that  has characterised Roche since its founding.  My sincere thanks for this. ", "page_idx": 16, "bbox": [67, 181.2001953125, 264, 313.3232727050781], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 62, "type": "text", "text": "The COVID-19 pandemic has dominated world  events for the past two years or so. It is not the  first time that known or yet unknown pathogens  have suddenly spread and presented us all with  major challenges, and it certainly will not be the  last. Roche itself was established under the effect  of a pandemic: Fritz Hoffmann had just taken up a  position as a merchant in Hamburg in the summer  of 1892 when cholera broke out. As a result of  this experience, he decided to set up an industrial  pharmaceutical company on his return to Basel.  His aim was to provide large quantities of effective  medicines of uniform quality; this was still a  revolutionary concept at the time. ", "page_idx": 16, "bbox": [67, 325.17626953125, 264, 493.2873840332031], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 63, "type": "text", "text": "During the 125 years since its establishment,  Roche has repeatedly found the courage to  reinvent itself – guided by scientific progress. I was  recently reminded of this during a visit to Poland,  where Roche opened a branch back in the early  last century. The impact of researchers such as  Leo Sternbach, a Polish chemist, was enormous: In  the 1960s he discovered the benzodiazepines Valium  and Librium, which have become indispensable in  the treatment of anxiety, insomnia and nervousness.  Roche is still actively involved in the field of  neuroscience. Ocrevus for the treatment of  multiple sclerosis is one of our most sought-after  medicinal products. ", "page_idx": 16, "bbox": [67, 505.140380859375, 264, 673.2513427734375], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 64, "type": "text", "text": "Further milestones in our company’s history  include our early adoption of biotechnology at a  time when almost nobody believed in it. We used the  discovery of monoclonal antibodies to revolutionise  cancer therapy. With our PCR technology, we were  also pioneers in molecular diagnostics. ", "page_idx": 16, "bbox": [277, 181.10430908203125, 474, 253.23934936523438], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 65, "type": "text", "text": "For Roche, innovation has always been about  identifying and seizing opportunities. This will  remain so in the future as well. Digitalisation has  substantially increased the pace of our company’s  transformation since I became Chairman of the  Board of Directors. We view health data from  medical practice as an opportunity to pursue the  ongoing development of personalised, and thus  even more effective, medicine. At the same time,  our analysis of these data supports laboratory  research and the development of new clinical trial  concepts; it enables us to accelerate approval  procedures for innovative therapies and make  them available to patients faster.  ", "page_idx": 16, "bbox": [277, 265.09234619140625, 468, 433.2034606933594], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 66, "type": "text", "text": "Going forward, we want to use digitalisation to  achieve more medical progress at lower cost. We  will therefore once again increase our investment  in research and development, even though our  R&D expenditure of 13.7 billion Swiss francs   $(+14\\%^{*})$    last year already exceeds that of any other  healthcare company worldwide.  ", "page_idx": 16, "bbox": [277, 445.05645751953125, 474, 529.1885375976562], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 67, "type": "text", "text": "One of Roche’s particular strengths is our long- term mindset. This privilege has a great deal to  do with the stability afforded us by the founding  families. For this, too, I would like to express  my sincere thanks. Thinking sustainably is in our  DNA. We are delighted and further motivated to  have been selected once again by the Dow Jones  Sustainability Indices as one of the world’s most  sustainable companies in the healthcare sector.  We received this recognition in 2021 for the  thirteenth year! ", "page_idx": 16, "bbox": [277, 541.04150390625, 468, 673.1614990234375], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 68, "type": "text", "text": "Last year we achieved an additional milestone:  The extraordinary General Meeting at the end  of November 2021 approved the buyback of the  Roche bearer shares held by Novartis for the past  20 years in a near-unanimous vote. I am confident  that this 19 billion Swiss francs transaction is in  the best strategic and financial interests of Roche  and all investors. It restores our full control over  strategic decisions without requiring us to restrict  our operative scope. ", "page_idx": 17, "bbox": [120, 97.2001953125, 312, 217.32327270507812], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 69, "type": "text", "text": "The strong product pipeline that Severin Schwan  describes in more detail in his letter on page 17  and our financial figures – Group sales rose   $9\\%$   to  62.8 billion Swiss francs and net income amounted  to 14.9 billion Swiss francs – confirm that Roche is  on the right path. In light of our good performance,  the Board of Directors is proposing a   $2\\%$   dividend  increase to 9.30 Swiss francs per share and non- voting equity security. Subject to your approval,  this will be the  $35^{\\mathrm{th}}$   consecutive dividend increase. ", "page_idx": 17, "bbox": [120, 229.17626953125, 312, 349.3501892089844], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 70, "type": "text", "text": "Finally, I would like to draw your attention to a  number of changes on the Roche Board of Directors.  After ten years as a member of the Board of  Directors, Paul Bulcke has decided not to stand  for re-election at the General Meeting in 2022.  ", "page_idx": 17, "bbox": [120, 361.20318603515625, 317, 421.3412170410156], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 71, "type": "text", "text": "Roche Board of Directors on 31 December 2021 \n\n ", "text_level": 1, "page_idx": 17, "bbox": [119, 506, 267, 516], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 72, "type": "text", "text": "Julie Brown (1962), B\\*, E, G  Bernard Poussot (1952), C, E, G  Dr Jörg Duschmalé (1984), Representative of the shareholder  group with pooled voting rights, B, E, G  Dr Christoph Franz (1960), Chairman,  $\\complement,\\complement^{*},\\complement,\\complement$    \n Prof. Dr Hans Clevers (1957), A, E, G  André Hoffmann (1958), Vice-Chairman, Representative of the  shareholder group with pooled voting rights, A\\*, C\\*, D, E, G  Dr Severin Schwan (1967), F  Dr Claudia Suessmuth Dyckerhoff (1967), A, E, G Dr Patrick Frost (1968), B, E, G  Paul Bulcke (1954), B, E, G  Anita Hauser (1969), A, E, G  Prof. Dr Richard P. Lifton (1953), C, E, G  ", "page_idx": 17, "bbox": [120, 530.2001953125, 312, 697.0001831054688], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 73, "type": "text", "text": "On behalf of the Board of Directors, I wish to  thank him sincerely for his valuable contributions  to Roche’s success. ", "page_idx": 17, "bbox": [331, 97.188232421875, 517, 133.33224487304688], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 74, "type": "text", "text": "I am delighted to propose Dr Jemilah Mahmood,  a doctor from Malaysia, as a new member of the  Board of Directors. She has great expertise in the  field of public health, especially in less developed  regions of the world. Her particular experience  will enable her to help Roche make our medicines  and diagnostic products even more accessible to  people all over the world. ", "page_idx": 17, "bbox": [331, 145.18524169921875, 517, 241.31430053710938], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 75, "type": "text", "text": "Roche is very special: focused on science-driven  innovation, committed to sustainability, rooted in  Switzerland and open to the world. ", "page_idx": 17, "bbox": [331, 253.16729736328125, 517, 289.3113098144531], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 76, "type": "text", "text": "I would like to thank you, our shareholders, for  your confidence and loyalty.\n ", "page_idx": 17, "bbox": [331, 301.164306640625, 504.489990234375, 325.3113098144531], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 77, "type": "image", "page_idx": 17, "img_path": "layout_images/roche-holdings_2021_7.jpg", "bbox": [328, 350, 445, 394], "page_size": [595.2760009765625, 793.7009887695312], "ocr_text": "", "vlm_text": "This image contains a handwritten signature that reads \"C. Tram.\""}
{"layout": 78, "type": "text", "text": "Dr Christoph Franz Chairman ", "page_idx": 17, "bbox": [331, 397.2001953125, 401.100341796875, 421.3501892089844], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 79, "type": "text", "text": "A  Corporate Governance and Sustainability Committee  B   Audit Committee  C  Remuneration Committee  D  Chairman’s/Nomination Committee  E  Non-executive director  F  Executive director  G  Independent member of the Board of Directors  \\*  Committee chairperson ", "page_idx": 17, "bbox": [331, 602.2001953125, 493.42755126953125, 697.0001831054688], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 80, "type": "image", "page_idx": 18, "img_path": "layout_images/roche-holdings_2021_8.jpg", "bbox": [2, 0, 593, 794], "page_size": [595.2760009765625, 793.7009887695312], "ocr_text": "", "vlm_text": "The image shows a group of people in formal attire, standing outside on a paved surface with trees and mountains in the background. The text \"Board of Directors\" and \"Roche\" is visible in the top corner, indicating that this might be a corporate group photo associated with Roche."}
{"layout": 81, "type": "image", "page_idx": 19, "img_path": "layout_images/roche-holdings_2021_9.jpg", "bbox": [0, 3, 596, 794], "page_size": [595.2760009765625, 793.7009887695312], "ocr_text": "", "vlm_text": "An individual is standing and smiling in a professional setting. They're wearing a navy blazer over a light blue shirt and beige pants. The background is a blurred office environment."}
{"layout": 82, "type": "text", "text": "Dear Shareholders ", "text_level": 1, "page_idx": 20, "bbox": [67, 122, 272, 145], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 83, "type": "text", "text": "Improving people’s lives by delivering medical  innovations – that is what Roche has been about for  125 years now. Many of our medicines which were  developed decades ago are still greatly benefiting  millions of people today. The World Health  Organization’s Model List of Essential Medicines  includes 32 of our products – a record high.  ", "page_idx": 20, "bbox": [67, 181.2001953125, 259, 265.3501892089844], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 84, "type": "text", "text": "In the future, too, Roche’s success will be based  on medical innovations.  Despite all the successes,  there is still a great need for better therapies  in many areas, such as cancer, dementia and  infections, far beyond COVID-19. A need for  effective treatments to give people with serious  diseases a better life or even cure them, a need  for precision diagnostics to find the cause of  a disease and treat it at the earliest possible  stage. Preventive diagnostics are also gaining  increasing significance. ", "page_idx": 20, "bbox": [67, 277.2001953125, 259, 409.3501892089844], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 85, "type": "text", "text": "Looking ahead, I am pleased with the continued  high demand for our newly launched medicines  and diagnostic tests as well as the development  of our product pipelines in both divisions. ", "page_idx": 20, "bbox": [67, 421.2001953125, 253, 469.3501892089844], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 86, "type": "text", "text": "Last year, we continued to make significant  progress for patients. Tecentriq became the first  cancer immunotherapy for people with early-stage  lung cancer to be approved – for many, this means  hope for a cure. Polivy is the first medicine in  20 years to significantly improve outcomes in a  form of aggressive blood cancer. ", "page_idx": 20, "bbox": [67, 481.2001953125, 259, 565.3502197265625], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 87, "type": "text", "text": "In ophthalmology, we were granted regulatory  approval for Susvimo, an innovative eye implant.  Susvimo offers an alternative to monthly injections  in the eyes and can thus make the lives of people  with wet age-related macular degeneration a great  deal easier. Furthermore, we applied for regulatory  approval for Vabysmo, the first in a new class  of eye medicines that targets two key signalling  pathways which cause retinal diseases. ", "page_idx": 20, "bbox": [67, 577.2001953125, 259, 685.3502197265625], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 88, "type": "text", "text": "The demand for effective treatments is also  extremely high for nervous system disorders.  Recent study data have highlighted the benefits  of Ocrevus for multiple sclerosis, and Enspryng  for NMOSD, a rare disease affecting the central  nervous system. Roche is researching and  developing over a dozen medicines to treat  neurological disorders, including Huntington’s,  Parkinson’s and Alzheimer’s disease.  ", "page_idx": 20, "bbox": [277, 181.2001953125, 470, 289.3501892089844], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 89, "type": "text", "text": "In Diagnostics, we have a world-leading portfolio  of diagnostic solutions for COVID-19, and have been  working tirelessly since the start of the pandemic  to constantly expand our range of coronavirus  tests. Roche is investing significant amounts in  establishing additional production capacity to  meet the continued high demand for routine  diagnostics too.  ", "page_idx": 20, "bbox": [277, 301.2001953125, 475, 397.3501892089844], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 90, "type": "text", "text": "Innovative diagnostics are essential for prevention,  early detection and treatment decisions in infectious  diseases, cancer and other serious conditions.  ", "page_idx": 20, "bbox": [277, 409.2001953125, 475, 445.3501892089844], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 91, "type": "text", "text": "We have further expanded our leading position  in the area of infectious diseases with two  targeted acquisitions. TIB Molbiol has brought a  substantial number of tests to our broad portfolio of  molecular diagnostic solutions, while the acquisition  of GenMark strengthens our commitment to  combating antibiotic resistance. We also launched  three molecular PCR diagnostic test panels  to simultaneously detect common respiratory  pathogens out of one patient sample.  ", "page_idx": 20, "bbox": [277, 457.2001953125, 475, 577.3502197265625], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 92, "type": "text", "text": "Accurate diagnosis enables patients to receive  the most appropriate treatment, and prevents  them from being exposed to antibiotics they might  not respond to. However, diagnostic tests play a  crucial role in more than just combating infectious  diseases. They can also help prevent other diseases,  such as cervical cancer or hepatitis C-related  liver cancer.  ", "page_idx": 20, "bbox": [277, 589.2001953125, 475, 685.3502197265625], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 93, "type": "text", "text": "Digitalisation, an area in which Roche is investing  heavily, is becoming an ever more significant  factor in medical progress. Roche embarked on  strategic partnerships with Foundation Medicine  (FMI) and Flatiron Health several years ago because  we recognise that combining high-quality genomics  with real-world data (patient data from clinical  practice) delivers completely new approaches.  Where data sets are available in sufficient quantity  and quality, they represent an enormous potential  going forward that is already within grasp today.  This is a crucial driver of our efforts to advance  personalised healthcare. For now, the focus is  on making a significant improvement for cancer  patients by accelerating the discovery and  development of new cancer medicines. ", "page_idx": 21, "bbox": [120, 97.2001953125, 315, 289.3053283691406], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 94, "type": "text", "text": "To treat cancer effectively, it is first necessary to  understand the molecular mechanisms underlying  the disease. In autumn 2021, Roche therefore  partnered with FMI to launch a genome profiling kit  for personalised cancer research. The kit is the first  to enable researchers to use FMI’s comprehensive  genomic profiling assay in their own laboratories.  Digital solutions enable recording, structuring and  analysing of patients’ data, supporting clinical  decision-making and driving forward research. ", "page_idx": 21, "bbox": [120, 301.1583251953125, 315, 421.2814025878906], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 95, "type": "text", "text": "Digital products, such as specific apps, are also  delivering ever better support for monitoring  and treatment in other therapeutic areas such  as neurology or ophthalmology. ", "page_idx": 21, "bbox": [331, 97.12841796875, 512, 145.26943969726562], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 96, "type": "text", "text": "Everything we have achieved would not have been  possible without the 100,000 people who work for  Roche worldwide, and I would like to thank them all  for their exemplary dedication and commitment.  Despite the challenges of the pandemic, our  people in research and development, production,  distribution and support functions around the  world are working tirelessly to ensure that patients  continue to receive life-saving medicines and  diagnostics. ", "page_idx": 21, "bbox": [331, 157.1224365234375, 521, 277.2455139160156], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 97, "type": "text", "text": "I would also like to thank you, our shareholders,  for the trust you have placed in our company.\n ", "page_idx": 21, "bbox": [331, 289.0985107421875, 512, 313.2455139160156], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 98, "type": "image", "page_idx": 21, "img_path": "layout_images/roche-holdings_2021_10.jpg", "bbox": [332, 353, 465, 391], "page_size": [595.2760009765625, 793.7009887695312], "ocr_text": "(Cre Fel mn,\n", "vlm_text": "This image appears to contain a signature. However, I can't determine whose signature it is."}
{"layout": 99, "type": "text", "text": "Dr Severin Schwan CEO Roche Group ", "page_idx": 21, "bbox": [331, 397.2001953125, 400, 421.3501892089844], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 100, "type": "text", "text": "Roche Corporate Executive Committee on 31 December 2021 \n\n ", "text_level": 1, "page_idx": 21, "bbox": [119, 530, 309, 540], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 101, "type": "text", "text": "Dr Alan Hippe (1967), Chief Financial and Information Officer Claudia Böckstiegel\\* (1964), General Counsel Dr Aviv Regev\\* (1971), Head Genentech Research and Early Development (gRED) Dr William Pao\\* (1967), Head Roche Pharma Research and Early Development (pRED) Dr Severin Schwan (1967), CEO Roche Group Cristina A. Wilbur (1967), Chief People Officer Bill Anderson (1966), CEO Roche Pharmaceuticals Barbara Schädler\\* (1962), Head Group Communications Dr James H. Sabry\\* (1958), Global Head Pharma Partnering Dr Thomas Schinecker (1975), CEO Roche Diagnostics\n ", "page_idx": 21, "bbox": [120, 554.2001953125, 349.52490234375, 673.0001831054688], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 102, "type": "text", "text": "\\*  Member of the Enlarged Corporate Executive Committee ", "page_idx": 21, "bbox": [120, 686.2001953125, 281, 697.0001831054688], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 103, "type": "image", "page_idx": 22, "img_path": "layout_images/roche-holdings_2021_11.jpg", "bbox": [2, 25, 595, 794], "page_size": [595.2760009765625, 793.7009887695312], "ocr_text": "", "vlm_text": "The image shows a group of people standing outdoors on a light-colored stone surface with a backdrop of tall, green trees. The individuals are dressed in business casual attire, standing spaced out from each other. At the top right corner, there's text indicating \"Corporate Executive Committee | Roche 19.\""}
{"layout": 104, "type": "image", "page_idx": 23, "img_path": "layout_images/roche-holdings_2021_12.jpg", "bbox": [1, 0, 596, 794], "page_size": [595.2760009765625, 793.7009887695312], "ocr_text": "", "vlm_text": "The image shows a close-up view of several blue bottle caps or lids arranged over a surface with circular openings. The perspective appears to be from above, focusing on the tops of the caps."}
{"layout": 105, "type": "text", "text": "Reporting and  ", "text_level": 1, "page_idx": 24, "bbox": [134, 467, 428, 527], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 106, "type": "text", "text": "Our reporting approach ", "text_level": 1, "page_idx": 25, "bbox": [120, 98, 388, 125], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 107, "type": "text", "text": "Roche is committed to transparent reporting and we endeavour to drive  our economic, social and environmental performance with the same  diligence as our financial performance. ", "page_idx": 25, "bbox": [121, 138.2001953125, 514.0551147460938, 207.80020141601562], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 108, "type": "text", "text": "Reporting scope and boundaries Our financial and non-financial reporting consists  of the Annual Report, the Finance Report and  the online report. It contains the annual financial  statements, consolidated financial statements and  non-financial performance indicators. It covers  all regions and divisions of the Roche Group from  1 January to 31 December 2021. The financial  reporting scope is defined and outlined in our  Finance Report, and there have been no significant  changes in scope in 2021 compared to 2020. ", "page_idx": 25, "bbox": [120, 241.2000732421875, 313, 373.3501892089844], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 109, "type": "text", "text": "GRI standards and materiality ", "text_level": 1, "page_idx": 25, "bbox": [120, 386, 244, 396.75], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 110, "type": "text", "text": "We have followed the GRI (Global Reporting  Initiative) G4 guidelines since 2014, and transitioned  to the GRI Standards in 2017. By using the GRI  guidelines, we disclose the most critical impacts  of our activities on the environment, society  and the economy. In this respect, we conducted  a first materiality analysis at the corporate  level in 2014. In 2018/2019, we conducted a  second global materiality assessment including  expert interviews and feedback from more than  600 stakeholders. The results of this assessment  are featured on pages 24 and 25 of this report  and are also published on our website ( see link  on page 24 ). ", "page_idx": 25, "bbox": [120, 397.2001953125, 313, 565.3502197265625], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 111, "type": "text", "text": "Risk management ", "text_level": 1, "page_idx": 25, "bbox": [120, 578, 194, 588], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 112, "type": "text", "text": "Our Risk Management Policy sets out Roche’s  approach to identifying, analysing, managing  and reporting internal and external risks and  opportunities. A consolidated Group Risk Report,  which covers all material risks and opportunities, is  discussed annually with the Corporate Executive  Committee and reviewed by the Board of Directors.  The effectiveness of the Group Risk Management  Process is regularly monitored by the Group  ", "page_idx": 25, "bbox": [120, 589.2001953125, 313, 697.3502197265625], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 113, "type": "text", "text": "Risk Advisory team and the overall process  reviewed by the Audit Committee of the Board of  Directors, and reviewed externally when appropriate.  Risk management is embedded at all levels of the  Roche Group. Our Pharmaceuticals and Diagnostics  divisions and global functions conduct a formal  risk and opportunity assessment process at least  once a year and must develop response plans for  their most material risks and opportunities. ", "page_idx": 25, "bbox": [330, 241.2001953125, 528, 349.3501892089844], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 114, "type": "text", "text": "Read more in ‘Corporate Governance’ on page 140. ", "page_idx": 25, "bbox": [330, 361.2001953125, 528, 373.3501892089844], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 115, "type": "text", "text": "We also identify long-term business sustainability  trends with associated risks and opportunities  on an annual basis and integrate these into our  existing Group Risk Management Process. Each  year, emerging trends (including associated risks  and opportunities) are identified from internal  and external sources. ", "page_idx": 25, "bbox": [330, 385.2001953125, 517, 469.3501892089844], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 116, "type": "text", "text": "Based on these findings the Sustainability Steering  Committee prioritises and selects the top business  sustainability trends. Among those identified trends  are healthcare evolution and societal crises.  ", "page_idx": 25, "bbox": [330, 481.2001953125, 528, 529.3502197265625], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 117, "type": "text", "text": "UN Sustainable Development Goals ", "text_level": 1, "page_idx": 25, "bbox": [331, 542, 477, 549.75], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 118, "type": "text", "text": "We support the United Nations Sustainable  Development Goals (SDGs) within the sphere of  our corporate business strategy. We contribute  to a number of the SDGs and are particularly  pleased to see a dedicated goal on health (SDG 3).  This goal is closely connected with the achievement  of universal health coverage, which goes hand  in hand with better access to quality essential  medicines and diagnostics. This fits in perfectly  with our vision to improve and save lives. Since  2016, the SDGs have been an integral part of our  annual reporting. ", "page_idx": 25, "bbox": [330, 553.2001953125, 528, 697.3502197265625], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 119, "type": "image", "page_idx": 26, "img_path": "layout_images/roche-holdings_2021_13.jpg", "bbox": [66, 95, 563, 220], "page_size": [595.2760009765625, 793.7009887695312], "ocr_text": ". 1 Povey 2 thee ZNO ENG\nSUSTAINABLE\nDEVELOPMEI\n\nGOALS het SY\n\nINDUSTRY, INNOVATION 10 REDUCED \"1 ‘SUSTAINABLE CITIES 12 RESPONSIBLE\nANDINFRASTRUCTURE INEQUALITIES ‘AND COMMUNITIES CONSUMPTION\n\nGENDER GLEAN WATER\nfnucton EQUALITY\n\n7 ‘AFFORDABLE AND\n‘AND SANITATION CLEAN ENERGY\n\nwi FS YF &\n\n‘ONLAND\n\neos © ¥\n\nDECENT WORK AND\nECONOMIC GROWTH\n\noi\n\n@\n", "vlm_text": "This image illustrates the United Nations Sustainable Development Goals (SDGs). These are 17 interlinked global goals designed to be a \"blueprint to achieve a better and more sustainable future for all\". Here's a list of the goals shown in the image:\n\n1. No Poverty\n2. Zero Hunger\n3. Good Health and Well-being\n4. Quality Education\n5. Gender Equality\n6. Clean Water and Sanitation\n7. Affordable and Clean Energy\n8. Decent Work and Economic Growth\n9. Industry, Innovation, and Infrastructure\n10. Reduced Inequalities\n11. Sustainable Cities and Communities\n12. Responsible Consumption and Production\n13. Climate Action\n14. Life Below Water\n15. Life on Land\n16. Peace, Justice, and Strong Institutions\n17. Partnerships for the Goals\n\nEach goal is represented by a unique symbol and color."}
{"layout": 120, "type": "text", "text": "Examples of our contribution to the UN goals  are listed on our UN SDG webpage ( see link on page 24 ) and are mapped to our material topics  as featured on page 25. ", "page_idx": 26, "bbox": [67, 301.2001953125, 255, 349.3501892089844], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 121, "type": "text", "text": "As a signatory of the UN Global Compact (UNGC),  we commit to integrate the universal principles  in the areas of human rights, labour, environment  and anti-corruption into our business strategy,  culture and daily operations and to report on the  results achieved each year. We will publish our first  Communication on Progress in the first quarter  of 2022. ", "page_idx": 26, "bbox": [67, 361.2001953125, 259.20294189453125, 457.3501892089844], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 122, "type": "text", "text": "External assurance ", "text_level": 1, "page_idx": 26, "bbox": [67, 470, 149, 480], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 123, "type": "text", "text": "Our non-financial reporting has been verified by  Price waterhouse Coopers AG (PwC), an independent  third party, focused on the materiality determination  process, the design of the sustainability risks and  opportunities determination process and on the  figures in the areas of safety, security, health and  environmental protection, people and contributions. Since 2019, and as a result of Roche’s strengthened  control framework, review procedures and  reporting aspects, the figures related to our  grants, donations and sponsorships to healthcare  and patient organisations have been subject to  reasonable assurance performed by PwC. This  figure is disclosed on the non-financial reporting  key performance indicators webpage, including  the PwC assurance report. ", "page_idx": 26, "bbox": [67, 481.2001953125, 265, 673.3502197265625], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 124, "type": "text", "text": "Business sustainability trends ", "text_level": 1, "page_idx": 26, "bbox": [320, 323, 477, 338], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 125, "type": "text", "text": "  ", "text_level": 1, "page_idx": 26, "bbox": [320, 349, 403, 356.75], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 126, "type": "text", "text": "Healthcare is moving towards a continuum of care approach, including  prevention, treatment and cure, offering a wider range of products and  service solutions. This is a unique opportunity to accelerate delivery of  truly integrated, patient-centric and personalised healthcare solutions.  For example, we have introduced our Navify Symptom Tracker, which  offers remote monitoring of COVID-19 symptoms. We are also developing  cloud-enabled integration engines to support digital health ecosystems  and mobile apps for patients and healthcare professionals, like the  mySugr app to monitor and manage diabetes on a smartphone. The risks  and opportunities associated with this new digital health arena are  assessed and managed through the Group Risk Management Process. ", "page_idx": 26, "bbox": [320, 361.2001953125, 551, 493.3501892089844], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 127, "type": "text", "text": "Societal crises   ", "text_level": 1, "page_idx": 26, "bbox": [319, 505, 378, 517], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 128, "type": "text", "text": "Ineffective social models with limited economic and educational  prospects are likely to lead to dissolution of societal solidarity and  exacerbate mental health deterioration and youth disillusionment. We  consider that it is our role to drive public-private partnerships and  initiatives, working in collaboration with governments and healthcare  providers, to tackle such risks. We also see an opportunity to demonstrate  that we are an employer of choice, acknowledging the importance of  health and well-being of our employees. We provide various offerings to  support employees and their families, from flexible working arrangements,  parental leave for men and women, childcare facilities and other  provisions to help employees combine their career and family roles, to  unpaid-leave options for people needing to care for an elderly relative. ", "page_idx": 26, "bbox": [320, 517.2001953125, 557, 661.3502197265625], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 129, "type": "text", "text": "See ‘Independent Assurance Report’ on page 190. ", "page_idx": 26, "bbox": [68.1239013671875, 685.2001953125, 257.0437927246094, 697.3502197265625], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 130, "type": "text", "text": "Materiality and impact ", "text_level": 1, "page_idx": 27, "bbox": [120, 97, 373, 124], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 131, "type": "text", "text": "Our purpose is  Doing now what patients need next . How we identify  and meet those needs – what we do every day – must be sustainable if we  are to succeed. It is why sustainability is built into our business strategy  and part of everyone’s job at Roche.  ", "page_idx": 27, "bbox": [121, 138.2001953125, 523.9708862304688, 231.80007934570312], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 132, "type": "text", "text": "Our approach is holistic and integrates the three  dimensions of sustainability: \n\n •\t  Society –  how we contribute to a better  tomorrow for all \n\n•\t  Environment –  how we minimise our impact  on nature\n\n •\t  Economy –  how we invest in medical advances,  create jobs and ensure livelihoods ", "page_idx": 27, "bbox": [120, 265.1282958984375, 305, 361.3471984863281], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 133, "type": "text", "text": "What does this mean for each of us at Roche,  every day? ", "page_idx": 27, "bbox": [120, 373.2001953125, 292, 397.3471984863281], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 134, "type": "text", "text": "Society ", "text_level": 1, "page_idx": 27, "bbox": [120, 410, 153, 421], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 135, "type": "text", "text": "We contribute to a better society by enabling  the right treatment for the right patient at the right  time for the right value. We do this by developing  new medicines and ways of diagnosing disease  and gaining insights from data. Our commitment  to expand access to these innovations will help  more patients live longer, better lives. And  with this comes a deep respect for the human  rights of everyone we reach, especially patients,  business partners, suppliers, local communities  and, of course, our colleagues around the world.  It is why we emphasise employee safety, health  and development while promoting diversity and  inclusion, integrity, mutual respect and equal  opportunities for all.   ", "page_idx": 27, "bbox": [120, 421.19720458984375, 309, 601.3052978515625], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 136, "type": "text", "text": "Environment ", "text_level": 1, "page_idx": 27, "bbox": [120, 614, 174, 624], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 137, "type": "text", "text": "The respect for a healthy planet and for the  environment has always been a priority of  our founding families and the company. We  are committed to halving the environmental  impact of our operations and products from  ", "page_idx": 27, "bbox": [120, 625.1552734375, 292, 685.2932739257812], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 138, "type": "text", "text": "2019 to 2029.  And we aim to reduce our own  greenhouse gas emissions to absolute zero by 2050,  while partnering with our suppliers to reduce their  emissions for our mutual benefit. ", "page_idx": 27, "bbox": [330, 265.2001953125, 527, 313.3412170410156], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 139, "type": "text", "text": "Economy ", "text_level": 1, "page_idx": 27, "bbox": [330, 326, 370, 336], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 140, "type": "text", "text": "Our business must meet the needs of patients  and continue creating quality jobs that provide  people and their families with secure livelihoods,  while earning competitive returns for our investors.  We do this by promoting innovation and by  translating science into pioneering medicines  and diagnostics that help patients live longer,  better and more productive lives – enabling them  to support themselves and contribute to their  local economies.  ", "page_idx": 27, "bbox": [330, 337.19122314453125, 527, 457.3143005371094], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 141, "type": "text", "text": "As described in our strategy our set-up is designed  for innovation. Our autonomous research and  development centres and alliances with more than  250 external partners foster a diversity of scientific  approaches and agility. Roche operates in over  100 countries where our local teams implement  our strategy. We measure our performance and  report to all our stakeholders the progress towards  the goals we have set ourselves.  ", "page_idx": 27, "bbox": [330, 469.16729736328125, 527, 577.2933349609375], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 142, "type": "text", "text": "Materiality assessment and stakeholder  engagement ", "text_level": 1, "page_idx": 27, "bbox": [331, 590, 496, 612], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 143, "type": "text", "text": "Engaging with our stakeholders is essential  to build trust and an understanding of their  expectations. By embedding their feedback in our  strategy and our daily business, we are able to  jointly address our common issues and develop  long-term solutions. ", "page_idx": 27, "bbox": [330, 613.1403198242188, 527, 685.2753295898438], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 144, "type": "image", "page_idx": 28, "img_path": "layout_images/roche-holdings_2021_14.jpg", "bbox": [327, 90, 477, 242], "page_size": [595.2760009765625, 793.7009887695312], "ocr_text": "sO\nPAS Y\n\nSociety Environment\n\nSustainability\n\nSF\n\nEconomy\n", "vlm_text": "The image is a circular diagram labeled \"Sustainability\" in the center, with three surrounding sections: \"Society,\" \"Environment,\" and \"Economy.\" Each section has a corresponding icon—figures for society, a plant for environment, and an arrow for economy. The diagram represents the three pillars of sustainability."}
{"layout": 145, "type": "text", "text": "In order to identify the topics that are particularly  relevant to Roche, our stakeholders and society  at large and to deliver lasting shared value, we  conducted an in-depth materiality assessment  at corporate level among our key stakeholders  in 2018/2019. Our approach to materiality  assessment is integrated – building on our Group  Risk Management Process – and inclusive, being  designed collaboratively with colleagues across  multiple functions. We gathered insights from a  broad range of internal and external stakeholders  to identify the most important and pressing  issues that Roche should address in the next three  to five years. We identified 19 material topics,  clustered in eight main categories, that stood out  as highly relevant to us and to our key stakeholders.  To properly address these topics, we have then  aligned them with our current goals and are  measuring performance through our defined set  of indicators. ", "page_idx": 28, "bbox": [67, 97.2000732421875, 262.7256164550781, 337.2962341308594], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 146, "type": "text", "text": "Our impact ", "text_level": 1, "page_idx": 28, "bbox": [82, 382, 140, 397], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 147, "type": "text", "text": "Our 2021 performance ", "page_idx": 28, "bbox": [213, 408.2001953125, 295.3508605957031, 421.7001953125], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 148, "type": "text", "text": "Supporting UN SDGs ", "page_idx": 28, "bbox": [484.11187744140625, 408.2001953125, 559.171875, 421.7001953125], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 149, "type": "text", "text": "Our material topics\\* ", "page_idx": 28, "bbox": [371, 408.2001953125, 447, 421.7001953125], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 150, "type": "text", "text": "Our impact ", "page_idx": 28, "bbox": [82, 408.2001953125, 123, 421.7001953125], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 151, "type": "image", "page_idx": 28, "img_path": "layout_images/roche-holdings_2021_15.jpg", "bbox": [487, 436, 561, 687], "page_size": [595.2760009765625, 793.7009887695312], "ocr_text": "4\nad|\nme\n\n13 feta\n\n5 titty\n\n9 joni,\n\nee\n", "vlm_text": "This image depicts several of the United Nations Sustainable Development Goals (SDGs) along with their icons:\n\n1. **Goal 3**: Good Health and Well-being\n2. **Goal 4**: Quality Education\n3. **Goal 5**: Gender Equality\n4. **Goal 9**: Industry, Innovation and Infrastructure\n5. **Goal 16**: Peace, Justice and Strong Institutions\n6. **Goal 17**: Partnerships for the Goals\n7. **Goal 6**: Clean Water and Sanitation\n8. **Goal 7**: Affordable and Clean Energy\n9. **Goal 13**: Climate Action\n10. **Goal 8**: Decent Work and Economic Growth\n\nThese goals are part of a global agenda to address various social, economic, and environmental challenges."}
{"layout": 152, "type": "text", "text": "•  \u0007 16.4 million patients  treated with  Roche medicines  •  \u0007 27 billion tests  conducted with  Roche Diagnostics products •   \u0007 80 new molecular entities  in  clinical development •   \u0007 36%   of women  in executive positions •   \u0007 44%   of women  in management •   \u0007 80/100   employee  engagement score ", "page_idx": 28, "bbox": [213, 445.2001953125, 340, 553.3502197265625], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 153, "type": "text", "text": "•  Access to healthcare •  Digitalisation •  Science and innovation •   \u0007 Product quality and safety •  Ethics and compliance  •  Employee engagement ", "page_idx": 28, "bbox": [371, 445.2001953125, 465.0106201171875, 517.3502197265625], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 154, "type": "text", "text": "Society  How we contribute to a  better tomorrow for all ", "page_idx": 28, "bbox": [82, 445.2001953125, 155, 481.3501892089844], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 155, "type": "text", "text": "Environment How we minimise our \n impact on nature ", "page_idx": 28, "bbox": [82, 565.2001953125, 149.6696014404297, 601.3472290039062], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 156, "type": "text", "text": "•  \u0007 \\~30% decrease  in our environmental  impact per employee since 2019 •  \u0007 72% of our electricity  coming from  sustainable sources •  \u0007 59% decrease  in greenhouse gas  emissions since 2004 ", "page_idx": 28, "bbox": [213, 565.2001953125, 340, 637.3502197265625], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 157, "type": "text", "text": "•  Energy efficiency ", "page_idx": 28, "bbox": [371, 565.2001953125, 435.8379821777344, 577.3502197265625], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 158, "type": "text", "text": "•   21.83% of sales  invested in R&D •   \u0007 100,920 employees ", "page_idx": 28, "bbox": [213, 649.2001953125, 324, 673.3502197265625], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 159, "type": "text", "text": "•  Long-term mindset ", "page_idx": 28, "bbox": [371, 649.2001953125, 439.3039245605469, 661.3502197265625], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 160, "type": "text", "text": "Economy  How we invest in medical advances,  create jobs and ensure livelihoods ", "page_idx": 28, "bbox": [82, 649.2001953125, 193.47869873046875, 685.3502197265625], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 161, "type": "text", "text": "Our strategy ", "text_level": 1, "page_idx": 29, "bbox": [120, 99, 261, 124], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 162, "type": "text", "text": "We focus on finding new medicines and diagnostics and on establishing  data-based insights that evolve the practice of medicine and that help  patients live longer, better lives. ", "page_idx": 29, "bbox": [120, 138.2001953125, 513.8880615234375, 207.80020141601562], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 163, "type": "text", "text": "Our business environment is undergoing tremendous  change. We are facing new challenges due to the  complexity of care and increasing pressure on  healthcare budgets. At the same time, we see new  opportunities arising from major advances in life  sciences and from digitalisation in healthcare.  ", "page_idx": 29, "bbox": [120, 241.2001953125, 317, 313.3382263183594], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 164, "type": "text", "text": "In these turbulent times, we are guided by our  common purpose:  Doing now what patients  need next . Our company has been bringing  novel diagnostics and treatments to patients for  125 years. Patients are and will remain at the core  of what we do. They are the reason we come to  work every day. ", "page_idx": 29, "bbox": [120, 325.19122314453125, 310, 409.3232727050781], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 165, "type": "text", "text": "What we do  ", "text_level": 1, "page_idx": 29, "bbox": [120, 422, 170, 432], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 166, "type": "text", "text": "We focus on our vision of fitting treatments to  patients: providing the right therapy for the right  patient to ensure the best response at the right  time for the right value. Our approach combines our  rich expertise in pharmaceuticals and diagnostics  with expanded data science capabilities to drive  more effective and efficient research and to enable  better therapeutic decisions for patients. ", "page_idx": 29, "bbox": [120, 433.17327880859375, 317, 529.3023681640625], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 167, "type": "text", "text": "Our pursuit of excellence in science rests on four  key elements: an exceptionally broad and deep  understanding of disease biology; the seamless  integration of our capabilities in pharmaceuticals  and diagnostics; a diversity of approaches to  maximise innovation; and a long-term orientation. ", "page_idx": 29, "bbox": [120, 541.1553344726562, 310, 613.2903442382812], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 168, "type": "text", "text": "Working in partnership with third parties, we  offer integrated solutions with improved medical,  health and economic benefits. We work with  many different stakeholders in the healthcare  ecosystem to broaden access to our offerings for  people who need them and, ultimately, to provide  ", "page_idx": 29, "bbox": [120, 625.143310546875, 310, 697.2783203125], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 169, "type": "text", "text": "a seamless patient journey. We will continue to  concentrate our energies on prescription medicines,  in vitro diagnostics and increasingly data and  insights, rather than diversify into other sectors  like generics, biosimilars or over-the-counter  medicines.  ", "page_idx": 29, "bbox": [331, 241.13128662109375, 527, 313.2663269042969], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 170, "type": "text", "text": "Our delivery is to create value for all our  stakeholders: being a partner of choice; bringing  significant medical benefit for patients, doctors  and payers; offering a great place to work for  employees; delivering a sustainable positive  contribution to society; and earning competitive  returns for our investors.\n ", "page_idx": 29, "bbox": [331, 325.11932373046875, 514, 409.2513732910156], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 171, "type": "text", "text": "How we do it ", "text_level": 1, "page_idx": 29, "bbox": [331, 422, 384, 432], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 172, "type": "text", "text": "Ultimately, delivering on our commitments takes  people with integrity, courage and a passion for  making a difference for patients. Our people are  proud to say: We are Roche. ", "page_idx": 29, "bbox": [331, 433.1972961425781, 514, 481.33831787109375], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 173, "type": "text", "text": "Our leadership inspires outcomes that matter  by embracing diversity and inclusion. Different  backgrounds, perspectives and experiences, across  the entire organisation, foster innovative solutions  for the benefit of patients. Our ways of working  enable agile and networked responses to the ever  increasing pace of change by balancing the needs  for stability, speed and flexibility. ", "page_idx": 29, "bbox": [331, 493.1913146972656, 527, 589.3203125], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 174, "type": "text", "text": "Our set-up is designed for innovation. Our  autonomous research and development centres  and alliances with more than 250 external partners  foster a diversity of scientific approaches and  agility. Our global geographical scale and reach  enables us to attract talent in the leading global  science clusters and to quickly bring our solutions  to people who need them. ", "page_idx": 29, "bbox": [331, 601.17333984375, 523, 697.3023071289062], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 175, "type": "text", "text": "What we do ", "text_level": 1, "page_idx": 30, "bbox": [66, 159, 172, 182], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 176, "type": "text", "text": "Our focus Fitting treatments to patients ", "page_idx": 30, "bbox": [68, 237.55517578125, 187.690673828125, 266.75518798828125], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 177, "type": "text", "text": "Our distinctiveness\n Excellence in science ", "page_idx": 30, "bbox": [68, 333.9331970214844, 155, 363.1332092285156], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 178, "type": "text", "text": "Our delivery Value for all stakeholders ", "page_idx": 30, "bbox": [68, 430.3111877441406, 172.21310424804688, 459.5111999511719], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 179, "type": "image", "page_idx": 30, "img_path": "layout_images/roche-holdings_2021_16.jpg", "bbox": [188.25, 226, 405, 466], "page_size": [595.2760009765625, 793.7009887695312], "ocr_text": "", "vlm_text": "The image shows an abstract geometric shape, resembling a hexagon. It features interlocking blue and white bands on a gray background, creating a 3D effect."}
{"layout": 180, "type": "text", "text": "How we do it ", "text_level": 1, "page_idx": 30, "bbox": [412, 157, 529, 183], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 181, "type": "text", "text": "Our leadership Inspiring outcomes that matter ", "page_idx": 30, "bbox": [414, 237.55517578125, 541.3312377929688, 266.75518798828125], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 182, "type": "text", "text": "Our ways of working Agile and networked ", "page_idx": 30, "bbox": [414, 333.9331970214844, 503.5408020019531, 363.1332092285156], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 183, "type": "text", "text": "Our set-up Built for innovation ", "page_idx": 30, "bbox": [414, 430.3111877441406, 492.1216125488281, 459.5111999511719], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 184, "type": "image", "page_idx": 31, "img_path": "layout_images/roche-holdings_2021_17.jpg", "bbox": [0, 1, 595, 793], "page_size": [595.2760009765625, 793.7009887695312], "ocr_text": "", "vlm_text": "The image appears to show a close-up of two racks of pipette tips, commonly used in laboratories for precise liquid handling. The racks are yellow, and each section holds multiple pipette tips."}
{"layout": 185, "type": "text", "text": "Diagnostics ", "text_level": 1, "page_idx": 32, "bbox": [130, 466, 376, 533], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 186, "type": "image", "page_idx": 33, "img_path": "layout_images/roche-holdings_2021_18.jpg", "bbox": [0, 0, 588, 794], "page_size": [595.2760009765625, 793.7009887695312], "ocr_text": "", "vlm_text": "The image shows a close-up of a person with facial hair, wearing a nose ring and earrings. The focus is on their eyes, nose, and mouth. The background is blurred."}
{"layout": 187, "type": "text", "text": "Diagnostic solutions - the backbone  of treatment decisions ", "text_level": 1, "page_idx": 34, "bbox": [66, 97, 456, 158], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 188, "type": "text", "text": "Whether it is cancer, infectious diseases or other serious health threats,  the quest for better solutions to healthcare’s greatest challenges depends  on diagnostics. ", "page_idx": 34, "bbox": [67, 174.2001953125, 476.2366943359375, 243.80020141601562], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 189, "type": "text", "text": "The COVID-19 pandemic profoundly raised  awareness of the role diagnostics play in disease  prevention and management. Although COVID-19  continues to dominate the healthcare landscape  and the pandemic remains a global threat, some  countries have made varying degrees of progress  towards containing the virus. At the end of 2021,  there were more than 293 million confirmed cases  of COVID-19, and more than five million deaths.  ", "page_idx": 34, "bbox": [67, 277.2001953125, 257, 385.3262634277344], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 190, "type": "text", "text": "The spread of the virus has placed an enormous  strain on health systems and heightened the need   or millions of tests. At Roche, we are proud of our  industry-leading portfolio of 22 COVID-19 solutions,  and we remain committed to developing and  bringing to market additional tests and solutions  to strengthen the global fight against the disease.  ", "page_idx": 34, "bbox": [67, 397.17926025390625, 264, 481.3113098144531], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 191, "type": "text", "text": "In March 2021, we launched the cobas  SARS-CoV-2 Set 1 variant test, which runs on our  cobas 6800/8800 systems. Developed to detect  and differentiate SARS-CoV-2 mutations in known  variants, this research-use-only test can help  scientists track mutation prevalence, assess the  spread of circulating variants, and monitor their  potential impact on treatments, vaccines, and public  health measures. The test has a pre-optimised assay  design, ready-to-use test cassettes, and predefined  software parameters, all of which reduce testing  complexity and shorten turnaround time. ", "page_idx": 34, "bbox": [67, 493.164306640625, 264, 637.2813110351562], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 192, "type": "text", "text": "In the first quarter of 2021, we also introduced  the SARS-CoV-2 Antigen Self Test Nasal for  self-administered testing at home. The test  enables patients to gather a sample from the  front area of the nose rather than the nasopharynx  and can identify infectious SARS-CoV-2 in just  15 minutes. Initially granted special approval in  several European countries, the test received  the CE mark in June, expanding its availability to  countries accepting the CE mark.  ", "page_idx": 34, "bbox": [277, 277.1282958984375, 472, 397.2513732910156], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 193, "type": "text", "text": "We further supplemented our COVID-19 portfolio  in June with the launch of the SARS-CoV-2 assay on  the cobas Liat system, making it the first 20-minute  point-of-care (PoC) PCR test to receive Emergency  Use Authorization in the US for asymptomatic  screening. The test detects all currently known  SARS-CoV-2 variants, and brings fast PCR testing  to near-patient settings, like clinician’s offices,  emergency rooms and urgent care clinics.  ", "page_idx": 34, "bbox": [277, 409.1043701171875, 472, 517.23046875], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 194, "type": "text", "text": "In December, we received FDA Emergency Use  Authorization for our COVID-19 At-Home Test,  which uses a simple anterior nasal swab sample  for convenient self-collection and self-testing by  individuals aged 14 years and older, and by an adult  for children aged 2–13 years old. It can produce  accurate, reliable and quick results in as few as  20 minutes for SARS-CoV-2 and all known variants  of concern, including Omicron.\n ", "page_idx": 34, "bbox": [277, 529.0834350585938, 472, 637.2094116210938], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 195, "type": "image", "page_idx": 35, "img_path": "layout_images/roche-holdings_2021_19.jpg", "bbox": [0, 67, 318, 408], "page_size": [595.2760009765625, 793.7009887695312], "ocr_text": "", "vlm_text": "The image shows a person holding a smartphone and interacting with an app on the screen. The phone displays a form or interface with fields that appear to be for entering information, possibly for a transaction or registration process. A hand is pointing towards the screen, perhaps ready to submit or interact with the app further."}
{"layout": 196, "type": "text", "text": "125 years of milestones ", "text_level": 1, "page_idx": 35, "bbox": [35, 443, 156, 458], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 197, "type": "text", "text": "Revolutionising diagnostics Polymerase chain reaction (PCR) is a trusted way to create unlimited  copies of DNA from just one original strand. The copied DNA can then be  used reliably in a wide variety of tests to diagnose or monitor diseases,  or for basic molecular biology research. ", "page_idx": 35, "bbox": [37, 468.2001953125, 268, 529.3502197265625], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 198, "type": "text", "text": "In 1983, Kary Mullis, a scientist at the Cetus Corporation, conceived PCR as  a method to copy DNA and synthesise large amounts of a specific target  DNA. Over the next two years, the team of Cetus scientists that recognised  the potential impact PCR could have on molecular biology researched,  refined and made the theoretical process a reality. ", "page_idx": 35, "bbox": [37, 541.2001953125, 275, 601.3502197265625], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 199, "type": "text", "text": "In 1991, Roche bought the rights to PCR from Cetus and invested in  refining the science for use in molecular diagnostics to detect diseases.  Roche Molecular Diagnostics has not only defined and refined PCR, but  it has remained the clear leader and trailblazer of this technology. ", "page_idx": 35, "bbox": [37, 613.2001953125, 268, 661.3502197265625], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 200, "type": "text", "text": "Navify Pass enables individuals to receive health credentials  easily and seamlessly on their mobile devices. ", "page_idx": 35, "bbox": [330, 98.2001953125, 513, 121.00019836425781], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 201, "type": "text", "text": "That same month, we added three additional  research-use-only (RUO) test kits for the detection  of mutations present in the novel B.1.1.529 Omicron  SARS-CoV-2 variant: VirSNiP SARS Spike ins214EPE \n\n (RUO), VirSNiP SARS-CoV-2 Spike S371L S373P \n\n (RUO), VirSNiP SARS Spike E484A (RUO). The  kits were developed with TIB Molbiol, our newly  acquired subsidiary. ", "page_idx": 35, "bbox": [330, 181.2001953125, 525, 277.3501892089844], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 202, "type": "text", "text": "The VirSNiP variant kits allow differentiation  between the range of unique mutations present  within the Omicron variant compared to other  SARS-CoV-2 variants and are for use on LightCycler  and cobas z 480 analysers. Using a technology  called quantitative polymerase chain reaction  (qPCR) they can help researchers with improved  variant detection and viral research, and are  among the first to address the range of unique  mutations of the Omicron variant. ", "page_idx": 35, "bbox": [330, 289.2001953125, 525, 409.3501892089844], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 203, "type": "text", "text": "Besides the novel assays, we also launched the  Navify Pass, a digital solution that allows people  to receive their COVID-19-related health data  in a mobile app. Available in various countries,  including the United Kingdom and the Netherlands,  this solution can be used to facilitate access to  events and travel and enable a return to normality. ", "page_idx": 35, "bbox": [330, 421.2001953125, 525, 505.3501892089844], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 204, "type": "text", "text": "Point-of-care testing plays an essential and  increasingly important role in healthcare as  it delivers high medical value solutions and  diagnostic information to patients and healthcare  professionals wherever and whenever it is needed.  The Roche point-of-care strategy focuses on  infectious diseases like COVID-19, influenza A/B  and sepsis, with tests for several other diseases  currently in development. ", "page_idx": 35, "bbox": [330, 517.2001953125, 525, 625.3502197265625], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 205, "type": "text", "text": "Diagnostics beyond COVID-19 ", "text_level": 1, "page_idx": 36, "bbox": [67, 134, 308, 159], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 206, "type": "text", "text": "Unfortunately, during a pandemic, many people  with other serious diseases face delays in treatment  and disease monitoring. To achieve the best  possible results, these patients depend heavily  on early diagnosis and rapid access to therapy.  To meet both COVID-19 and other testing needs,  we significantly increased installations of our  high-throughput systems cobas 6800/8800, and  have now installed more than 1,700. As a result,  every 24 hours, laboratories around the world can  perform three million more tests than they could  before the pandemic. Health systems can use the  additional capacities for screening, diagnosis, and  treatment monitoring in other areas, such as cancer,  cardiovascular disease and women’s health.  ", "page_idx": 36, "bbox": [67, 181.2001953125, 264, 361.3501892089844], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 207, "type": "text", "text": "In spite of the pressures of meeting the ongoing  demand for COVID-19 tests, we launched several  tests and solutions for other health conditions  in 2021. Many of these conditions are not only a  tremendous stress and strain on the patient, but also  on their loved ones and on the healthcare system.  ", "page_idx": 36, "bbox": [67, 373.2001953125, 264, 445.3501892089844], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 208, "type": "text", "text": "In oncology, we added important new tests to  aid in the fight against cancer. In March, we  expanded the label for the Ventana ALK (D5F3)  assay to identify ALK-positive lung cancer patients  who are eligible for targeted treatment with  Lorbrena (lorlatinib, Pfizer). This assay is the only  immuno his to chemistry test approved by the FDA  as a companion diagnostic for Lorbrena. The test  has previously been approved as a companion  diagnostic for three other targeted treatments,  including Xalkori (crizotinib, Pfizer), Zykadia (ceritinib,  Novartis) and Roche’s Alecensa (alectinib). This  label expansion advances Roche’s commitment  to personalised healthcare (PHC). It provides lung  cancer patients with access to more treatment  options and a better chance for progression-free  survival, compared to the standard of care.  ", "page_idx": 36, "bbox": [67, 457.2001953125, 264, 661.3502197265625], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 209, "type": "text", "text": "A month later, we launched the Elecsys Anti-p53  immunoassay to help diagnose bowel, breast, and  ", "page_idx": 36, "bbox": [67, 673.2001953125, 258, 697.3502197265625], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 210, "type": "text", "text": "oesophageal cancer. A mutation of p53 is present in  half of solid tumour cancers and is the most common  genetic change identified so far in human cancers.  This test is especially impactful in oesophageal  cancer, the sixth most common cause of cancer  death worldwide. It can be particularly difficult to  treat as it often has no signs or symptoms in the  early stages.  ", "page_idx": 36, "bbox": [277, 181.2001953125, 475, 277.3501892089844], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 211, "type": "text", "text": "Also in support of our PHC approach towards  cancer care, we received FDA approval in October  for the Ventana PD-L1 (SP263) assay to be used  as a companion diagnostic to identify patients with  non-small cell lung cancer eligible for treatment  with our Tecentriq immunotherapy. The approval  was based on the results from the phase III  IMpower010 study and expands our industry-leading  portfolio of companion diagnostics.  ", "page_idx": 36, "bbox": [277, 289.2001953125, 475, 397.3501892089844], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 212, "type": "text", "text": "We also launched the Elecsys Growth Differentiation  Factor 15 (GDF-15) immunoassay, which detects  a specific form of weight loss known as cachexia  in patients with solid tumours. The test, which has  received the FDA Breakthrough Device Designation,  helps determine eligibility for treatment that targets  this highly prevalent complication of cancer.  ", "page_idx": 36, "bbox": [277, 409.2001953125, 475, 493.3501892089844], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 213, "type": "text", "text": "The Ventana MMR RxDx Panel, launched in April,  is the first FDA-approved companion diagnostic  for identifying patients with advanced or recurring  endometrial cancer who are best suited for  treatment with GSK’s immunotherapy drug Jemperli  (dostarlimab-gxly). Endometrial cancer is the most  common gynaecologic cancer in the US and about  90,000 women globally die from endometrial cancer  each year. Currently, only limited treatment options  exist for women whose disease progresses on or  after first-line therapy; ours is the first companion  diagnostic to identify endometrial cancer patients  eligible for anti-PD1 immunotherapy. The test was  also FDA approved in August to help determine,  based on cancer biomarkers, which patients with  solid tumours may benefit from Jemperli.  ", "page_idx": 36, "bbox": [277, 505.2001953125, 475, 697.3502197265625], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 214, "type": "image", "page_idx": 37, "img_path": "layout_images/roche-holdings_2021_20.jpg", "bbox": [0, 67, 319, 408], "page_size": [595.2760009765625, 793.7009887695312], "ocr_text": "", "vlm_text": "The image shows a person wearing gloves holding what appears to be a medical or laboratory cartridge. In the foreground, there's another cartridge labeled \"Elecsys®,\" which is likely related to diagnostic equipment or testing tools. The setting looks like a laboratory or clinical environment."}
{"layout": 215, "type": "text", "text": "In October, we announced the IMPACT (IMproving  Primary screening And Colposcopy Triage) clinical  trial data showing a clear benefit in using our  CINtec Plus Cytology test for women who are at  higher risk of developing cervical cancer. More than  604,000 women are diagnosed with cervical cancer  each year and approximately 342,000 die from  this preventable cancer caused by infection with  high-risk types of the human papillomavirus (HPV).  Results from the trial of more than 35,000 women  aged 25–65 years, were published in the  International Journal of Cancer .  ", "page_idx": 37, "bbox": [120, 445.2001953125, 316, 589.3502197265625], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 216, "type": "text", "text": "In the study, women who were positive for high- risk HPV received a follow-up triage test to help  determine if their cervical cells were transforming  to cervical pre-cancer. The biomarker-based  CINtec Plus Cytology test showed a significantly  higher sensitivity in detecting cervical pre-cancers,  compared to Pap cytology. The Roche test aids  clinicians in more confidently determining which  ", "page_idx": 37, "bbox": [120, 601.2001953125, 316, 697.3502197265625], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 217, "type": "text", "text": "Our systems, tests and software solutions help laboratories  improve their efficiency, quality controls and information sharing,  and support physicians and patients in treatment decisions. ", "page_idx": 37, "bbox": [331, 98.2003173828125, 524, 133.0003204345703], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 218, "type": "text", "text": "women are at increased risk for high-grade  cervical pre-cancer and require immediate further  diagnostic procedures, and which women may  need repeat testing or routine screening. ", "page_idx": 37, "bbox": [331, 181.2001953125, 524, 229.35018920898438], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 219, "type": "text", "text": "", "page_idx": 37, "bbox": [330, 242, 450, 248.75], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 220, "type": "text", "text": "Cardiovascular disease (CVD) remains the leading  cause of death globally, claiming the lives of  nearly 18 million people each year. 1  The COVID-19  pandemic has made management of this disease  even more challenging, especially as many patients  are unaware that they have the disease, and  are reluctant to seek care even if experiencing  classic symptoms like chest pain. Biomarkers  play a critical role in improving the diagnosis  and management of heart attacks and heart  failure. In April, we announced additional testing  capabilities for two key biomarkers: high-sensitive  cardiac troponin T (cTnT-hs) and N-terminal  pro-brain natriuretic peptide (NT-proBNP).  ", "page_idx": 37, "bbox": [331, 253.2001953125, 524, 421.3501892089844], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 221, "type": "text", "text": "Heart failure affects more than 64 million people  worldwide and places great stress on patients,  caregivers and healthcare systems. Despite  treatment and hospitalisation, the outlook is poor.  One of the new Elecsys NT-proBNP test extensions  can identify which patients with type 2 diabetes are  at greater risk for developing heart failure. Another  helps identify patients at risk of developing atrial  fibrillation, an abnormal heart rhythm that can  lead to stroke, brain damage or death. The new  extensions for Elecsys cTnT-hs testing help predict  heart attack risk and mortality in non-cardiac  surgery patients, and can assess long-term  cardiovascular event risk in asymptomatic patients.  ", "page_idx": 37, "bbox": [331, 433.2001953125, 524, 601.3502197265625], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 222, "type": "text", "text": "Infectious disease threats beyond COVID-19 Although COVID-19 retains the world’s attention,  a range of other infectious diseases affect millions  of people, and rank among the top three causes  of death worldwide. We continue to develop tests  and solutions for infectious diseases beyond  COVID-19.  ", "page_idx": 37, "bbox": [331, 613.2001953125, 524, 697.3502197265625], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 223, "type": "text", "text": "In March, we launched the Elecsys Epstein-Barr  virus (EBV) immunoassay panel to improve EBV  staging in countries accepting the CE mark.  Infecting more than  $90\\%$   of the world’s population  by adulthood, EBV normally remains dormant,  but can become threatening to those with  weakened immune systems, such as transplant  patients. This panel includes three immunoassays  to detect specific EBV antibodies: Elecsys IgM,  Elecsys EBV VCA IgG and Elecsys EBNA IgG. The  panel helps clinicians make faster decisions on  treatment for transplant patients, and can also  be used to rule out other acute infections, such  as undetected HIV.  ", "page_idx": 38, "bbox": [67, 181.2001953125, 257, 349.3501892089844], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 224, "type": "text", "text": "Also newly approved is a claim extension for our  Elecsys BRAHMS Procalcitonin (PCT) immunoassay  to monitor patients on antibiotic therapy, which  is around 420 million patients a year. This aids  in identifying resistance and enables targeted  antibiotic use. It also detects severe bacterial  infections in as many as 50 million patients a year  for earlier therapeutic intervention.  ", "page_idx": 38, "bbox": [67, 361.2001953125, 257, 457.3501892089844], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 225, "type": "text", "text": "With the completion of our GenMark Diagnostics  acquisition, we have strengthened and broadened  our infectious diseases portfolio and taken a  major step into syndromic panel testing (also  known as multiplex testing). By detecting the most  common pathogens that cause disease together  on a single rapid test, with a single patient sample,  clinicians can prescribe the right therapeutic  within hours – rather than days, when compared  with conventional testing algorithms. Roche and  GenMark can benefit patients, laboratories and  healthcare providers through this combined  expertise and portfolio. ", "page_idx": 38, "bbox": [67, 469.2001953125, 257, 625.3502197265625], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 226, "type": "text", "text": "Acute respiratory infections, including serious  complications from infections with SARS-CoV-2,  are among the world’s leading causes of death  and disability. In September, we launched three  respiratory test panels in CE markets to help  identify multiple pathogens with overlapping  symptoms. These test panels can be run on the  cobas omni Utility Channel of the high-volume  cobas 6800/8800 systems. These three new  molecular diagnostic panels use a single patient  sample to test for influenza A and influenza  B as well as respiratory syncytial virus (RSV);  adenovirus (ADV), human metapneumovirus  (hMPV) and enterovirus/rhinovirus (EV/RV);  and parainfluenza 1, 2, 3 and 4. The tests can  be run together or alone. When compared to  conventional diagnostic methods, these flexible  syndromic panels reduce unnecessary testing  and provide important insights to clinicians  more quickly. Moreover, these tests can be  combined with our COVID-19 testing on the  cobas 6800/8800 systems.  ", "page_idx": 38, "bbox": [67, 637.2001953125, 257, 697.3502197265625], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 227, "type": "text", "text": "", "page_idx": 38, "bbox": [277, 181.2001953125, 462, 385.3501892089844], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 228, "type": "text", "text": "Patients with respiratory infections often have  signs and symptoms that are not specific enough  to discern the root cause of the illness. This  latest set of syndromic respiratory solutions  allows clinicians to choose the appropriate tests  based on the healthcare setting, any seasonal  outbreaks, and patient needs. By testing only what  is medically relevant and necessary, they enable  targeted therapy, avoid misuse of antibiotics and  reduce unnecessary intervention.  ", "page_idx": 38, "bbox": [277, 397.2001953125, 468, 517.3502197265625], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 229, "type": "text", "text": "Through our acquisition of the TIB Molbiol Group  in December, we are able to further expand our  portfolio with more than 45 CE-IVD assays and more  than 100 research use assays on our LightCycler  PCR systems and MagNA Pure sample preparation  systems. We have successfully partnered with  TIB Molbiol for more than 20 years and this  collaboration was instrumental in creating our  first SARS-CoV-2 detection test in January 2020,  mere days after this novel virus had first been  sequenced. ", "page_idx": 38, "bbox": [277, 529.2001953125, 474, 661.3502197265625], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 230, "type": "text", "text": "Transforming healthcare through digitalisation  and advanced technology ", "text_level": 1, "page_idx": 39, "bbox": [119, 98, 503, 153], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 231, "type": "text", "text": "In 2021, more than 27 billion tests were conducted  with Roche products. This includes more than  one billion tests to diagnose SARS-CoV-2 infections  or measure related antibodies. In addition, it  includes millions of tests for other health conditions.  Over time, the thousands of data points individual  patients create throughout their journeys not only  help identify changes in their health, but also  enable tracking of similar patient cohorts across  institutions and geographies. This will eventually  allow for comparison of outcomes as well as  predictive measures through artificial intelligence  (AI) and machine learning.  ", "page_idx": 39, "bbox": [121, 181.2001953125, 317, 337.3501892089844], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 232, "type": "text", "text": "With the goal of improving patient care by  expanding access to innovative image analysis, we  launched the Digital Pathology Open Environment.  With this open environment, Roche is building an  open application programming interface (API) framework to enable third-party companies  to deploy their algorithms within Navify Digital  Pathology, the cloud version of Roche uPath  enterprise software. In addition to the Digital  Pathology Open Environment, we announced  in October collaborations with PathAI and Ibex  Medical Analytics for AI-based digital pathology  applications. ", "page_idx": 39, "bbox": [121, 349.2001953125, 317, 505.3501892089844], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 233, "type": "text", "text": "Our growing involvement with AI underscores our  belief that it holds significant promise for advancing  pathology imaging, which can benefit cancer  patients through more precise diagnosis. This in  turn can help clinicians identify targeted treatments  that could lead to better results.  ", "page_idx": 39, "bbox": [121, 517.2001953125, 317, 589.3502197265625], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 234, "type": "text", "text": "For breast cancer, we announced in January the  CE-IVD launch of our automated digital pathology  algorithms, uPath HER2 (4B5) image analysis  and uPath HER2 Dual ISH image analysis, to  help determine the best treatment strategy for  each patient. In December, we launched three  new research-use-only (RUO) automated digital  pathology algorithms, uPath Ki-67 (30-9), uPath  ER (SP1) and uPath PR (1E2) image analysis,  also for breast cancer. These three are important  biomarkers and they complete our digital pathology  breast panel of image analysis algorithms.  ", "page_idx": 39, "bbox": [121, 601.2001953125, 317, 685.3502197265625], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 235, "type": "text", "text": "", "page_idx": 39, "bbox": [330, 181.2001953125, 526, 241.35018920898438], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 236, "type": "text", "text": "For earlier detection of liver cancer, specifically  hepatocellular carcinoma (HCC), the CE mark  was granted in November for our Elecsys GAAD  algorithmic score, which combines gender, age and  Roche’s Elecsys AFP and Elecsys PIVKA-II assays.  Liver cancer is one of the few cancers that is on  the rise and is responsible for 830,000 deaths a  year. However, when detected and managed early,  patient five-year survival rates can increase up to   $70\\%$  . Our algorithmic score helps aid in diagnosis  of patients with chronic liver disease, such as  hepatitis or cirrhosis, when followed-up with CT or  MRI scanning. This provides clinicians with more  accurate information to support their treatment  decisions and could help increase access to liver  cancer testing. ", "page_idx": 39, "bbox": [330, 253.2001953125, 526, 445.3501892089844], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 237, "type": "text", "text": "In digitalisation for the point-of-care setting, the  cobas pulse system represents a major advance.  This revolutionary new glucose management  solution is the first professional blood glucose  meter with an Android-based operating system  loaded with industry-leading medical apps that can  perform essential functions for nurses, doctors  and lab managers. With cobas pulse launched in  November, we believe that the system will serve  as a gateway to future digital health services and  medical practice.  ", "page_idx": 39, "bbox": [330, 457.2001953125, 526, 589.3502197265625], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 238, "type": "text", "text": "Improved lab management for improved  patient outcomes ", "text_level": 1, "page_idx": 39, "bbox": [331, 602, 495, 624], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 239, "type": "text", "text": "Innovative tests, digital insights and enhanced  laboratory management solutions are transforming  healthcare and improving outcomes. With this new  digital era come great opportunities to benefit  patients and laboratories around the world. By  ", "page_idx": 39, "bbox": [330, 625.2001953125, 526, 685.3502197265625], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 240, "type": "image", "page_idx": 40, "img_path": "layout_images/roche-holdings_2021_21.jpg", "bbox": [277, 65, 596, 406], "page_size": [595.2760009765625, 793.7009887695312], "ocr_text": "", "vlm_text": "The image shows a person using a tablet device. They seem to be in a lab-like environment, and the tablet is displaying some icons or application interfaces. The person is wearing a light blue or white lab coat. There is another person blurred in the background."}
{"layout": 241, "type": "text", "text": "Digitalisation in healthcare is continually improving our ability  to collect, curate and make sense of vast quantities of diverse  patient data.  ", "page_idx": 40, "bbox": [67, 98.2003173828125, 250, 133.0003204345703], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 242, "type": "text", "text": "identifying and developing innovative predictive  diagnostics, testing enables early detection  and treatment, which can significantly improve  outcomes. In addition, AI can help increase the  number of cases reviewed by pathologists while  reducing human error, improving accuracy and  enabling personalised treatment plans.  ", "page_idx": 40, "bbox": [67, 181.2001953125, 250, 265.3501892089844], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 243, "type": "text", "text": "In the third quarter, we launched updated  and expanded lab analytical applications  for our customers, including Viewics LabOPS  Molecular. This newly expanded offering provides  insights across the entire menu of the Roche  cobas 6800/8800 systems using data directly  uploaded from the analytics to Roche.  ", "page_idx": 40, "bbox": [67, 277.2001953125, 258, 361.3501892089844], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 244, "type": "text", "text": "Viewics LabOPS Core has been approved for  launch in several regions around the world, further  enhancing our digital diagnostics portfolio. This  application provides laboratory and hospital  personnel with an easier way to track, review  and identify operational trends and challenges.  Its visibility guides the decision-making process  towards optimising operations, customer delivery  and overall lab performance in a targeted and  efficient manner. LabOPS Core is providing a  set of turnkey analytics, thereby enabling data-driven decisions to improve the operational  effectiveness of the clinical laboratories. ", "page_idx": 40, "bbox": [67, 373.2001953125, 258, 529.3502197265625], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 245, "type": "image", "page_idx": 40, "img_path": "layout_images/roche-holdings_2021_22.jpg", "bbox": [277, 416, 596, 695], "page_size": [595.2760009765625, 793.7009887695312], "ocr_text": "", "vlm_text": "The image shows a person wearing safety goggles, gloves, and a lab coat, interacting with a touchscreen or a similar interface in what appears to be a laboratory setting. The background includes lab equipment and a scientific environment."}
{"layout": 246, "type": "text", "text": "In 2021 we also launched new diagnostic  platforms such as the cobas pure, cobas pro  (high throughput) and cobas 5800. These new  systems will enhance our offering by enabling  comparable results for labs of different sizes – the  first two in the Serum Work Area space for core  laboratories, and the latter for molecular labs. ", "page_idx": 40, "bbox": [67, 541.2001953125, 258, 625.3502197265625], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 247, "type": "text", "text": "At Roche, our goal is to provide patient-centric  continuity of care at every stage of the patient  journey: from prevention to diagnosis through  treatment monitoring and after-care.  ", "page_idx": 40, "bbox": [67, 637.2001953125, 250, 685.3502197265625], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 248, "type": "text", "text": "Diabetes Care ", "text_level": 1, "page_idx": 41, "bbox": [121, 99, 236, 120], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 249, "type": "text", "text": "Diabetes management is complex and personal, and  achieving therapy goals is an ongoing challenge.  We believe that the more personalised and tailored  the therapy is, the better the outcomes. This is why  we continue to implement solutions to leverage  our integrated personalised diabetes management  approach. ", "page_idx": 41, "bbox": [121, 145.2001953125, 317.34393310546875, 229.35018920898438], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 250, "type": "text", "text": "In April 2021, Diabetes Care began offering  the Accu-Chek Insight insulin pump paired with  Diabeloop’s hybrid closed-loop system within the  scope of our previously announced partnership.  People living with diabetes in Germany, Italy, Spain,  Switzerland and the Netherlands are now able to  use the Accu-Chek Insight insulin pump as part  of Diabeloop’s DBLG1 system, which features a  self-learning algorithm hosted on a dedicated  ", "page_idx": 41, "bbox": [121, 241.2001953125, 313, 349.3501892089844], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 251, "type": "text", "text": "The mySugr app fully integrates with our RocheDiabetes  Care Platform. ", "text_level": 1, "page_idx": 41, "bbox": [120, 386, 282, 408], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 252, "type": "image", "page_idx": 41, "img_path": "layout_images/roche-holdings_2021_23.jpg", "bbox": [0, 416, 318, 696], "page_size": [595.2760009765625, 793.7009887695312], "ocr_text": "", "vlm_text": "The image shows a person holding a smartphone displaying a health or fitness app. The screen contains various data points represented by numbers and icons, possibly tracking exercises or health metrics like steps, calories, or heart rate. The interface is colorful, with several metrics organized in circular icons."}
{"layout": 253, "type": "text", "text": "handset. This algorithm analyses data in real time  and decides whether to stop insulin delivery, adjust  basal rates, or even deliver an automatic correction  bolus when needed. ", "page_idx": 41, "bbox": [330, 145.2001953125, 525, 193.35018920898438], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 254, "type": "text", "text": "Also in April, mySugr (acquired by Roche in 2017)  announced the integration of the Novo Nordisk  NovoPen 6 and NovoPen Echo Plus into the mySugr  app logbook on iOS. The integration follows the  collaboration agreement signed between Roche  and Novo Nordisk in 2019. Users can record their  insulin data in the mySugr app, track and combine  it with blood glucose values, activities, meals  and other relevant diabetes data. The solution  is currently available in Sweden and Denmark as  well as in pilot projects in selected healthcare  institutions in Germany and Austria.  ", "page_idx": 41, "bbox": [330, 205.2001953125, 525, 349.3501892089844], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 255, "type": "text", "text": "The mySugr app is an integral part of the Diabetes  Care open ecosystem and offers features like  structured documentation of data, accurate insulin  dose calculations, reminders and coaching to help  people better manage their daily diabetes routine.  It fully integrates with our RocheDiabetes Care  Platform which enables healthcare professionals  to have a comprehensive overview of all relevant  patient data and, as of 2021, also features  Remote Patient Monitoring – which is even more  important as people with diabetes are spending  significantly less time with their physicians due to  the COVID-19 pandemic. ", "page_idx": 41, "bbox": [330, 361.2001953125, 525, 517.3502197265625], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 256, "type": "text", "text": "In May 2021, we signed a collaboration agreement  with Eli Lilly and Company to integrate data from  the company’s connected insulin pen solution  into Roche’s open ecosystem through the mySugr  app. When paired with the mySugr app, the Tempo  Smart Button will automatically transfer data via  Bluetooth technology into the mySugr logbook  and thus into Roche’s open diabetes management  ecosystem. ", "page_idx": 41, "bbox": [330, 529.2001953125, 525, 637.3502197265625], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 257, "type": "image", "page_idx": 42, "img_path": "layout_images/roche-holdings_2021_24.jpg", "bbox": [57, 93, 568, 671], "page_size": [595.2760009765625, 793.7009887695312], "ocr_text": "Test results produced with our systems\n\n27 billion\n\ncobas 6800/8800 systems installed\n\nActive in-licensing agreements 1772\n300\nActive out-licensing agreements J\n190 Diagnostics\nfacts\n2021 COVID-19 tests\n\\ enabled per month\n\n60+ million\n\nNew assays, panels and\n\nalgorithms in oncology\nDiabetes Care Jf 22\nva\n4 \\\nDiagnostics ‘ Tests and solutions currently\n\\ in our COVID-19 portfolio\n\nnew launches\n\n22\n2021\n\nDigital decision support and\nlaboratory insight solutions f~\n\n38\n\nNew assays, claim extensions\nand solutions for infectious\n\\ and cardiovascular diseases\n\n6\n", "vlm_text": "The image presents data related to diagnostics for the year 2021. It includes the following information:\n\n- **Test Results Produced:** 27 billion\n- **Systems Installed:** 1772 cobas 6800/8800 systems\n- **COVID-19 Tests:** Enabled over 60 million per month\n- **In-Licensing Agreements:** 300 active agreements\n- **Out-Licensing Agreements:** 190 active agreements\n\nFor new launches in 2021:\n- **Diabetes Care Products:** 4\n- **Digital Decision Support Solutions:** 38\n- **Oncology Assays, Panels, Algorithms:** 22\n- **COVID-19 Portfolio Tests and Solutions:** 22\n- **Assays for Infectious/Cardiovascular Diseases:** 6\n\nThe infographic contains circular charts to visually represent these data points."}
{"layout": 258, "type": "image", "page_idx": 43, "img_path": "layout_images/roche-holdings_2021_25.jpg", "bbox": [0, 0, 595, 794], "page_size": [595.2760009765625, 793.7009887695312], "ocr_text": "", "vlm_text": "The image shows a family of four walking together outdoors. They appear to be enjoying a sunny day in a grassy area with trees in the background. The group includes two adults and two children, all smiling and interacting with each other."}
{"layout": 259, "type": "text", "text": "Lung cancer patient ‘going for the cure’ ", "text_level": 1, "page_idx": 44, "bbox": [66, 99, 395, 126], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 260, "type": "text", "text": "Amanda Nerstad, a mom with ALK-positive lung cancer, shares her story  on the importance of biomarker testing and raising money for a cure. ", "text_level": 1, "page_idx": 44, "bbox": [65, 152, 460, 195], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 261, "type": "text", "text": "Jogging through the hills of her Tennessee home in  the United States, Amanda found herself gasping  for breath. A friend had just been diagnosed with  pneumonia, and the young mom wondered if she  might have the same. ", "page_idx": 44, "bbox": [67, 229.2003173828125, 261, 289.3383483886719], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 262, "type": "text", "text": "A trip to the doctor that day in 2016 launched a  harrowing journey. Within days, Amanda, a non- smoker who is diligent about health and fitness, was  diagnosed with stage IV lung cancer. Told she might  have as little as two weeks to live, Amanda’s first  thought was of her daughters, Isabella and Greta.  “I put notes in their lunchboxes every morning – have  a great day, Mommy loves you – and I thought, ‘who’s  going to write their notes?’ It was devastating.’’ ", "page_idx": 44, "bbox": [67, 301.19134521484375, 261, 409.3174133300781], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 263, "type": "text", "text": "In search of clues to what was driving Amanda’s  cancer, her oncologist ordered more tests. After  nervously waiting for results from biomarker testing,  the Nerstads found something powerful – hope. ", "page_idx": 44, "bbox": [67, 421.17041015625, 261, 469.3114318847656], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 264, "type": "text", "text": "The welcome news ", "text_level": 1, "page_idx": 44, "bbox": [67, 482, 146, 493], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 265, "type": "text", "text": "Amanda, now 44, tested positive for a change in  the anaplastic lymphoma kinase – or ALK – gene,  found in about four percent of non-small cell lung  cancer cases. She was a candidate for targeted  treatment specifically for people who test positive  for this mutation. The first few months of treatment  left Amanda exhausted and ill. Then, her doctor  suggested a new ALK-targeted therapy. Today she  celebrates a complete metabolic response, with  no evidence of disease and few side effects.  ", "page_idx": 44, "bbox": [67, 493.16143798828125, 261, 613.284423828125], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 266, "type": "text", "text": "Amanda is on a mission to spread the word about  the importance of biomarker testing, sharing her  experiences with survivors – many young moms  like herself. She fundraises through ALK Positive, a  non-profit organisation that has raised more than  USD 3 million for ALK-positive lung cancer research.  ", "page_idx": 44, "bbox": [67, 625.137451171875, 261, 697.2724609375], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 267, "type": "text", "text": "Lemonade for a cure ", "text_level": 1, "page_idx": 44, "bbox": [278, 229, 364, 241], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 268, "type": "text", "text": "Through neighbourhood lemonade stands inspired  by her daughters, and incredible support from  family and friends, the Nerstad family has raised  USD 350,000 for lung cancer research since  2016. Among the projects they have helped fund  is an ALK vaccine study they hope will turn this  terminal disease into a chronic illness. “We’re going  for the cure,” Amanda says. “Having ALK-positive  lung cancer has given us a platform to raise money  for research for that cure.” ", "page_idx": 44, "bbox": [277, 241.116455078125, 471, 361.2395324707031], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 269, "type": "text", "text": "She is also driven to change the negative bias  toward lung cancer patients. “Everyone wants to  know what you did to get lung cancer. No one ever  asks someone with breast cancer how they got  it, but one of the first questions everyone asks me  is whether I smoked. It’s important to know that  anyone who has lungs can get lung cancer.” ", "page_idx": 44, "bbox": [277, 373.092529296875, 471, 457.2245788574219], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 270, "type": "text", "text": "Amanda is also dedicated to inspiring researchers  and industry leaders – including Roche as we  celebrate our 125-year anniversary – to drive  innovation. “I hope that in the next 125 years, Roche  will help move research forward, and that annual  cancer testing will be available to everyone to  hopefully catch cancer early,” she says.  ", "page_idx": 44, "bbox": [277, 469.07757568359375, 475, 553.2095947265625], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 271, "type": "text", "text": "Surrounded by positivity ", "text_level": 1, "page_idx": 44, "bbox": [277, 566, 380, 577], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 272, "type": "text", "text": "Amanda finds joy in making a difference for other  cancer warriors, and in the sweet moments wrapped  in the love of family. “We are determined in every  aspect of our life because time is very important  to us. We live in the now, and enjoy the moments.”  And how lovely they are – laughter around the dinner  table and snuggles on the couch with a favourite  movie. “We surround ourselves with positivity, and  embrace every day together,” Amanda says. “We  are going for the cure.” ", "page_idx": 44, "bbox": [277, 577.0595703125, 475, 697.1826171875], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 273, "type": "image", "page_idx": 45, "img_path": "layout_images/roche-holdings_2021_26.jpg", "bbox": [0, 0, 596, 794], "page_size": [595.2760009765625, 793.7009887695312], "ocr_text": "", "vlm_text": "The image shows a collection of clear glass vials with measurement markings. Nearby, there are yellow caps with red centers, likely intended to seal the vials. This setup is typically found in laboratory or medical environments."}
{"layout": 274, "type": "text", "text": "", "text_level": 1, "page_idx": 46, "bbox": [134, 483, 479, 529], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 275, "type": "image", "page_idx": 47, "img_path": "layout_images/roche-holdings_2021_27.jpg", "bbox": [0, 0, 593, 794], "page_size": [595.2760009765625, 793.7009887695312], "ocr_text": "*, =\n“Ssaue\n\n‘ hey\nBSenueiws\n\n—— = & s1)\n\n¥ ¥ Oma’,\n\n", "vlm_text": "The image shows a close-up of a person wearing glasses, a face mask, and a hair covering or cap, possibly indicating they are in a medical or clean environment."}
{"layout": 276, "type": "text", "text": "Driving patient benefit ", "text_level": 1, "page_idx": 48, "bbox": [66, 97, 317, 124], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 277, "type": "text", "text": "The burden of poor health is increasing; growing populations, higher  life expectancies, an increase in chronic diseases, and continued  discrepancies in access to healthcare – all of this means demand for  healthcare continues to grow and systems are struggling to keep up. ", "page_idx": 48, "bbox": [66, 138.2001953125, 445, 231.80020141601562], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 278, "type": "text", "text": "This is why both our industry and our society need  to rethink how we innovate and how we can provide  care in a sustainable way. ", "page_idx": 48, "bbox": [67, 265.2003173828125, 261, 301.3443298339844], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 279, "type": "text", "text": "Roche has a long history of developing and  delivering breakthrough medicines that have made  a meaningful difference in the lives of millions  of people worldwide. But in today’s world, there  is more we can and must do. We are making  fundamental changes to the way we operate, how  we work with our stakeholders and partners, and  how we leverage developments in science and  technology to deliver what matters most: more  patient benefit at far less cost to society. ", "page_idx": 48, "bbox": [67, 313.19732666015625, 261, 433.3204040527344], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 280, "type": "text", "text": "It is time to be bold. New approaches are needed,  and we are going to do our part to bring about  solutions. ", "page_idx": 48, "bbox": [67, 445.17340087890625, 261, 481.3174133300781], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 281, "type": "text", "text": "Our efforts during the pandemic – joining  forces for patients and society COVID-19 spurred us to rethink how we partner  to develop diagnostics and treatment options,  and to work at speeds we never could have  imagined, all with the goal of delivering innovation  for patients.  ", "page_idx": 48, "bbox": [67, 493.17041015625, 261, 577.3024291992188], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 282, "type": "text", "text": "Building on our partnering efforts from 2020,  we continued to work with Gilead Sciences on  a combination study evaluating two medicines  (Roche’s Actemra/RoActemra and Gilead’s Veklury)  in hospitalised patients with severe COVID-19- associated pneumonia. We also furthered our  work with Regeneron on its antibody cocktail of  casirivimab and imdevimab (Ronapreve)   ( please see  the story on page 55 ). And we worked with Atea  ", "page_idx": 48, "bbox": [67, 589.1553955078125, 261, 697.2814331054688], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 283, "type": "text", "text": "Pharmaceuticals on AT-527, their investigational  antiviral medicine for COVID-19.  ", "page_idx": 48, "bbox": [278, 265.2000732421875, 471, 289.3470764160156], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 284, "type": "text", "text": "Ronapreve  \n\n •\t  In March, new phase III data showed that  Ronapreve reduced hospitalisation or death by   $70\\%$   in non-hospitalised patients with COVID-19.\n\n •\t  In April, a phase III prevention trial showed that  subcutaneous administration of Ronapreve  reduced the risk of symptomatic COVID-19  infections by  $81\\%$  .\n\n •\t  In June, the University of Oxford announced  preliminary phase III results from the UK  RECOVERY study in patients hospitalised with  COVID-19. Results showed that Ronapreve  reduced the risk of death in those who had not  mounted a natural antibody response of their  own (seronegative).\n\n •\t  In July, Japan was the first country to approve  Ronapreve for treatment of mild to moderate  COVID-19, followed by EU approval for treatment  and prevention in November.\n\n •\t  In September, phase II/III trial data showed that  Ronapreve significantly reduced viral load within  seven days of treatment in patients hospitalised  with COVID-19.\n\n •\t  In September, the WHO recommended the use  of Ronapreve in non-severe COVID-19 patients  who are at highest risk of severe disease, and in  patients with severe and critical infection who  have a seronegative status.\n\n •\t  In October, Ronapreve (together with Actemra/ RoActemra and AT-527) was included in the EU  Commission’s portfolio of the ten most promising  COVID-19 treatments. ", "page_idx": 48, "bbox": [278, 313.19708251953125, 471, 697.3441162109375], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 285, "type": "image", "page_idx": 49, "img_path": "layout_images/roche-holdings_2021_28.jpg", "bbox": [0, 67, 320, 406], "page_size": [595.2760009765625, 793.7009887695312], "ocr_text": "", "vlm_text": "The image shows a box of Actemra, which contains a solution for injection. It is labeled with the dosage information: 162 mg/0.9 mL and mentions Tocilizumab. Actemra is often used to treat certain inflammatory conditions."}
{"layout": 286, "type": "text", "text": "•\t  In November, the new SARS-CoV-2 variant  Omicron (B.1.1.529) was classified as a variant of  concern by the WHO. While analyses have shown  that Ronapreve does not retain neutralising  activity against the Omicron variant, Ronapreve  retains its activity against all other main  variants of concern, including Delta. Activity  of Ronapreve against potential future variants  will be continually assessed.\n\n ", "page_idx": 49, "bbox": [120, 445.2001953125, 313, 553.3262939453125], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 287, "type": "text", "text": "Actemra/RoActemra ", "text_level": 1, "page_idx": 49, "bbox": [119, 566, 198, 576], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 288, "type": "text", "text": "•\t  In June, Roche’s Actemra/RoActemra received  US FDA Emergency Use Authorization for the  treatment of COVID-19 in hospitalised adults  and children. ", "page_idx": 49, "bbox": [120, 577.17626953125, 304, 625.34423828125], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 289, "type": "text", "text": "Throughout the pandemic, our production and logistics teams have  demonstrated a deep commitment to serving patients worldwide.\n\n ", "page_idx": 49, "bbox": [331, 98.2001953125, 526, 121.00019836425781], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 290, "type": "text", "text": "•\t  In July, the WHO issued new treatment guidelines  for COVID-19 which recommend interleukin-6  (IL-6) receptor blockers such as Actemra/ RoActemra for patients hospitalised with severe  or critical COVID-19.\n\n ", "page_idx": 49, "bbox": [331, 181.2001953125, 526, 241.34121704101562], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 291, "type": "text", "text": "•\t  In December, the European Commission  extended the marketing authorisation for  Actemra/RoActemra to include the treatment of  COVID-19 in adults who are receiving systemic  corticosteroids and require supplemental oxygen  or mechanical ventilation. This decision came just  hours after the recommendation by the European  Medicines Agency’s Committee for Medicinal  Products for Human Use reflecting the urgent  need for our medicines to tackle the COVID-19  pandemic.\n\n ", "page_idx": 49, "bbox": [331, 241.188232421875, 526, 373.3232727050781], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 292, "type": "text", "text": "AT-527 ", "text_level": 1, "page_idx": 49, "bbox": [330, 386, 357, 395], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 293, "type": "text", "text": "•\t  In June, Atea Pharmaceuticals announced  interim results from the phase II AT-03A-001 trial  in hospitalised patients with moderate COVID-19  who were at high risk of poor outcomes. These  interim results indicated rapid and sustained  antiviral activity against SARS-CoV-2 in patients  in a hospitalised setting.\n\n ", "page_idx": 49, "bbox": [331, 397.17327880859375, 526, 481.3352355957031], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 294, "type": "text", "text": "•\t  In October, Atea Pharmaceuticals announced  results from the phase II MOONSONG study  of AT-527 in non-hospitalised patients with  mild or moderate COVID-19. The study did  not meet its primary endpoint, showing no  significant reduction in viral load from baseline  when compared to placebo in the overall study  population. \n\n ", "page_idx": 49, "bbox": [331, 481.1822509765625, 526, 577.3322143554688], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 295, "type": "text", "text": "•\t  In November, Roche and Atea Pharmaceuticals  communicated that Roche decided to end its  partnership with Atea on the AT-527 programme  to focus efforts on other COVID-19 activities.  ", "page_idx": 49, "bbox": [331, 577.17919921875, 526, 625.34423828125], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 296, "type": "image", "page_idx": 50, "img_path": "layout_images/roche-holdings_2021_29.jpg", "img_caption": "Pharmaceuticals clinical pipeline ", "bbox": [65, 135, 514, 535], "page_size": [595.2760009765625, 793.7009887695312], "ocr_text": "Phase I Phase II Phase III\n27 5 6\nOncology a | |\n4 3 1\nInflammation/Immunology | ||\n6 7 4\nNeuroscience EEE\n2 1\nInfectious diseases es |\n4 4\nOphthalmology |\n1 1\nMetabolics ee |||\n1\nOthers ay\n\nRegistration\n\n1\n\n", "vlm_text": "The image is a chart showing the clinical pipeline of pharmaceuticals across various stages of drug development. It categorizes pharmaceuticals into different therapeutic areas and shows how many drugs are in each phase:\n\n- **Oncology**: 27 in Phase I, 5 in Phase II, 6 in Phase III, 1 in Registration.\n- **Inflammation/Immunology**: 4 in Phase I, 3 in Phase II, 1 in Phase III.\n- **Neuroscience**: 6 in Phase I, 7 in Phase II, 4 in Phase III.\n- **Infectious diseases**: 2 in Phase I, 1 in Phase II.\n- **Ophthalmology**: 4 in Phase I, 4 in Phase II, 2 in Registration.\n- **Metabolics**: 1 in Phase I, 1 in Phase II.\n- **Others**: 1 in Phase I. \n\nEach therapeutic area is represented by a different colored bar."}
{"layout": 297, "type": "text", "text": "Advancing clinical trials ", "text_level": 1, "page_idx": 51, "bbox": [120, 135, 318, 158], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 298, "type": "text", "text": "Clinical trials are essential to medical progress.  Data from trials helps scientists and clinicians  understand how investigational medicines affect  different groups of people with specific genetic  markers for disease, and supports the development  of more targeted, personalised treatments.  ", "page_idx": 51, "bbox": [120, 181.2001953125, 314, 253.33523559570312], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 299, "type": "text", "text": "The more accurately the make-up of clinical  trials represents real-world demographics, the  more robust the data, and ultimately the more  effective medicines might be for patients who  need them. ", "page_idx": 51, "bbox": [120, 265.188232421875, 307, 325.3262634277344], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 300, "type": "text", "text": "We are deeply committed to addressing barriers  to clinical trial participation, widening access  to expanded and innovative diagnostic and  therapeutic solutions, and diversifying genetic  data by advancing inclusive research globally.  ", "page_idx": 51, "bbox": [120, 337.17926025390625, 307, 397.3172912597656], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 301, "type": "text", "text": "Missed opportunities ", "text_level": 1, "page_idx": 51, "bbox": [120, 410, 209, 420.75], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 302, "type": "text", "text": "Across industry, around   $80\\%$   of global clinical  trial participants are of European ancestry, which  represents only  $8\\%$   of the global population. 1   Additionally, more than   $87\\%$   of genomic data  available is of European ancestry, leaving a  significant amount of data undiscovered. ", "page_idx": 51, "bbox": [120, 421.16729736328125, 307, 493.3412170410156], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 303, "type": "text", "text": "These gaps mean that trial results are not always  applicable to all patient populations, and we miss  out on an enormous amount of valuable data  in our studies. Consider, for instance, that even  though black women have a mortality rate for  breast cancer that is approximately   $40\\%$   greater  than that of Caucasian women, they represent  only   $6\\%$   of women in trials studying the disease. ", "page_idx": 51, "bbox": [120, 505.2001953125, 307, 601.3292236328125], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 304, "type": "text", "text": "Determining which treatments will work best for  which patients requires a great deal of clinical and  genomic data. Currently, data available for public  ", "page_idx": 51, "bbox": [120, 613.2001953125, 310.4588623046875, 649.34423828125], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 305, "type": "text", "text": "study comprises mostly European populations.  With little representation from communities  of non-European descent, it can be difficult to  understand how diverse genetic variants play  a role in the progression of a disease.  ", "page_idx": 51, "bbox": [330, 181.19122314453125, 508, 241.32925415039062], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 306, "type": "text", "text": "Closing the gaps – real world demographics  matter ", "text_level": 1, "page_idx": 51, "bbox": [331, 254, 511, 275], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 307, "type": "text", "text": "Over the past several years, we have been focusing  our efforts on closing gaps in our clinical trials  by ensuring accurate representation of patient  populations around the world. In 2021, results  from a research collaboration between Genentech  and Stanford University, known as Trial Pathfinder,  were published in the scientific journal  Nature .   The study highlights how real-world data and  artificial intelligence (AI) could be used to help  address under representation in clinical research  for non-small cell lung cancer (NSCLC).  ", "page_idx": 51, "bbox": [330, 277.17626953125, 523, 409.3382263183594], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 308, "type": "text", "text": "While recent studies show a majority of NSCLC  patients do not meet the criteria to participate in  clinical trials due to restrictive inclusion criteria,  and   $86\\%$  of trials fail to complete recruitment  within the targeted time, Trial Pathfinder showed  that using a data-driven approach to eliminate  restrictive eligibility criteria could increase  the total number of eligible patients by   $107\\%$  ,  to more than twice as many by including more  women and African-Americans, as well as a  broader range of ages, without compromising  the study outcome.  ", "page_idx": 51, "bbox": [330, 421.2001953125, 515, 565.3172607421875], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 309, "type": "text", "text": "In 2020, as the pandemic disproportionately and  devastatingly impacted people of colour, we  initiated a clinical trial of one of our investigational  medicines for COVID-19 pneumonia. Global  trial sites that enrolled high-risk and minority  populations were included in order to enhance  ", "page_idx": 51, "bbox": [330, 577.2001953125, 523, 649.335205078125], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 310, "type": "image", "page_idx": 52, "img_path": "layout_images/roche-holdings_2021_30.jpg", "bbox": [278, 67, 596, 405], "page_size": [595.2760009765625, 793.7009887695312], "ocr_text": "", "vlm_text": "The image shows a person walking outdoors. They are wearing a light head covering, a polka-dotted top, and are carrying a large beige bag over their shoulder. They appear to be looking up, and there is a building in the background."}
{"layout": 311, "type": "text", "text": "We are deeply committed to addressing barriers to clinical trial  participation in patient populations around the world. ", "page_idx": 52, "bbox": [67, 98.2001953125, 261, 121.00019836425781], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 312, "type": "text", "text": "the understanding of the clinical profile of Actemra/ RoActemra in these patients, and to allow access  to underserved and minority populations, which  are not commonly represented in clinical trials.  Approximately  $85\\%$   of participants represented  communities of colour, including Hispanic/Latinx,  Native American and black populations. ", "page_idx": 52, "bbox": [67, 181.2000732421875, 261, 265.3351135253906], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 313, "type": "text", "text": "Advancing the participation of representative  patient populations ", "page_idx": 52, "bbox": [67, 277.1881103515625, 261, 301.3351135253906], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 314, "type": "text", "text": "In 2021, Genentech initiated the Advancing  Inclusive Research Site Alliance, a coalition  of clinical research centres that are building  a sustainable ecosystem in order to facilitate  the inclusion of historically underrepresented  people in all clinical research. Together, we aim  to advance the participation of diverse patient  populations in our oncology trials, test recruitment  and retention approaches, and establish best  practices that can be leveraged across the  industry and other disease areas to help achieve  health equity for all people. ", "page_idx": 52, "bbox": [67, 301.18212890625, 261, 445.2992248535156], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 315, "type": "image", "page_idx": 52, "img_path": "layout_images/roche-holdings_2021_31.jpg", "bbox": [277, 416, 596, 695], "page_size": [595.2760009765625, 793.7009887695312], "ocr_text": "——\nj\n\n", "vlm_text": "The image appears to show a stack of glass slides, possibly microscope slides, with some labels or markings. The slides seem to be arranged in a filing system, and the slide in focus has some staining, possibly for biological or medical analysis."}
{"layout": 316, "type": "text", "text": "Our four inaugural partners who are successfully  including diverse populations in their clinical  trial efforts are: Mays Cancer Center in San  Antonio, Texas; O’Neal Comprehensive Cancer  Center in Birmingham, Alabama; West Cancer  Center in Memphis, Tennessee; and City of Hope  Comprehensive Cancer Center in Los Angeles,  California. ", "page_idx": 52, "bbox": [67, 457.2001037597656, 261, 553.3291625976562], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 317, "type": "text", "text": "We recognise that bringing about real change  requires both partnership and industry-wide  investments. By partnering across the healthcare  ecosystem, we can collectively combine scientific  advances, new technologies, and real-world  data to create new standards for inclusive  clinical research.  ", "page_idx": 52, "bbox": [67, 565.18212890625, 261, 649.3141479492188], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 318, "type": "text", "text": "Shaping the next 125 years of science ", "text_level": 1, "page_idx": 53, "bbox": [120, 135, 433, 158], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 319, "type": "text", "text": "The pace at which new drugs are discovered and  developed is rapidly increasing. There has never  been a more exciting time to transform how we  deliver care for patients, and we are committed  to exploring uncharted areas to access previously  unreachable targets. We, along with our partners,  envision a future where the latest and greatest  science and technology will drive innovation and  unlock the future of healthcare.  ", "page_idx": 53, "bbox": [120, 181.2001953125, 316, 289.3501892089844], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 320, "type": "text", "text": "Gene therapy ", "text_level": 1, "page_idx": 53, "bbox": [120, 302, 177, 312], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 321, "type": "text", "text": "Gene therapies have the potential to address  previously untreated diseases and replace existing  therapies with potential one-time treatments. On  a quest to follow the science and strengthen our  presence in this promising emerging modality, two  years ago Roche acquired Spark Therapeutics, a  leading gene therapy company. Today, Spark’s  expertise combined with Roche’s broad R&D skills,  commercial capability and global reach, along  with those of our partners, puts us in the unique  position to unlock the full potential of gene therapy. ", "page_idx": 53, "bbox": [120, 313.2001953125, 316, 445.3501892089844], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 322, "type": "text", "text": "To further our work in this area, in August 2021, we  entered into a research collaboration and license  agreement with Shape Tx, who have developed  a novel form of gene therapy that edits genetic  messages at the level of mRNA without any changes  to DNA. We are excited to work together with them  to develop therapies for certain targets in the areas  of Alzheimer’s disease, Parkinson’s disease, and  rare diseases. ", "page_idx": 53, "bbox": [120, 457.2001953125, 316, 565.3502197265625], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 323, "type": "text", "text": "Cell therapy ", "text_level": 1, "page_idx": 53, "bbox": [120, 578, 172, 588], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 324, "type": "text", "text": "Cell therapy is another promising emerging  modality with over 1,000 active cell therapy  studies ongoing worldwide and more than  500 product candidates under development.  In  cancer immunotherapy, cell therapy is showing  potential to be an effective approach to harness a  person’s immune system to fight cancer. To follow  this hypothesis, Genentech has been collaborating  with Adaptive Biotechnologies since 2019 to  develop a type of personalised cellular therapy. ", "page_idx": 53, "bbox": [120, 589.2001953125, 316, 685.3502197265625], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 325, "type": "text", "text": "", "page_idx": 53, "bbox": [330, 181.2001953125, 521, 205.35018920898438], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 326, "type": "text", "text": "Genentech further expanded its commitment to  cell therapies with a new collaboration signed with  Adaptimmune Therapeutics in September 2021  to develop T-cell therapies for various solid  tumours and with another collaboration entered  in December 2021 with Lineage Cell Therapeutics  to further develop and commercialise their retinal  pigment epithelium (RPE) cell therapy for specific  ocular disorders. We also have ongoing partnerships  with companies like BioNTech (mRNA-based) and  Nykode Therapeutics (DNA-based) to develop  therapies aimed at training the immune system to  recognise the patient’s own neoantigens – similar  to the vaccines used to successfully provide  immunity to SARS-CoV-2 infections.  ", "page_idx": 53, "bbox": [330, 217.2001953125, 528, 397.3501892089844], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 327, "type": "text", "text": "Advances in data and technology for patients More than one million medical papers are  published each year. No clinician has enough time  to immerse themselves in the latest, increasingly  complex research, and decide on the right therapy  for each individual patient. Advances in data,  technology and analytics will not only enable  clinicians to make better treatment decisions  faster, but they will allow us to solve problems and  bridge gaps across the healthcare ecosystem,  from drug discovery, development and approval,  to diagnosis, disease monitoring and access to care.  We envision a future where data, technologies and  analytics routinely accelerate drug discovery and  development, and enable better patient care. In  2021, employees across the Roche Group worked  together with our partners to bring this future  closer – as exemplified by the following initiatives:  ", "page_idx": 53, "bbox": [330, 409.2001953125, 528, 625.3502197265625], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 328, "type": "text", "text": "Discovering and selecting the best drug  candidates ", "text_level": 1, "page_idx": 53, "bbox": [331, 638, 495, 660], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 329, "type": "text", "text": "In drug discovery, there are many benefits  to utilising artificial intelligence (AI). Roche’s  ", "page_idx": 53, "bbox": [330, 661.2001953125, 503, 685.3502197265625], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 330, "type": "image", "page_idx": 54, "img_path": "layout_images/roche-holdings_2021_32.jpg", "bbox": [279, 67, 596, 407], "page_size": [595.2760009765625, 793.7009887695312], "ocr_text": "", "vlm_text": "The image shows two people in a laboratory setting operating scientific equipment. They are wearing lab coats, and one person is using a touchscreen control panel on a large piece of equipment. The environment appears clean and modern."}
{"layout": 331, "type": "text", "text": "We envision a future where the latest and greatest science and  technology will drive innovation and unlock the future of healthcare. ", "page_idx": 54, "bbox": [68, 98.2001953125, 264.6507568359375, 121.00019836425781], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 332, "type": "text", "text": "Pharmaceutical Research and Early Development  (pRED) organisation developed a machine- learning operational is ation platform (ML Ops)  that enables the embedding of machine-learning  models in the daily routines for non-data  scientists, bringing AI to their fingertips. Teams  are using the platform to predict different  properties for small molecules, enabling a faster  selection of good drug candidates. Following  the same aspiration, Roche and Genentech  have teamed up with companies like Reverie  Labs and Genesis Therapeutics to generate new  compound designs and predict their properties,  thereby advancing preclinical development  of small molecule medicines. In addition,  Genentech recently acquired Prescient Design,  which will support the application of ML to the  optimisation and de novo design of therapeutic  antibodies. ", "page_idx": 54, "bbox": [68, 181.2000732421875, 251, 409.35009765625], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 333, "type": "text", "text": "The power of prediction in clinical trials AI and other computational approaches can  be used to analyse large amounts of data  gathered in clinical trials, leading to a better  understanding of patient outcomes. For example,  as part of our IMvigor010 study in urothelial  cancer, scientists looked into various biomarkers  that can be found directly in the blood to assess if  some patients with these specific biomarkers need  additional therapy. The retrospective analysis of  the data showed that patients without a detectable  amount of circulating tumour DNA (ctDNA) had  a better chance of becoming disease-free, and  better overall survival rates. These results led  directly to the initiation of another phase III study  in adjuvant bladder cancer with a prospective  selection of ctDNA-positive patients. This  outcome has the potential to change clinical  practice by improving the probability of success  of clinical trials and allowing for smaller, shorter  trials focused on patients that need additional  treatments.  ", "page_idx": 54, "bbox": [67, 421.2001037597656, 260, 685.35009765625], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 334, "type": "text", "text": "125 years of milestones ", "text_level": 1, "page_idx": 54, "bbox": [320, 443, 442, 458], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 335, "type": "text", "text": "Taking risks for patients  For years, the origin of multiple sclerosis (MS) – an autoimmune disease  of the central nervous system – was a mystery. T-cells were identified as  the primary culprit and treatments for MS focused on them. ", "page_idx": 54, "bbox": [320, 468.2001953125, 553, 517.3502197265625], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 336, "type": "text", "text": "Dr Stephen Hauser, current director of the Weill Institute for  Neurosciences, University of California (UCSF), and other researchers  hypothesised that B-cells – another component of the immune system –  also played a critical role in causing the inflammation leading to MS.  This research was met with scepticism in the scientific community and  no academic funding was granted.  ", "page_idx": 54, "bbox": [320, 529.2001953125, 553, 601.3502197265625], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 337, "type": "text", "text": "Genentech was willing to take the risk and agreed to go forward with  an early-phase clinical trial that had an estimated 15% chance of  success. After three decades of research, they were able to refine a new  molecule, a breakthrough that opened up new treatment possibilities  and revolutionised our understanding of MS. ", "page_idx": 54, "bbox": [320, 613.2001953125, 553, 673.3502197265625], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 338, "type": "image", "page_idx": 55, "img_path": "layout_images/roche-holdings_2021_33.jpg", "bbox": [0, 65, 319, 698], "page_size": [595.2760009765625, 793.7009887695312], "ocr_text": "", "vlm_text": "The image consists of two parts:\n\n1. The top part shows a grid of images featuring magnified purple-stained cells, likely related to some kind of microscopic examination, possibly for medical or scientific purposes.\n\n2. The bottom part shows several small vials with blue caps organized in boxes, alongside a person handling labels or packaging, wearing protective clothing typically used in laboratory or sterile environments."}
{"layout": 339, "type": "text", "text": "Our increasing data and insights capabilities allow us to focus  on our vision of providing the right therapy for the right patient  at the right time. ", "page_idx": 55, "bbox": [331, 98.2003173828125, 513, 133.0003204345703], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 340, "type": "text", "text": "Gathering and making sense of large  amounts of data ", "text_level": 1, "page_idx": 55, "bbox": [331, 182, 481, 203], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 341, "type": "text", "text": "Advances in technology also highlight the  fact that an incredible amount of data is  being collected across various stakeholders,  countries and systems. Across the Roche Group,  we  are focused on better ways to gather,  structure and make sense of data. Our Direct  Data Connection (DDC) initiative, for example, is  reinventing the flow of data from clinical trial  sites back to Roche. By automating the end-to- end stream of patient trial data from electronic  health record (EHR) systems to sponsor electronic  data capture (EDC) systems, the DDC initiative  eliminates the need for duplicative, manual data  entry and allows real-time, error-free access  to clinical trial data. In 2021, this user-friendly  software solution was tested at sites around  the world, and received positive feedback  from site coordinators and study team members  who are now able to make real-time decisions  for patients.  ", "page_idx": 55, "bbox": [331, 205.2001953125, 520, 445.3501892089844], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 342, "type": "text", "text": "Another example of our work in this area is our  new partnership with the Alan Turing Institute,  UK’s national institute for data science and  AI. Teams will develop and apply advanced  analytics methodologies to generate insights  from multiple types of healthcare data. This  will improve our understanding of the impact of  patients’ individual disease characteristics and  their response to different therapies, with the  ultimate goal of enhancing clinical care for people  around the world. ", "page_idx": 55, "bbox": [331, 457.2001953125, 520, 589.3502197265625], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 343, "type": "image", "page_idx": 56, "img_path": "layout_images/roche-holdings_2021_34.jpg", "bbox": [61, 104, 544, 329], "page_size": [595.2760009765625, 793.7009887695312], "ocr_text": "Products out-licensing Acquisitions\n\nagreements and divestments / 1\n\n8\n\nProduct, technology or\ndiscovery licence agreements\n\n15\nAgreements derived from Number of new\nexisting alliances .\n9 partnerships\nin 2021\nPHC agreements\nResearch and discovery 13\ncollaborations\n\n14\n", "vlm_text": "The image is a circular chart showing the number of new partnerships in 2021, broken down by category:\n\n- Products out-licensing agreements and divestments: 8\n- Acquisitions: 1\n- Product, technology, or discovery license agreements: 15\n- PHC agreements: 13\n- Research and discovery collaborations: 14\n- Agreements derived from existing alliances: 9"}
{"layout": 344, "type": "image", "page_idx": 56, "img_path": "layout_images/roche-holdings_2021_35.jpg", "bbox": [83, 375, 543, 674], "page_size": [595.2760009765625, 793.7009887695312], "ocr_text": "Japan — Chugai\n\n5\n\n© Polivy\n\n@ MabThera/Rituxan\n\n© Evrysdi\n\n@ Ronapreve 2indications\n\nChina\n\n11\n\nAvastin 2indications\nGazyva/Gazyvaro\nHemlibra\n\nKadcyla\n\nTecentriq\n\nTecentrig + pemetrexed\nEnspryng\n\nEvrysdi\n\nXofluza 2 indications\n\nMajor approvals\n\nin 2021\n\nUS\n\n6\n\n@ Alecensa\n\n@ MabThera/Rituxan\n\n@ Tecentriq\n\n@ Actemra/RoActemra\n\n© Xolair\n\n® Susvimo (port delivery system\nwith ranibizumab)\n\nEurope\n\n11\n\n@ Gavreto\n@ Tecentriq\n\n© Venclexta/Venclyxto + azacitidine\n@ Actemra/RoActemra (COVID-19)\n~~ Enspryng\n\n© Evrysdi\n\n@ Ronapreve 2 indications\n\n®@ Xofluza Sindications\n", "vlm_text": "The image is a circular chart titled \"Major approvals in 2021\" with sections for Japan – Chugai, US, China, and Europe, each listing the number of approvals and specific drugs:\n\n**Japan – Chugai (5 approvals)**\n- Polivy\n- MabThera/Rituxan\n- Evrysdi\n- Ronapreve (2 indications)\n\n**US (6 approvals)**\n- Alecensa\n- MabThera/Rituxan\n- Tecentriq\n- Actemra/RoActemra\n- Xolair\n- Susvimo (port delivery system with ranibizumab)\n\n**China (11 approvals)**\n- Avastin (2 indications)\n- Gazyva/Gazyvaro\n- Hemlibra\n- Kadcyla\n- Tecentriq\n- Tecentriq + pemetrexed\n- Enspryng\n- Evrysdi\n- Xofluza (2 indications)\n\n**Europe (11 approvals)**\n- Gavreto\n- Tecentriq\n- Venclexta/Venclxyto + azacitidine\n- Actemra/RoActemra (COVID-19)\n- Enspryng\n- Evrysdi\n- Ronapreve (2 indications)\n- Xofluza (3 indications)"}
{"layout": 345, "type": "image", "page_idx": 57, "img_path": "layout_images/roche-holdings_2021_36.jpg", "bbox": [0, 66, 531, 690], "page_size": [595.2760009765625, 793.7009887695312], "ocr_text": "The pandemic has drastically altered the scale and urgency needed\n", "vlm_text": "The image shows scenes inside a pharmaceutical or laboratory setting. \n\n1. The top section depicts a cleanroom with stainless steel equipment and two people in protective clothing working at a computer.\n2. The bottom left shows two people wearing surgical masks and caps, suggesting a focus on sterile or controlled environments.\n3. The bottom right shows an individual handling items on a production line, also dressed in protective gear.\n\nThe overall theme suggests manufacturing or research related to medical or pharmaceutical products."}
{"layout": 346, "type": "text", "text": "Opening up new possibilities in the fight  against COVID-19 ", "text_level": 1, "page_idx": 58, "bbox": [66, 98, 392, 152], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 347, "type": "text", "text": "In the face of the COVID-19 pandemic, the  healthcare community looked for ways to  address the ongoing situation around the world.  Acknowledging the great responsibility we feel  to society, coupled with our capabilities and  expertise, we asked ourselves: “What can we  do to help?”  ", "page_idx": 58, "bbox": [67, 181.2001953125, 257, 265.3501892089844], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 348, "type": "text", "text": "While we worked tirelessly to develop testing  solutions and to investigate some of our  medicines in COVID-19, we understood it would  take extraordinary mobilisation and collaboration  across the entire healthcare ecosystem to defeat  it. Strong partnerships have always been a  cornerstone of our work at Roche – approximately  half of our medicines are the result of successful  collaborations with companies and institutions  around the world. We knew we could contribute  our scientific knowledge and clinical research  expertise in infectious diseases and in antibody- based therapeutics as well as our skilled workforce  and specialised manufacturing capabilities. The  pandemic has drastically altered the scale and  urgency needed to develop and distribute COVID-19  treatments and diagnostic tests, leading us to  collaborate in new ways and to work at speeds we  never could have imagined. Now was not the time  to go it alone, and that meant reaching out to all  parties, including competitors, to see what we  could do together. ", "page_idx": 58, "bbox": [67, 277.2001953125, 263, 541.3502197265625], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 349, "type": "text", "text": "When we entered into our partnership with US  biotechnology company Regeneron, we embarked  on a journey full of new experiences, challenges  and one jaw-dropping milestone after another.  ", "page_idx": 58, "bbox": [67, 553.2001953125, 257, 601.3502197265625], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 350, "type": "text", "text": "The collaboration to jointly develop and increase  global distribution of Regeneron’s COVID-19  antibody combination called for both parties to  embrace a new mindset and challenge our ways  of doing things.  ", "page_idx": 58, "bbox": [277, 181.2000732421875, 471, 241.35006713867188], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 351, "type": "text", "text": "The results were – in a word – amazing. Within  only 123 days, and while not knowing if the clinical  studies would be successful, the teams completed  the drug substance technology transfer, a  process that usually takes about nine months. It  only took six months from the day when Roche  first received the manufacturing details until we  delivered the first products to countries around the  world. Thanks to the shared vision and momentum  of this partnership, the trials for the antibody  combination moved from phase I to phase III in  only 13 months. Data from the trials in early 2021  were promising, particularly in prophylaxis and the  treatment of high-risk and hospitalised patients.  While we entered into bilateral agreements with an  increasing number of countries where the antibody  combination was authorised for emergency use,  we received the first official approvals from Japan  in July, followed by the EU in November.  ", "page_idx": 58, "bbox": [277, 253.2000732421875, 471, 481.35009765625], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 352, "type": "text", "text": "If it was not for a willingness to take risks as well  as the tireless effort and unwavering commitment  of all involved, none of this would have been  possible. Despite feelings of uncertainty and fear,  and the difficult operating conditions due to global  lockdowns, the teams embraced the challenge  with an open mind and a goal in sight – to develop  and manufacture potentially life-saving medicines,  the impact of which would be felt around the world. ", "page_idx": 58, "bbox": [277, 493.2001037597656, 471, 601.35009765625], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 353, "type": "image", "page_idx": 59, "img_path": "layout_images/roche-holdings_2021_37.jpg", "bbox": [0, 0, 594, 794], "page_size": [595.2760009765625, 793.7009887695312], "ocr_text": "", "vlm_text": "The image shows a group of people outdoors, possibly in a residential area. There is a woman in a wheelchair smiling and interacting with children who are riding bicycles and a scooter. The scene is relaxed and appears to be during the fall, with trees in the background having orange and red leaves."}
{"layout": 354, "type": "text", "text": "An elusive diagnosis, a lifetime of perseverance  and hope ", "text_level": 1, "page_idx": 60, "bbox": [65, 98, 461, 152], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 355, "type": "text", "text": "At age 17, Liz Adams was diagnosed with spinal muscular atrophy (SMA) –  a rare neuromuscular disorder that results in the loss of motor neurons  and progressive muscle degeneration. Liz is now 39. Thanks to her positive  mindset, she feels more content than ever.  ", "page_idx": 60, "bbox": [68, 174.2001953125, 475.0768127441406, 267.8002014160156], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 356, "type": "text", "text": "Liz was almost two years old when she started to  walk. Throughout her childhood, she experienced  physical weakness. As she got older, she wondered  why she frequently fell down, her hands shook,  and why she could not run as fast as her friends. By  the time she was 13, her symptoms had worsened,  and she asked her parents to take her to the doctor.  “That started the long process of going from doctor  to doctor, and nobody knew what was wrong with  me,” says Liz.  ", "page_idx": 60, "bbox": [66, 301.2001953125, 259, 421.3501892089844], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 357, "type": "text", "text": "Because SMA was not well known at the time,  another four years passed until she was finally  diagnosed. At that point, her parents were told  there was nothing that could be done. Most  people with type 3 SMA lose their ability to walk  at some point in their lives, and require mobility  support. “It was hard to hear that. But my dad  was very determined to make the best of it,” she  adds. In the years following her diagnosis, Liz  and her parents figured out some exercises, read  and educated themselves about SMA, and built a  support system with friends and family.  ", "page_idx": 60, "bbox": [66, 433.2001953125, 259, 577.3502197265625], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 358, "type": "text", "text": "Liz went on to college, where she studied  American Sign Language and pottery. “I’m a very  hands-on person and a challenge does not turn  me away. After I graduated, I lived in South Korea  for 14 months, and taught English as a foreign  language,” Liz explains. At that point, Liz was  walking with a cane. But she still enjoyed travelling  and working, and developed an adventurous spirit.  After returning home from Korea, she became an  interpreter for the deaf, working in public schools  in Fayetteville, North Carolina.  ", "page_idx": 60, "bbox": [66, 589.2001953125, 259, 649.3502197265625], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 359, "type": "text", "text": "", "page_idx": 60, "bbox": [276, 301.2001953125, 470, 373.3501892089844], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 360, "type": "text", "text": "Liz is now married and a mum of four kids –  Sam, Joyful, Rebekah and David. While she now  uses a wheelchair, she enjoys exercising and  spending time outdoors. “I usually swim two to  three times a week and regularly use the rowing  machine. That invigorates me a lot,” says Liz.  She is also really excited about participating  in an upcoming 10 km race, the first one in  her wheelchair. An overarching attitude of  perseverance has really stuck with Liz her entire  life. “I love to set goals for myself. Setting high  goals and trying to reach them, even if it’s a  modified version of the original goal, motivates  me a lot,” she explains.  ", "page_idx": 60, "bbox": [276, 385.2001953125, 464, 553.3502197265625], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 361, "type": "text", "text": "Liz is excited about recent scientific developments  in SMA, and is encouraged by the growth in  awareness of the disease over the last decade.  “Starting from my personal experience in the late  1990s when no therapy was available to having  treatment options and possibilities, is just amazing!”  concludes Liz with a smile.  ", "page_idx": 60, "bbox": [276, 565.2001953125, 470, 649.3502197265625], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 362, "type": "image", "page_idx": 61, "img_path": "layout_images/roche-holdings_2021_38.jpg", "bbox": [0, 0, 595, 793], "page_size": [595.2760009765625, 793.7009887695312], "ocr_text": "", "vlm_text": "The image appears to show a close-up of a laboratory setting, with an orange rack containing red wells or vials. Some of the wells are occupied, possibly with test tubes or containers. The numbers visible suggest a numbering system, often used to keep track of samples. It's likely used for scientific or medical purposes."}
{"layout": 363, "type": "text", "text": "Personalised  healthcare ", "text_level": 1, "page_idx": 62, "bbox": [128, 468, 401, 600], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 364, "type": "image", "page_idx": 63, "img_path": "layout_images/roche-holdings_2021_39.jpg", "bbox": [0, 0, 595, 794], "page_size": [595.2760009765625, 793.7009887695312], "ocr_text": "", "vlm_text": "This is a close-up image of a person with dark hair. They are looking directly at the camera, and the image focuses on the upper part of their face."}
{"layout": 365, "type": "text", "text": "The future of healthcare lies \n in tailor-made solutions  ", "text_level": 1, "page_idx": 64, "bbox": [65, 96, 378, 159], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 366, "type": "text", "text": "Improving lives has always been at the heart of what we do. And, more  than once in our 125-year history, our commitment to innovative science  has led to life-changing discoveries for patients. ", "page_idx": 64, "bbox": [67, 174.2001953125, 464.8591003417969, 243.80020141601562], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 367, "type": "text", "text": "Recently, we have focused much of our attention  on developing new technologies that can enable  us to personalise healthcare.  ", "page_idx": 64, "bbox": [67, 277.2001953125, 262, 313.3442077636719], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 368, "type": "text", "text": "Our efforts to develop an individualised approach  to care date back to the early 1990s, when Roche  and Genentech pioneered what is now commonly  known as personalised healthcare (PHC). Back  then, bringing targeted treatments to patients  was a goal. Today, it is a reality. By combining our  unique expertise in pharmaceuticals, diagnostics,  and data-driven insights, we continue to move  forward. And we remain united in our goal of  integrating all elements of care in order to create  a truly personalised experience for patients. ", "page_idx": 64, "bbox": [67, 325.19720458984375, 262, 457.3172912597656], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 369, "type": "text", "text": "Introducing the care continuum ", "text_level": 1, "page_idx": 64, "bbox": [67, 470, 199, 481], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 370, "type": "text", "text": "As part of our goal to expand personalised  healthcare, we have shifted from treating diseases  to focusing on a holistic, people-centric approach  that spans the entire care continuum. This change  entails a fundamental shift in the way we understand  and deliver healthcare.  ", "page_idx": 64, "bbox": [67, 481.16729736328125, 262, 553.3023681640625], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 371, "type": "text", "text": "To ensure the care continuum approach is  successful, we are tapping into our deep internal  resources and expertise. At the same time, we are  capitalising on the strengths of our independent  affiliates, such as Flatiron Health and Foundation  Medicine. And, we are also partnering with external  stakeholders across the healthcare ecosystem to  help deliver the right treatment to the right patient  at the right time. ", "page_idx": 64, "bbox": [67, 565.1553344726562, 262, 673.2813110351562], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 372, "type": "text", "text": "Early and comprehensive diagnosis Advanced diagnostics and measurement tools  allow us to predict who is likely to become ill,  diagnose illness earlier, and understand the unique  characteristics of each patient’s condition and  response to treatment. Digital solutions can help  close gaps along the care continuum in areas from  prevention to disease monitoring and are even more  effective when they incorporate third-party data.  ", "page_idx": 64, "bbox": [278, 277.1282958984375, 474, 385.2543640136719], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 373, "type": "text", "text": "One of the major challenges in diagnosis is the  preparation of the specimen. DNA is especially  complex to prepare for sequencing and prone to  human error. In 2021, we launched the Avenio Edge  System to simplify and automate next-generation  sequencing sample preparation, reduce human error  and advance precision medicine for the future. ", "page_idx": 64, "bbox": [278, 397.10736083984375, 474, 481.2394104003906], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 374, "type": "text", "text": "We also recently introduced an open digital  pathology environment that enables pathologists  to exchange data securely, and also provides  access to Roche image analysis tools, as well  as third-party technology. Among the first  collaborations within this framework was a joint  development agreement made in October 2021  with Ibex Medical Analytics, a global leader in  artificial intelligence (AI)-based cancer diagnostics.  Under the agreement, we will jointly develop an  embedded image analysis workflow for pathologists  to seamlessly access Ibex’s AI algorithms, insights  and decision support tools using Navify Digital  Pathology, which is the cloud version of our uPath  enterprise software. ", "page_idx": 64, "bbox": [278, 493.0924072265625, 474, 673.2003784179688], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 375, "type": "image", "page_idx": 64, "img_path": "layout_images/roche-holdings_2021_40.jpg", "bbox": [490, 531, 595, 695], "page_size": [595.2760009765625, 793.7009887695312], "ocr_text": "UN SDGs\n\nooo 17 anesues\nAND WELL EEG FORTHESOALS\n\n“eB\n\nMaterial topics\n\n- Patient centricity\n\n- R&D efficiency\n\n- Personalised healthcare\n\n- Real-world data\n\n- Preparedness for\nageing society\n\n", "vlm_text": "The image lists United Nations Sustainable Development Goals (UN SDGs) and related material topics. It highlights:\n\n- SDG 3: Good Health and Well-being\n- SDG 17: Partnerships for the Goals\n\nThe listed material topics include:\n\n- Patient centricity\n- R&D efficiency\n- Personalised healthcare\n- Real-world data\n- Preparedness for ageing society"}
{"layout": 376, "type": "text", "text": "Powered by data and analytics High-quality data and rigorous analytics make up  the engine that drives PHC. But today, healthcare  produces a vast amount of untapped data, which  holds the potential to unlock valuable insights.  The broad range of Roche diagnostic solutions  alone produces billions of data points each  year. Every single one of them holds high-quality  information that could spark a small advancement  in personalised healthcare. Brought together,  they can contribute to longitudinal data on a  massive scale, enabling a more comprehensive  view of patients. ", "page_idx": 65, "bbox": [120, 181.2001953125, 311, 337.3501892089844], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 377, "type": "text", "text": "Maximising the true potential of data and  data-enabled technology hinges on patient trust.  To build and maintain that trust, we maintain the  highest standards in data privacy, de-identification  and security. Additionally, we are increasing our  expertise in data handling and have added various  digital health offerings to our portfolio.  ", "page_idx": 65, "bbox": [120, 349.2001953125, 311, 433.3501892089844], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 378, "type": "text", "text": "Early in 2021, Roche announced the launch  of Navify Pass, an important expansion of our  broad response to the COVID-19 pandemic. The  cloud-based solution consists of a mobile app  for individuals and healthcare professionals, as  well as a back-end tool for testing sites. Navify  Pass also enables unconventional point-of-care  sites to fully digitise their workflows, from the  first test performed to government reporting.  The application enables individuals to store  results from self-administered tests, as well as  those administered in a medical facility or other  professional site. ", "page_idx": 65, "bbox": [120, 445.2001953125, 311, 601.3502197265625], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 379, "type": "text", "text": "Remote patient monitoring and management  Roche has been at the forefront of diagnostics  and disease monitoring for decades. In the  early 1980s, we were among the first to develop  an at-home, automated, self-monitoring blood  glucose meter for people with diabetes. Today, we  are ushering in a new era in which physicians use  novel, more sensitive quantitative measures and  patients are empowered to monitor themselves  for a variety of diseases. The ability to establish  a deep understanding of a patient’s metrics, both  on a daily basis and over time, can lead to more  tailored, more effective care.  ", "page_idx": 65, "bbox": [120, 613.2001953125, 311, 697.3502197265625], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 380, "type": "text", "text": "", "page_idx": 65, "bbox": [331, 181.2001953125, 528, 253.35018920898438], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 381, "type": "text", "text": "Data indicates that continuously reporting  symptoms of disease or effects of cancer therapy  can facilitate a shared approach to disease  management between patients and their care teams.  It can also increase survival and improve quality of  life, while reducing symptom burden, emergency  room visits, and hospital is at ions. ", "page_idx": 65, "bbox": [331, 265.2001953125, 528, 349.3501892089844], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 382, "type": "text", "text": "The continued reliance on clinic visits as the  primary way to assess and monitor patients remains  a fundamental limitation of healthcare. Personal  technologies, including wearables and medical  devices, can allow patients to play a more active  role in tracking and managing their health.  ", "page_idx": 65, "bbox": [331, 361.2001953125, 528, 433.3501892089844], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 383, "type": "text", "text": "Multiple sclerosis (MS) is an insidious and  unpredictable disease that can be hard to track and  measure. The launch of the smartphone application  Floodlight in the US, Germany and Finland helps  make precision monitoring a reality for people living  with MS. Through simple tasks, such as drawing a  shape, the app enables physicians and patients  to shed a light on the impact of the disease on the  individual patient. Furthermore, each data point  contributes to a unique data set designed to move  MS research forward.  ", "page_idx": 65, "bbox": [331, 445.2001953125, 528, 577.3502197265625], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 384, "type": "text", "text": "In collaboration with Moorfields Eye Hospital in  London, Roche piloted Home Vision Monitor, an  interactive smartphone- and tablet-based app that  empowers patients to test and monitor changes  in their vision. The app was designed for people  with diseases that affect the macula, such as  age-related macular degeneration and diabetes.  More than 350 Moorfields patients have used the  app, with  $70\\%$   claiming it offers them peace of  ", "page_idx": 65, "bbox": [331, 589.2001953125, 528, 697.3502197265625], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 385, "type": "image", "page_idx": 66, "img_path": "layout_images/roche-holdings_2021_41.jpg", "bbox": [280, 68, 596, 406], "page_size": [595.2760009765625, 793.7009887695312], "ocr_text": "", "vlm_text": "The image shows a person holding two smartphones. One phone displays a QR code scanning screen, while the other shows a blurred interface, possibly also related to QR codes or digital communication. There is a packet or a small product on the surface below the phones."}
{"layout": 386, "type": "text", "text": "Navify Pass is a cloud-based solution consisting of a mobile  application for individuals and healthcare professionals, as well  as a back-end tool for testing sites. ", "page_idx": 66, "bbox": [68, 98.2001953125, 263, 133.0001983642578], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 387, "type": "text", "text": "mind in the knowledge they are documenting any  changes in their vision in between check-ups. ", "page_idx": 66, "bbox": [68, 181.2000732421875, 263, 205.35006713867188], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 388, "type": "text", "text": "Partnerships and collaborations ", "text_level": 1, "page_idx": 66, "bbox": [67, 218, 201, 227.75], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 389, "type": "text", "text": "Unlocking the full potential of PHC – and integrating  advances in medical science, data, and technology  into the care continuum – demands holistic thinking  and collaboration among stakeholders across the  healthcare ecosystem. As part of our commitment  to accelerating this effort, we are partnering with  other organisations to create new approaches  and solutions. ", "page_idx": 66, "bbox": [68, 229.2000732421875, 263, 325.35009765625], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 390, "type": "text", "text": "Roche joined the Autism Sharing Initiative, a  new project to build the first global network for  sharing genomics and clinical data to accelerate  breakthrough discoveries and precision healthcare  in autism. Using a new technology, the initiative  allows search and analysis to be performed across  multiple individual data sets while that information  remains in its protected local environments.  ", "page_idx": 66, "bbox": [68, 337.2001037597656, 263, 433.35009765625], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 391, "type": "text", "text": "In June 2021, Genentech presented the results  of its collaborative efforts with PathAI, which  improved clinical assessments of non-small cell lung  cancer. The partnership with PathAI accelerates  our understanding of patient response to lung  cancer treatments.  ", "page_idx": 66, "bbox": [67, 445.2001037597656, 265, 517.35009765625], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 392, "type": "text", "text": "While we develop our own innovative products and  digital solutions, we also work with stakeholders to  jointly address obstacles, and make PHC solutions  accessible to patients around the world. In March  2021, Roche Canada signed a memorandum of  collaboration with the British Columbia Cancer  Agency and the Canadian Personalized Healthcare  Innovation Network known as PREDiCT (Precision  Oncology Evidence Development in Cancer  Treatment). If proven successful, the initiative will  generate and assess real-world evidence (RWE),  which may be used to shape new sustainable  reimbursement pathways for personalised cancer  treatments. This critical step in sustainable  ", "page_idx": 66, "bbox": [67, 529.2000732421875, 259, 697.35009765625], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 393, "type": "text", "text": "125 years of milestones ", "text_level": 1, "page_idx": 66, "bbox": [320, 443, 442, 458], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 394, "type": "text", "text": "A turning point in cancer treatment  For most of the last century, cancer was categorised only by its location  in the body. As a result, treatment results varied significantly. ", "page_idx": 66, "bbox": [320, 468.2001953125, 553, 505.3501892089844], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 395, "type": "text", "text": "In September 1998, the FDA approved Roche and Genentech’s breast  cancer therapy, Herceptin. In many regards, that approval marked a  turning point in cancer treatment.  ", "page_idx": 66, "bbox": [320, 517.2001953125, 540, 553.3502197265625], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 396, "type": "text", "text": "The monoclonal antibody was specifically designed to treat patients with  metastatic breast cancer whose tumours overexpress the HER2 protein.  Herceptin was not only the first targeted treatment for a solid tumour,  but also the first drug to be paired with a companion diagnostic. By  identifying patients with an improved risk-benefit profile, those patients  gained critical time that would otherwise have been spent in search of a  viable treatment.  ", "page_idx": 66, "bbox": [320, 565.2001953125, 553, 649.3502197265625], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 397, "type": "text", "text": "healthcare transformation can lead to better  care at a lower cost, for people and society  ( please see the story on page 69 ).  ", "page_idx": 67, "bbox": [120, 181.2001953125, 308, 217.35018920898438], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 398, "type": "text", "text": "Foundation Medicine and Flatiron Health, both  independent affiliates of the Roche Group, are  pioneers in the field of healthcare data and  analytics. Together, they have built a clinico- genomic database that links two of the largest  sources of clinical and genomic real-world data  (RWD) into an integrated data set that serves as  a valuable resource for accelerating precision  oncology. Some 98,000 linked patient records  were available for research at the end of 2021,  reflecting growth of about   $40\\%$   in just a year. ", "page_idx": 67, "bbox": [120, 229.2001953125, 308, 361.3501892089844], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 399, "type": "text", "text": "Flatiron Health ", "text_level": 1, "page_idx": 67, "bbox": [121, 374, 184, 384], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 400, "type": "text", "text": "Flatiron Health has continuously expanded its  US network of community oncology practices  and academic medical centres; its community  oncology partners alone saw a daily average of  47,500 patients in 2021. In addition, 370 oncologists  are already using the Flatiron Assist decision  support tool to quickly select evidence-based  treatment options for their patients. Also in 2021,  Flatiron began to expand its network beyond the  US, building new partnerships to derive RWD from  hospitals and health networks in Europe and Asia.  ", "page_idx": 67, "bbox": [120, 385.2001953125, 314, 517.3502197265625], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 401, "type": "text", "text": "Despite the impact of COVID-19 on traditional  clinical trials, the Prospective Clinico-Genomic  (PCG) study – a partnership among Flatiron,  Foundation Medicine, Genentech, and US  community and academic oncology practices –  enrolled more than 940 patients with metastatic  lung cancer across 23 sites. The study was  designed to more seamlessly integrate clinical  research into clinical care, and offer participants  serial genomic testing they may not have  otherwise had access to.  ", "page_idx": 67, "bbox": [120, 529.2001953125, 308, 661.3502197265625], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 402, "type": "text", "text": "In 2021, Flatiron published several important  studies, including one that highlighted the  ", "page_idx": 67, "bbox": [120, 673.2001953125, 308, 697.3502197265625], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 403, "type": "text", "text": "impact of the pandemic on the time elapsed  between diagnosis and the initiation of systemic  treatment in cancer patients. The American  Society of Clinical Oncology (ASCO) accepted this  study, as well as extensive additional work to help  oncology practices assess and address frontline  impacts.  ", "page_idx": 67, "bbox": [330, 181.2000732421875, 519, 265.3500671386719], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 404, "type": "text", "text": "As part of their leadership in RWE regulatory  and policy frameworks, Flatiron helped establish  the RWE Alliance, an industry organisation  whose goal is to collectively identify, develop  and advocate technical, regulatory and policy  solutions that advance the use of RWE for  regulatory decisions.  ", "page_idx": 67, "bbox": [330, 277.2001037597656, 514, 361.35009765625], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 405, "type": "text", "text": "Furthermore, Flatiron has taken major steps to  ensure that the interests and priorities of patients  are considered in their research strategy. These  steps include the launch of formal mechanisms  for patient engagement in the US and the UK. ", "page_idx": 67, "bbox": [330, 373.2001037597656, 519, 433.35009765625], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 406, "type": "text", "text": "Foundation Medicine  ", "text_level": 1, "page_idx": 67, "bbox": [331, 446, 418, 456], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 407, "type": "text", "text": "Together, Roche and Foundation Medicine offer  a portfolio of comprehensive genomic profiling  (CGP) tests for solid and haematological tumours.  These tests enable easier, faster and better  clinical decisions. As partners, the two companies  are leading the implementation and uptake of  CGP around the world with the goal of developing  personalised treatment strategies in oncology,  as well as smarter, more efficient diagnostic  solutions. Foundation Medicine services are now  available in over 100 countries worldwide. ", "page_idx": 67, "bbox": [330, 457.2001037597656, 519, 589.35009765625], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 408, "type": "text", "text": "In August 2021, Japan’s health authorities  approved the use and reimbursement of  FoundationOne Liquid CDx, a blood-based CGP  test that analyses more than 300 cancer-related  genes in solid tumours. This provides a better  understanding of what is driving a patient’s  cancer to grow and gives insight into personalised  treatment options for each patient.  ", "page_idx": 67, "bbox": [330, 601.2000732421875, 519, 697.35009765625], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 409, "type": "image", "page_idx": 68, "img_path": "layout_images/roche-holdings_2021_42.jpg", "bbox": [277, 66, 596, 406], "page_size": [595.2760009765625, 793.7009887695312], "ocr_text": "", "vlm_text": "The image shows a person wearing protective gear, including gloves and a face shield, working in a laboratory setting. They are using a pipette to handle a liquid sample, with test tubes stored in ice nearby."}
{"layout": 410, "type": "text", "text": "Foundation Medicine tests enable easier, faster and better clinical  decision-making through comprehensive genomic profiling (CGP). ", "page_idx": 68, "bbox": [67, 98.2003173828125, 262, 121.00032043457031], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 411, "type": "text", "text": "Additionally, the FDA approved companion  diagnostic claims for FoundationOne CDx and  FoundationOne Liquid CDx in bile duct cancer and  non-small cell lung cancer (NSCLC). Foundation  Medicine now has 37 companion diagnostic  approvals across its two FDA-approved tests. ", "page_idx": 68, "bbox": [67, 181.2001953125, 262, 253.35018920898438], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 412, "type": "text", "text": "In partnership with Natera, Foundation Medicine  launched the FoundationOne Tracker, for research  use only. The Tracker is a personalised circulating  tumour DNA (ctDNA) monitoring assay that  combines Foundation Medicine’s tissue-based  CGP platform with Natera’s expertise in ctDNA  monitoring. In addition, Roche launched a new  genomic profiling kit that helps cancer researchers  sequence tumours without having to send tissue  samples to centralised laboratories. The Avenio  CGP kit powered by FoundationOne (research- use-only) allows healthcare professionals to apply  high-quality CGP in their local labs, giving more  patients the opportunity to participate in a trial  that leverages CGP. ", "page_idx": 68, "bbox": [67, 265.2001953125, 262, 445.3501892089844], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 413, "type": "image", "page_idx": 68, "img_path": "layout_images/roche-holdings_2021_43.jpg", "bbox": [277, 416, 596, 694], "page_size": [595.2760009765625, 793.7009887695312], "ocr_text": "", "vlm_text": "The image shows two people in lab coats walking past a wall with the words \"FOUNDATION MEDICINE\" written on it. There is also a logo next to the text."}
{"layout": 414, "type": "text", "text": "In 2021, Foundation Medicine also made several  updates across its portfolio to help expand access  to precision oncology. The integration with Flatiron  Health’s OncoEMR platform improves the efficiency  of clinical decision-making by enabling electronic  ordering, order tracking, and receipt of Foundation  Medicine’s CGP test results. The forthcoming  integration with Epic’s electronic medical record  system will also streamline access to genomic  insights for precision cancer care.  ", "page_idx": 68, "bbox": [67, 457.2001953125, 262, 577.3502197265625], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 415, "type": "text", "text": "Genomic data also helps us to better understand,  diagnose and treat patients with rare cancers on  a more personalised level. The ongoing CUPISCO  study – a randomised trial using CGP to assign  patients with cancer of unknown primary (CUP) to  targeted or immunotherapy treatment – aims to  shed further light on a disease with a high medical  need. In addition, using FoundationCore, one of  the largest CGP databases in oncology, allows  ", "page_idx": 68, "bbox": [67, 589.2001953125, 262, 697.3502197265625], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 416, "type": "image", "page_idx": 69, "img_path": "layout_images/roche-holdings_2021_44.jpg", "bbox": [0, 67, 318, 409], "page_size": [595.2760009765625, 793.7009887695312], "ocr_text": "", "vlm_text": "The image shows a person wearing a lab coat and glasses, intently looking at a computer screen. The monitor displays images that appear to be related to microscopy or pathology. There is a microscope in the background, suggesting a lab or medical research setting."}
{"layout": 417, "type": "image", "page_idx": 69, "img_path": "layout_images/roche-holdings_2021_45.jpg", "bbox": [0, 416, 318, 697], "page_size": [595.2760009765625, 793.7009887695312], "ocr_text": "", "vlm_text": "The image shows a person wearing gloves and holding a small glass vial with a stopper. This is often indicative of a medical or laboratory setting."}
{"layout": 418, "type": "text", "text": "Genomic data helps us to better understand, diagnose and treat  patients with rare cancers on a more personalised level. ", "page_idx": 69, "bbox": [330, 98.2003173828125, 520, 121.00032043457031], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 419, "type": "text", "text": "researchers to learn more about the characteristics  of NTRK fusion-positive cancers, a very rare  molecular subgroup of cancer. ", "page_idx": 69, "bbox": [330, 181.2001953125, 526, 217.35018920898438], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 420, "type": "text", "text": "Making PHC accessible for everyone More than two decades have passed since Roche  took its first steps into the field of personalised  healthcare. Those initial efforts have led us  to where we are today – delivering innovative  personalised solutions that help millions of people  around the globe. Today, PHC is embedded across  our organisation. We maintain a clear focus on the  entire care continuum, and on our goal of making  PHC accessible to everyone.  ", "page_idx": 69, "bbox": [330, 229.2001953125, 520, 349.3501892089844], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 421, "type": "text", "text": "Technology and science are constantly shifting  the boundaries. What seemed impossible yesterday  may be within our grasp today, and may transform  a patient’s life tomorrow. We are excited by the  opportunity to deliver better outcomes to more  people around the world through care tailored to  each individual. ", "page_idx": 69, "bbox": [330, 361.2001953125, 526, 445.3501892089844], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 422, "type": "image", "page_idx": 70, "img_path": "layout_images/roche-holdings_2021_46.jpg", "bbox": [59, 92, 565, 656], "page_size": [595.2760009765625, 793.7009887695312], "ocr_text": "Personalised healthcare -\n\nThe care continuum\n\nEnabled by data and analytics\n\nEarly and accurate\n\nOnedine 4 diagnosis\nremote care and \\\nmonitoring\nPatient\n% Tailored\nRapid access to optimal i *\nap / care plan\ninterventions\nCountries with Foundation Flatiron Health patient records\nMedicine services available for research\n>100 \\ / 3.2 million\n+20% growth over 2020\nPHC\nTests processed by Navify Pass“ facts \\ Partnering deals signed\n345,166 2021 13\n_ a Companion diagnostic approvals\nCommunity cancer care sites _ for the two FDA-approved\nin Flatiron Health US network J “ %\\ Foundation Medicine tests\n\n800 37\n", "vlm_text": "The image is an infographic about personalized healthcare, focusing on the care continuum. It highlights how patient care is enabled by data and analytics, emphasizing several key areas:\n\n1. **Ongoing remote care and monitoring**\n2. **Early and accurate diagnosis**\n3. **Tailored care plan**\n4. **Rapid access to optimal interventions**\n\nBelow this, there are some facts for 2021, labeled as \"PHC facts,\" which include:\n\n- Countries with Foundation Medicine services: over 100\n- Tests processed by Navify Pass: 345,166\n- Community cancer care sites in Flatiron Health US network: 800\n- Flatiron Health patient records available for research: 3.2 million (20% growth over 2020)\n- Partnering deals signed: 13\n- Companion diagnostic approvals for the two FDA-approved Foundation Medicine tests: 37"}
{"layout": 423, "type": "image", "page_idx": 71, "img_path": "layout_images/roche-holdings_2021_47.jpg", "bbox": [0, 65, 531, 685], "page_size": [595.2760009765625, 793.7009887695312], "ocr_text": "The combined power of advanced imaging technology, artificial\n\nintelligence and large databases of real-world data provides\n", "vlm_text": "The image consists of three parts:\n\n1. The top section shows two scientists or researchers in a laboratory. They are working with a microscope and computers displaying microscopic images.\n\n2. The bottom left section depicts a person sitting in a hallway, possibly in a medical facility, holding a phone.\n\n3. The bottom right section shows a hand pointing at medical scans, likely X-rays or MRI images, indicating a focus on medical imaging or diagnosis.\n\nOverall, the image suggests themes of scientific research, medical examination, and technology in healthcare."}
{"layout": 424, "type": "text", "text": "Hope for the future of personalised cancer care  in Canada ", "text_level": 1, "page_idx": 72, "bbox": [67, 99, 464, 150], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 425, "type": "text", "text": "For more than 20 years, Roche has helped  lay the scientific groundwork for personalised  healthcare with treatments that target the  underlying biology of a person’s individual disease  and with targeted diagnostics that help doctors  determine the right therapy for their patients.  Unlocking the value of advances in medical science,  data and technology towards a more personalised  approach – and integrating them into how we  care for people – demands holistic thinking and  collaboration among stakeholders across the  healthcare ecosystem. We know that meaningful  change can only happen when we work together.  ", "page_idx": 72, "bbox": [67, 181.2001953125, 259, 337.3501892089844], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 426, "type": "text", "text": "Real-world data (RWD), or patient data that is  collected as part of routine healthcare practice  instead of through clinical trials, is becoming  increasingly important to fill gaps and capture  insights that can help guide how a patient is  diagnosed and treated. The demand for RWD  by regulatory, reimbursement and healthcare  decision makers continues to grow, particularly  for personalised cancer therapies that target  rare mutations where traditional clinical trial  evidence is limited and challenging to collect.  ", "page_idx": 72, "bbox": [67, 349.2001953125, 251, 481.3501892089844], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 427, "type": "text", "text": "The tide is turning, however, and our recent  partnership in British Columbia, Canada, is setting  the stage for what we hope will lead to faster  patient access to innovative treatments and  technologies across many disease areas. In March  2021, Roche Canada, the British Columbia Cancer  Agency and the Canadian Personalized Healthcare  Innovation Network signed a memorandum of  collaboration which is the first public-private  collaboration in personalised healthcare in British  Columbia and represents an important milestone  in transforming the healthcare system in Canada.  ", "page_idx": 72, "bbox": [67, 493.2001953125, 259, 613.3502197265625], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 428, "type": "text", "text": "", "page_idx": 72, "bbox": [277, 181.2000732421875, 475, 205.35006713867188], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 429, "type": "text", "text": "This collaborative project is aimed at reducing  fragmentation and improving decision-making based  on learnings from patients in real time. PREDiCT –  Precision Oncology Evidence Development in Cancer  Treatment – is a programme piloting a framework  that will help guide healthcare decision makers  to utilise RWD in their clinical, regulatory and  reimbursement decisions. We are hopeful that this  will mean earlier, more precise diagnosis for patients  and access to the right treatment at the right time.  Our ultimate goal is to scale this framework beyond  British Columbia to other provinces in Canada.  We also know that what we learn from PREDiCT  may translate beyond borders to other Roche  affiliates worldwide. ", "page_idx": 72, "bbox": [277, 217.2000732421875, 475, 397.35009765625], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 430, "type": "text", "text": "Although there is much work yet to be done, in  less than a year the PREDiCT collaboration is  already showing signs of progress. More patients  in British Columbia are being diagnosed with more  precise testing at an earlier stage following a  cancer diagnosis. Additionally, key system changes  to integrate data have also begun which will allow  decision makers to utilise the PREDiCT framework.  Work is already underway to expand the programme  into new disease areas and geographies. PREDiCT  is just one example of how we are partnering across  society to co-create new approaches and solutions,  being mindful of the urgency of this moment. To  us, personalised healthcare means far more than  improving treatment – it is about improving life for  every person. And we are hopeful that our efforts  in this area will do just that.  ", "page_idx": 72, "bbox": [277, 409.2001037597656, 475, 613.35009765625], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 431, "type": "image", "page_idx": 73, "img_path": "layout_images/roche-holdings_2021_48.jpg", "bbox": [0, 1, 596, 794], "page_size": [595.2760009765625, 793.7009887695312], "ocr_text": "", "vlm_text": "The image shows a person with medium-length brown hair, smiling. They are wearing a green jacket over a gray hoodie. The background is outdoors with trees and a blurred sky."}
{"layout": 432, "type": "text", "text": "How targeting a cancer’s unique drivers  is transforming patient care ", "text_level": 1, "page_idx": 74, "bbox": [65, 98, 398, 154], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 433, "type": "text", "text": "Kissing your young children goodnight every evening is a precious ritual  treasured by parents worldwide. ", "text_level": 1, "page_idx": 74, "bbox": [65, 177, 463, 218], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 434, "type": "text", "text": "But Mary Bodley, 51, cherishes these moments  more than most – because she was not sure she  would be around for her children. Six years ago,  Mary was diagnosed with invasive, ductal grade 2,  HER2-negative and ER-positive breast cancer. ", "page_idx": 74, "bbox": [67, 253.2001953125, 258, 313.3382263183594], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 435, "type": "text", "text": "When she received her diagnosis, her first thoughts  were for her young family. “I was more scared  about telling my family and the impact it would  have on my daughters,” Mary says. “It was there  and then that I knew I was going to fight this. I  was determined to see their communions and  confirmations and hear about their first boyfriend  or girlfriend.” ", "page_idx": 74, "bbox": [67, 325.19122314453125, 258, 421.3202819824219], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 436, "type": "text", "text": "Mary lives in County Dublin, Ireland, and is  currently on sick leave from her role as an Internal  Communications Manager at Roche Ireland. She  firmly believes that the reason she has been able  to progress so far is a friend’s suggestion that  she look into genomic profiling,  ", "page_idx": 74, "bbox": [67, 433.2001953125, 258, 505.3352355957031], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 437, "type": "text", "text": "Genomic profiling helps doctors tailor treatment  to a patient’s unique tumour based on its individual  ‘fingerprint’. The process can detect, from a tissue  or blood sample, mutations in a cancer’s DNA  which may be driving its growth and identify specific  treatments which can target that individual tumour.  This allows doctors to refine and tailor treatment  based on the mutation rather than the location of  the cancer in the body.  ", "page_idx": 74, "bbox": [67, 517.188232421875, 258, 625.314208984375], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 438, "type": "text", "text": "After a round of successful treatment, Mary was  given the all-clear. But, just two years later, her  cancer returned. Again, treatment was a success,  and again she was given the all-clear. But just  months later, she discovered a lump in her neck  and her worst fears were confirmed – the cancer  had returned once more. ", "page_idx": 74, "bbox": [67, 637.1671752929688, 258, 661.314208984375], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 439, "type": "text", "text": "", "page_idx": 74, "bbox": [276, 253.1641845703125, 464, 313.3022155761719], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 440, "type": "text", "text": "Mary had an added complication: each time  her cancer returned, it evolved. It began as  HER2-negative and ER-positive breast cancer,  then recurred as HER2-positive and ER-negative,  and finally as triple negative. Thankfully, genomic  testing was able to provide treatment options  that could work well with Mary’s tumour.  ", "page_idx": 74, "bbox": [276, 325.15521240234375, 464, 409.2872619628906], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 441, "type": "text", "text": "“I’ve gone down several different treatment  paths and they’ve kept me alive for six and a  half years,” she says. “Genomic testing is a huge  part of that. The current treatment is working  well and all my cancer tumours are stable at  the moment.”  ", "page_idx": 74, "bbox": [276, 421.1402587890625, 464, 493.2752990722656], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 442, "type": "text", "text": "As Roche celebrates its 125-year anniversary,  Mary says: “It’s my hope that over the next  125 years, Roche’s fantastic people will have  created and rolled out a medicine that can cure  all forms of breast cancer. And, I also hope a  bulletproof method for preventing breast cancer  will have been created, which could be implanted  into all women from the age of 40.”  ", "page_idx": 74, "bbox": [276, 505.1282958984375, 464, 601.25732421875], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 443, "type": "text", "text": "“For now, their incredible work has given me  precious extra time which I am so grateful for  and I can still kiss my two girls goodnight every  evening.” ", "page_idx": 74, "bbox": [276, 613.1102905273438, 464, 661.2512817382812], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 444, "type": "image", "page_idx": 75, "img_path": "layout_images/roche-holdings_2021_49.jpg", "bbox": [0, 0, 594, 791], "page_size": [595.2760009765625, 793.7009887695312], "ocr_text": "", "vlm_text": "The image shows a close-up of several laboratory test tubes or vials placed in a pink rack. The photo is taken from above, highlighting the circular openings of the tubes."}
{"layout": 445, "type": "text", "text": "", "text_level": 1, "page_idx": 76, "bbox": [131, 473, 280, 520], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 446, "type": "text", "text": "to healthcare ", "text_level": 1, "page_idx": 76, "bbox": [130, 543, 410, 597], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 447, "type": "image", "page_idx": 77, "img_path": "layout_images/roche-holdings_2021_50.jpg", "bbox": [0, 2, 592, 794], "page_size": [595.2760009765625, 793.7009887695312], "ocr_text": "", "vlm_text": "The image shows a close-up of a person's face. It appears to focus on the facial features, capturing a direct and expressive look."}
{"layout": 448, "type": "text", "text": "Striving for improved access  to healthcare around the world  ", "text_level": 1, "page_idx": 78, "bbox": [66, 97, 413, 159], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 449, "type": "text", "text": "At Roche, we know that life-changing innovation is only meaningful if it  reaches those who need it. We also understand that millions of patients  all over the world still do not have access to quality healthcare.  ", "page_idx": 78, "bbox": [68, 174.2001953125, 459.5584716796875, 243.80020141601562], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 450, "type": "text", "text": "Multiple barriers continue to stand in their way,  and the situation has been exacerbated by the  ongoing pandemic, which is contributing to  increasing global inequalities.  ", "page_idx": 78, "bbox": [68, 277.2001953125, 253, 325.3501892089844], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 451, "type": "text", "text": "During this second year of the COVID-19 pandemic,  healthcare systems around the world experienced  significantly increased pressure. Throughout  this time, we have continued to work closely with  governments, healthcare providers, laboratories,  regulatory authorities, and organisations around  the world, not only by increasing our production  of critical diagnostic tests and medicines, but  also by helping strengthen healthcare systems  to support the fight against the pandemic and  minimise its impact. In parallel, we have worked  to help improve access to quality healthcare  for non-communicable diseases, and to provide  non-COVID-19-related diagnostics and treatments  which have been delayed or even cancelled.  ", "page_idx": 78, "bbox": [68, 337.2001953125, 263, 517.3502197265625], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 452, "type": "text", "text": "Our access strategy remains focused on addressing  root causes at both global and country levels.  We work in collaboration with global and local  stakeholders, with a focus on pricing and access  programmes, particularly in low- and middle-income  countries (LMICs) where we support their efforts to  achieve universal health coverage (UHC).  ", "page_idx": 78, "bbox": [68, 529.2001953125, 263, 613.3502197265625], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 453, "type": "text", "text": "We put access at the centre of our business,  and consider it a key part of our commitment to  improving patient outcomes. As we bring our  innovations to patients, we look deeply into the  causes that prevent access to optimal healthcare;  from screening and diagnosis to treatment.  ", "page_idx": 78, "bbox": [68, 625.2001953125, 263, 697.3502197265625], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 454, "type": "text", "text": "We know that every country has a different situation,  and their healthcare systems present unique  challenges. So we draw on our breadth of expertise  and innovation that spans the patient journey, and  work closely with many partners to develop and  deliver tailored access solutions that reflect each  country’s individual healthcare needs.  ", "page_idx": 78, "bbox": [278, 277.2001953125, 475, 361.3501892089844], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 455, "type": "text", "text": "Now more than ever, it is important and urgent  for us to acknowledge our shared responsibility  to build resilient and sustainable healthcare  systems. We believe that comprehensive UHC helps  support stable economies and strong societies,  and is fundamental to addressing inequality in  access to healthcare, particularly in LMICs. We are  accelerating our ongoing efforts in this area with  our goal to double the number of patients receiving  our innovative therapies in low- and lower-middle- income countries by the end of 2026, and it remains  our ambition to double patient access to novel,  high-medical-value diagnostic solutions to people  around the world. ", "page_idx": 78, "bbox": [278, 373.2001953125, 475, 541.3502197265625], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 456, "type": "text", "text": "Tailoring solutions to LMICs Around  $80\\%$   of the world’s population lives in LMICs.  We have long been committed to LMICs, and have  a range of programmes to broaden access to our  medicines and diagnostics in those countries.  ", "page_idx": 78, "bbox": [278, 553.2001953125, 475, 613.3502197265625], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 457, "type": "text", "text": "We believe in harnessing new technologies in  healthcare to improve patient outcomes, including  in settings with limited resources. This is why we  are using digital solutions, such as Navify Digital  Pathology, to help with virtual diagnosis and to  train pathologists virtually, which is particularly  ", "page_idx": 78, "bbox": [278, 625.2001953125, 475, 697.3502197265625], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 458, "type": "image", "page_idx": 78, "img_path": "layout_images/roche-holdings_2021_51.jpg", "bbox": [489, 544, 595, 695], "page_size": [595.2760009765625, 793.7009887695312], "ocr_text": "1 rover 8 fovea\nhtt — —i/>\n\nQiciensnce 17 Fortes\n", "vlm_text": "The image displays a graphic related to the United Nations Sustainable Development Goals (SDGs). It highlights:\n\n- Goal 1: No Poverty\n- Goal 3: Good Health and Well-being\n- Goal 9: Industry, Innovation, and Infrastructure\n- Goal 17: Partnerships for the Goals\n\nBelow the goals, it lists \"Material topics,\" which include:\n- Long-term mindset\n- Availability of healthcare"}
{"layout": 459, "type": "text", "text": "valuable in regions with limited pathology services,  such as Africa. We are also developing new tools  to support patients in taking a more active role  in their disease management. For example, we  have created iThemba Life, a mobile health  application which delivers HIV viral load results,  education, reminders and support directly to users’  smartphones. The app empowers people living with  HIV to remain adherent to treatment and engaged  in care. In 2021, we extended its functionality to  cover cervical cancer to address a key challenge  of loss to follow-up.  ", "page_idx": 79, "bbox": [120, 181.2001953125, 317, 325.3172912597656], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 460, "type": "text", "text": "Programmes and partnerships that support  access along the patient journey  Our strengths in pharmaceuticals and diagnostics  position us to play an early role in the patient  journey and identify barriers to access. We have  learned a great deal through our partnerships and  can apply those learnings to future initiatives. ", "page_idx": 79, "bbox": [120, 337.1702880859375, 317, 421.3023376464844], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 461, "type": "text", "text": "Examples of our programmes and partnerships:\n\n •\t  In 2021, we expanded our Global Access Program  to include SARS-CoV-2 PCR testing to increase  access in low- and middle-income countries  during the ongoing pandemic. \n\n •\t  We have been awarded World Health  Organization’s (WHO) pre qualification for HIV  and HCV tests, and WHO guidelines now include  cobas MTB and cobas MTB-RIF/INH tests, all on  the cobas 6800/8800 systems. For patients living  in areas with limited healthcare resources, WHO  pre qualification ensures access to the highest- quality diagnostics.\n\n •\t  Our Diagnostics Division continued its partnership  with the non-profit organisation (RED) on a shared  mission to emphasise the importance of diagnostic testing in the fight against COVID-19 and the  ongoing HIV/AIDS epidemic, and to mitigate  further impact of COVID-19 on health systems in  order to reach patients where access is limited.\n\n •\t  Roche joined the World Economic Forum’s Ending  Workplace TB initiative, a coalition of companies  and key organisations active in the fight against  tuberculosis.\n\n ", "page_idx": 79, "bbox": [120, 433.15533447265625, 317, 697.3502197265625], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 462, "type": "text", "text": "•\t  We continue to have a strong partnership with the  City Cancer Challenge (C/Can). Our joint mission  is to improve access to equitable, quality cancer  care in cities around the world. As of December  2021, C/Can is working in 9 cities reaching  an estimated 54.2 million people and brings  together more than 1,200 health professionals,  149 institutions and 77 global partners from  around the world.\n\n •\t  In the US, the Genentech Patient Foundation  provides free medicine to approximately  60,000 people each year.\n\n •\t  Through a partnership with the ECHO Institute, we  are working to establish a remote telementoring  programme for health workers in underserved  or rural communities, enabling them to diagnose  and treat patients faster and more effectively.  The ECHO platform connects national centres  of excellence to remote areas. In 2021, Roche  was setting up ECHO clinics in various countries  (Philippines, Indonesia, Pakistan, India, Malaysia,  Guatemala and Canada for their First Nations  Population), with several already launched. \n\n •\t  Roche officially joined the Go Further Partnership,  which was established in 2018 as an innovative,  public-private partnership between the  U.S. President’s Emergency Plan for AIDS Relief  (PEPFAR), the George W. Bush Institute, UNAIDS  and Merck. Go Further is committed to creating  a healthier future for women and aims to reduce  new cervical cancer cases by   $95\\%$   among  women living with HIV in 12 African countries. ", "page_idx": 79, "bbox": [330, 181.2001953125, 528, 589.3292236328125], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 463, "type": "text", "text": "Our responsible approach to medicine pricing  Because we endeavour to ensure that affordability  is not a barrier to access, we take the pricing of  our medicines and innovations very seriously. Our  pricing strategy reflects the WHO’s definition of fair  pricing, balancing the need for both affordability  and incentives for innovation with the needs of  patients today and tomorrow.  ", "page_idx": 79, "bbox": [330, 601.1821899414062, 528, 697.3112182617188], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 464, "type": "text", "text": "We have long been committed to low- and middle-income countries  in order to broaden access to our medicines and diagnostics. ", "page_idx": 80, "bbox": [68, 98.2001953125, 261, 121.00019836425781], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 465, "type": "text", "text": "Like other healthcare stakeholders, we believe  that differential pricing can be an effective  solution to address affordability constraints of  a specific country. Our International Differential  Pricing (IDP) approach allows our local organisations  to adjust prices to reflect a country’s relative  income and their ability to pay, ensuring that our  innovations are fairly priced and can reach patients  in need. This approach has been proven to greatly  improve patient access to innovative medicines,  particularly in developing countries where price  is a primary barrier.  ", "page_idx": 80, "bbox": [68, 181.2000732421875, 265.3250732421875, 325.35009765625], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 466, "type": "text", "text": "Partnering to improve access in women’s health Our work in women’s health exemplifies our tailored  approach to access. Roche is committed to a  woman’s health at every stage of her life, supporting  needs around reproduction, fertility and pregnancy,  as well as disease prevention and treatment through  a variety of diagnostic screenings, monitoring  assays and innovative medicines. Our efforts to  support and improve women’s health are aligned  with the WHO’s Global Strategy for Women’s,  Children’s and Adolescents’ Health, 2016–2030,  and its Every Woman Every Child movement.  ", "page_idx": 80, "bbox": [67, 337.2001037597656, 265, 481.35009765625], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 467, "type": "text", "text": "A key example of this commitment is our work in  women’s cancers, such as breast and gynaecologic  cancers. In our efforts to combat cervical cancer,  we work with countries to further strengthen  healthcare systems and help establish national  cervical cancer programmes to eliminate the  disease. Over  $85\\%$   of annual cervical cancer  deaths occur in LMICs where we are helping  overcome barriers to care, specifically by  increasing awareness around screening. Roche  is collaborating with partners to help countries  implement national HPV screening and treatment  programmes ( please see the story on page 81 ). ", "page_idx": 80, "bbox": [67, 493.2001037597656, 265, 649.35009765625], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 468, "type": "text", "text": "125 years of milestones ", "text_level": 1, "page_idx": 80, "bbox": [320, 443, 442, 458], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 469, "type": "text", "text": "Revolutionising the care of people living with HIV  Since entering the diagnostics space in 1968, Roche has had a strong  focus on infectious diseases. Following the identification of HIV in  the 1980s, we were at the forefront of developing diagnostics for  HIV, particularly molecular tests for early infant diagnosis and viral  load testing to monitor treatment response. This revolutionised the  management and care of HIV-positive patients. ", "page_idx": 80, "bbox": [320, 468.2001953125, 552, 553.3502197265625], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 470, "type": "text", "text": "To enable equitable access to HIV testing in resource-limited settings,  and to support the UNAIDS 2020 targets, Roche created the Global Access  Program in 2014. Through this programme, Roche provides sustainable  pricing to governments and funders and works with partners to build the  infrastructure and capabilities required to run diagnostic programmes.  Each year, over 8 million people   in Africa use our viral load testing to  manage their HIV infection and to date over 11 million babies have been  tested for HIV with Roche tests. ", "page_idx": 80, "bbox": [320, 565.2001953125, 557, 661.3502197265625], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 471, "type": "text", "text": "Across the Asia-Pacific region, HPV continues to  be responsible for the majority of cervical cancer  cases. In some countries, cervical cancer is the  ", "page_idx": 80, "bbox": [67, 661.2000732421875, 254.25656127929688, 697.35009765625], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 472, "type": "image", "page_idx": 81, "img_path": "layout_images/roche-holdings_2021_52.jpg", "bbox": [0, 66, 318, 410], "page_size": [595.2760009765625, 793.7009887695312], "ocr_text": "", "vlm_text": "The image shows a person using a magnifying glass to examine mammogram images, which are displayed on a lightbox. These images are likely related to breast cancer screening."}
{"layout": 473, "type": "image", "page_idx": 81, "img_path": "layout_images/roche-holdings_2021_53.jpg", "bbox": [0, 417, 317, 696], "page_size": [595.2760009765625, 793.7009887695312], "ocr_text": "", "vlm_text": "The image shows a person sitting in a chair undergoing a medical procedure, likely dialysis. The person has tubes connected to their arm, which are typical in such treatments. They are wearing a headscarf, and there are medical devices visible in the background."}
{"layout": 474, "type": "text", "text": "We support programmes around the world that are aimed at  increasing access to diagnostics and treatments for breast cancer. ", "page_idx": 81, "bbox": [331, 98.2003173828125, 525, 121.00032043457031], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 475, "type": "text", "text": "second most common cancer. In August 2021, the  APEC Roadmap to Promote Sustainable Economic  Advancement for Women Through Cervical Cancer  Prevention and Control (2021–2025) was officially  endorsed by the 21 members of the Asia-Pacific  Economic Cooperation (APEC). Roche contributed  to the development of this new roadmap to include  cervical cancer screening, especially using HPV  molecular testing.  ", "page_idx": 81, "bbox": [331, 181.2001953125, 525, 289.3292541503906], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 476, "type": "text", "text": "In 2020, breast cancer overtook lung cancer as  the world’s most commonly diagnosed cancer. It  is responsible for one in six of all cancer deaths  among women. In line with the new WHO Global  Breast Cancer Initiative and our focus on women’s  health, we increased the number of people treated  with Perjeta in China by   $65\\%$   from August 2020  to August 2021. In the UK, we have also seen  $80\\%$    of breast cancer patients switch to Phesgo, a  subcutaneous fixed-dose combination of Perjeta  and Herceptin, with a shorter and less invasive  mode of administration. This has reduced the  number of patients who receive their medicines  via intravenous infusion, freeing up capacity in  hospitals. ", "page_idx": 81, "bbox": [331, 301.1822509765625, 525, 481.2903747558594], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 477, "type": "text", "text": "Towards better access in the future Looking forward, our work to expand access will  continue to be a priority. By working in partnership  with stakeholders across the healthcare spectrum –  from governments and payers to non-governmental  organisations, multilaterals and insurance  companies – we will continue to develop tailored  solutions that help overcome barriers to create  rapid, broad and sustainable access. ", "page_idx": 81, "bbox": [331, 493.14337158203125, 525, 601.2694091796875], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 478, "type": "text", "text": "Women 4 Cancer  ", "text_level": 1, "page_idx": 82, "bbox": [67, 205, 144, 216], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 479, "type": "text", "text": "Kenya ", "text_level": 1, "page_idx": 82, "bbox": [66, 222, 102, 233], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 480, "type": "text", "text": "Roche is supporting the EMPOWER programme, which  seeks to contribute to the prevention, early diagnosis,  treatment and education of women in the community  on breast and cervical cancer. ", "page_idx": 82, "bbox": [67, 242.2001953125, 223, 289.00018310546875], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 481, "type": "text", "text": "Pink Consulting Rooms  ", "text_level": 1, "page_idx": 82, "bbox": [66, 361, 173, 373], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 482, "type": "text", "text": "Colombia ", "text_level": 1, "page_idx": 82, "bbox": [67, 377, 119, 389], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 483, "type": "text", "text": "To address problems around breast cancer diagnosis  and treatments, Roche has supported the set up of  over 150 Pink Consulting Rooms, testing over one  million women and diagnosing more than 14,000. ", "page_idx": 82, "bbox": [67, 398.2001953125, 223, 445.00018310546875], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 484, "type": "text", "text": "Hepatitis C diagnosis Pakistan ", "text_level": 1, "page_idx": 82, "bbox": [402, 205, 499, 233], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 485, "type": "image", "page_idx": 82, "img_path": "layout_images/roche-holdings_2021_54.jpg", "bbox": [241, 228, 387, 384], "page_size": [595.2760009765625, 793.7009887695312], "ocr_text": "Some\n\naccess projects\n\naround the world\n\n", "vlm_text": "The image shows a circular chart with three segments in different colors: a mustard yellow, a dark purple, and a light gray. Inside the circle, there is text saying, \"Some access projects around the world.\""}
{"layout": 486, "type": "text", "text": "This partnership supports  underprivileged people with  hepatitis C testing and diagnosis.  ", "page_idx": 82, "bbox": [404, 242.2001953125, 500.76629638671875, 277.00018310546875], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 487, "type": "text", "text": "Bridge   LATAM\\* ", "text_level": 1, "page_idx": 82, "bbox": [445, 313, 491, 341], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 488, "type": "text", "text": "This initiative is implementing  national programmes aimed at  cervical cancer elimination. ", "page_idx": 82, "bbox": [446, 350.2001953125, 535, 385.00018310546875], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 489, "type": "text", "text": "Cervical cancer screening and triage  Thailand ", "text_level": 1, "page_idx": 82, "bbox": [347, 408, 514, 437], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 490, "type": "text", "text": "To support Thailand’s goal of eradicating cervical  cancer, Roche has been partnering with the government  and the healthcare community to raise awareness of  HPV DNA testing. ", "page_idx": 82, "bbox": [348, 446.2001953125, 510.3381042480469, 493.00018310546875], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 491, "type": "image", "page_idx": 83, "img_path": "layout_images/roche-holdings_2021_55.jpg", "bbox": [1, 67, 529, 406], "page_size": [595.2760009765625, 793.7009887695312], "ocr_text": "SILENCE\nPLEASE\n\n", "vlm_text": "The image shows a waiting area or hallway painted in pink, with several people sitting on benches along the wall. A sign on the wall reads \"SILENCE PLEASE.\" There are blue doors visible, and it seems to be a public space like a clinic or an office."}
{"layout": 492, "type": "image", "page_idx": 83, "img_path": "layout_images/roche-holdings_2021_56.jpg", "img_caption": "Working in collaboration with healthcare systems and our partners  is key to resolving critical access barriers to therapies. ", "bbox": [0, 415, 525, 697], "page_size": [595.2760009765625, 793.7009887695312], "ocr_text": "", "vlm_text": "The image shows a person wearing gloves and a lab coat holding a tray with multiple test tubes. This setting suggests a laboratory or medical environment, which aligns with the caption discussing collaboration with healthcare systems to address access barriers to therapies."}
{"layout": 493, "type": "text", "text": "Tackling healthcare’s greatest challenges  in women’s health  ", "text_level": 1, "page_idx": 84, "bbox": [66, 98, 410, 151], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 494, "type": "text", "text": "At Roche, we challenge not only ourselves but  entire healthcare systems to bring life-changing  solutions to patients across the globe. Why?  Because it is what society expects of us, and it is  why we come to work every day. We are relentlessly  looking towards the needs of tomorrow in the hope  that one day, our vision of a brighter, healthier world  will become reality. But each passing year brings  new challenges, including access to diagnostics  and treatments for diseases like cervical cancer.  ", "page_idx": 84, "bbox": [67, 181.2001953125, 261, 301.3501892089844], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 495, "type": "text", "text": "More than  $90\\%$   of cervical cancer cases result  from human papillomavirus (HPV), a sexually  transmitted infection for which a vaccine already  exists. 1  Despite being almost   $100\\%$   preventable  with vaccination and screening, approximately  300,000 women succumb to the disease every  year,  making it one of the most common causes  of cancer death in women. ", "page_idx": 84, "bbox": [67, 313, 261, 409.3501892089844], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 496, "type": "text", "text": "Many countries are moving to HPV DNA testing  as a more effective and efficient disease  prevention strategy. In fact, the World Health  Organization (WHO) recently endorsed it as the  first-choice method for cervical cancer screening. Recommended clinical guidelines have also been  evolving in favour of HPV tests for first-line primary  screening, supported by an interest to improve  outcomes, and the availability of technologies to  help laboratories achieve the efficiency and scale  they need to meet the demands of high-volume  cervical screening programmes. ", "page_idx": 84, "bbox": [67, 421.2001953125, 261, 565.3502197265625], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 497, "type": "text", "text": "The rapidity and scale at which comprehensive  testing portfolios were developed during the  pandemic left many to wonder: Could the same  not be done to curb the spread of other life- threatening diseases? After all, Roche’s cobas  instruments used for COVID-19 testing are some  of the same used for cervical cancer screening.  This, in and of itself, could be a game changer that  could allow countries who would not have had the  infrastructure in place prior to the pandemic to  utilise these machines to help address significant  gaps in women’s health. ", "page_idx": 84, "bbox": [67, 577.2001953125, 261, 613.3502197265625], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 498, "type": "text", "text": "", "page_idx": 84, "bbox": [277, 181.2001953125, 468, 289.3501892089844], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 499, "type": "text", "text": "But life-changing innovation is only impactful if  it reaches those who need it. Over   $85\\%$   of global  cervical cancer deaths occur in middle- and low- income countries, where diagnostic discrepancies  and disparities are most prevalent.  This is why we  have adjusted our focus so that we not only develop  and deliver advanced diagnostic solutions but  also address the significant disparities in cervical  cancer, especially in regions where the burden  of the disease is at its peak. Roche added HPV  screening to our Global Access Program to make  cutting-edge diagnostic solutions available to  women in the greatest need.  ", "page_idx": 84, "bbox": [277, 301.2001953125, 473, 457.3501892089844], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 500, "type": "text", "text": "The world is watching and waiting for advances  to be made in women’s health. In July 2021, the  WHO announced updated screening guidelines  that will help realise its goal of eliminating cervical  cancer by 2030. Our Diagnostics Division remains  committed to investing in advancements that will  significantly improve prevention strategies and  provide women with the protection and care they  deserve. Empowering women to take control  over their health lies at the core of our ambition  to transform healthcare and while progress has  been made, we know we can still do more.  ", "page_idx": 84, "bbox": [277, 469.2001953125, 468, 613.3502197265625], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 501, "type": "image", "page_idx": 85, "img_path": "layout_images/roche-holdings_2021_57.jpg", "bbox": [0, 0, 596, 794], "page_size": [595.2760009765625, 793.7009887695312], "ocr_text": ":\n$\n2.\n3\n3\n:\n3\n§\nMs\n‘.\nx\nbe\n\n", "vlm_text": "The image shows a person in a colorful, patterned long dress holding books. They are walking through a bookstore or library aisle with shelves filled with books on both sides."}
{"layout": 502, "type": "text", "text": "When words save lives ", "text_level": 1, "page_idx": 86, "bbox": [66, 99, 252, 123], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 503, "type": "text", "text": "Agnès Kraidy is a journalist and activist from Abidjan, Côte d’Ivoire.  She is also a breast cancer survivor campaigning for every woman to  have access to diagnostics, medicines and, above all, information. ", "page_idx": 86, "bbox": [67, 138.2000732421875, 446.8782958984375, 207.80007934570312], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 504, "type": "text", "text": "“I felt a lump in my left breast. Very small, but  clearly noticeable,” Agnès explains. She knew  something wasn’t right, so she immediately went to  her company doctor to get it checked. “AIthough  non-surgical treatments were available, the  doctors recommended that I have a mastectomy.  I realised that, like many women in Côte d’Ivoire,  I had very little information and knowledge about  breast cancer.’’ And this despite the fact that the  disease affects approximately 2,300 women in the  country  each year, with half of those diagnosed  not surviving.  ", "page_idx": 86, "bbox": [65, 241.2001953125, 257, 385.3172912597656], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 505, "type": "text", "text": "Giving hope and changing perspectives Ultimately, Agnès didn’t go ahead with a  mastectomy. But she was determined that all  women in Côte d’Ivoire needed to learn more  about this dreadful illness. “I want them to be able  to share knowledge with others affected. This is  also why I wrote a book about my journey and the  lessons I’ve learned along the way.” Unsurprisingly,  Tu me fous les boules! Vaincre le cancer  was the  catalyst for a large awareness campaign across  the country. ", "page_idx": 86, "bbox": [65, 397.2001953125, 257, 529.3203125], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 506, "type": "text", "text": "Obstacles at every step of the patient journey Despite more awareness being raised thanks to  Agnès’s efforts, people in Côte d’Ivoire still face  a multitude of barriers to access the diagnostics  and treatments they deserve. One of these  barriers is the affordability of treatment as there  is no reimbursement policy for cancer treatments.  Since 2014 and in close collaboration with the  government, Roche has been helping increase  access to high-quality care across the country.  For instance, the first agreement, made under  the National Programme against Cancer, provides  free testing for HER2-positive breast cancer  ", "page_idx": 86, "bbox": [65, 541.2001953125, 257, 697.3141479492188], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 507, "type": "text", "text": "through the public health system. As part of our  current work with the government, Herceptin is  free for all HER2-positive breast cancer patients.  ", "page_idx": 86, "bbox": [277, 241.1671142578125, 475, 277.3111267089844], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 508, "type": "text", "text": "“We are happy to now have basic diagnostics,  but what if you need a biopsy or something even  more sophisticated to ensure you are treated  correctly?” Agnès asks. “There are simply not  enough healthcare professionals or well-equipped  hospitals for the number of patients in need.”  ", "page_idx": 86, "bbox": [277, 289.2001953125, 475, 361.3352355957031], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 509, "type": "text", "text": "Geography can also prevent access. Côte  d’Ivoire’s oncology centres are mostly located  in Abidjan, which means long journeys and high  accommodation costs for anyone living outside of  the city centre. “This is yet another obstacle for  people who simply cannot afford these costs for  the many months of their treatment,” says Agnès.  Therefore, in 2021, Roche supported the setting  up of a new oncology centre in Bouaké to bring  screening, diagnosis and follow-up closer to those  living in other parts of the country. ", "page_idx": 86, "bbox": [277, 373.2001953125, 475, 505.3202819824219], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 510, "type": "text", "text": "While words can save lives, partnerships can too “There are many people who have the power to  create solutions to the barriers patients face  –  but  they often don’t wish to challenge the status quo. I  call this the cancer of ignorance.” This is why Agnès  is advocating ongoing investment in awareness  campaigns and patient support programmes, as  well as partnerships across different sectors.  ", "page_idx": 86, "bbox": [277, 517.2001953125, 475, 613.3291625976562], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 511, "type": "text", "text": "Despite the numerous challenges, Agnès looks  positively to the future and is thankful that some  improvements have already been made. “As our focus  continues to be how we can save more lives, we will  continue to overcome barriers to bring effective  solutions to patients everywhere in Côte d’Ivoire.”  ", "page_idx": 86, "bbox": [277, 625.2001953125, 475, 697.335205078125], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 512, "type": "image", "page_idx": 87, "img_path": "layout_images/roche-holdings_2021_58.jpg", "bbox": [1, 1, 593, 793], "page_size": [595.2760009765625, 793.7009887695312], "ocr_text": "", "vlm_text": "The image shows a close-up view of a yellow grid structure. It appears to be an abstract pattern with a slight blur in the background, which has blue and white elements. This might be a photograph of a grid-like part of a plastic object."}
{"layout": 513, "type": "text", "text": "People  and culture ", "text_level": 1, "page_idx": 88, "bbox": [129, 468, 376, 599], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 514, "type": "image", "page_idx": 89, "img_path": "layout_images/roche-holdings_2021_59.jpg", "bbox": [1, 0, 593, 794], "page_size": [595.2760009765625, 793.7009887695312], "ocr_text": "", "vlm_text": "The image shows a close-up of a person with blue eyes, brown hair, and wearing a plaid scarf. There is no additional context or caption text provided."}
{"layout": 515, "type": "text", "text": "We are #RocheProud ", "text_level": 1, "page_idx": 90, "bbox": [65, 98, 297, 121], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 516, "type": "text", "text": "The pandemic changed many of our personal and professional routines,  while also reaffirming our connection to our shared purpose and  strengthening our sense of belonging and pride working for Roche.  ", "page_idx": 90, "bbox": [66, 138.2001953125, 461.5084533691406, 207.80020141601562], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 517, "type": "text", "text": "The happiness and engagement of our people  is fundamental to our success. In 2021, we  conducted our biennial Global Employee Opinion  Survey (GEOS). Seventy-eight percent of all  Roche employees participated in the survey  and shared how happy they are to be working at  Roche. Those results are especially satisfying  when we consider that the survey followed a  particularly intense period. We underwent critical  purpose-driven transformations while maintaining  a relentless focus on ongoing business initiatives.  At the same time, we worked to ensure we  remained supportive of our people and patients  in the face of the COVID-19 pandemic.  ", "page_idx": 90, "bbox": [67, 241.2001953125, 260, 409.3501892089844], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 518, "type": "text", "text": "Because of the ongoing pandemic-related  challenges, we faced many unpredictable and  difficult situations. Nevertheless, our people  remained highly engaged, evidenced with a score  of 80 out of 100, unchanged from the 2019 GEOS  survey. These results keep Roche in the top quartile  of the global healthcare industry according to  the GEOS benchmark, and validate our continued  efforts to sustain a great working environment.  ", "page_idx": 90, "bbox": [67, 421.2001953125, 260, 529.3502197265625], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 519, "type": "text", "text": "It is clear from the survey that our people are  happy working at Roche, enjoy an inclusive and  rewarding culture, and feel optimistic about our  future and the positive impact we have on patients.  ", "page_idx": 90, "bbox": [67, 541.2001953125, 260, 589.3502197265625], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 520, "type": "text", "text": "A focus on the safety and well-being  of our people ", "text_level": 1, "page_idx": 90, "bbox": [67, 602, 218, 624], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 521, "type": "text", "text": "As a company, we are committed to serving the  needs of our patients and society. As an employer,  we are committed to providing a safe and inclusive  working environment that enables our people to  grow, thrive and reach their full potential. Our  culture is people-centred and purpose-driven.  ", "page_idx": 90, "bbox": [67, 625.2001953125, 260, 697.3502197265625], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 522, "type": "text", "text": "We know the important role we play as a critical  global supplier of healthcare solutions. This has  been even more evident throughout the COVID-19  pandemic, and is why business continuity, under  these circumstances, carries higher expectations.  ", "page_idx": 90, "bbox": [277, 241.2001953125, 473, 301.3501892089844], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 523, "type": "text", "text": "Throughout 2021, we took special care in  implementing adequate on-site safety measures  to protect our employees across research and  development, manufacturing and the global supply  chain. We also worked diligently to ensure the  safety of everyone in our global support functions,  particularly those working at customer premises  who were more likely to be exposed to the virus.  The health and safety of our employees is always  paramount, and is also key to maintaining a reliable  supply of medicines and diagnostic solutions for  the patients and customers who need them. We  are committed to going the extra mile to ensure  all aspects of our work – including our workplaces  as well as third-party manufacturers and suppliers –  remain safe and healthy.  ", "page_idx": 90, "bbox": [277, 313.2001953125, 473, 505.3501892089844], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 524, "type": "text", "text": "In these unprecedented times, the mental and  physical well-being of all our employees demand  greater focus. To help support both aspects,  we have put a number of assistance programmes  in place. These programmes provide guidance  on working from home, mental health, nutrition,  ergonomics, social well-being, sleep, fitness,  mindfulness and resilience.  ", "page_idx": 90, "bbox": [277, 517.2001953125, 462, 613.3502197265625], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 525, "type": "text", "text": "During our global Live Well week in September,  renowned keynote speakers shared their insights  on resilience, friendship and happiness. We also  offered multiple complementary activities both  on-site and virtually, ranging from online yoga and  other fitness classes to a 21-day resilience challenge.  ", "page_idx": 90, "bbox": [277, 625.2001953125, 473, 697.3502197265625], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 526, "type": "image", "page_idx": 90, "img_path": "layout_images/roche-holdings_2021_60.jpg", "bbox": [489, 555, 595, 694], "page_size": [595.2760009765625, 793.7009887695312], "ocr_text": "UN SDGs\n4 Sion 5 itn\n\nwi ¢\n\nMaterial topics\n\n- Talent attraction\nand retention\n\n- Organisational agility\n\n- Patient centricity\n", "vlm_text": "The image features references to UN Sustainable Development Goals (SDGs). It highlights:\n\n- SDG 4: Quality Education\n- SDG 5: Gender Equality\n\nBelow these, the image lists \"Material topics,\" which include:\n\n- Talent attraction and retention\n- Organisational agility\n- Patient centricity"}
{"layout": 527, "type": "text", "text": "Diversity & Inclusion at work  Another critical aspect of our culture is providing  an inclusive work environment, where authenticity  and respect are inherent and a sense of belonging  is nurtured. To ensure we maintain that environment,  we have explicitly emphasised Diversity & Inclusion  (D&I) as a crucial part of Roche’s history and  cultural identity.  ", "page_idx": 91, "bbox": [120, 181.2001953125, 316, 277.3292541503906], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 528, "type": "text", "text": "In 2021 we introduced our updated D&I vision  and strategic pillars. We also established a D&I  Council, which oversees the strategic and overall  governance of D&I, and ensures that D&I is properly  integrated into our business strategies.  ", "page_idx": 91, "bbox": [120, 289.1822509765625, 316, 349.3202819824219], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 529, "type": "text", "text": "Our updated D&I strategy focuses on four pillars: \n\n •\t Patients: Addressing the unmet needs  of diverse patients and communities \n Specific activities in this pillar include diversity in  clinical trials and inclusive research. One example  is EMPACTA (Evaluating Minority Patients with  Actemra), the first global, phase III COVID-19  clinical trial designed specifically to enrol patient  populations that are often underrepresented in  clinical studies and have been disproportionately  affected by the pandemic.\n\n •\t People: Building a workforce that reflects  the societies we serve\n In this pillar, we increased data transparency and  released our gender pay equity report. Based on  our organisation-wide analysis – and taking into  consideration global grading, job structure, level  in organisation, etc. – we found no significant  difference in pay between men and women  in similar jobs. In accordance with the United  Nations Sustainable Development Goal number  five to “achieve gender equality and empower  all women and girls”, we continue to commit  ourselves to further advancing the opportunities  for women within the organisation, most notably  by increasing the proportion of female leaders in  executive positions by an additional  $2\\%$   in 2021. ", "page_idx": 91, "bbox": [120, 361.17327880859375, 316, 685.3111572265625], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 530, "type": "text", "text": "•\t Culture: Ensuring our employees can thrive  and deliver their best work, while also  remaining true to themselves\n When employees feel comfortable presenting  themselves as they choose, and confident  they are protected from discrimination based  on gender, culture, race, sexual orientation, or  any other aspect, they are free to focus on  doing their best work. To ensure we measure  this accurately, we have integrated an inclusion  index in GEOS. \n\n •\t Society: Advancing positive change in society  For this pillar, we foster supplier and vendor  diversity and invest in STEM (Science, Technology,  Engineering, Mathematics), activities to inspire  and support future talents. ", "page_idx": 91, "bbox": [330, 181.2001953125, 528, 373.3412170410156], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 531, "type": "text", "text": "Additionally, our senior leaders demonstrated a  strong engagement with D&I through their individual  D&I commitments, which were shared across the  organisation. ", "page_idx": 91, "bbox": [330, 385.1942138671875, 528, 433.3352355957031], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 532, "type": "text", "text": "Over the course of the year, we celebrated D&I  through multiple events and activities, including  the Choose to Challenge campaign, which  was launched in connection with International  Women’s Day (IWD) and continued throughout  the year. The campaign called on participants to  call out gender bias and inequality and celebrate  women’s achievements. It included a photo  challenge which encouraged Roche employees  to raise their hands and show solidarity for IWD,  and challenge the status quo for greater gender  equality in the world.  ", "page_idx": 91, "bbox": [330, 445.188232421875, 517, 589.3052978515625], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 533, "type": "text", "text": "Pride Month in June was another highlight. We  celebrated with our affiliates around the world,  and Roche in Switzerland was awarded the   ${\\mathsf{L}}{\\mathsf{G B T}}{\\mathsf{I}}{\\mathsf{Q}}+$   certification by the Swiss LGBTI-Label,  an organisation that certifies Swiss companies  that advocate internal equality for the LGBTIQ+  community.  ", "page_idx": 91, "bbox": [330, 601.1582641601562, 517, 685.290283203125], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 534, "type": "image", "page_idx": 92, "img_path": "layout_images/roche-holdings_2021_61.jpg", "bbox": [278, 66, 596, 404], "page_size": [595.2760009765625, 793.7009887695312], "ocr_text": "", "vlm_text": "The image shows a group of people in a laboratory setting wearing lab coats and safety goggles. They appear to be engaged in a scientific activity, with lab equipment visible, such as pipettes and possibly a Bunsen burner in use."}
{"layout": 535, "type": "text", "text": "We are proud of our inclusive work environment, where authenticity  and respect are inherent and a sense of belonging is nurtured.  ", "page_idx": 92, "bbox": [67, 98.2001953125, 265, 121.00019836425781], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 536, "type": "text", "text": "During our D&I Month in November we brought  together employees from across the organisation  to intensify our commitment to Diversity & Inclusion.  Employees could choose from over 60 virtual  events, inspiring discussions and engaging sessions,  such as Unconscious Bias Training, Advancing  Inclusive Research, Health Equity, Neurodiversity,  and many more. ", "page_idx": 92, "bbox": [67, 181.2000732421875, 265, 277.3500671386719], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 537, "type": "text", "text": "We recognise and value the uniqueness of each  individual, regardless of their gender, race,  age, skin colour, religion, marital status, sexual  orientation, heritage, or physical or mental ability.  This is why Roche does not – nor will it ever – tolerate  discrimination in any shape or form. Furthermore,  we firmly condemn any type of harassment – mental,  physical or sexual – or any other infringement  violating an employee’s right to dignity and respect  in the workplace. ", "page_idx": 92, "bbox": [67, 289.2001037597656, 265, 409.35009765625], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 538, "type": "image", "page_idx": 92, "img_path": "layout_images/roche-holdings_2021_62.jpg", "bbox": [277, 416, 596, 694], "page_size": [595.2760009765625, 793.7009887695312], "ocr_text": "", "vlm_text": "The image shows a person wearing a white shirt, cleaning a table with a spray bottle and a cloth. They are in a room with overhead lights and tables, suggesting a cafeteria or dining area. The shirt has a logo on it."}
{"layout": 539, "type": "text", "text": "Our stance on D&I has been further strengthened  in our updated employment policy. We are deeply  convinced that our success depends on the talent  and performance of our dedicated and diverse  workforce. Moreover, we strongly believe in the  potential of every single employee and remain  committed to unlocking the potential of all our  people to bring our purpose to life.  ", "page_idx": 92, "bbox": [67, 421.2001037597656, 256, 517.35009765625], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 540, "type": "text", "text": "", "text_level": 1, "page_idx": 92, "bbox": [67, 531, 196, 536.75], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 541, "type": "text", "text": "Creating a truly diverse and inclusive workplace  and living our new ways of working will directly  impact our ability to achieve our long-term  ambitions and deliver on our purpose of  doing  now what patients need next . We believe  the greatest ideas arise through collaboration  and co-creation. By asking tough questions,  exchanging perspectives and challenging not  only ourselves, but also shifting paradigms,  we are capable of innovating and developing  life-changing solutions.  ", "page_idx": 92, "bbox": [67, 541.2000732421875, 247, 673.35009765625], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 542, "type": "image", "page_idx": 93, "img_path": "layout_images/roche-holdings_2021_63.jpg", "bbox": [0, 68, 318, 406], "page_size": [595.2760009765625, 793.7009887695312], "ocr_text": "", "vlm_text": "The image shows a person with long hair, wearing a brown knitted cardigan and a black top, using a tablet at a high table. There is a glass of water on the table next to the tablet. The setting appears to be indoors, possibly by a window."}
{"layout": 543, "type": "text", "text": "125 years of milestones ", "text_level": 1, "page_idx": 93, "bbox": [35, 443, 156, 457], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 544, "type": "text", "text": "Alice Keller shatters the glass ceiling Alice Keller had talent. Talent that Emil C. Barell, CEO of Roche from 1920  until 1953, recognised when he brought her into the company. He had a  feeling for brilliant people and did not care much for the convention of  the times. Whether man or woman, it did not matter. He was a champion  of excellence in any form. ", "page_idx": 93, "bbox": [36, 468.2001953125, 269.2904052734375, 541.3502197265625], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 545, "type": "text", "text": "In 1926, he posted Alice to a position in Japan. After a 35-day journey  by boat, she arrived in Tokyo to handle the country’s product launches  and correspondence with Basel. Alice loved Japan and, unsurprisingly,  excelled at the role. Within three years, she was promoted to Director  of Roche Japan, making her the first woman senior executive at Roche.  It was a sensational development at the time. ", "page_idx": 93, "bbox": [36, 553.2001953125, 264, 625.3502197265625], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 546, "type": "text", "text": "Women like Alice paved the way for the inclusion of people with diverse  backgrounds, experiences, skills and perspectives, which is key to our  success today, and in the future. ", "page_idx": 93, "bbox": [36, 637.2001953125, 264, 673.3502197265625], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 547, "type": "text", "text": "In 2021, we increased the use of technology and digitalisation and  introduced a number of new approaches and tools to provide our  people with around-the-clock support. ", "page_idx": 93, "bbox": [331, 98.2003173828125, 525, 133.0003204345703], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 548, "type": "text", "text": "Our rapidly changing environment is prompting  us to think differently about how to sustain our  competitiveness. But we are no stranger to  change – our capacity to adapt and undergo  transformations has been in our DNA since our  founding 125 years ago. We have reinvented  ourselves, advanced science and technology,  and adjusted our ways of working multiple  times throughout our history. The most recent  implementation of agile working methodologies  and operating models has boosted the speed  and efficiency with which we deliver our solutions  to patients and healthcare providers. ", "page_idx": 93, "bbox": [331, 181.2001953125, 525, 337.3143005371094], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 549, "type": "text", "text": "While the pandemic forced a physical distance  among many of us, it also revolutionised our  ways of working, making us much more agile  and collaborative. Roche continued its broad  transformation journey and, despite the confusion  and uncertainty created by the pandemic, our  people have never shown more engagement and  dedication for co-creating the future and shaping  healthcare systems than they have throughout  these challenging times. ", "page_idx": 93, "bbox": [331, 349.16729736328125, 525, 469.2903747558594], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 550, "type": "text", "text": "Evolving our ways of leading Our new ways of working go hand in hand with  new ways of leading. Every Roche employee  deserves to work and thrive under great leadership,  which is why we have been operating under our  seven leadership commitments for many years.  At the same time, the role of our leaders has  evolved  –  and continues to  do so . ", "page_idx": 93, "bbox": [331, 481.14337158203125, 525, 577.3502197265625], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 551, "type": "text", "text": "Over the past several years, we have continued to  utilise Kinesis and Synergy, our senior leadership  development programmes. But the pandemic forced  us to re-think the way we organise and run our  programmes and events. For instance, the Global  Virtual Leadership Development Initiative was  launched virtually in 2021 which, incidentally, gave  a much broader audience access to this valuable tool.  ", "page_idx": 93, "bbox": [331, 589.4065551757812, 529, 685.2533569335938], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 552, "type": "image", "page_idx": 94, "img_path": "layout_images/roche-holdings_2021_64.jpg", "bbox": [278, 68, 596, 406], "page_size": [595.2760009765625, 793.7009887695312], "ocr_text": "Ii\n", "vlm_text": "The image shows a modern office space with large windows allowing natural light to fill the room. There are three people sitting at a wooden table, engaged in conversation, with laptops open in front of them. The setting includes a high ceiling with minimalist lighting and a few stools around the table. The office has an open-plan design with a spacious and clean aesthetic."}
{"layout": 553, "type": "text", "text": "Our implementation of agile working methodologies and operating  principles has boosted the speed and efficiency with which we  deliver our solutions to patients and healthcare providers. ", "page_idx": 94, "bbox": [67, 98.2003173828125, 259, 133.0003204345703], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 554, "type": "text", "text": "As we become more agile, the need for a shift  towards shared leadership  –  one that fosters  trust and ownership  –  becomes evident. We are  developing a networked organisation where  decisions can no longer be made in silos due to the  high interconnected ness and interdependence  across the company. This approach requires  leaders to apply the VACC principles  –  visionary,  architect, coach and catalyst  –  when leading  and serving their teams and the organisation.  The VACC leadership approach aligns with our  creative mindset, and supports our co-creating  vision, allowing us to achieve results, actively and  authentically drive change and further enable  role models who continuously push for learning  and empowerment.  ", "page_idx": 94, "bbox": [67, 181.40528869628906, 259, 373.2784118652344], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 555, "type": "text", "text": "Our unique efforts and investments in developing  coaching skills in our leaders have been recognised  by the International Coaching Federation (ICF). In  autumn 2021, we were awarded the 2021 ICF PRISM  Award Special Mention. This award recognises  Roche’s approach to making coaching an integral  element of its leadership culture, while fulfilling  the highest professional standards and creating  measurable positive impacts. ", "page_idx": 94, "bbox": [67, 385.4053039550781, 262, 493.2784118652344], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 556, "type": "text", "text": "At Roche, we want everyone to build the capability  to lead and learn. By encouraging self-leadership  and fostering a learning mindset, we help our  people thrive. To achieve this, we have refined our  existing people development strategy and provided  a portfolio of activities and training to support  self-growth and individual leadership. ", "page_idx": 94, "bbox": [67, 505.4053039550781, 262, 589.2783813476562], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 557, "type": "text", "text": "Enhancing everyone’s experience ", "text_level": 1, "page_idx": 94, "bbox": [67, 603, 207, 610.75], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 558, "type": "text", "text": "When we unveiled our new approach to engaging  and developing our employees a few years ago, we  set the goal of becoming an agile organisation. In  2021, we took a significant step towards increasing  the use of technology and digitalisation to improve  the employee experience. ", "page_idx": 94, "bbox": [67, 613.4052734375, 262, 685.2783813476562], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 559, "type": "text", "text": "We introduced a number of new approaches and  tools to provide our people with round-the-clock  support. Additionally, we set up a broad range  of internal and external training and learning  opportunities, each designed to strengthen the  foundations of an agile, self-organised workplace. ", "page_idx": 94, "bbox": [277, 481.4053039550781, 465, 553.2783813476562], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 560, "type": "text", "text": "As a business function, People & Culture has also  undergone its own significant transformation.  We refreshed our workforce strategies, revamped  our organisational growth efforts and updated  our core processes and practices. Thanks to  these efforts, People & Culture has not only  become more efficient as a strategic partner,  but has also established new standards in the  creation of value for the long-term success of  our organisation.  ", "page_idx": 94, "bbox": [277, 565.4052734375, 465, 685.2783813476562], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 561, "type": "image", "page_idx": 95, "img_path": "layout_images/roche-holdings_2021_65.jpg", "bbox": [0, 67, 318, 405], "page_size": [595.2760009765625, 793.7009887695312], "ocr_text": "", "vlm_text": "The image shows two people in an office setting. An older person with short white hair is holding a measuring tape and appears to be measuring the armrest of a chair. A younger person with dark hair and a beard is seated at a desk in front of a computer, looking down at something on the desk. There's a mouse on the desk near the computer. The environment looks professional and focused."}
{"layout": 562, "type": "image", "page_idx": 95, "img_path": "layout_images/roche-holdings_2021_66.jpg", "bbox": [1, 432, 317, 692], "page_size": [595.2760009765625, 793.7009887695312], "ocr_text": "Employee health and safety\n\n0.179 0.173 0.174 0.158\n\non 0.148\n0.061 ae we\n\nOOa7 0.045 0.042\n6,298\n\n4.828 4,773\n\n4215\n400 a\nee 334\n270\nr T T ¥\n2016 2017 2018 2019 2020 2021\n_ Lost-time illness rate “> Roche accident rate*\n_ Working days lost per year due to accidents @ Number of work-related accidents\n\n* The Roche accident rate is a three-year average\n", "vlm_text": "The image is a line graph titled \"Employee health and safety\" showing data from 2016 to 2021. It presents three metrics:\n\n1. **Lost-time illness rate** (dark red line): Decreases from 2016 to 2021, with slight fluctuations.\n   - Starts at 0.179 in 2016 and ends at 0.148 in 2021.\n\n2. **Roche accident rate** (red line, three-year average): Gradually decreases.\n   - Starts at 0.061 in 2016 and ends at 0.042 in 2021.\n\n3. **Working days lost per year due to accidents** (yellow line): Decreases over the years.\n   - Starts at 6,298 in 2016 and ends at 4,215 in 2021.\n\n4. **Number of work-related accidents** (light pink line): Shows a downward trend.\n   - Starts at 400 in 2016 and ends at 270 in 2021.\n\nThe graph indicates an overall improvement in employee health and safety over the period."}
{"layout": 563, "type": "text", "text": "Throughout the pandemic, we have provided tailored resources  and support for employees working from home, including  ergonomic assessments. ", "page_idx": 95, "bbox": [331, 98.2003173828125, 516, 133.0003204345703], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 564, "type": "text", "text": "Occupational health and safety In 2021 the pandemic continued to impact  operations at Roche. However, manufacturing and  related activities were kept running during this time.  In some countries, due to decreasing case numbers,  operations resumed on-site at least temporarily  while in other countries, most employees continued  to work remotely. ", "page_idx": 95, "bbox": [331, 181.2001953125, 527, 277.3292541503906], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 565, "type": "text", "text": "Sites managed the pandemic locally using a  uniform risk-based approach to mitigate the  likelihood of workplace transmission and offered  SARS-CoV-2 testing and, in many cases, vaccination  to their employees working on-site or from home.  Sites provided tailored support and resources  to employees working from home consisting of  information and programmes to maintain health  and well-being, support setting up an ergonomic  working environment at home and remote access  to employee assistance and counselling. Roche  actively supported, where possible, community  programmes to deliver vaccines, provided up-to- date evidence-based information and dismantled  barriers for employees to get vaccinated against  SARS-CoV-2 and influenza. ", "page_idx": 95, "bbox": [331, 289.1822509765625, 527, 481.2873840332031], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 566, "type": "text", "text": "One of our primary objectives is to provide a safe  workplace for our employees, both on- and off-site.  Occupational accidents, which include operating  motor vehicles, present significant risks to Roche  that are actively managed as part of our risk  management programme. Included in our current  set of goals (2020–2025), we aim, once again, to  continuously improve the safety of our employees.  Our goals are to keep the Roche accident rate (RAR)  below 0.05 (RAR corresponds to the number of  working days lost due to occupational accidents per  employee per year) and to reduce vehicle collisions  per million kilometres by   $10\\%$  , both by 2025. ", "page_idx": 95, "bbox": [331, 493.2001953125, 527, 649.314208984375], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 567, "type": "image", "page_idx": 96, "img_path": "layout_images/roche-holdings_2021_67.jpg", "img_caption": "100,920 employees\\* ", "bbox": [61, 117, 565, 593], "page_size": [595.2760009765625, 793.7009887695312], "ocr_text": "North America\n\n28,586\n\nLatin America J\n\n4,774\n\n51%\n\n44%\n\n25%\n\n40%\n\n| |\nWomen**\n\nin total workforce\nin management\non the BoD\n\non the CEC\n\nby region\n\nAfrica\n\n/ 1,068\nAsia\n/ 22,674\n\n7\n\nPart-time\n\n11%\n\nAustralia/New Zealand\n\n638\n\nFull-time\n\n89%\n\n\\ Europe\n\n43,181\n\nPharmaceuticals [I 46,889\nDiagnostics 39,266\n\nChugai fil 7,711\n\nCorporate and others B 7,054\n\nl\nEmployees* by ODG***\n\n", "vlm_text": "The image is a graphical representation of employee data for a company. It includes the following information:\n\n- **Total Employees:** 100,920\n- **By Region:**\n  - North America: 28,586\n  - Latin America: 4,774\n  - Europe: 43,181\n  - Africa: 1,068\n  - Asia: 22,674\n  - Australia/New Zealand: 638\n\n- **Employment Type:**\n  - Part-time: 11%\n  - Full-time: 89%\n\n- **Women in Workforce:**\n  - 51% in total workforce\n  - 44% in management\n  - 25% on the Board of Directors (BoD)\n  - 40% on the Corporate Executive Committee (CEC)\n\n- **Employees by Division/Group:**\n  - Pharmaceuticals: 46,889\n  - Diagnostics: 39,266\n  - Chugai: 7,711\n  - Corporate and others: 7,054\n\nThis information is presented in a combination of a circular diagram and bar charts."}
{"layout": 568, "type": "image", "page_idx": 97, "img_path": "layout_images/roche-holdings_2021_68.jpg", "bbox": [0, 6, 595, 794], "page_size": [595.2760009765625, 793.7009887695312], "ocr_text": "", "vlm_text": "The image shows a smiling man sitting on a yellow chair. He is wearing a blue jacket over a striped shirt. He has glasses and is sitting with his hands clasped together."}
{"layout": 569, "type": "text", "text": "A lifelong career at Roche ", "text_level": 1, "page_idx": 98, "bbox": [66, 98, 284, 124], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 570, "type": "text", "text": "When Hans Aeberhard embarked on his Roche apprenticeship in Basel  in 1972, he could not have imagined he would eventually retire from  the company after 49 years, 4 months and 21 days. ", "page_idx": 98, "bbox": [67, 150.2001953125, 451.344482421875, 219.80020141601562], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 571, "type": "text", "text": "Hans grew up in Basel. It is common in Switzerland  for teenagers to complete a short apprenticeship  during their final year at school before deciding  on a career. Although he had no concrete vocation  in mind, Hans knew his profession should be  something technical and offer good prospects  for growth and development. His choice to  become a chemical technician was influenced by  his teachers, who were very enthusiastic about  the opportunities that existed at Roche. His older  brother, who had started an apprenticeship as  a chemical technician a few years earlier, also  approved. “I am very happy with the path I chose,”  Hans says. “My job was never boring; I was able to  develop professionally and personally, and work  in an innovative environment.” ", "page_idx": 98, "bbox": [67, 253.2001953125, 259, 445.3501892089844], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 572, "type": "text", "text": "The highlights ", "text_level": 1, "page_idx": 98, "bbox": [67, 458, 128, 469], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 573, "type": "text", "text": "Looking back, there are plenty of highlights that fill  Hans with pride and fond memories. He has a deep  appreciation for how Roche has been family-owned  for generations. This leadership, he is convinced,  is reflected in the culture and how employees are  always treated with respect by colleagues and  managers alike.   ", "page_idx": 98, "bbox": [67, 469.2001953125, 259, 553.3502197265625], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 574, "type": "text", "text": "Working at the cutting edge of innovation and  technology was always a key motivator. “We were  the pioneers of liquid crystal technology and in  the mid-1990s we set up a state-of-the-art, fully  computerised manufacturing building on campus.  These were the early years of digitalisation.” ", "page_idx": 98, "bbox": [67, 565.2001953125, 259, 637.3502197265625], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 575, "type": "text", "text": "His personal highlights include his promotion to  foreman and becoming a line manager. Leading  people was more than a job, it was a personal  commitment. He developed a genuine interest  ", "page_idx": 98, "bbox": [67, 649.2001953125, 249, 697.3502197265625], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 576, "type": "text", "text": "in people and strove to discover and develop  their potential. Hans’s colleagues are close to  his heart. “I met a lot of people who shared their  experience and expertise and helped me grow,”  he explains. “In fact, many of my colleagues have  become friends.”  ", "page_idx": 98, "bbox": [277, 253.2001953125, 464, 325.3501892089844], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 577, "type": "text", "text": "The challenges ", "text_level": 1, "page_idx": 98, "bbox": [277, 338, 342, 349], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 578, "type": "text", "text": "During his career, there were only a handful of  challenges. The hardest were reorganisations,  which often involved downsizing. “It is difficult  to sustain a high-performing team when your  department gets reorganised,” he says. “Especially  when you have to say goodbye to great people.” ", "page_idx": 98, "bbox": [277, 349.2001953125, 471, 421.3501892089844], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 579, "type": "text", "text": "The past two years of the pandemic have been a  challenge for those in the manufacturing sector  as well. For Hans and his wife, however, working  from home during this period provided a way to  ease into his retirement in August 2021.  ", "page_idx": 98, "bbox": [277, 433.2001953125, 464, 493.3501892089844], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 580, "type": "text", "text": "A new chapter in life ", "text_level": 1, "page_idx": 98, "bbox": [277, 505, 363, 517], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 581, "type": "text", "text": "After 49 years, what advice can Hans offer for a  successful and fulfilling career? “Perseverance and  don’t give in when things get tough. Be authentic  and speak up, but know when to hold back,” he  explains. “And lastly, be a team player and respect  your colleagues.” ", "page_idx": 98, "bbox": [277, 517.2001953125, 471, 589.3502197265625], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 582, "type": "text", "text": "Looking to the next 125 years, Hans hopes that  Roche will sustain its unique legacy and keep  employees and patients at the core of what we do.  For himself, he hopes that he and his family stay  happy and healthy. Although he is now retired, Hans  will not fully disconnect from his profession: both  of his sons have decided to follow in his footsteps  and become pharma technologists. ", "page_idx": 98, "bbox": [277, 601.2001953125, 471, 697.3502197265625], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 583, "type": "image", "page_idx": 99, "img_path": "layout_images/roche-holdings_2021_69.jpg", "bbox": [0, 0, 596, 794], "page_size": [595.2760009765625, 793.7009887695312], "ocr_text": "", "vlm_text": "The image shows a close-up of solar panels. The grid pattern and dark blue color are characteristic of photovoltaic solar cells used to convert sunlight into electricity."}
{"layout": 584, "type": "text", "text": "Environment ", "text_level": 1, "page_idx": 100, "bbox": [129, 471, 386, 527], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 585, "type": "image", "page_idx": 101, "img_path": "layout_images/roche-holdings_2021_70.jpg", "bbox": [0, 0, 587, 794], "page_size": [595.2760009765625, 793.7009887695312], "ocr_text": "", "vlm_text": "This image shows a close-up of a man's face with a beard. He is wearing a dark-colored turtleneck. The focus is on his eyes and facial hair."}
{"layout": 586, "type": "text", "text": "Environmental protection – going  beyond our achievements ", "text_level": 1, "page_idx": 102, "bbox": [66, 97, 441, 160], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 587, "type": "text", "text": "What is known today as Safety, Security, Health and Environmental  Protection (SHE) at Roche was conceived out of an industrial accident  roughly 45 years ago. ", "page_idx": 102, "bbox": [68, 174.2001953125, 451.4153137207031, 243.80020141601562], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 588, "type": "text", "text": "In 1976, a blast at one of our subsidiaries in Italy,  known today as the Seveso incident, resulted in  the release of toxic chemicals into the air. The  aftermath of the incident brought about the  standardisation of industrial safety regulations  that would greatly influence the future of SHE  at Roche, and beyond. ", "page_idx": 102, "bbox": [67, 277.2001953125, 252, 361.3501892089844], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 589, "type": "text", "text": "The Seveso incident was tragic. But it was also  a huge opportunity for Roche to evolve our  approach to environmental protection. Since the  late 1970s, protecting the environment has been  an integral part of our operations. We approach  it with the same sense of responsibility, and just  as methodically, as we do with issues concerning  quality, productivity and cost efficiency. Wherever  possible and economically viable, we strive for  continuous improvement in SHE and we seek  sustainable, long-term improvement by changing  behaviour, adapting equipment to the most  recent standards, and developing innovative  processes throughout our organisation. In order  to ensure disasters like the Seveso incident do not  recur, we devote special attention to prevention  by reducing risks, which is key to effective  environmental management. ", "page_idx": 102, "bbox": [67, 373.2001953125, 256, 589.3502197265625], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 590, "type": "text", "text": "As a company with production operations around  the world, Roche is exposed to risks that could  possibly damage people, goods, the environment,  or our reputation. Audits, consulting, training  and culture, combined with a professional  risk management system, minimise these risks.  Expert teams at each Roche site identify risks,  develop mitigation plans and communicate  policy and guidelines to employees and other  stakeholders and support them in implementing  the necessary measures. ", "page_idx": 102, "bbox": [67, 601.2001953125, 256, 637.3502197265625], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 591, "type": "text", "text": "", "page_idx": 102, "bbox": [278, 277.2001953125, 459, 373.3501892089844], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 592, "type": "text", "text": "Many of the environmental challenges that have  occupied us for the last 40–50 years include  waste, as well as emissions to air and water. And  today, climate change is at the forefront. As the  changing climate has introduced new risks, such  as resource scarcity and a heightened occurrence  of natural disasters, the Roche SHE operational  risk management strategy includes forecasting  and evaluating the financial implications that  situations such as extreme weather or water  scarcity could have on its operations. ", "page_idx": 102, "bbox": [278, 385.2001953125, 467, 517.3502197265625], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 593, "type": "text", "text": "We have been developing environmental  protection goals since 2005. Our current five-year  goal period runs from 2020 to 2025. The goals  we set in the areas of people, environment and  business are challenging, but achievable. By  managing SHE professionally and proactively,  we can maintain the current high levels of  SHE performance and standards across the  organisation. ", "page_idx": 102, "bbox": [278, 529.2001953125, 467, 637.3502197265625], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 594, "type": "image", "page_idx": 102, "img_path": "layout_images/roche-holdings_2021_71.jpg", "bbox": [489, 543, 595, 695], "page_size": [595.2760009765625, 793.7009887695312], "ocr_text": "UN SDGs\n\nay\n=\n\nRS\n=\n\n6 fates\ng\n18 on\n\n®\n\nMaterial topics\n- Energy efficiency\n\npage:\n\n- Long-term mindset\n\n", "vlm_text": "The image highlights three UN Sustainable Development Goals (SDGs):\n\n1. Goal 6: Clean Water and Sanitation\n2. Goal 7: Affordable and Clean Energy\n3. Goal 13: Climate Action\n\nAdditionally, it mentions \"Material topics\" which include:\n\n- Energy efficiency\n- Long-term mindset"}
{"layout": 595, "type": "text", "text": "Embracing our environmental responsibilities ", "text_level": 1, "page_idx": 103, "bbox": [121, 135, 489, 158], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 596, "type": "text", "text": "Environmental responsibility has guided Roche’s  activities for many years. We started reporting  on greenhouse gas (GHG) emissions as early as  1990. Since 2004 we have been implementing  carbon dioxide reduction measures that have led  to a combined  $59\\%$   decrease in carbon dioxide  generated from within our operations (scope 1)  and from purchased energy (scope 2). ", "page_idx": 103, "bbox": [120, 181.2001953125, 307, 277.3501892089844], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 597, "type": "text", "text": "However, our operations have impacts that  extend far past the company gates. We purchase  materials, components and services that enable  us to develop and manufacture the products  our patients need. These, too, form part of  our environmental responsibilities. In 2021, we  completed our total GHG emissions inventory,  which now includes emissions associated with  all goods and services purchased by Roche. We  can now extend our focus to hot spots within our  supply chain and develop mitigation strategies  that will benefit the environment by minimising  our carbon footprint. In parallel, it will bring  long-term financial and reputational benefits  for Roche and our suppliers. ", "page_idx": 103, "bbox": [120, 289.2001953125, 307, 469.3501892089844], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 598, "type": "text", "text": "", "text_level": 1, "page_idx": 103, "bbox": [120, 482, 263, 488.75], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 599, "type": "text", "text": "To be effective in managing our extended GHG  responsibilities, we have identified the best ways  to work with different segments of our supply  base. In 2021, we identified 90 suppliers, across  our Pharmaceuticals and Diagnostics Divisions,  whose products and services account for nearly  one-third of our total carbon footprint. By engaging  these suppliers in active dialogue, we are working  with them to further develop their sustainability  strategies. This partnership also encourages  greater transparency and better decision-making. ", "page_idx": 103, "bbox": [120, 493.2001953125, 317, 625.3502197265625], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 600, "type": "text", "text": "We support our suppliers in their efforts to  decarbonise their operations and processes. One  of these strategies involves a pilot project through  which we partnered with a UK-based energy supplier  to offer our supply chain partners renewable  energy at a combined and more competitive rate.  We used this project as research to gauge the  receptiveness of suppliers when we offered to  actively support their sustainability journey by  providing commercially valuable solutions. We  will be monitoring the results to determine further  strategies, and have extended the offer to other  high-spend, high-emission suppliers, representing   $80\\%$   of Roche’s spending in the UK, as well as  smaller and more diverse suppliers. ", "page_idx": 103, "bbox": [120, 637.2001953125, 317, 685.3502197265625], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 601, "type": "text", "text": "", "page_idx": 103, "bbox": [330, 181.2001953125, 526, 313.3501892089844], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 602, "type": "text", "text": "Another area of focus for these partnerships  concerns the reuse of materials. A number of  collaboration projects have been established  with our suppliers to understand opportunities to  reduce levels of waste, including plastic. Interactive  workshops held with key suppliers have focused  on single-use technology and filters and looked at  ways to recycle, reuse and substitute materials. ", "page_idx": 103, "bbox": [330, 325.2001953125, 526, 421.3501892089844], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 603, "type": "text", "text": "Our future is sustainable ", "text_level": 1, "page_idx": 103, "bbox": [330, 433, 433, 444], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 604, "type": "text", "text": "As of 2021,  $72\\%$   of our electricity comes from  sustainable sources. In the continual pursuit to  further reduce GHG emissions from scope 1  and 2 sources, we have developed a clear and  defined process to generate progress by setting  challenging but realistic goals, developing action  plans on how to achieve these goals, and then  implementing them. ", "page_idx": 103, "bbox": [330, 445, 526, 541.3502197265625], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 605, "type": "text", "text": "Our scope 3 programme is also constantly evolving  as new innovations become available. Over the  next 12 months, we will finalise our scope 3 carbon  reduction strategies, and set targets based on the  potential for reduction. We will extend the number  of suppliers we actively collaborate with and outline  our expectations of them. Our longer-term ambition  is to gradually move towards product-specific  reporting for our suppliers, which can be used to  monitor carbon dioxide reductions and to inform  our product choices. ", "page_idx": 103, "bbox": [330, 553.2001953125, 526, 685.3502197265625], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 606, "type": "image", "page_idx": 104, "img_path": "layout_images/roche-holdings_2021_72.jpg", "bbox": [278, 66, 596, 408], "page_size": [595.2760009765625, 793.7009887695312], "ocr_text": "", "vlm_text": "The image shows an industrial facility with large storage tanks and pipelines. The foreground is blurred and contains wildflowers or grass, while the background features trees and a cloudy sky."}
{"layout": 607, "type": "text", "text": "We are committed to a sustainable energy future and are  implementing innovative technologies to improve energy efficiency. ", "page_idx": 104, "bbox": [68, 98.2001953125, 261.8287048339844, 121.00019836425781], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 608, "type": "text", "text": "We are also using the power of our people to  drive change. Across Roche, everyone can have  their voice heard, and everyone can contribute  to our sustainability efforts by sharing their ideas  on our innovation platform. These can touch  on any aspect of the sustainable development  agenda – whether environmental, social (including  human rights) or economic. Our refreshed Supply  Chain Sustainability Council, an internal decision- making body at the executive level, reviews these  ideas and business cases to decide on the ones  to resource for implementation and support. This  level of focus and prioritisation of sustainability  within our business allows ideas and concepts  to be turned into impactful deliverables and  wide-scale change. ", "page_idx": 104, "bbox": [68, 181.2001953125, 256, 373.3083190917969], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 609, "type": "text", "text": "Our scope 3 strategy and execution centres on  three key themes:\n ", "page_idx": 104, "bbox": [68, 385.16131591796875, 247, 409.3083190917969], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 610, "type": "text", "text": "•\t  Reducing, reusing and recycling \n This involves influencing business travel  behaviours, reducing spend on non-essential  goods and services and recycling or reusing  materials.\n\n •\t  Substituting and innovating\n This involves substituting non-sustainable  energies with sustainable energies, considering  environmental stewardship in product designs  and alternative logistics methods and routing.\n\n •\t  Engaging and partnering with suppliers \n and supply chains \n This involves transitioning suppliers towards  renewable electricity and incorporating  sustainability as a core element of global supplier  relationship management strategies. ", "page_idx": 104, "bbox": [67, 421.16131591796875, 261, 613.3381958007812], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 611, "type": "text", "text": "We recognise that we cannot deliver sustainable  supply chains alone. This is why we will build on  our existing industry collaboration to extend our  reach so that we can influence and learn from  other industries’ approaches to sustainability. ", "page_idx": 104, "bbox": [67, 625.191162109375, 251, 685.3292236328125], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 612, "type": "text", "text": "Steering towards a sustainable energy future ", "text_level": 1, "page_idx": 104, "bbox": [319, 443, 556, 459], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 613, "type": "text", "text": "Roche recognises climate change as one of the largest global risks  and addresses it as a matter of urgency. Expert teams, with a problem-to- solution-focused mindset, have been addressing this global issue for more  than 15 years. Most greenhouse gas (GHG) emissions at Roche originate  from the transformation and use of energy. Instead of compensating with  offsets, the teams pursue programmes that actively reduce GHG emissions.  As a priority these include reducing energy consumption and increasing  energy efficiency before substituting with energy from sustainable  sources. With these measures, we have already reduced GHG emissions by  more than 59% since 2004. At the Basel and Kaiseraugst site, for example,  the energy consumption of the buildings and operations is minimised by  innovative design and they are heated with waste heat and heat from the  environment in a carbon dioxide-neutral way. We will continue to optimise  energy use throughout the company striving towards one of our goals of  reducing scope 1 and 2 GHG emissions to zero by 2050. ", "page_idx": 104, "bbox": [320, 469.2001953125, 559, 649.3502197265625], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 614, "type": "text", "text": "Environmental performance data ", "text_level": 1, "page_idx": 105, "bbox": [120, 135, 394, 158], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 615, "type": "text", "text": "We are continuously monitoring our environmental  performance, and our aim is to collect data on  at least  $95\\%$   of each key performance indicator.  By doing so, we ensure compliance with our high  standards and objectives and guarantee that our  processes and equipment are state of the art. Since  2005, we have shown progressive improvement  in reducing our environmental footprint. Roche  measures its environmental impact using the eco- balance metric, which measures the environmental  impact of pollutant emissions or resource extraction  activities in eco-points per unit of quantity. These  points are added up and related to the total number  of employees. This enables us to monitor our  environmental impact per employee, taking business  growth into account. Since 2019 we have reduced  ", "page_idx": 105, "bbox": [120, 181.2001953125, 318, 373.3053283691406], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 616, "type": "text", "text": "125 years of milestones ", "text_level": 1, "page_idx": 105, "bbox": [37, 443, 158, 457], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 617, "type": "text", "text": "Former Nutley site embodies Roche’s legacy  Roche takes environmental responsibility seriously and is determined to  create long-term social value for communities. The Nutley remediation  project was no exception. The Nutley site was closed in 2012 and Roche  was committed to making sure the 118-acre former US headquarters  carried on its legacy of innovation and social responsibility. ", "page_idx": 105, "bbox": [36, 468.2001953125, 268, 541.3502197265625], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 618, "type": "text", "text": "A pioneering approach to environmental investigation and remediation  and a novel divestment strategy cut years from traditional timelines and  attracted a developer for the property, which sold in 2016 with Roche  retaining responsibility for the site clean-up. ", "page_idx": 105, "bbox": [36, 553.2001953125, 268, 601.3502197265625], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 619, "type": "text", "text": "Now called ON3, the campus boasts research institutions and a private  clinical laboratory with approximately 6,000 employees (compared to  1,500 when the site closed). Other tenants will include healthcare, biotech,  retail and hospitality leaders. As was our vision, ON3 is contributing to the  area’s economic and social well-being for generations to come. ", "page_idx": 105, "bbox": [36, 613.2001953125, 275, 673.3502197265625], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 620, "type": "text", "text": "our impact by approximately   $30\\%$  . This puts us on  a clear path to reach   $56\\%$   by 2025.  ", "page_idx": 105, "bbox": [331, 181, 527, 205.30233764648438], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 621, "type": "text", "text": "We are committed to contributing to a sustainable  energy future. To make this vision a reality, we are  implementing innovative technologies, improving  energy efficiency and increasing the use of  sustainable energy. Such considerations positively  impact our environmental footprint by, for example,  dramatically reducing GHG emissions. ", "page_idx": 105, "bbox": [331, 217.15533447265625, 527, 301.2873840332031], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 622, "type": "text", "text": "Greenhouse gas reduction efforts ", "text_level": 1, "page_idx": 105, "bbox": [330, 314, 472, 322.75], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 623, "type": "text", "text": "Our success at reducing energy consumption  and carbon dioxide emissions can be credited to  Roche’s GHG management approach. In 2021, for  example, our Diagnostics site in Meylan, France,  became the first Roche site to reduce GHG  emissions from stationary sources (eg, heating and  purchased electricity) to zero. The site consists  of a new energy-efficient building that is provided  with electricity from sustainable sources as well  as biomethane. The site is now focusing on its car  fleet strategy to optimise further emissions. ", "page_idx": 105, "bbox": [331, 325.13739013671875, 527, 457.2574768066406], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 624, "type": "text", "text": "At three of Roche’s technical production sites, the  heating, ventilation, and air conditioning systems in  the cleanrooms have been optimised. Such areas  utilise high ventilation rates to meet room air quality  requirements. This optimisation has reduced carbon  dioxide emissions by approximately 5,000 tonnes  per year and resulted in annual monetary savings of  approximately CHF 700,000. Once the project has  been expanded to all pharmaceutical production  sites, it is estimated that monetary savings will  increase to approximately CHF 2 million per year  with a maximum reduction in carbon dioxide  emissions of 11,000 tonnes per year. ", "page_idx": 105, "bbox": [331, 469.2001953125, 527, 625.314208984375], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 625, "type": "text", "text": "Similar GHG reduction measures are in place as  part of our five-year goals. By 2025 our sustainable  energy future activities will result in a further  $40\\%$    reduction of carbon dioxide emissions from scope 1  and 2 sources. ", "page_idx": 105, "bbox": [331, 637.2001953125, 527, 697.3381958007812], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 626, "type": "image", "page_idx": 106, "img_path": "layout_images/roche-holdings_2021_73.jpg", "bbox": [88, 125, 539, 415], "page_size": [595.2760009765625, 793.7009887695312], "ocr_text": "Energy consumption\n9.1%\nEmissions to water ff\n\n5.8%\n\nWater consumption\n\n1.8%\n\n™) Noise pollution\n1.0%\n\nLandfilled waste\n| 1.5%\n\nEmissions to air\n\n80.8%\n\neco-balance\n", "vlm_text": "The image is a circular chart titled \"Roche eco-balance 2021.\" It displays various environmental impacts with corresponding percentages:\n\n- Emissions to air: 80.8%\n- Energy consumption: 9.1%\n- Emissions to water: 5.8%\n- Water consumption: 1.8%\n- Landfilled waste: 1.5%\n- Noise pollution: 1.0%"}
{"layout": 627, "type": "text", "text": "We stipulate that company car fleets  ", "page_idx": 106, "bbox": [434, 434.2001953125, 541.0830078125, 445.00018310546875], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 628, "type": "image", "page_idx": 106, "img_path": "layout_images/roche-holdings_2021_74.jpg", "bbox": [64, 465.25, 541, 612.75], "page_size": [595.2760009765625, 793.7009887695312], "ocr_text": "Grid electricity\n\n26.2%\n\nOur first priority is to reduce usage of energy.\nFor the energy we use, we look for ways of\nimproving efficiencies, such as heat recovery.\nIn addition we encourage the use of renewable\nenergy wherever it makes sense.\n\nNatural gas\n\n28.9%\n\nEnergy use by\nselected types\n2021\n\nconsist of vehicles which use less tha\n2MJ/km. By 2030, all vehicles will ope\nusing energy from sustainable source\n\nCompany vehicles\n\n4.3%\n\nBusiness air travelling\n\n1.7%\n\nVideo and teleconferencing facilities\nhave been established at all sites anc\nwidely used. Employees are encourag\nto use trains and to consolidate seve!\n", "vlm_text": "The image is an infographic showing energy use by selected types in 2021. It includes percentages for various energy sources depicted in a circular chart. The specific types and their respective usages are:\n\n- **Natural gas**: 28.9%\n- **Grid electricity**: 26.2%\n- **Company vehicles**: 4.3%\n- **Business air travelling**: 1.7%\n\nAdditional text describes the organization's efforts in reducing energy usage and promoting renewable energy, alongside notes on company transport and teleconferencing usage."}
{"layout": 629, "type": "text", "text": "business trips into one. ", "page_idx": 106, "bbox": [434, 638.2001953125, 500.21832275390625, 649.0001831054688], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 630, "type": "image", "page_idx": 107, "img_path": "layout_images/roche-holdings_2021_75.jpg", "bbox": [6, 93, 541, 697], "page_size": [595.2760009765625, 793.7009887695312], "ocr_text": "Scope 3 Scope 2 : Capital goods*\n7,898,074 168,735 589,317\n95.0% 39.9% 7.5%\n\na\n\n\\\n\nScope I, 2?, 3° Scope I', 2? cope 3°\n_f GHG emissions GHG emissions GHG emissions\n/ (tcO,) (tcO,) (tCO,)\nPurchased goods\n= Scope! Scope 1 / \\ and services‘\n254,060 254,060 6,795,889\n3.0% 60.1% 86.0%\n= Scope 2\n168,735 MMB Fuel-andenergy-related activities\n2.0% 81,647\n1.0%\nMM Transportation and distribution\n228,274\n2.9%\n\nHE waste generated in operations\n37,920\n0.5%\n\nMS) Business travel\n15,392\n0.2%\n\nMM) Use of sold products\n149,635\n1.9%\n\nSustainability is a top priority at our sites. In Kaiseraugst,\nSwitzerland, for example, the energy consumption of the buildings\n\nand operations is minimised through innovative design.\n", "vlm_text": "The image contains an infographic showing greenhouse gas (GHG) emissions data divided into Scope 1, Scope 2, and Scope 3 emissions, expressed in tons of CO₂. There are percentages indicating the share of each category:\n\n- **Scope 1 and 2 Emissions**:\n  - Scope 1: 254,060 tons CO₂ (60.1%)\n  - Scope 2: 168,735 tons CO₂ (39.9%)\n\n- **Scope 3 Emissions**: 7,898,074 tons CO₂ (95.0%)\n  - Purchased goods and services: 6,795,889 tons CO₂ (86.0%)\n  - Capital goods: 589,317 tons CO₂ (7.5%)\n  - Fuel- and energy-related activities: 81,647 tons CO₂ (1.0%)\n  - Transportation and distribution: 228,274 tons CO₂ (2.9%)\n  - Waste generated in operations: 37,920 tons CO₂ (0.5%)\n  - Business travel: 15,392 tons CO₂ (0.2%)\n  - Use of sold products: 149,635 tons CO₂ (1.9%)\n\nThere is also a photo of a site in Kaiseraugst, Switzerland, illustrating efforts in sustainability, such as the energy-efficient design of buildings."}
{"layout": 631, "type": "table", "page_idx": 108, "img_path": "layout_images/roche-holdings_2021_76.jpg", "table_caption": "Energy consumption  in terajoules ", "bbox": [66, 100, 478, 160], "page_size": [595.2760009765625, 793.7009887695312], "ocr_text": "2021 2020 2019 2018\n\nTotal (scope 1 and scope 2) 8,306 8,420 8,983 9,185\nEnergy (scope 1 and scope 2) consumption (GJ/employee) 79 81 89 1\n\n", "vlm_text": "The table presents energy consumption data over four years (2018-2021) for \"Total (scope 1 and scope 2)\" and \"Energy (scope 1 and scope 2) consumption (GJ/employee).\"\n\n- Total (scope 1 and scope 2):\n  - 2021: 8,306\n  - 2020: 8,420\n  - 2019: 8,983\n  - 2018: 9,185\n\n- Energy consumption (GJ/employee):\n  - 2021: 79\n  - 2020: 81\n  - 2019: 89\n  - 2018: 91"}
{"layout": 632, "type": "text", "text": " ${\\complement}{\\mathsf{J}}=$   gigajoule ", "page_idx": 108, "bbox": [67, 167, 103.31361389160156, 176.55259704589844], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 633, "type": "table", "page_idx": 108, "img_path": "layout_images/roche-holdings_2021_77.jpg", "table_caption": "Halogenated hydrocarbons  in tonnes\\* ", "table_footnote": "\\*   Global inventory including Chugai, Genentech and Ventana \\*\\*  Includes data from additional Roche sites as well as a wider scope of halogenated hydrocarbons than in previous years ", "bbox": [66, 204, 479, 291], "page_size": [595.2760009765625, 793.7009887695312], "ocr_text": "2021 2020 2019 2018\n\nInventory 88.6\" 92.0 90.8 91.3\nReleases 1.5 1.5 2.2 2.2\n\n", "vlm_text": "The table presents data for the years 2021, 2020, 2019, and 2018 related to \"Inventory\" and \"Releases.\"\n\n- **Inventory**:\n  - 2021: 88.6**\n  - 2020: 92.0\n  - 2019: 90.8\n  - 2018: 91.3\n\n- **Releases**:\n  - 2021: 1.5\n  - 2020: 1.5\n  - 2019: 2.2\n  - 2018: 2.2"}
{"layout": 634, "type": "text", "text": "Emissions into the air  in tonnes ", "page_idx": 108, "bbox": [67, 317.62139892578125, 178.8210906982422, 328.42138671875], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 635, "type": "table", "page_idx": 108, "img_path": "layout_images/roche-holdings_2021_78.jpg", "table_footnote": "\\*  Volatile organic compounds ", "bbox": [67, 335, 479, 419], "page_size": [595.2760009765625, 793.7009887695312], "ocr_text": "VOCs*\nParticulates\nNitrogen oxides\nSulphur dioxide\n\n2021\n86\n\n18\n118\n\n2020\n73\n16\n\n113\n\n2019\n85\n13\n\n133\n\n2018\n85\n20\n\n201\n\n", "vlm_text": "The table shows data on air pollutant emissions over four years (2021, 2020, 2019, and 2018). The pollutants measured are:\n\n- VOCs (Volatile Organic Compounds)\n  - 2021: 86\n  - 2020: 73\n  - 2019: 85\n  - 2018: 85\n\n- Particulates\n  - 2021: 18\n  - 2020: 16\n  - 2019: 13\n  - 2018: 20\n\n- Nitrogen oxides\n  - 2021: 118\n  - 2020: 113\n  - 2019: 133\n  - 2018: 201\n\n- Sulphur dioxide\n  - 2021: 4\n  - 2020: 3\n  - 2019: 4\n  - 2018: 5"}
{"layout": 636, "type": "text", "text": "Water usage and discharge ", "page_idx": 108, "bbox": [67, 447.731689453125, 168.51309204101562, 458.53167724609375], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 637, "type": "text", "text": "Water withdrawn (million  $\\mathsf{m}^{3}$  ) Water consumed (million  $\\mathsf{m}^{3}$  ) Organic matter discharged to waterways after treatment (t) Heavy metals discharged to waterways after treatment   $(\\mathsf{k g})$  ", "page_idx": 108, "bbox": [68, 483.7315979003906, 268, 530.5316772460938], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 638, "type": "table", "page_idx": 108, "img_path": "layout_images/roche-holdings_2021_79.jpg", "bbox": [291, 467, 479, 533], "page_size": [595.2760009765625, 793.7009887695312], "ocr_text": "2021\n\n15.4\n2]\n76\n131\n\n2020\n\n14.9\n2.8\n76\n174\n\n2019\n\n15.9\n\n3.1\n127\n228\n\n2018\n\n16.6\n\n3.4\n185\n149\n\n", "vlm_text": "The table contains numerical data corresponding to four different years: 2021, 2020, 2019, and 2018. Here are the values for each year:\n\n- **2021**\n  - 15.4\n  - 2.7\n  - 76\n  - 131\n\n- **2020**\n  - 14.9\n  - 2.8\n  - 76\n  - 174\n\n- **2019**\n  - 15.9\n  - 3.1\n  - 127\n  - 228\n\n- **2018**\n  - 16.6\n  - 3.4\n  - 185\n  - 149\n\nThere are no labels or description provided for the data."}
{"layout": 639, "type": "table", "page_idx": 108, "img_path": "layout_images/roche-holdings_2021_80.jpg", "table_caption": "Landfilled and incinerated waste  in tonnes ", "bbox": [61, 565, 458, 652], "page_size": [595.2760009765625, 793.7009887695312], "ocr_text": "2021 2020 2019\n\nNon-hazardous 10,357 11,139 10,500 1\nHazardous 15,110** 13,352 17,422 1\nContaminated soil (hazardous) 61,230 38* 91,951 7\n\nConstruction waste (non-hazardous) 8,470 5,919\n", "vlm_text": "The table shows quantities (probably in tons or similar units) of different types of waste over three years: 2021, 2020, and 2019. The categories are:\n\n- Non-hazardous\n  - 2021: 10,357\n  - 2020: 11,139\n  - 2019: 10,500\n\n- Hazardous\n  - 2021: 15,110\n  - 2020: 13,332\n  - 2019: 17,422\n\n- Contaminated soil (hazardous)\n  - 2021: 61,230\n  - 2020: 38\n  - 2019: 91,951\n\n- Construction waste (non-hazardous)\n  - 2021: 8,470\n  - 2020: 5,919\n  - 2019: 14,360\n\nThe numbers with asterisks indicate special notes or clarifications."}
{"layout": 640, "type": "text", "text": "\\*   Less contaminated soil was removed in 2020 due to reduced remediation activities at the Kesslergrube, Germany\n\n \\*\\*  The increase in hazardous waste is due to the reallocation of electronic waste to hazardous waste ", "page_idx": 108, "bbox": [68, 657.4962768554688, 362.909912109375, 675.9462890625], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 641, "type": "image", "page_idx": 109, "img_path": "layout_images/roche-holdings_2021_81.jpg", "bbox": [1, 0, 594, 793], "page_size": [595.2760009765625, 793.7009887695312], "ocr_text": "", "vlm_text": "The image shows a person wearing a yellow shirt and gray pants, standing in front of a colorful, abstract art background with various patterns."}
{"layout": 642, "type": "text", "text": "SHE is about managing risks for people,  the environment and our assets ", "text_level": 1, "page_idx": 110, "bbox": [64, 96, 392, 153], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 643, "type": "text", "text": "Peter Schnurrenberger and his team have evolved our Safety, Security,  Health and Environmental Protection (SHE) function to become an integral  part of our business activities over the past 21 years. ", "page_idx": 110, "bbox": [68, 174.2001953125, 473.9751892089844, 243.80020141601562], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 644, "type": "text", "text": "Driven by the strong belief that protecting people,  the environment and our assets is integral to the  success of our company and the betterment of  society, Peter and his team have developed a  comprehensive SHE management system that is  embedded throughout our organisation and is a  core pillar of how we do business.  ", "page_idx": 110, "bbox": [67, 277.2001953125, 257, 361.3501892089844], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 645, "type": "text", "text": "Societal expectations have increased over time,  which are reflected in more laws and regulations  regarding SHE. “People realise now, more than ever,  that we must act to protect the planet, ourselves  and future generations,” says Peter. “We know that  despite the progress that has been made, there is \n still more to do, and an opportunity to improve.”  ", "page_idx": 110, "bbox": [67, 373.2001953125, 257, 457.3501892089844], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 646, "type": "text", "text": "When looking towards the future, Peter sees a  number of key issues that we must tackle as an  organisation. “An obvious area is climate change,”  he says. “If we want to reduce the associated risks,  we need bold action. At Roche, we have set a goal  to eliminate all greenhouse gas emissions by 2050.  We are developing roadmaps towards this goal  and action plans are being implemented across all  areas of our business. The faster we act, the less  greenhouse gases will be in the atmosphere.” ", "page_idx": 110, "bbox": [67, 469.2001953125, 257, 589.3502197265625], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 647, "type": "text", "text": "Another key issue is water – the basis of all  life – and an indispensable basic material for the  manufacturing of pharmaceutical and diagnostic  products. Water scarcity is increasing in several  regions around the world as is the need for  clean water. “We must further reduce our water  consumption and reuse and recycle wherever  feasible,” Peter reflects. “But it is not only the  ", "page_idx": 110, "bbox": [67, 601.2001953125, 252, 697.3502197265625], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 648, "type": "text", "text": "quantity, but also the quality of water that matters.  Society is becoming less accepting of non-natural  chemicals in the water.” We know that we need to  further reduce pollution with such chemicals, in  particular if they are not readily decomposable.  Where this is not possible we need to be transparent  about any associated risks versus the benefits. ", "page_idx": 110, "bbox": [276, 277.2001953125, 474, 361.3501892089844], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 649, "type": "text", "text": "Standardising information is another area of focus  for Roche. By not only being transparent with  our reporting, but also advocating harmonised  reporting systems, we know that society will benefit  from increased knowledge and reassurance.  “Today we see standards drifting apart, becoming  far too complex and detailed, thus creating a lot  of bureaucratic burden with questionable value  relative to the effort,” says Peter. “We need to work  with all stakeholders to create a simple, informative  and robust reporting framework.” ", "page_idx": 110, "bbox": [276, 373.2001953125, 474, 505.3501892089844], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 650, "type": "text", "text": "Finally, with increasing global dependencies, the  risk of events with widespread impact is increasing  as well.  “As a global healthcare company, we need  to be well prepared for such situations as we must  ensure uninterrupted supply of our products to  patients,” Peter says. “Our responsibility to patients  and society is the driving force behind our SHE  activities and it is not taken lightly.” At the end of the  day, we know that in order to achieve our goals, we  need educated, highly committed and passionate  people driving our efforts in SHE. There is a lot  of work to be done, but it is our responsibility to  move these activities forward in order to protect  the health, safety and well-being of generations  to come. ", "page_idx": 110, "bbox": [276, 517.2001953125, 474, 697.3502197265625], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 651, "type": "image", "page_idx": 111, "img_path": "layout_images/roche-holdings_2021_82.jpg", "bbox": [1, 0, 596, 794], "page_size": [595.2760009765625, 793.7009887695312], "ocr_text": "", "vlm_text": "The image features two circular objects mounted on a rod against a muted, earthy background. The objects appear to be positioned at an angle. The design is minimalistic with a geometric composition."}
{"layout": 652, "type": "text", "text": "Community  ", "text_level": 1, "page_idx": 112, "bbox": [132, 470, 362, 523], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 653, "type": "text", "text": "engagement ", "text_level": 1, "page_idx": 112, "bbox": [132, 549, 396, 600], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 654, "type": "image", "page_idx": 113, "img_path": "layout_images/roche-holdings_2021_83.jpg", "bbox": [0, 0, 595, 794], "page_size": [595.2760009765625, 793.7009887695312], "ocr_text": "", "vlm_text": "This image shows a close-up of a smiling person with short, dark hair, wearing a blue collared shirt."}
{"layout": 655, "type": "text", "text": "Community impact – our lasting  tradition of philanthropy at Roche ", "text_level": 1, "page_idx": 114, "bbox": [66, 96, 449, 161], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 656, "type": "text", "text": "For over 100 years, we have remained committed to making a sustainable  difference in communities in which we operate, and beyond. It is part of  our commitment to society. ", "page_idx": 114, "bbox": [68, 174.2001953125, 469.8822937011719, 243.80020141601562], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 657, "type": "text", "text": "Our first and longest philanthropic partnership is  with the International Committee of the Red Cross  (ICRC). We began supporting the ICRC in 1918 in  an effort to help the displaced and hungry across  Europe. Over the years, our partnership with the  ICRC has continued to evolve and grow.  ", "page_idx": 114, "bbox": [67, 277.2001953125, 257, 349.3352355957031], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 658, "type": "text", "text": "In 2005, we became a founding member of the  ICRC Corporate Support Group. Since 2015, we  have supported the ICRC’s access to water initiative  in Mali. In total, over one million people benefited  from this programme. We are proud of our many  enduring partnerships with organisations like  the ICRC and our collaborative efforts to make  a difference for communities around the world. ", "page_idx": 114, "bbox": [67, 361.188232421875, 262, 457.3172912597656], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 659, "type": "text", "text": "From our partnerships to our core pillars, we take  a long-term approach to philanthropy. We have  a well-established strategy, and maintain a clear  focus on our engagements. Our philanthropic  strategy is built around four pillars: community  projects, supporting the arts, investing in  education and providing humanitarian support.  We strictly adhere to specific criteria throughout  our partner and project selection processes.  Those criteria include quality, innovation and  sustainability.  ", "page_idx": 114, "bbox": [67, 469.1702880859375, 257, 601.290283203125], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 660, "type": "text", "text": "Grassroots community engagement Our biggest employee engagement and  philanthropic event is the Roche Children’s Walk.  The event began in 2003 as an employee-driven  pilot project across our sites in Basel, Nutley and  Palo Alto. All of the funds raised through the walk  go to Re&Act, our independent global charity, and  ", "page_idx": 114, "bbox": [67, 613.143310546875, 257, 697.2753295898438], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 661, "type": "text", "text": "to local non-governmental organisations (NGOs),  in support of early childhood development and  education efforts around the world. ", "page_idx": 114, "bbox": [277, 277.1282653808594, 473, 313.27227783203125], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 662, "type": "text", "text": "In response to the pandemic and related restrictions  on gatherings, our employees got creative and  re-invented the event to include a wide range of  innovative fundraising activities. In 2021, these  events included plogging (a combination of jogging  and picking up litter) in South Korea, volunteering  at an orphanage in Côte d’Ivoire, ‘walking meeting’  challenges in Spain and virtual boxing workshops  in Colombia. In total, over 26,000 people from  138 sites across 60 countries participated in  fundraising activities. ", "page_idx": 114, "bbox": [277, 325.1252746582031, 473, 457.245361328125], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 663, "type": "text", "text": "Every year, our colleagues nominate employee  ambassadors to visit Re&Act children’s projects  and witness first-hand the impact of their  fundraising activities. In 2021, a group of nine  ambassadors made a virtual visit to Child’s Dream,  Re&Act’s newest partner. This NGO is focused on  children’s education in Southeast Asia.  ", "page_idx": 114, "bbox": [277, 469.0983581542969, 473, 553.2304077148438], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 664, "type": "text", "text": "During the visit, the ambassadors had the chance  to meet the founders of Child’s Dream, see the  schools and computer labs we are helping to build  in Cambodia, and hear directly from students  about how the scholarships are changing their  lives. While meeting in person is ideal, this virtual  immersion was truly inspirational, and the money  saved on travel went to local children’s NGOs in  the ambassadors’ respective countries.  To learn  more about Child’s Dream, please see the story  on page 117. ", "page_idx": 114, "bbox": [277, 565.0833740234375, 473, 697.203369140625], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 665, "type": "text", "text": "Art as a means to connect with communities  Our long history of supporting groundbreaking  contemporary art and cultural projects has included  explorations of the parallels between innovations  in art and innovations in science. Exposure to new  ideas and perspectives helps to foster a culture  of openness and creativity at Roche. It also helps  to promote diversity and inclusion by celebrating  different cultures and disciplines.   ", "page_idx": 115, "bbox": [120, 181.2003173828125, 316, 289.3501892089844], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 666, "type": "text", "text": "In 2003, we began collaborating with the Lucerne  Festival, an international festival of contemporary  classical music on a unique project called Roche  Commissions. Every two years, we commission  a new orchestral work from one of the world’s  most talented composers. Starting in 2013, this  partnership was extended to include Roche  ", "page_idx": 115, "bbox": [120, 301.2001953125, 309, 385.3501892089844], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 667, "type": "text", "text": "125 years of milestones ", "text_level": 1, "page_idx": 115, "bbox": [35, 444, 156, 457], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 668, "type": "text", "text": "Good, clean health for South Africa \n Phelophepa. It means “good, clean health” in Sotho. For over 14 million  people in rural South Africa, it has meant access to affordable primary  healthcare. In 1994, Roche and Transnet, a freight logistics company,  came together to establish Phelophepa, the world’s first comprehensive  primary healthcare facility on rail.  ", "page_idx": 115, "bbox": [37, 468.2001953125, 268, 541.3502197265625], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 669, "type": "text", "text": "What started as a three-car train was expanded to two 19-coach trains  in 2012. They provide a range of healthcare services including dental,  oph thal mo logical, psychological and general health. As the main external  sponsor, Roche provided additional support during the COVID-19 pandemic  including protective and sanitising equipment. ", "page_idx": 115, "bbox": [37, 553.2001953125, 275, 613.3502197265625], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 670, "type": "text", "text": "Young Commissions to engage new contemporary  classical composers and expose our scientists to  leading-edge experiences in sound.  ", "page_idx": 115, "bbox": [330, 181.2001953125, 521, 217.35018920898438], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 671, "type": "text", "text": "In 2021, one of the young composers, Australian- born Kirsten Milenko, debuted her new piece,  Traho .  It pays homage to the unfathomable losses Australia  experienced as a result of the wildfires that raged  there from 2019 to 2020 and that resulted in the  loss of billions of animals and millions of hectares  of burnt land. During the piece, the musicians sang  in tribute to those who perished, and helped to  keep their memory alive in the public mind.  ", "page_idx": 115, "bbox": [330, 229.2001953125, 528, 337.3501892089844], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 672, "type": "text", "text": "With 169 nationalities represented at Roche, we  are committed to diversity and inclusion in all that  we do. Our support of projects like Culturescapes,  a multidisciplinary Swiss festival that promotes  cross-border cultural dialogue, helps us to  celebrate our diversity by bringing some of its  unique facets to our employees.  ", "page_idx": 115, "bbox": [330, 349.2001953125, 521, 433.3501892089844], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 673, "type": "text", "text": "In 2021, Culturescapes focused on the Amazon  region, bringing artists from Brazil, Colombia, Peru  and Ecuador to Switzerland. Topics explored during  the festival included climate change, access to  water, violence and peace. Collaboration with  the festival was wide-ranging, and Roche PhDs,  postdocs and employees from Latin America  had access to performances and workshops with  the artists.  ", "page_idx": 115, "bbox": [330, 445.2001953125, 528, 553.3502197265625], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 674, "type": "text", "text": "To bring the benefits of this event to as many  people as possible, Roche Brazil hosted a virtual  Culturescapes week. Throughout the week,  they shared music from the artists, provided  ", "page_idx": 115, "bbox": [330, 565.2001953125, 521, 613.3502197265625], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 675, "type": "text", "text": "In 2021, Transnet launched a third train to support Phelophepa’s COVID-19  response. Over 16,000 people were vaccinated and over 127,000 patients  received basic healthcare.  ", "page_idx": 115, "bbox": [37, 625.2001953125, 273, 661.3502197265625], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 676, "type": "image", "page_idx": 116, "img_path": "layout_images/roche-holdings_2021_84.jpg", "bbox": [278, 67, 596, 405], "page_size": [595.2760009765625, 793.7009887695312], "ocr_text": "", "vlm_text": "The image shows an orchestra on stage with musicians holding various instruments such as violins, cellos, and wind instruments. They appear to be concluding a performance as some audience members can be seen applauding. A person in the center is standing and smiling, possibly acknowledging the applause."}
{"layout": 677, "type": "text", "text": "One of the Roche Young Commission’s 2021 recipients, Kirsten  Milenko, following the debut of her new orchestral work  Traho   ( above ). Ibã Sales, shaman of the indigenous Huni Kuin people in  Brazil, performed with the Burned Instruments Orchestra during  Culturescapes 2021 Amazonia   ( below ). ", "page_idx": 116, "bbox": [67, 98.2003173828125, 252, 157.0003204345703], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 678, "type": "text", "text": "mind and body workshops, and offered talks  about some of the social issues the artists are  exploring through their work. During an extended  working-from-home period, this event provided  a valuable outlet for connecting with colleagues  through creativity, exploring diversity and inclusion  in a new way, and feeling a sense of pride about  engaging in Roche philanthropy. ", "page_idx": 116, "bbox": [67, 181.2001953125, 259.72198486328125, 277.3501892089844], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 679, "type": "text", "text": "Getting students excited about STEM At Roche, science and technology is at the heart  of what we do. That is why we are committed to  supporting interest in these disciplines among  young people through international and local  programmes. By improving access to education  and real-world science and technology, we hope  to support the next generation of innovators. ", "page_idx": 116, "bbox": [67, 289.2001953125, 252, 385.3501892089844], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 680, "type": "text", "text": "For more than 50 years, Roche has supported  Swiss Youth in Science, which promotes science  and technology among young people. In 2009, we  became a founding sponsor of the International  Swiss Talent Forum, the organisation’s think tank  programme. This annual meeting brings young  people from around the world together to discuss  current global issues.  ", "page_idx": 116, "bbox": [67, 397.2001953125, 255, 493.3501892089844], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 681, "type": "text", "text": "We are also proud to support and host Science  on the Move, a Switzerland-wide school  competition, run biennially in cooperation with  the SimplyScience Foundation. In 2021, ten of the  25 schools participating presented projects on  the theme of ‘Smart Systems’ to a jury of Roche  scientists, academics and industry experts. The  winning class will take a science-themed trip to  London in 2022.  ", "page_idx": 116, "bbox": [67, 505.2001953125, 255, 613.3502197265625], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 682, "type": "image", "page_idx": 117, "img_path": "layout_images/roche-holdings_2021_85.jpg", "bbox": [0, 66, 318, 698], "page_size": [595.2760009765625, 793.7009887695312], "ocr_text": "", "vlm_text": "The image consists of two photos. \n\nThe top photo shows two women wearing masks in conversation. One woman is holding a child, and the other is holding a booklet with a picture on it. They are seated in a room with blue walls. \n\nThe bottom photo depicts a scene in a different room where healthcare workers are interacting with a woman and a child. The healthcare workers are also wearing masks, and they appear to be discussing health-related materials laid out on a table. The room has brick walls."}
{"layout": 683, "type": "text", "text": "Healthcare workers and volunteers from 1000 Days Fund, an  NGO committed to reducing childhood stunting in Indonesia,  showing mothers the impact of poor nutrition on children’s health.  Roche helped to establish the country’s first Impact Stunting  Centre of Excellence. ", "page_idx": 117, "bbox": [331, 98.2003173828125, 523, 157.0003204345703], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 684, "type": "text", "text": "It goes on without us ", "text_level": 1, "page_idx": 117, "bbox": [331, 194, 417, 204], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 685, "type": "text", "text": "As a healthcare company, we are committed to  building stronger and healthier communities by  supporting human and social services systems  in places where they are needed most. We  seek partners who aim to implement simple and  meaningful measures that will result in lasting  improvements and a sustainable impact on society.  ", "page_idx": 117, "bbox": [331, 205.2001953125, 523, 289.3501892089844], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 686, "type": "text", "text": "For example, we supported the 1000 Days Fund  in Indonesia, which was established to help reduce  childhood stunting. This condition is defined as  shortness in height for a child’s age arising from  prolonged malnutrition, and affects both physical  and cognitive development. With our support,  the NGO established the country’s first Impact  Stunting Centre of Excellence, which provides  tools and training to community healthcare  workers and parents.  ", "page_idx": 117, "bbox": [331, 301.2001953125, 523, 421.3501892089844], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 687, "type": "text", "text": "In 2021, three additional centres opened, directly  benefiting 44,100 people, including healthcare  workers, parents and children. In addition, the  model has garnered support from the Ministry of  Health, and attracted new donors, enabling them  to continue to scale up and further integrate into  the healthcare system. Ensuring the sustainability  of a project – including its ability to go on without  us – is central to philanthropy at Roche. ", "page_idx": 117, "bbox": [331, 433.2001953125, 523, 541.3502197265625], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 688, "type": "text", "text": "Another sustainable way we are supporting our  communities is through the global philanthropic  secondment programme which allows Roche  employees to volunteer with an NGO supporting  global health and education. In 2021, Walter Lee,  from Roche Diagnostics ( see photo on page 110 ),   supported Terre des Hommes, a children’s aid  organisation, in defining a model to introduce a  new global health technology, a digital stethoscope,  in low- and middle-income countries to improve  outcomes for children. ", "page_idx": 117, "bbox": [331, 553.2001953125, 528, 685.3502197265625], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 689, "type": "text", "text": "International Committee of the Red Cross  ", "text_level": 1, "page_idx": 118, "bbox": [333, 97, 521, 109], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 690, "type": "text", "text": "1918 ", "text_level": 1, "page_idx": 118, "bbox": [333, 112, 361, 126], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 691, "type": "text", "text": "We have supported the ICRC for over 100 years. In 2005, we became a  founding member of the ICRC Corporate Support Group. We have contributed  to water and habitat activities in several countries across Africa. ", "page_idx": 118, "bbox": [334, 134.2003173828125, 554.439208984375, 169.0003204345703], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 692, "type": "text", "text": "Over one million people have benefited from the access to water initiative  in Mali. ", "page_idx": 118, "bbox": [334, 182.2003173828125, 545.8235473632812, 205.0003204345703], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 693, "type": "text", "text": "Child’s Dream  ", "text_level": 1, "page_idx": 118, "bbox": [66, 205, 132, 217], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 694, "type": "text", "text": "2019 ", "text_level": 1, "page_idx": 118, "bbox": [67, 221, 96, 233], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 695, "type": "text", "text": "We are working with Child’s Dream, our most  recent Re&Act partner, to improve education  for children in Southeast Asia. ", "page_idx": 118, "bbox": [68, 242.2001953125, 200, 277.00018310546875], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 696, "type": "text", "text": "Over 4,000 students have benefited from new  classrooms, computer labs and scholarships  in Cambodia. ", "page_idx": 118, "bbox": [68, 290.2001953125, 200, 325.00018310546875], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 697, "type": "text", "text": "UNICEF   ", "text_level": 1, "page_idx": 118, "bbox": [67, 361, 106, 372], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 698, "type": "text", "text": "2003 ", "text_level": 1, "page_idx": 118, "bbox": [67, 377, 97, 388], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 699, "type": "text", "text": "We have been working together to support access  to education for children from disadvantaged  backgrounds in several countries throughout Africa  and Asia.  ", "page_idx": 118, "bbox": [68, 398.2001953125, 218.1007080078125, 445.00018310546875], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 700, "type": "text", "text": "Over 450,000 children have benefited from  educational programmes across Ethiopia, Malawi,  Nepal and the Philippines.  ", "page_idx": 118, "bbox": [68, 458.2001953125, 212, 493.00018310546875], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 701, "type": "text", "text": "World Wide Fund for Nature  1961 ", "text_level": 1, "page_idx": 118, "bbox": [409, 217, 541, 246], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 702, "type": "text", "text": "The WWF was co-founded by Dr Lukas (Luc)  Hoffmann, grandson of Roche founder Fritz  Hoffmann-La Roche and his wife Adèle. Roche  has continued to support the WWF ever since.  ", "page_idx": 118, "bbox": [411, 254.2001953125, 544, 301.00018310546875], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 703, "type": "text", "text": "Over 3,000 people have benefited from rebuilding  efforts in Nepal, Kenya and Zimbabwe. ", "page_idx": 118, "bbox": [411, 314.2001953125, 554, 337.00018310546875], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 704, "type": "text", "text": "Swiss Youth in Science  ", "text_level": 1, "page_idx": 118, "bbox": [410, 385, 514, 397], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 705, "type": "text", "text": "1967 ", "text_level": 1, "page_idx": 118, "bbox": [410, 400, 437, 413], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 706, "type": "text", "text": "We have been supporting Swiss Youth in Science,  which seeks to promote science and technology  to young people, for over 50 years. ", "page_idx": 118, "bbox": [411, 422.2001953125, 554, 457.00018310546875], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 707, "type": "text", "text": "Over 15,000 students have been reached by  Swiss Youth in Science programmes. ", "page_idx": 118, "bbox": [411, 470.2001953125, 538, 493.00018310546875], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 708, "type": "text", "text": "Phelophepa healthcare trains ", "text_level": 1, "page_idx": 118, "bbox": [151, 517, 288, 531], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 709, "type": "text", "text": "1994 ", "text_level": 1, "page_idx": 118, "bbox": [151, 533, 178, 546], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 710, "type": "text", "text": "We have been the main external sponsor of Phelophepa,  a free mobile healthcare clinic that travels to rural areas  in South Africa, since its first journey over 25 years ago. ", "page_idx": 118, "bbox": [152, 554.2001953125, 316, 589.0001831054688], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 711, "type": "text", "text": "Over 14 million people have benefited from basic  healthcare services, trainings and jobs through  Phelophepa in South Africa. ", "page_idx": 118, "bbox": [152, 602.2001953125, 292, 637.0001831054688], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 712, "type": "image", "page_idx": 119, "img_path": "layout_images/roche-holdings_2021_86.jpg", "bbox": [0, 0, 595, 794], "page_size": [595.2760009765625, 793.7009887695312], "ocr_text": "", "vlm_text": "The image shows two people standing in front of a tree with red leaves. They are both facing the camera and smiling. The person on the left wears a dark sweater over a collared shirt, and the person on the right wears a blue button-up shirt."}
{"layout": 713, "type": "text", "text": "How a balance of heart and head helped  Child’s Dream become a reality ", "text_level": 1, "page_idx": 120, "bbox": [65, 97, 407, 154], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 714, "type": "text", "text": "Marc Jenni and Daniel Siegfried gave up careers in banking to set up a charity  for children in Asia. They started from nothing and built an association that  delivers health, education and – perhaps most important of all – hope.  ", "page_idx": 120, "bbox": [67, 174.2001953125, 496.10150146484375, 243.80020141601562], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 715, "type": "text", "text": "“Good philanthropy requires perfect balance  between heart and head – your heart needs to  really understand and care about the people  you are trying to help, and your head must stay  rational and make good decisions.” ", "page_idx": 120, "bbox": [66, 277.2001953125, 256, 337.3382263183594], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 716, "type": "text", "text": "Daniel is talking about the secret to success  of Child’s Dream – a charitable, not-for-profit  organisation supporting children and young  adults in Myanmar, Laos, Cambodia and Thailand.  Co-founded by Marc and Daniel in 2003, the  organisation now employs over 50 people. They  work to reduce childhood mortality and improve  health and hygiene in schools and communities,  while also increasing access to quality education.  ", "page_idx": 120, "bbox": [66, 349.19122314453125, 256, 457.3172912597656], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 717, "type": "text", "text": "Marc and Daniel both admit that the balance is not  always easy to maintain – the current situation in  Myanmar in particular is “absolutely devastating”,  says Daniel, “making it really difficult for me not to  become emotional about it and lose that balance.”  But over the last 18 years, they have managed to  navigate that line, and deliver meaningful change  and real hope for thousands of children.  ", "page_idx": 120, "bbox": [66, 469.1702880859375, 256, 565.29931640625], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 718, "type": "text", "text": "A meaningful mission ", "text_level": 1, "page_idx": 120, "bbox": [67, 578, 155, 589], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 719, "type": "text", "text": "They set up Child’s Dream after successful but  unfulfilling careers in banking in Switzerland, Hong  Kong and Singapore. Those experiences provided  a gateway to Southeast Asia and a first realisation  of some of the challenges faced by local children.  For the two of them, that realisation was a pivotal  moment. “Daniel basically had an epiphany that  he wanted to do something meaningful, and he  suggested we set up a children’s charity,” says  Marc. “We sat there in a little guest house in front  of a blank piece of paper, and through the night  our ideas formed. We are both so happy that it  developed from there into something so meaningful.” ", "page_idx": 120, "bbox": [66, 589.1492919921875, 256, 697.2753295898438], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 720, "type": "text", "text": "", "page_idx": 120, "bbox": [277, 277.1282653808594, 476, 325.269287109375], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 721, "type": "text", "text": "Productive partnership ", "text_level": 1, "page_idx": 120, "bbox": [277, 337, 376, 349], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 722, "type": "text", "text": "The organisation established a partnership with  Roche in 2019, with three clear areas of focus in  Cambodia: improving school building infrastructure,  with a five-year goal of 150 new primary, secondary  or high school classrooms benefiting 6,000 students  a year; supporting computer laboratory facilities,  with the aim of ten fully equipped computer  laboratories to vastly improve IT skills and  knowledge; and finally, backing 350 high school  scholarships to help marginalised students improve  job and social mobility opportunities. ", "page_idx": 120, "bbox": [277, 349.1192932128906, 476, 481.2393798828125], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 723, "type": "text", "text": "“The partnership works because we have a shared  purpose and Roche is very engaged in the work we  are doing,” says Daniel. “And the impact is very real.  We will provide new school buildings for thousands  of children in Cambodia, some of whom are the  most marginalised, with difficult backgrounds. And  with computer labs comes digital literacy, which is  so important to bring new opportunities.”  ", "page_idx": 120, "bbox": [277, 493.0923767089844, 476, 589.2213745117188], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 724, "type": "text", "text": "They emphasise that we can all make a difference. It  does not have to mean travelling to the other side of  the world – it can mean being “a social worker in your  own network”, whether that’s your family members,  your neighbours or your local community. “But try  to maintain that balance between heart and head,”  says Marc. “And remember, even after the biggest  storm, the sun will come out and shine again.” ", "page_idx": 120, "bbox": [277, 601.0743408203125, 476, 697.203369140625], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 725, "type": "image", "page_idx": 121, "img_path": "layout_images/roche-holdings_2021_87.jpg", "bbox": [0, 2, 561, 789], "page_size": [595.2760009765625, 793.7009887695312], "ocr_text": "", "vlm_text": "The image appears to be abstract, with blurred colors and shapes in shades of blue and brown. There are no recognizable objects or figures, so it seems to be more of an artistic or abstract photo."}
{"layout": 726, "type": "text", "text": "Business ethics ", "text_level": 1, "page_idx": 122, "bbox": [132, 472, 449, 522], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 727, "type": "image", "page_idx": 123, "img_path": "layout_images/roche-holdings_2021_88.jpg", "bbox": [0, 0, 594, 794], "page_size": [595.2760009765625, 793.7009887695312], "ocr_text": "-\n\n", "vlm_text": "The image shows a close-up of a person wearing a light-colored headscarf. The person is smiling and looking directly at the camera."}
{"layout": 728, "type": "text", "text": "Integrity as a driver  for business ethics  ", "text_level": 1, "page_idx": 124, "bbox": [66, 97, 286, 159], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 729, "type": "text", "text": "Upholding high standards of ethics, integrity and sustainability is not  just about complying with laws and regulations; it is about making  a positive impact on society in everything we do.  ", "page_idx": 124, "bbox": [68, 174.2001953125, 446.7666931152344, 243.80020141601562], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 730, "type": "text", "text": "At Roche, we believe that integrity is the basis of a  sustainable and successful business. We start with  ourselves: Every employee has the responsibility to  behave with integrity and in accordance with our  shared company values and compliance guidelines.  Because our commitment is also reflected in the  expectations we place on our partners around  the world, we require our distributors, suppliers  and service providers to meet our integrity  standards. We emphasise sustainability and expect  our business partners to help foster social and  economic development in the communities in which  they operate. ", "page_idx": 124, "bbox": [67, 277.2001953125, 261, 433.3143005371094], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 731, "type": "text", "text": "We also continue to focus our efforts on our  stakeholders’ understanding of – and trust in –  our organisation. To help ensure that trust, we  remain independent of any political affiliation. In  2021, we spent CHF 10.6 million in Switzerland.  That spending included payments to industry  associations and various chambers of commerce,  financial assistance for trade unions, and donations  to political parties at cantonal and federal levels.  Donations to political parties were each in the low  double-digit thousand range in Swiss francs, and  together accounted for approximately   $2\\%$   of the  total contributions and donations. ", "page_idx": 124, "bbox": [67, 445.16729736328125, 261, 601.2813720703125], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 732, "type": "text", "text": "The COVID-19 pandemic has had an impact on how  we work together within Roche, including how we  ensure compliance at our affiliates worldwide. In  2021, we implemented new ways of working, which  empowered our compliance network to focus  more on collaboration and exchange, allowing us  to further strengthen our shared ethical mindset  across the organisation. ", "page_idx": 124, "bbox": [67, 613.2001953125, 261, 685.335205078125], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 733, "type": "text", "text": "", "page_idx": 124, "bbox": [277, 277.1851806640625, 475, 301.3321838378906], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 734, "type": "text", "text": "Fostering collaboration through a OneRoche  approach ", "page_idx": 124, "bbox": [277, 313.1851806640625, 475, 337.3321838378906], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 735, "type": "text", "text": "Although we have several distinct businesses  and partners within the Roche Group, we know  that fostering collaboration through a OneRoche  approach is key to our overall success. This  approach was the driving force behind many of our  compliance and risk and opportunity management  efforts in 2021.  ", "page_idx": 124, "bbox": [277, 337.17919921875, 475, 421.3112487792969], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 736, "type": "text", "text": "One example of this was an initiative aimed at  enhancing effectiveness and collaboration across  our assurance functions including, but not limited to,  compliance, quality, safety, health and environment.  The insights of this comprehensive and collaborative  gap analysis revealed a high level of competence  in many key areas. Moving forward, we see a great  opportunity to continue fostering collaboration  across the assurance functions to ensure Roche is  holding itself to the highest standards and providing  pragmatic solutions to the business, with the  ultimate goal of improving patients’ lives. ", "page_idx": 124, "bbox": [277, 433.16424560546875, 475, 577.2813110351562], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 737, "type": "text", "text": "Building on a common set of values across divisions  and countries, two more examples demonstrate how  we want to move towards a more holistic, consistent  and sustainable approach to compliance.  ", "page_idx": 124, "bbox": [277, 589.13427734375, 475, 637.2752685546875], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 738, "type": "text", "text": "In 2021, we harmonised our compliance and risk  and opportunity management process across all  divisions. The intent of this initiative was to improve  ", "page_idx": 124, "bbox": [277, 649.1282958984375, 475, 685.2723388671875], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 739, "type": "image", "page_idx": 124, "img_path": "layout_images/roche-holdings_2021_89.jpg", "bbox": [490, 544, 595, 694], "page_size": [595.2760009765625, 793.7009887695312], "ocr_text": "UN SDGs\n\n(Bie 17 Frnt\nMaterial topics\n\n~ Human rights\n\n- Ethics and transparency\n- Patient centricity\n\n- Availability of healthcare\n- Compliance\n", "vlm_text": "The image contains information about UN Sustainable Development Goals (SDGs) 16 and 17, which focus on:\n\n- **16:** Peace, Justice, and Strong Institutions\n- **17:** Partnerships for the Goals\n\nIt also lists material topics related to these goals:\n\n- Human rights\n- Ethics and transparency\n- Patient centricity\n- Availability of healthcare\n- Compliance"}
{"layout": 740, "type": "text", "text": "efficiencies, minimise redundancies and enhance  transparency. ", "page_idx": 125, "bbox": [120, 181.2001953125, 310, 205.35018920898438], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 741, "type": "text", "text": "As part of our overall review of our approach  to business ethics incident management, we  also developed a new system for internal non- compliance case management and reporting. The  system enables stronger collaboration between  the different functions involved in the management  of the cases, especially Compliance, the Internal  Investigations team and People & Culture. ", "page_idx": 125, "bbox": [120, 217.2001953125, 314, 313.3501892089844], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 742, "type": "text", "text": "Collaboration with patients ", "text_level": 1, "page_idx": 125, "bbox": [120, 326, 234, 336], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 743, "type": "text", "text": "Along with evolving and improving our internal  processes, we are also striving for and engaging  in important dialogues outside of Roche. We  know we can learn a great deal from patients, and  adhering to stringent ethical standards is key to  impactful and effective interactions with them. In  2021, we developed a supportive coaching tool  called Compliance Patient Engagement Navigator.  The tool supports the business in identifying the  applicable principles and rules, and provides  robust guidance, enabling Roche employees to  build compliant and sustainable relationships  with patients and patient organisations ( please  see the story on page 127 ).  ", "page_idx": 125, "bbox": [120, 337.2001953125, 310, 505.3501892089844], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 744, "type": "text", "text": "Adapting to meet changing needs ", "text_level": 1, "page_idx": 125, "bbox": [120, 518, 259, 528.75], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 745, "type": "text", "text": "As the healthcare system continues to transform  rapidly, we must look at and respond effectively  to how we spend money. In late 2020, Roche  finalised a new policy on third-party spend. The  policy moved us from providing tactical guidance  that focused on procurement activities to providing  Roche-wide principles and parameters governing  how we spend money. The new framework allows  us to set operational procurement rules and  processes at a local level, while establishing  globally applicable due diligence and sustainability  requirements. ", "page_idx": 125, "bbox": [120, 529.2001953125, 314, 673.3502197265625], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 746, "type": "text", "text": "In 2021, we formed a team of supplier risk  management professionals who are providing  support to and enabling our procurement team, as  well as the rest of the organisation. They are also  developing state-of-the-art tools to facilitate risk  assessment and management.  ", "page_idx": 125, "bbox": [330, 181.2001953125, 528, 253.35018920898438], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 747, "type": "text", "text": "To provide further support to employees working in  procurement and sourcing, we implemented a new  online due diligence tool in 2021. The tool provides  guidance on how to mitigate risks related to finance,  supply, sustainability, technology, intellectual  property, quality and contracts. The guidance is  based on the inherent risks associated with the  type of supplier, and how and where we expect  to engage with them. ", "page_idx": 125, "bbox": [330, 265.2001953125, 528, 373.3501892089844], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 748, "type": "text", "text": "Working together to mitigate risks and protect  human rights ", "text_level": 1, "page_idx": 125, "bbox": [331, 386, 523, 408], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 749, "type": "text", "text": "Roche’s commitment to human rights is reflected in  the stringent requirements we place on ourselves  and on our more than 60,000 suppliers worldwide.  We regard our suppliers and service providers  as partners, and put our efforts into creating a  relationship of mutual trust and collaboration in  order to ensure that our standards are met. ", "page_idx": 125, "bbox": [330, 409.2001953125, 528, 493.3501892089844], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 750, "type": "text", "text": "One important element of these relationships is our  Supplier Sustainability Assurance Visit programme  (SSAV), which gives us the ability to positively  impact labour conditions at our suppliers’ facilities.  The Roche Supplier Code of Conduct binds our  suppliers to adhere to clearly stated performance  expectations, including performance on human  rights, and allows Roche to conduct SSAVs to help  ensure compliance through collaboration and  capability building. All our suppliers are evaluated  annually through a standardised, risk-based process  to identify those at high risk for human rights  violations against vulnerable populations (children,  underage workers, migrants, local underprivileged  ", "page_idx": 125, "bbox": [330, 505.2001953125, 528, 673.3502197265625], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 751, "type": "image", "page_idx": 126, "img_path": "layout_images/roche-holdings_2021_90.jpg", "bbox": [278, 68, 596, 408], "page_size": [595.2760009765625, 793.7009887695312], "ocr_text": "", "vlm_text": "The image shows a construction site with heavy machinery. There's a large piece of equipment with a drilling rig, a crane, and a loader. The ground is wet, reflecting the machinery above."}
{"layout": 752, "type": "text", "text": "Modern and safe remediation methods at the Kesslergrube site in  Grenzach, Germany, protect the water of the nearby Rhine river. ", "page_idx": 126, "bbox": [68, 98.2001953125, 254, 121.00019836425781], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 753, "type": "text", "text": "communities and people with low levels of  education). Suppliers determined to be at high  risk are included in the SSAV programme. ", "page_idx": 126, "bbox": [68, 181.2000732421875, 242, 217.35006713867188], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 754, "type": "text", "text": "Looking to the future, it is essential for us to  constantly develop and expand our human  rights requirements and guidelines in order to  ensure we continue to meet the highest possible  standards. In 2021, we updated our methodology  to address industry sectors that were not  previously considered, as well as non-Organisation  for Economic Co-operation and Development  (OECD) countries where performance standards  may be lower, and human rights risks associated  with certain commodities. To ensure we are  properly addressing the issue of child labour,  we also integrated the UNICEF Children’s Rights  in the Workplace Index in our methodology for  identifying high risk suppliers for inclusion into  our SSAV programme. ", "page_idx": 126, "bbox": [68, 229.2000732421875, 259.25335693359375, 421.35009765625], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 755, "type": "text", "text": "Despite the ongoing challenges of the COVID-19  pandemic, Roche continued the SSAV programme  in 2021 using a carefully developed remote auditing  protocol, and adopting a hybrid virtual and on-site  approach. In 2021, we conducted 26 SSAVs  (7 in EMEA, 14 in APAC, 1 in North America and  4 in LATAM). There were 52 human rights related  observations ( see graph on page 125 ). ", "page_idx": 126, "bbox": [67, 433.2001037597656, 264, 529.35009765625], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 756, "type": "text", "text": "Following every audit, suppliers commit to a  documented corrective action plan to address each  audit finding. Our SSAV programme also includes  follow-up audits to verify that corrective actions  adequately address the identified findings.  ", "page_idx": 126, "bbox": [67, 541.2000732421875, 264, 601.35009765625], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 757, "type": "text", "text": "Human rights come first ", "text_level": 1, "page_idx": 126, "bbox": [67, 614, 168, 625], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 758, "type": "text", "text": "One example that illustrates how we partner with our  suppliers to help increase human rights standards  is our effort to reduce our environmental impacts  by converting the Roche fleet to electric vehicles.  ", "page_idx": 126, "bbox": [67, 625.2000732421875, 264, 673.35009765625], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 759, "type": "text", "text": "125 years of milestones ", "text_level": 1, "page_idx": 126, "bbox": [319, 443, 441, 458], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 760, "type": "text", "text": "Doing our part for generations to come Between the 1950s and 1970s, the Kesslergrube site in Germany served  as a mixed landfill for domestic, industrial and chemical waste for the  local community and businesses, including Roche. Eventually the area  was covered up and in 2011, authorities decided that it was in need of  remediation in order to protect the local groundwater resource and the  adjacent river Rhine. ", "page_idx": 126, "bbox": [320, 468.2001953125, 556, 553.3502197265625], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 761, "type": "text", "text": "Recognising the social and ethical responsibility we have to protect the  environment and generations to come, in 2014 we began one of the most  complex remediation projects in Germany that is still ongoing today. Going  way beyond what is legally required, our goal is not only to eliminate as  much of the existing soil and groundwater contamination as possible, but  with our proactive approach, to create a positive impact by making the  remediated area available for re-use. ", "page_idx": 126, "bbox": [320, 565.2001953125, 556, 649.3502197265625], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 762, "type": "image", "page_idx": 127, "img_path": "layout_images/roche-holdings_2021_91.jpg", "bbox": [0, 66, 318, 407], "page_size": [595.2760009765625, 793.7009887695312], "ocr_text": "", "vlm_text": "The image shows a person in a blue uniform handling a bottle, placing it into a small open box on what appears to be a production or packaging line. There are multiple boxes and bottles, indicating a systematic process, possibly related to pharmaceuticals or laboratory work."}
{"layout": 763, "type": "text", "text": "Compliance ", "text_level": 1, "page_idx": 127, "bbox": [35, 443, 99, 457], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 764, "type": "text", "text": "In 2021, 161 employees used the Roche Group SpeakUp Line, operated by  an external provider, which is available in 53 languages in 103 countries.  The Chief Compliance Officer received 567 reports of alleged violations  of the Code of Conduct via the Business Ethics Incident Reporting system.  Of these, 214 were unfounded, 216 were founded, and 137 are still under  investigation. As a result, 88 employment contracts and 8 agreements  with business partners were terminated on grounds of unethical behaviour. ", "page_idx": 127, "bbox": [36, 469.2001953125, 275.766845703125, 553.3502197265625], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 765, "type": "text", "text": "We work closely with suppliers around the world to ensure we  are adhering to the highest ethical standards in all areas of  our business. ", "page_idx": 127, "bbox": [331, 98.2003173828125, 518, 133.0003204345703], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 766, "type": "text", "text": "Protecting human rights is key in these efforts,  as we believe that greenhouse gas reductions  will not come at the expense of human rights.  ", "page_idx": 127, "bbox": [331, 181.2001953125, 518, 217.35018920898438], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 767, "type": "text", "text": "Our objective is to not only ensure that  manufacturers providing electric fleet vehicles  are in full compliance with OECD Guidance on  Responsible Supply Chains, but also to be able to  trace conflict minerals to smelters and refiners  compliant with our human rights expectations.  ", "page_idx": 127, "bbox": [331, 229.2001953125, 518, 301.3501892089844], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 768, "type": "text", "text": "Accordingly, all our suppliers of electric vehicles  must be in full compliance with OECD guidance,  have an ethical mineral sourcing code of conduct  that protects miners and families, and have a  recycling programme for conflict minerals.  ", "page_idx": 127, "bbox": [331, 313.2001953125, 518, 373.3501892089844], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 769, "type": "text", "text": "Roche has ceased negotiations with electric  vehicle manufacturers that refuse our Supplier  Code of Conduct and our right to audit, and  do not have their own equivalent sustainable  supplier code of conduct. It is our policy to not do  business with any supplier who refuses to accept  the principles of our Supplier Code of Conduct,  and our right to audit for compliance with our  sustainability principles. ", "page_idx": 127, "bbox": [331, 385.2001953125, 518, 493.3501892089844], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 770, "type": "image", "page_idx": 128, "img_path": "layout_images/roche-holdings_2021_92.jpg", "bbox": [60, 185, 535, 448], "page_size": [595.2760009765625, 793.7009887695312], "ocr_text": "General and Packaging\nadministrative services 4\n‘ . J\n\n5 \\\n\nExcessive overtime\nLack of labour policy and practices\n\nContract research\n\nFacilities and maintenance Pa : Human rights-related organisations\n/\n\n6 findings per / 19\n\nExcessive overtime, incorrect industry 2021 Lack of labour policy; excessive\n\novertime compensation overtime; delayed payment of wages\n\nLaboratory supplies a\n7 \\ was .\n\n\\. Logistics and transportation\nInadequate maintenance of employee time 11\n\nrecords; incorrect overtime compensation\n\nNot granted annual leave;\n", "vlm_text": "The image is a circular chart showing human rights-related findings per industry in 2021. \n\n- **General and administrative services**: 5 findings, issues include lack of labor policy and practices.\n- **Packaging**: 4 findings, issue is excessive overtime.\n- **Contract research organizations**: 19 findings, issues include lack of labor policy, excessive overtime, and delayed payment of wages.\n- **Logistics and transportation**: 11 findings, issue is not being granted annual leave.\n- **Laboratory supplies**: 7 findings, issues include inadequate maintenance of employee time records and incorrect overtime compensation.\n- **Facilities and maintenance**: 6 findings, issues include excessive overtime and incorrect overtime compensation."}
{"layout": 771, "type": "image", "page_idx": 129, "img_path": "layout_images/roche-holdings_2021_93.jpg", "bbox": [0, 67, 531, 691], "page_size": [595.2760009765625, 793.7009887695312], "ocr_text": "Patients are at the heart of everything we do. We work closely with\n\nthe patient community to listen, learn and integrate their feedback\n", "vlm_text": "The image consists of three scenes:\n\n1. A person by a lake playing with a black dog in the early morning light.\n2. A person in a wheelchair carrying a basket of laundry and opening a door.\n3. A person with short hair and an IV in their arm, putting on an earring. There is text nearby saying, \"Patients are at the heart of everything we do. We work closely with the patient community to listen, learn and integrate their feedback.\""}
{"layout": 772, "type": "text", "text": "Reflecting on our responsibility to patients  ", "text_level": 1, "page_idx": 130, "bbox": [68, 135, 416, 159], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 773, "type": "text", "text": "When we look at our history, we are humbled by the  trust patients and their families have placed in us.  They have trusted our research, the medicines and  diagnostics we have developed, and the integrated  solutions we have launched to help improve their  quality of life. The responsibility we have to patients  and those who care for them is the driving force  behind our approach to patient partnership.   ", "page_idx": 130, "bbox": [67, 181.2001953125, 261, 277.3501892089844], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 774, "type": "text", "text": "Over the last 125 years, we have worked to  understand gaps that exist in the treatment of  diseases like cancer, multiple sclerosis, spinal  muscular atrophy and so many more. And while we  have tried to keep the people impacted by these  diseases in mind, we have not always asked for  their perspective on what they value in their care.  So, over the years, we have made a concerted  effort to learn about how we can and  should  work  with the patient community to integrate their  feedback into our work.   ", "page_idx": 130, "bbox": [67, 289.2001953125, 261, 421.3501892089844], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 775, "type": "text", "text": "Patients today take centre stage at Roche. We  engage them early and systematically across our  business to ensure that our thinking on disease  management is shaped by their feedback on the  outcomes that matter most to them, such as  survival, relief of symptoms and cure of disease.  We have, in the past, been challenged by regulatory  authorities and payers on the outcomes we have  measured for some of our medicines. This has  required us to take a step back and consult the  patient community to refine our thinking. Our  hope is that by proactively getting the patient  community’s perspective, we will answer the  right research questions upfront.  ", "page_idx": 130, "bbox": [67, 433.2001953125, 261, 601.3502197265625], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 776, "type": "text", "text": "Beyond research, patients and their families  educate us about how they live, how they cope  ", "page_idx": 130, "bbox": [67, 613.2001953125, 244, 637.3502197265625], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 777, "type": "text", "text": "and what concessions they make in their day- to-day lives. These insights guide us on how we  can help improve the patient experience from  diagnosis to treatment to ongoing monitoring and  patient support. Our work to engage patients in  the right way is centralised through our Global  Patient Partnership team and Worldwide Patient  Partnership Network who partner across the  company to drive our collaboration with patient  communities within our core geographies.   ", "page_idx": 130, "bbox": [277, 181.2000732421875, 464, 301.35009765625], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 778, "type": "text", "text": "Our collaboration with patients culminates  in our long-standing commitment to help the  community network, share and mobilise on broad  health system topics through the International  Experience Exchange with Patient Organizations  (IEEPO). Over the past 13 years, IEEPO has  become a signature Roche offering that helps  patient groups share learnings, identify synergies  in their markets, and collaborate on health  topics that will make healthcare accessible  to everyone around the world. It is also an  opportunity for patient groups to tell us what we  are not doing well and how we can improve. With  close to 600 patient groups from  $^{70+}$   countries  participating in this platform ( www.ieepo.com ),  IEEPO has become central to our vision for  patient partnership.   ", "page_idx": 130, "bbox": [277, 313.2001037597656, 464, 517.35009765625], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 779, "type": "text", "text": "This collaborative approach has resulted in  Roche ranking first in corporate reputation  amongst our peer group of ‘Big Pharma’ as  announced in 2021. 1  This recognition is a  testament to not only our vision for partnering  with patients, but to their willingness to share  and trust in us. It is a responsibility that has  driven us for the last 125 years and one that  we will carry into the next 125.  ", "page_idx": 130, "bbox": [277, 529.2000732421875, 464, 637.35009765625], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 780, "type": "image", "page_idx": 131, "img_path": "layout_images/roche-holdings_2021_94.jpg", "bbox": [7, 1, 596, 790], "page_size": [595.2760009765625, 793.7009887695312], "ocr_text": "", "vlm_text": "The image shows a person sitting in a chair. The individual is wearing glasses, a light blue button-up shirt, and a dark tie with a pattern. The background appears to be an indoor setting with windows."}
{"layout": 781, "type": "text", "text": "Integrity underpins every aspect of our business ", "text_level": 1, "page_idx": 132, "bbox": [67, 98, 467, 126], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 782, "type": "text", "text": "Adriano Treve joined Roche 36 years ago as a trainee for the region of Iran,  Saudi Arabia, Bangladesh, Pakistan and Cyprus. For the past three years,  he has served as Area Head for Turkey, Russia, Iran, Central and Eastern  Europe, Central Asia and the Indian subcontinent.  ", "page_idx": 132, "bbox": [67, 138.2001953125, 479.24468994140625, 231.80020141601562], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 783, "type": "text", "text": "Adriano passionately believes that integrity  is vital to Roche’s cultural mindset, and to our  future success. We conduct business within a  framework of the highest professionalism. Full  compliance with legal and regulatory requirements  is a prerequisite of our licence to operate, and is  vital to our sustainability, our reputation and our  future. Integrity extends beyond simply ensuring  that correct procedures are followed. It must be  ingrained within our culture. ", "page_idx": 132, "bbox": [67, 265.2001953125, 260, 385.3501892089844], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 784, "type": "text", "text": "Our Code of Conduct defines us, what we stand  for, and what Roche expects of us. Our core values  are courage, passion and integrity. As Adriano  explains: “When we are confident that our managers  and colleagues will respond with integrity, we are  empowered to express our concerns. When we  trust our colleagues, non-compliant behaviours are  less likely to occur – a concern that is discussed  becomes an issue avoided.” This is an approach  Adriano has extended across his teams, ensuring  that everyone he directly works with feels they are  able to speak up with confidence and without the  fear of retaliation. All employees can also use the  anonymous Roche Group SpeakUp Line to report a  compliance concern via the intranet or by phone. ", "page_idx": 132, "bbox": [67, 397.2001953125, 260, 577.3502197265625], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 785, "type": "text", "text": "Adriano supports the Roche policy of zero tolerance  of non-compliance. “This is not as draconian as it  may sound; an open and supportive culture means  there is less opportunity for unethical behaviours  to emerge,” he says. “Concerns are raised early  and discussed openly, and actions are taken to  ensure non-compliant behaviour is avoided.” Our  Code of Conduct applies across the organisation,  regardless of geography or culture. Zero tolerance  of non-compliance is universal. However, this  does not preclude the flexibility to accommodate  different cultures, as long as integrity is preserved.  For example, in some countries small gifts, like  chocolates, are used to show respect in business  interactions. But in other regions, this would be  unacceptable. When advising his team, Adriano is  guided by the principle of ‘integrity of motivation’.  Why is this being suggested? Does it form a normal  part of local business practices? Or is it likely to  alter the basis of our engagement with a business  partner? Even in circumstances where modest  business gifts are normal, they must remain ‘token’  in nature; cultural variance is never a licence  for excess. ", "page_idx": 132, "bbox": [67, 589.2001953125, 260, 697.3502197265625], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 786, "type": "text", "text": "", "page_idx": 132, "bbox": [276, 265.2001953125, 472, 445.3501892089844], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 787, "type": "text", "text": "Integrity in leadership, coupled with a conscious  effort to foster that behaviour within our teams, is  crucial to Roche. We will continue to behave with  consistent and demonstrable personal integrity,  and will consistently cultivate and encourage these  values in our areas of responsibility. Our integrity- driven mindset makes us an ideal partner around the  world, allowing us to serve wider groups of patients.  We are compliant not merely because we are  required to be, but because it is the right thing to do. ", "page_idx": 132, "bbox": [276, 457.2001953125, 472, 577.3502197265625], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 788, "type": "text", "text": "As we celebrate our 125-year anniversary, Adriano  reflects on the future of Roche in the years to come.  “Roche is already future-fit, living by the same  principles today that will guide success in the next  125 years,” he says. “The most important thing to  me is that we continue to attract talent of the same  high calibre as we do today – people rooted in the  Roche heartland making a meaningful difference  for patients.” ", "page_idx": 132, "bbox": [276, 589.2001953125, 472, 697.3502197265625], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 789, "type": "image", "page_idx": 133, "img_path": "layout_images/roche-holdings_2021_95.jpg", "bbox": [0, 7, 595, 794], "page_size": [595.2760009765625, 793.7009887695312], "ocr_text": "", "vlm_text": "The image shows part of a design or emblem with the text \"ROCH\" visible at the top. Below the text, there is a stylized depiction of a creature, possibly a griffin or similar mythological animal. The design appears to be on a glass or transparent surface."}
{"layout": 790, "type": "text", "text": "Business \n performance ", "text_level": 1, "page_idx": 134, "bbox": [125, 476, 404, 613], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 791, "type": "image", "page_idx": 135, "img_path": "layout_images/roche-holdings_2021_96.jpg", "img_caption": "Key figures 2021 ", "bbox": [64, 107, 546, 651], "page_size": [595.2760009765625, 793.7009887695312], "ocr_text": "", "vlm_text": "The image is a chart showing financial figures for 2021 compared to 2020. It includes group sales, pharmaceuticals sales, diagnostics sales, core operating profit, R&D core investments, and dividends, all expressed in CHF millions.\n\nHere are the details:\n\n- **Group sales**\n  - 2021: 62,801 (+9.3%)\n  - 2020: 58,323 (+1.0%)\n\n- **Pharmaceuticals sales**\n  - 2021: 45,041 (+3.1%)\n  - 2020: 44,532 (-2.4%)\n\n- **Diagnostics sales**\n  - 2021: 17,760 (+29.5%)\n  - 2020: 13,791 (+13.9%)\n\n- **Core operating profit**\n  - 2021: 21,897 (+4.1%)\n  - 2020: 21,536 (+4.4%)\n\n- **R&D core investments**\n  - 2021: 13,708 (+14.3%)\n  - 2020: 12,153 (+8.2%)\n\n- **Dividend**\n  - 2021: 9.30\n  - 2020: 9.10\n\nThe increases or decreases in percentages are indicated next to each figure."}
{"layout": 792, "type": "image", "page_idx": 136, "img_path": "layout_images/roche-holdings_2021_97.jpg", "bbox": [133, 203, 497, 428], "page_size": [595.2760009765625, 793.7009887695312], "ocr_text": "Diagnostics\n\nvy 39,266\n\nPharmaceuticals\n\n46,889 \\\n\nEmployees**\n\nby Operating\n\nDivisional Group\n\nCorporate and others\nChugai 7,054\n7,711\n\n", "vlm_text": "The image is a pie chart showing the distribution of employees by operating divisional group. Here are the numbers:\n\n- Pharmaceuticals: 46,889 employees\n- Diagnostics: 39,266 employees\n- Chugai: 7,711 employees\n- Corporate and others: 7,054 employees\n\nThe chart visually represents each group's proportion."}
{"layout": 793, "type": "text", "text": "Research and development sites in  Pharmaceuticals and Diagnostics worldwide  27 ", "page_idx": 136, "bbox": [68, 464.78289794921875, 302, 515.98291015625], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 794, "type": "text", "text": "Manufacturing sites in Pharmaceuticals and Diagnostics worldwide  20 ", "page_idx": 136, "bbox": [337, 464.78289794921875, 547.67041015625, 515.98291015625], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 795, "type": "text", "text": "Treated with Roche medicines  16.4 million patients ", "page_idx": 136, "bbox": [68, 542.4049072265625, 229.43634033203125, 575.6049194335938], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 796, "type": "text", "text": "On the WHO Model List of Essential Medicines  32 Roche medicines ", "page_idx": 136, "bbox": [68, 601.0347900390625, 315.39837646484375, 634.2348022460938], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 797, "type": "text", "text": "Roche Group ", "text_level": 1, "page_idx": 137, "bbox": [120, 122, 263, 147], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 798, "type": "text", "text": "In 2021, Group sales rose   $9\\%^{*}$     ${}.8\\%$   in CHF) to  CHF 62.8 billion. Core operating profit increased   $4\\%$     $2\\%$   in CHF), reflecting the strong underlying  business performance, and core EPS grew  $6\\%$    (  $3\\%$   in CHF). The Swiss franc’s appreciation  against almost all currencies affected the results  expressed in Swiss francs compared to constant  exchange rates. ", "page_idx": 137, "bbox": [120, 181, 309, 277.3500671386719], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 799, "type": "text", "text": "IFRS net income was CHF 14.9 billion. This  represents an increase of  $2\\%$     $(-1\\%$   in CHF),  driven by the operating results.  ", "page_idx": 137, "bbox": [120, 289.2001953125, 283, 325.3501892089844], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 800, "type": "text", "text": "In December, Roche completed the CHF 19.0 billion  repurchase of Roche shares held by Novartis. This  restores Roche’s full strategic flexibility while  retaining its operational scope of action. ", "page_idx": 137, "bbox": [120, 337.2001953125, 314, 385.3501892089844], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 801, "type": "text", "text": "Pharmaceuticals Division sales increased by  $3\\%$    to CHF 45.0 billion. Strong demand for newly  launched medicines to treat severe diseases,  namely Hemlibra (haemophilia), Ocrevus (multiple  sclerosis), Tecentriq (cancer), Evrysdi (spinal  muscular atrophy) and Phesgo (cancer) drove this  growth; medicines for the treatment of COVID-19  also contributed to sales growth (Ronapreve  for high-risk COVID-19 patients and Actemra/ RoActemra for severe COVID-19 pneumonia). ", "page_idx": 137, "bbox": [120, 397, 309, 517.3502197265625], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 802, "type": "text", "text": "Overall, the medicines launched in the last  ten years 1  contributed an additional CHF 5.7 billion  in new sales. The impact of competition from  biosimilars for the cancer medicines Avastin,  Herceptin and MabThera/Rituxan has slowed down  as expected (combined CHF 4.5 billion of sales  reduction); and the second half of the year saw  signs of recovery from the COVID-19 pandemic.  ", "page_idx": 137, "bbox": [120, 529.2001953125, 314, 553.3502197265625], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 803, "type": "text", "text": "", "page_idx": 137, "bbox": [331, 181.2000732421875, 521, 253.35006713867188], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 804, "type": "text", "text": "The Diagnostics Division reported strong sales  growth of  $29\\%$   to CHF 17.8 billion. The division’s  base business showed strong momentum  throughout 2021 (overall  $+16\\%,$  . With sales  totalling CHF 4.7 billion, Roche’s leading portfolio  of COVID-19 tests contributed significantly to the  division’s overall sales. ", "page_idx": 137, "bbox": [331, 265.2000732421875, 521, 349.3501892089844], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 805, "type": "text", "text": "Outlook for 2022 ", "text_level": 1, "page_idx": 137, "bbox": [331, 362, 402, 372], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 806, "type": "text", "text": "Sales are expected to be stable or grow in the  low-single digits (at constant exchange rates).  Core earnings per share are targeted to grow  in the low- to mid-single digit range (at constant  exchange rates), including the accretive effect  of the recent share repurchase. Roche expects  to increase its dividend in Swiss francs further.  ", "page_idx": 137, "bbox": [331, 373.2001953125, 511, 457.3501892089844], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 807, "type": "text", "text": "Roche anticipates sales of COVID-19 medicines  and diagnostics to decrease by approximately  CHF 2 billion to around CHF 5 billion, and sales  losses to biosimilars in the current year to  be roughly CHF 2.5 billion. Excluding those  effects, Group sales are expected to grow in  the high-single digit range. ", "page_idx": 137, "bbox": [331, 469.2001953125, 511, 553.3502197265625], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 808, "type": "image", "page_idx": 137, "img_path": "layout_images/roche-holdings_2021_98.jpg", "bbox": [0, 590, 106, 694], "page_size": [595.2760009765625, 793.7009887695312], "ocr_text": "UN SDG\n\n8 aaa\ni\n\nMaterial topic\n- Long-term mindset\n", "vlm_text": "The image relates to the United Nations Sustainable Development Goal (SDG) 8, which focuses on \"Decent Work and Economic Growth.\" It also mentions a \"Material topic\" of having a \"Long-term mindset.\""}
{"layout": 809, "type": "text", "text": "Pharmaceuticals Division 45,041\t +3.1% ", "page_idx": 138, "bbox": [78, 240.0230712890625, 192.14463806152344, 271.22308349609375], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 810, "type": "image", "page_idx": 138, "img_path": "layout_images/roche-holdings_2021_99.jpg", "bbox": [238, 254, 388, 403], "page_size": [595.2760009765625, 793.7009887695312], "ocr_text": "", "vlm_text": "This image shows a donut chart representing \"Sales in 2021 (CHF millions).\" The donut is mostly one color, with a small segment in a different color, indicating a proportion of sales. No specific data values are provided."}
{"layout": 811, "type": "text", "text": "Diagnostics ", "text_level": 1, "page_idx": 139, "bbox": [120, 123, 247, 147], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 812, "type": "text", "text": "Diagnostics sales grew by  $29\\%$  , driven by strong  momentum in the base business and continued  high demand for COVID-19 testing.  ", "page_idx": 139, "bbox": [120, 181, 302, 217.35018920898438], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 813, "type": "text", "text": "Sales grew strongly across the world:  Europe, Middle East and Africa (EMEA)  $37\\%$  Asia-Pacific  $29\\%$  , North America   $16\\%$  , and  Latin America   $48\\%$  .  ", "page_idx": 139, "bbox": [120, 229.2001953125, 298, 277.3501892089844], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 814, "type": "text", "text": "The division has also seen strong sales growth  across all customer areas: ", "page_idx": 139, "bbox": [120, 289.2001953125, 298, 313.3501892089844], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 815, "type": "text", "text": "Core Lab  sales increased by  $2\\uparrow\\%$   due to its  immuno diagnostics business, with infectious  and cardiac tests as main contributors. Sales  grew across all regions, most strongly in EMEA  and Asia-Pacific.  ", "page_idx": 139, "bbox": [120, 325, 298, 385.3501892089844], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 816, "type": "text", "text": "This customer area focuses on central labs  and provides diagnostics solutions in the  areas of immunoassays, clinical chemistry and  custom biotech.  ", "page_idx": 139, "bbox": [120, 397.2001953125, 298, 445.3501892089844], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 817, "type": "text", "text": "Molecular Lab  sales grew  $29\\%$  , led by the virology  business. The Delta variant continued to push  growth in COVID-19 testing such as high-throughput  PCR tests. Sales increased in all regions, led by  the North America and Asia-Pacific regions.  ", "page_idx": 139, "bbox": [120, 457.2001953125, 316, 517.3502197265625], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 818, "type": "text", "text": "This customer area focuses on molecular labs  and provides diagnostics solutions for pathogen  ", "page_idx": 139, "bbox": [120, 529.2001953125, 302, 553.3502197265625], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 819, "type": "text", "text": "detection and monitoring, donor screening,  sexual health and genomics.  ", "page_idx": 139, "bbox": [330, 181.2000732421875, 508, 205.35006713867188], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 820, "type": "text", "text": "Point of Care  sales continued to grow  significantly  $(+158\\%)$  . The SARS-CoV-2 Rapid  Antigen test was the main growth driver,  especially in the EMEA region.  ", "page_idx": 139, "bbox": [330, 217.2000732421875, 508, 265.3500671386719], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 821, "type": "text", "text": "This customer area provides diagnostics  solutions immediately at the point of care such  as in emergency rooms, medical practices and  directly with patients; it includes SARS-CoV-2  rapid tests and blood gas and electrolyte tests. ", "page_idx": 139, "bbox": [330, 277.2001037597656, 508, 337.35009765625], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 822, "type": "text", "text": "Diabetes Care  sales increased  $5\\%$  , driven by  the blood glucose monitoring business (such as  the Accu-Chek Guide system).  ", "page_idx": 139, "bbox": [330, 349.2001037597656, 508, 385.35009765625], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 823, "type": "text", "text": "This customer area focuses on integrated  personalised diabetes management for people  with diabetes and healthcare professionals. ", "page_idx": 139, "bbox": [330, 397.2001037597656, 508, 433.35009765625], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 824, "type": "text", "text": "Pathology Lab  sales increased  $12\\%$  . This  was mainly due to growth in the advanced  staining business.  ", "page_idx": 139, "bbox": [330, 445.2001037597656, 490, 481.35009765625], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 825, "type": "text", "text": "This customer area focuses on pathology labs  and provides diagnostics solutions for tissue  biopsies and companion diagnostics. These  targeted diagnostics support the specific  therapy decisions for each patient. ", "page_idx": 139, "bbox": [330, 493.2001037597656, 508, 553.35009765625], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 826, "type": "text", "text": "Sales by Customer Area in 2021 ", "page_idx": 140, "bbox": [70.42749786376953, 253.034912109375, 212.19651794433594, 266.534912109375], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 827, "type": "image", "page_idx": 140, "img_path": "layout_images/roche-holdings_2021_100.jpg", "bbox": [123, 265.25, 547, 518], "page_size": [595.2760009765625, 793.7009887695312], "ocr_text": "Core\n\nMolecular\n\nLab\n\nLab\n\nPoint of Care\n\nDiabetes Care\n\nPathology Lab\n\nCHF millions\n\n7,473\n\n4,812\n\n2,583\n\n1,690\n\n1,202\n\n+21%\n\n+29%\n\n+138%\n\n+3%\n\n+12%\n", "vlm_text": "The image is a bar chart comparing revenue in CHF millions for various labs and care sectors. The values and growth percentages are:\n\n- Core Lab: 7,473 million (+21%)\n- Molecular Lab: 4,812 million (+29%)\n- Point of Care: 2,583 million (+138%)\n- Diabetes Care: 1,690 million (+3%)\n- Pathology Lab: 1,202 million (+12%)"}
{"layout": 828, "type": "text", "text": "Pharmaceuticals ", "text_level": 1, "page_idx": 141, "bbox": [120, 122, 305, 145], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 829, "type": "text", "text": "Pharmaceuticals Division sales increased by  $3\\%$  ;  the continued strong demand for newly launched  medicines more than offset the impact of  biosimilars.  ", "page_idx": 141, "bbox": [120, 181, 313, 229.35006713867188], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 830, "type": "text", "text": "In the United States, sales decreased by   $2\\%$  . While  sales of Actemra/RoActemra, Hemlibra, Ocrevus,  Evrysdi and Tecentriq increased, the impact of  biosimilars and the COVID-19 pandemic affected  total growth as expected.  ", "page_idx": 141, "bbox": [120, 241, 313, 301.35009765625], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 831, "type": "text", "text": "In Europe, sales grew  $7\\%$  . Growth of recently  launched medicines more than compensated  for the impact of biosimilars and the COVID-19  pandemic.  ", "page_idx": 141, "bbox": [120, 313, 296, 361.35009765625], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 832, "type": "text", "text": "In Japan, sales increased by  $26\\%$  , driven by  strong demand for new medicines. This more than  compensated for competition from biosimilars  and government price cuts.  ", "page_idx": 141, "bbox": [120, 373.2001037597656, 313, 421.35009765625], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 833, "type": "text", "text": "Sales in the International region grew by  $4\\%$  . In  China, sales were stable: Growth of Perjeta,  Alecensa and Heceptin was offset by the impact  from biosimilars. Excluding China, sales increased  by  $6\\%$  , mainly driven by new product sales, partially  offset by the biosimilars competition.  ", "page_idx": 141, "bbox": [120, 433, 313, 505.35009765625], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 834, "type": "text", "text": "Ocrevus  (first approved in 2017; CHF 5.1 billion,   $+19\\%,$  ). Relapsing and primary progressive forms  of multiple sclerosis; two-hour only infusion. The  demand for this treatment in both indications  remained strong, mainly in the United States, while  the pandemic still had a certain negative impact.  ", "page_idx": 141, "bbox": [120, 517.2000732421875, 313, 589.35009765625], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 835, "type": "text", "text": "New and returning patients both boosted growth,  the latter group generating stronger sales. ", "page_idx": 141, "bbox": [330, 181.2001953125, 524, 205.35018920898438], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 836, "type": "text", "text": "Perjeta  (first approved in 2012; CHF 4.0 billion,   $+4\\%,$  . HER2-positive breast cancer. Sales increased  mostly due to high demand in China in both early  and metastatic breast cancer settings. In the  United States, sales of Perjeta declined by   $1\\%$   due  to certain patients being switched to Kadcyla and  due to the launch of Phesgo in 2020.  ", "page_idx": 141, "bbox": [330, 217.2001953125, 524, 301.3501892089844], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 837, "type": "text", "text": "Tecentriq  (first approved in 2016; CHF 3.3 billion,   $+24\\%,$  . Cancer immunotherapy (either alone or in  combinations) for various types of cancer, eg, lung,  bladder, breast and liver cancer. Sales increased  in all regions, most notably in Japan, primarily due  to the demand for treatment of hepatocellular  carcinoma (HCC). US sales were higher, driven by  the new indications for HCC and first-line non-small  cell lung cancer (NSCLC). ", "page_idx": 141, "bbox": [330, 313.2001953125, 524, 421.3501892089844], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 838, "type": "text", "text": "Hemlibra  (first approved in 2017; CHF 3.0 billion,   $+41\\%,$  ). Haemophilia A with and without factor VIII  inhibitors; only prophylactic treatment that can be  administered subcutaneously once weekly, every  two or every four weeks. Sales continued to show  a strong uptake, especially in the United States  and Europe. ", "page_idx": 141, "bbox": [330, 433.2001953125, 524, 517.3502197265625], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 839, "type": "text", "text": "Kadcyla  (first approved in 2013; CHF 2.0 billion,   $+16\\%$  . HER2-positive breast cancer. Sales growth  was driven by the usage of Kadcyla in the early  breast cancer setting. Sales benefited from patients  switching to this new standard of treatment. ", "page_idx": 141, "bbox": [330, 529.2001953125, 528, 589.3502197265625], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 840, "type": "image", "page_idx": 142, "img_path": "layout_images/roche-holdings_2021_101.jpg", "img_caption": "Top-selling pharmaceuticals in 2021 ", "bbox": [66, 133, 541, 648], "page_size": [595.2760009765625, 793.7009887695312], "ocr_text": "", "vlm_text": "The image is a bar chart showing the top-selling pharmaceuticals in 2021, listed with their revenue in CHF millions and the percentage change from the previous year. Here’s the information presented:\n\n1. **Ocrevus (Neuroscience)**\n   - Revenue: CHF 5,055 million\n   - Change: +19%\n\n2. **Perjeta (Oncology)**\n   - Revenue: CHF 3,955 million\n   - Change: +4%\n\n3. **Actemra/RoActemra (Immunology)**\n   - Revenue: CHF 3,562 million\n   - Change: +27%\n\n4. **Tecentriq (Oncology)**\n   - Revenue: CHF 3,315 million\n   - Change: +24%\n\n5. **Avastin (Oncology)**\n   - Revenue: CHF 3,056 million\n   - Change: -37%\n\n6. **Hemlibra (Haemophilia)**\n   - Revenue: CHF 3,022 million\n   - Change: +41%\n\n7. **Herceptin (Oncology)**\n   - Revenue: CHF 2,694 million\n   - Change: -28%\n\n8. **MabThera/Rituxan (Oncology/Immunology)**\n   - Revenue: CHF 2,565 million\n   - Change: -38%\n\n9. **Kadcyla (Oncology)**\n   - Revenue: CHF 1,982 million\n   - Change: +16%\n\n10. **Xolair (Immunology)**\n    - Revenue: CHF 1,942 million\n    - Change: +5%"}
{"layout": 841, "type": "image", "page_idx": 143, "img_path": "layout_images/roche-holdings_2021_102.jpg", "bbox": [0, 3, 596, 792], "page_size": [595.2760009765625, 793.7009887695312], "ocr_text": "", "vlm_text": "This image appears to show a group of clear glass rods or tubes. They seem to be arranged in a cluster, with a blurred effect that gives a sense of depth and light reflection."}
{"layout": 842, "type": "text", "text": "Corporate \n Governance ", "text_level": 1, "page_idx": 144, "bbox": [127, 468, 404, 583], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 843, "type": "text", "text": "Principles ", "text_level": 1, "page_idx": 145, "bbox": [120, 98, 232, 122], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 844, "type": "text", "text": "Business activities with a focus on sustainable  value creation and innovation, a management  culture conforming to recognised standards  of good corporate governance and a policy of  transparent communication embody Roche’s  corporate governance principles, which build  the basis for the successful implementation of  Roche’s commitment to serving all its stakeholders. ", "page_idx": 145, "bbox": [120, 157.48370361328125, 312, 253.63369750976562], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 845, "type": "text", "text": "A strong Board of Directors, which represents  the interests of the shareholders and all other  stakeholders, and highly skilled managers who  act with integrity are extremely important. ", "page_idx": 145, "bbox": [120, 265.48370361328125, 312, 313.6336975097656], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 846, "type": "text", "text": "Roche ranked as one of the top three most  sustainable healthcare companies in the  Pharmaceuticals index of the Dow Jones  Sustainability Indices (DJSI) for the   $15^{\\mathrm{th}}$   year  running. This recognition is based on an in-depth  analysis of economic, social and environmental  performance. The DJSI serve as a benchmark for  investors who integrate sustainability considerations  into their portfolios. Sustainability is at the core of  our business practices and this award reflects our  commitment to running our business in a way that  is ethical, responsible and creates long-term value  for stakeholders. ", "page_idx": 145, "bbox": [120, 325.48370361328125, 316, 481.6336975097656], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 847, "type": "text", "text": "This Corporate Governance Report sets out the  structures, processes and rules which Roche  takes as the basis for well-functioning corporate  ", "page_idx": 145, "bbox": [120, 493.48370361328125, 312, 529.6337280273438], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 848, "type": "text", "text": "governance. In doing so, Roche complies with  all relevant corporate governance requirements,  in particular with all applicable laws, the Swiss  Stock Exchange (SIX Swiss Exchange) directives  and the Swiss Code of Best Practice for Corporate  Governance promulgated by the Swiss business  federation ‘economiesuisse’. The company’s internal  governance framework, particularly its Articles  of Incorporation and Bylaws, embodies all the  principles needed to ensure that the company’s  businesses are managed and supervised in a manner  consistent with good corporate governance,  including the necessary checks and balances. 1 ", "page_idx": 145, "bbox": [331, 157.48370361328125, 528, 313.6336975097656], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 849, "type": "text", "text": "The printed Annual Report contains selected links  to the Roche website ( https://www.roche.com ).  Readers are thus provided not only with a ‘snapshot’  of our company at the reporting date but are also  directed to sources which they can consult at any  time for up-to-date information about corporate  governance at Roche. Whereas each Annual Report  covers a single financial year ending 31 December,  our website contains information of a more  permanent nature, as well as the latest Roche news.  The company’s Articles of Incorporation, Bylaws  and the curricula vitae of current and former (status  as per end of term and as at the reporting date on  31 December of each year, at least of the last five  years) members of the Board of Directors and the  Corporate Executive Committee are published on  our website. ", "page_idx": 145, "bbox": [331, 325.48370361328125, 528, 529.6337280273438], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 850, "type": "image", "page_idx": 146, "img_path": "layout_images/roche-holdings_2021_103.jpg", "bbox": [64, 151, 560, 375], "page_size": [595.2760009765625, 793.7009887695312], "ocr_text": "Annual General Meeting\ni\nBoard of Directors Board Committees\n\nan d Board Cc omm ittee S Chairman’s/Nomination Committee\n\nRemuneration Committee\nAudit Committee\n\nCorporate Governance and Sustainability Committee\n\nCorporate Executive Committee\n\nCorporate Executive Committee CEO CEO CEO Chief Financial and Chief People\n\nRoche Group Pharmaceuticals Diagnostics Information Officer Officer\n\nEnlarged Corporate Executive\n\nC omm itte e gRED pRED Partnering Communications General Counsel\n", "vlm_text": "The image is an organizational chart of a company's governance structure. It includes:\n\n1. **Annual General Meeting**\n2. **Board of Directors and Board Committees:**\n   - Board of Directors\n   - Chairman’s/Nomination Committee\n   - Remuneration Committee\n   - Audit Committee\n   - Corporate Governance and Sustainability Committee\n\n3. **Corporate Executive Committee:**\n   - CEO Roche Group\n   - CEO Pharmaceuticals\n   - CEO Diagnostics\n   - Chief Financial and Information Officer\n   - Chief People Officer\n\n4. **Enlarged Corporate Executive Committee:**\n   - gRED\n   - pRED\n   - Partnering\n   - Communications\n   - General Counsel"}
{"layout": 851, "type": "text", "text": "Board of Directors ", "text_level": 1, "page_idx": 147, "bbox": [120, 98, 325, 122], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 852, "type": "text", "text": "In accordance with Art. 8 of the Federal Act  on the Statutory Principles for Federal Council  Ordinances on Combating the COVID-19 Epidemic  (COVID-19 Act) and Art. 27 of the Ordinance 3 on  Measures to Combat the Coronavirus (COVID-19)  (COVID-19 Ordinance 3), the   $103^{\\scriptscriptstyle\\mathrm{rd}}$   Annual General  Meeting (AGM) of Roche Holding Ltd was held on  16 March 2021 without the physical participation  of shareholders. Shareholders have been requested  to exercise their rights via the independent proxy,  Testaris AG, and to address their questions to the  company in writing.  ", "page_idx": 147, "bbox": [120, 157.48370361328125, 318, 301.6336975097656], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 853, "type": "text", "text": "the structure and composition of its remaining  committees as shown on page 146 (see also  page 14 and page 151 ‘Board of Directors and  Corporate Executive Committee’). ", "page_idx": 147, "bbox": [331, 157.48370361328125, 516, 205.63369750976562], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 854, "type": "text", "text": "On 15 March 2022, at the forthcoming AGM the  Board of Directors nominates the Chairman and all  remaining members of the Board of Directors for  re-election, with the exception of Mr Paul Bulcke  and Prof. Dr Hans Clevers. Paul Bulcke has been  serving on the Board of Directors since 2011  and has decided not to stand for re-election at  the AGM in 2022, following almost eleven years  of tenure. Prof. Dr Hans Clevers, who joined the  Board of Directors in 2019, will step down from  this position and be appointed the new Head of  Roche pRED effective 18 March 2022. He will  become a member of the enlarged Corporate  Executive Committee. The Board of Directors  proposes Dr Jemilah Mahmood, currently the  Special Advisor on Public Health to Malaysia’s  prime minister, for election to the Board of  Directors at the AGM 2022. ", "page_idx": 147, "bbox": [331, 217.48370361328125, 520, 433.6336975097656], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 855, "type": "text", "text": "At the AGM of Roche Holding Ltd, on 16 March 2021,  shareholders re-elected Dr Christoph Franz as  Chairman of the Board of Directors for a term of one  year as provided by the Articles of Incorporation. ", "page_idx": 147, "bbox": [120, 313.48370361328125, 318, 361.6336975097656], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 856, "type": "text", "text": "Furthermore, the AGM re-elected André Hoffmann,  Julie Brown, Paul Bulcke, Prof. Dr Hans Clevers,  Dr Jörg Duschmalé, Dr Patrick Frost, Anita Hauser,  Prof. Dr Richard P. Lifton, Bernard Poussot,  Dr Severin Schwan and Dr Claudia Suessmuth  Dyckerhoff as members of the Board of Directors  for a term of one year as provided by the Articles  of Incorporation. ", "page_idx": 147, "bbox": [120, 373.48370361328125, 312.92474365234375, 469.6336975097656], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 857, "type": "text", "text": "Moreover, the Board of Directors nominates  Dr Christoph Franz, André Hoffmann, Prof. Dr  Richard P. Lifton, Bernard Poussot and in addition  Dr Patrick Frost for election to the Remuneration  Committee at the AGM in 2022. ", "page_idx": 147, "bbox": [331, 445.48370361328125, 516, 505.6336975097656], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 858, "type": "text", "text": "In addition, the AGM elected Dr Christoph Franz,  André Hoffmann, Prof. Dr Richard P. Lifton and  Bernard Poussot as members of the Remuneration  Committee for a term of one year. ", "page_idx": 147, "bbox": [120, 481.48370361328125, 309, 529.6337280273438], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 859, "type": "text", "text": "The Board of Directors nominates Testaris AG for  election as independent proxy by the AGM in 2022  for the period from 2022 until the conclusion of  the 2023 ordinary AGM of shareholders. ", "page_idx": 147, "bbox": [331, 517.4837036132812, 520, 565.6337280273438], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 860, "type": "text", "text": "At its organising meeting immediately following  the AGM, the Board of Directors determined  ", "page_idx": 147, "bbox": [120, 541.4837036132812, 297, 565.6337280273438], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 861, "type": "text", "text": "Board of Directors\n and Board Committees ", "page_idx": 147, "bbox": [36, 622.414794921875, 146.03082275390625, 657.3148193359375], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 862, "type": "image", "page_idx": 148, "img_path": "layout_images/roche-holdings_2021_104.jpg", "bbox": [62, 153, 565, 634], "page_size": [595.2760009765625, 793.7009887695312], "ocr_text": "Nationality*\n\nFrance Belgium\n\nfemale\n\n25%\n\nNetherlands /\n\\ Switzerland\n\n1\nAustria / ’\n1\nUS /\n2\n\\ Germany\n3\n<5 years Sa 4\nMO <s5years 6-10 years | 5\n55-65 years 11-20 years ] 2\nMO xs years >2l years ia 1\n| | |\nAge Tenure**\nAverage tenure — incl. CEO: 7.92\n\n(years) excl. CEO: 7.82\n", "vlm_text": "The image is an infographic about the composition of a Board of Directors. It includes:\n\n1. **Nationality Breakdown**:\n   - Switzerland: 7 members\n   - Germany: 3 members\n   - US: 2 members\n   - France, UK, Netherlands, Austria, Belgium: 1 member each\n\n2. **Gender Breakdown**:\n   - 25% female\n   - 75% male\n\n3. **Age Distribution**:\n   - <55 years: 3 members\n   - 55–65 years: 6 members\n   - >65 years: 3 members\n\n4. **Tenure Distribution**:\n   - <5 years: 4 members\n   - 6–10 years: 5 members\n   - 11–20 years: 2 members\n   - >21 years: 1 member\n\n5. **Average Tenure**:\n   - Including CEO: 7.92 years\n   - Excluding CEO: 7.82 years"}
{"layout": 863, "type": "table", "page_idx": 149, "img_path": "layout_images/roche-holdings_2021_105.jpg", "table_footnote": "Curricula vitae (CVs) of members of the Board of Directors:  a) current members:  https://www.roche.com/about/governance/board of directors.htm b) former members (at least of the last five years):  https://www.roche.com/about/governance/ec_bod_former.htm c) \u0007 information of CVs at the reporting date on 31 December of each year (at least of the last five years):  https://www.roche.com/about/governance/arch iv former cvs.htm   ", "bbox": [35, 154, 527, 406], "page_size": [595.2760009765625, 793.7009887695312], "ocr_text": "Composition as at 31.12.2021\n\nBoard of Directors\n\nSecretary to the\nBoard of Directors\n\nName (year of birth)\n\nDr Christoph Franz (1960)\n\nAndré Hoffmann (1958)\n\n(representative of the shareholder group with pooled voting rights)\nDr Jérg Duschmalé (1984)\n\n(representative of the shareholder group with pooled voting rights)\nJulie Brown (1962)\n\nPaul Bulcke (1954)\n\nProf. Dr Hans Clevers (1957)\n\nDr Patrick Frost (1968)\n\nAnita Hauser (1969)\n\nProf. Dr Richard P. Lifton (1953)\n\nBernard Poussot (1952)\n\nDr Severin Schwan (1967)\n\nDr Claudia Suessmuth Dyckerhoff (1967)\n\nDr Annette Luther (1970)\n\n€.D EG Chairman\nCs DREGE Vice-Chairman\n\nBjE.G\n\nBE E.G\nBaEnG\nA,E,G\nBaEnG\nA,E,G\nCxE-G)\nCle (Gi\nF\n\nA,E,G\n\nFirst elected\n\n2011\n1996\n\n2020\n\ni)\nSs\nA) A) a} a| a) oO) 0) a] oe\n\n", "vlm_text": "The table lists members of a Board of Directors as of December 31, 2021. It includes their names, years of birth, committee assignments (denoted by letters and asterisks), roles on the board (e.g., Chairman or Vice-Chairman), and the year they were first elected. Additionally, there is a reference to the Secretary to the Board of Directors, Dr. Annette Luther, born in 1970. The information also notes specific representatives of a shareholder group with pooled voting rights."}
{"layout": 864, "type": "text", "text": "A\t Corporate Governance and Sustainability Committee\t D\t Chairman’s/Nomination Committee\t G\t Independent member of the Board of Directors\t ", "page_idx": 149, "bbox": [36, 412.7710876464844, 183, 439.2210998535156], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 865, "type": "text", "text": "B\t Audit Committee\t E\t Non-executive director\t \\*\t Committee chairperson C\t Remuneration Committee\t F\t Executive director ", "page_idx": 149, "bbox": [241, 412.7710876464844, 312, 439.2210998535156], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 866, "type": "text", "text": "", "page_idx": 149, "bbox": [359, 412.7710876464844, 436.94232177734375, 430.7210998535156], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 867, "type": "table", "page_idx": 149, "img_path": "layout_images/roche-holdings_2021_106.jpg", "bbox": [38, 454, 527, 513], "page_size": [595.2760009765625, 793.7009887695312], "ocr_text": "Board of Directors\n\nCommittees\n\nA\n\nAndré Hoffmann (Chair)\n\nProf. Dr Hans Clevers\n\nAnita Hauser\n\nDr Claudia Suessmuth Dyckerhoff\n\nB\n\nJulie Brown (Chair)\nDr Jorg Duschmalé\nPaul Bulcke\n\nDr Patrick Frost\n\nc D\nAndré Hoffmann (Chair) Or Christoph Franz (Chair)\nDr Christoph Franz André Hoffmann\n\nProf. Dr Richard P. Lifton\nBernard Poussot\n", "vlm_text": "The table lists the members of various committees within the Board of Directors:\n\n- **Committee A**\n  - André Hoffmann (Chair)\n  - Prof. Dr Hans Clevers\n  - Anita Hauser\n  - Dr Claudia Suessmuth Dyckerhoff\n\n- **Committee B**\n  - Julie Brown (Chair)\n  - Dr Jörg Duschmalé\n  - Paul Bulcke\n  - Dr Patrick Frost\n\n- **Committee C**\n  - André Hoffmann (Chair)\n  - Dr Christoph Franz\n  - Prof. Dr Richard P. Lifton\n  - Bernard Poussot\n\n- **Committee D**\n  - Dr Christoph Franz (Chair)\n  - André Hoffmann"}
{"layout": 868, "type": "text", "text": "Corporate Executive Committee ", "text_level": 1, "page_idx": 150, "bbox": [66, 98, 420, 123], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 869, "type": "text", "text": "All memberships of the Corporate Executive  Committee remained unchanged in 2021. ", "page_idx": 150, "bbox": [67, 157.48370361328125, 233.90203857421875, 181.63070678710938], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 870, "type": "text", "text": "Information on each member of the Corporate  Executive Committee and of the Enlarged  ", "page_idx": 150, "bbox": [67, 193.48370361328125, 241, 217.63070678710938], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 871, "type": "text", "text": "Corporate Executive Committee Enlarged Corporate Executive  Committee ", "page_idx": 150, "bbox": [67, 262.03680419921875, 221, 327.6834716796875], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 872, "type": "text", "text": "Corporate Executive Committee is listed below  (see also page 18 and page 151 ‘Board of Directors  and Corporate Executive Committee’). ", "page_idx": 150, "bbox": [278, 157.48370361328125, 471.0314636230469, 193.62771606445312], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 873, "type": "table", "page_idx": 150, "img_path": "layout_images/roche-holdings_2021_107.jpg", "bbox": [271, 249, 560, 324], "page_size": [595.2760009765625, 793.7009887695312], "ocr_text": "CEO CEO CEO Chief Financial and Chief People\nRoche Group Pharmaceuticals Diagnostics Information Officer Officer\n\ngRED pRED Partnering Communications General Counsel\n", "vlm_text": "The table is divided into two sections, each listing roles within committees:\n\n1. **Corporate Executive Committee**\n   - CEO Roche Group\n   - CEO Pharmaceuticals\n   - CEO Diagnostics\n   - Chief Financial and Information Officer\n   - Chief People Officer\n\n2. **Enlarged Corporate Executive Committee**\n   - gRED\n   - pRED\n   - Partnering\n   - Communications\n   - General Counsel"}
{"layout": 874, "type": "table", "page_idx": 150, "img_path": "layout_images/roche-holdings_2021_108.jpg", "table_footnote": "Curricula vitae (CVs) of the members of the Corporate Executive Committee and the Enlarged Corporate Executive Committee: a) current members:  https://www.roche.com/about/governance/executive committee.htm b) former members (at least five years back):  https://www.roche.com/about/governance/ec_bod_former.htm c) \u0007 information of CVs at the reporting date on 31 December of each year (at least of the last five years): \n https://www.roche.com/about/governance/arch iv former cvs.htm ", "bbox": [65, 367, 560, 679], "page_size": [595.2760009765625, 793.7009887695312], "ocr_text": "Composition as at 31.12.2021\n\nCorporate Executive Committee\n\nEnlarged Corporate\nExecutive Committee\n\nSecretary to the Corporate\nExecutive Committee\nStatutory Auditors\n\nof Roche Holding Ltd\n\nChief Compliance Officer\n\nName (year of birth)\n\nDr Severin Schwan (1967)\nBill Anderson (1966)\n\nDr Thomas Schinecker (1975)\nDr Alan Hippe (1967)\nCristina A. Wilbur (1967)\n\nDr Aviv Regev (1971)\n\nDr William Pao (1967)\n\nDr James H. Sabry (1958)\nBarbara Schadler (1962)\nClaudia Béckstiegel (1964)\nPer-Olof Attinger (1960)\n\nPosition\n\nCEO Roche Group\nCEO Roche Pharmaceuticals\nCEO Roche Diagnostics\n\nChief Financial and Information Officer\n\nChief People Officer\n\nHead Genentech Research &\nEarly Development (gRED)\n\nHead Roche Pharma Research &\nEarly Development (pRED)\nGlobal Head Pharma Partnering\nHead Group Communications\nGeneral Counsel\n\nKPMG Klynveld Peat Marwick Goerdeler SA (reporting years 2004-2008)\n\nKPMG AG (since 2009)\n\nAuditor in charge: John A. Morris (2004-2010)\n\nlan Starkey (2011-2017)\n\nMark Baillache (as of business year 2018)\n\nPascale Schmidt (1973)\n\nSince\n\n2008\n\niS)\nfo)\nfos)\n\nN\nSo\niS)\nCSOD om\n\n2020\n", "vlm_text": "The table details the composition of a corporate committee as of December 31, 2021. It includes the following sections:\n\n1. **Corporate Executive Committee:**\n   - Dr. Severin Schwan (1967), CEO Roche Group, since 2008.\n   - Bill Anderson (1966), CEO Roche Pharmaceuticals, since 2019.\n   - Dr. Thomas Schinecker (1975), CEO Roche Diagnostics, since 2019.\n   - Dr. Alan Hippe (1967), Chief Financial and Information Officer, since 2011.\n   - Cristina A. Wilbur (1967), Chief People Officer, since 2016.\n\n2. **Enlarged Corporate Executive Committee:**\n   - Dr. Aviv Regev (1971), Head Genentech Research & Early Development (gRED), since 2020.\n   - Dr. William Pao (1967), Head Roche Pharma Research & Early Development (pRED), since 2018.\n   - Dr. James H. Sabry (1958), Global Head Pharma Partnering, since 2018.\n   - Barbara Schädler (1962), Head Group Communications, since 2019.\n   - Claudia Böckstiegel (1964), General Counsel, since 2020.\n\n3. **Secretary to the Corporate Executive Committee:**\n   - Per-Olof Attinger (1960), since 2010.\n\n4. **Statutory Auditors of Roche Holding Ltd:**\n   - KPMG Klynveld Peat Marwick Goerdeler SA (reporting years 2004-2008).\n   - KPMG AG (since 2009).\n   - Auditors in charge: John A. Morris (2004–2010), Ian Starkey (2011–2017), Mark Baillache (as of business year 2018).\n\n5. **Chief Compliance Officer:**\n   - Pascale Schmidt (1973), since 2020."}
{"layout": 875, "type": "text", "text": "Group structure and shareholders ", "text_level": 1, "page_idx": 151, "bbox": [120, 98, 497, 123], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 876, "type": "text", "text": "Roche’s operating businesses are organised into  two divisions: Pharmaceuticals and Diagnostics.  ", "page_idx": 151, "bbox": [120, 157.48370361328125, 305, 181.63369750976562], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 877, "type": "text", "text": "The Pharmaceuticals Division comprises the  two business segments Roche Pharmaceuticals  and Chugai, whereas Genentech as the former  third segment has been integrated into Roche  Pharmaceuticals.  ", "page_idx": 151, "bbox": [120, 193.48370361328125, 305, 253.63369750976562], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 878, "type": "text", "text": "In 2021, as part of a transformation initiative,  the Diagnostics Division replaced the previous  business area structure of its four business areas  Centralised and Point of Care Solutions, Molecular  Diagnostics, Tissue Diagnostics and Diabetes Care  with new customer areas. Sales are presented by  the following customer areas: Core Lab, Molecular  Lab, Point of Care, Diabetes Care, Pathology Lab  (for details see Finance Report, page 27). ", "page_idx": 151, "bbox": [120, 265.48370361328125, 310, 373.6336975097656], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 879, "type": "text", "text": "Business activities are carried out through Group  subsidiaries and associated companies. Detailed  information on Roche Holding Ltd and on significant  subsidiaries and associated companies (including  company name, listing information, domicile, share  capital and equity interest) is listed in the Finance  Report, Note 33 to the Roche Group Consolidated  Financial Statements (‘List of subsidiaries and  associates’, page 138). ", "page_idx": 151, "bbox": [331, 157.48370361328125, 525, 265.6336975097656], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 880, "type": "text", "text": "Major shareholders are listed in the Finance  Report, Notes 22 and 32 to the Roche Group  Consolidated Financial Statements (‘Equity  attributable to Roche shareholders’ and ‘Related  parties’, pages 95 and 135), and in Note 4 to  the Financial Statements of Roche Holding Ltd  (‘Significant shareholders’, page 181). In addition,  significant shareholders are published on the  ", "page_idx": 151, "bbox": [331, 277.48370361328125, 521, 373.6336975097656], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 881, "type": "table", "page_idx": 151, "img_path": "layout_images/roche-holdings_2021_109.jpg", "bbox": [34, 417, 528, 550], "page_size": [595.2760009765625, 793.7009887695312], "ocr_text": "Pharmaceuticals\n\nUntil 2020: Business areas As of 2021: Customer areas\nCentralised and Point of Care Solutions Core Lab\nDiagnostics Molecular Lab\ng Molecular Diagnostics oe .\nPoint of Care\nTissue Diagnostics Pathology Lab\n\nComposition as at 31.12.2021 Diabetes Care Diabetes Care\n", "vlm_text": "The table shows the structure of a company in two main divisions: Pharmaceuticals and Diagnostics.\n\n### Pharmaceuticals:\n- **Roche Pharmaceuticals (including Genentech)**\n- **Chugai**\n\n### Diagnostics:\n- **Until 2020: Business areas**\n  - Centralised and Point of Care Solutions\n  - Molecular Diagnostics\n  - Tissue Diagnostics\n  - Diabetes Care\n\n- **As of 2021: Customer areas**\n  - Core Lab\n  - Molecular Lab\n  - Point of Care\n  - Pathology Lab\n  - Diabetes Care\n\nThe table indicates a shift from business areas to customer areas in the Diagnostics division as of 2021."}
{"layout": 882, "type": "text", "text": "relevant webpage ( see link below\\* ) of the disclosure  office of SIX Exchange Regulation.  ", "page_idx": 152, "bbox": [68, 157.48370361328125, 263.3099365234375, 181.63070678710938], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 883, "type": "text", "text": "André Hoffmann, Vice-Chairman of the Board  of Directors, Chairman of the Remuneration  Committee and of the Board’s Corporate  Governance and Sustainability Committee and  member of the Board’s Chairman’s/Nomination  Committee, and Dr Jörg Duschmalé, member of  the Board of Directors and of the Board’s Audit  Committee, serve in their respective capacities on  the Board and its committees as representatives  of the shareholder group with pooled voting  rights and receive the remuneration set forth  in the Remuneration Report on page 174 and in  the Finance Report, Note 32 to the Roche Group  Consolidated Financial Statements (‘Related  parties’, page 135). No other relationships exist  with the shareholders with pooled voting rights. ", "page_idx": 152, "bbox": [68, 193.48370361328125, 256.83447265625, 385.5888366699219], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 884, "type": "text", "text": "There are no cross-shareholdings. ", "page_idx": 152, "bbox": [68, 397.44183349609375, 195.18350219726562, 409.5918273925781], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 885, "type": "text", "text": "André Hoffmann, Chairman of the Corporate Governance and  Sustainability Committee and of the Remuneration Committee, and  Dr Jörg Duschmalé, member of the Audit Committee. ", "page_idx": 152, "bbox": [68, 662.4837036132812, 259, 697.28369140625], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 886, "type": "image", "page_idx": 152, "img_path": "layout_images/roche-holdings_2021_110.jpg", "bbox": [277, 391, 595, 694], "page_size": [595.2760009765625, 793.7009887695312], "ocr_text": "", "vlm_text": "The image shows a person wearing a suit and tie, standing in a well-lit room with a mural in the background. The person has glasses and their hands are on their hips."}
{"layout": 887, "type": "text", "text": "Capital structure ", "text_level": 1, "page_idx": 153, "bbox": [120, 98, 311, 123], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 888, "type": "text", "text": "Information on Roche’s capital structure is provided  in the Finance Report, Notes to the Financial  Statements of Roche Holding Ltd (page 178).  Additional details are contained in the Articles of  Incorporation of Roche Holding Ltd. ", "page_idx": 153, "bbox": [120, 157.48370361328125, 315, 217.63369750976562], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 889, "type": "text", "text": "Movement in recognised amounts during the last  three financial years are detailed in the Finance  Report, Notes to the Financial Statements of  Roche Holding Ltd (page 178). ", "page_idx": 153, "bbox": [120, 229.48370361328125, 307, 277.6336975097656], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 890, "type": "text", "text": "At an extraordinary General Meeting, held on  26 November 2021, the shareholders agreed  to reduce the company’s share capital from  CHF 160,000,000 by an amount of CHF 53,309,000  to CHF 106,691,000 through the cancellation of  53,309,000 bearer shares with a nominal value  of CHF 1 each which were repurchased by the  company from Novartis Holding AG pursuant to the  repurchase agreement dated 3 November 2021.  The difference between the acquisition cost  and the nominal value of the bearer shares to be  cancelled was accounted for through a reduction  of voluntary reserves and retained earnings. ", "page_idx": 153, "bbox": [120, 289.48370361328125, 315, 445.6336975097656], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 891, "type": "text", "text": "There is no authorised or conditional capital. ", "page_idx": 153, "bbox": [120, 457.48370361328125, 307, 469.6336975097656], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 892, "type": "text", "text": "In addition, 702,562,700 non-voting equity  securities (NES) have been issued in bearer form.  They do not form part of the share capital and  confer no voting rights. Each NES confers the  same rights as one share to participate in available  earnings and in any liquidation proceeds following  repayment of the share capital. Roche’s NES  and the rights pertaining thereto (including the  provisions protecting the interests of NES holders)  are described in  $\\S4$   of the Articles of Incorporation  of Roche Holding Ltd. ", "page_idx": 153, "bbox": [120, 481.48370361328125, 315, 541.6337280273438], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 893, "type": "text", "text": "", "page_idx": 153, "bbox": [331, 157.48370361328125, 526, 229.63369750976562], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 894, "type": "text", "text": "Information on debt instruments which have  been issued and on outstanding bonds is  provided in the Finance Report, Note 21 to the  Roche Group Consolidated Financial Statements  (‘Debt’, page 91). ", "page_idx": 153, "bbox": [331, 241.48370361328125, 514.3077392578125, 301.6336975097656], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 895, "type": "text", "text": "Information on employee stock options is provided  in the Finance Report, Note 27 to the Roche  Group Consolidated Financial Statements (‘Equity  compensation plans’, page 109), including detailed  information on the Stock-settled Stock Appreciation  Rights (S-SARs) Plan, the Restricted Stock Units  (RSUs) Plan, Roche Connect and the Roche  Option Plan. ", "page_idx": 153, "bbox": [331, 313.48370361328125, 526, 409.6336975097656], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 896, "type": "text", "text": "Roche has issued no options apart from employee  stock options as described in the Finance Report,  Note 27 to the Roche Group Consolidated Financial  Statements (‘Equity compensation plans’, page 109)  and options issued in connection with debt  instruments. ", "page_idx": 153, "bbox": [331, 421.48370361328125, 526, 493.6336975097656], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 897, "type": "text", "text": "Neither the options awarded to employees nor  the debt instruments which have been issued have  any effect on Roche’s share capital. ", "page_idx": 153, "bbox": [331, 505.48370361328125, 526, 541.6337280273438], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 898, "type": "text", "text": "Board of Directors  and Corporate Executive Committee ", "text_level": 1, "page_idx": 154, "bbox": [66, 96, 468, 154], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 899, "type": "text", "text": "Information on each member of the Board of  Directors and on each member of the Corporate  Executive Committee is listed on pages 146 and 147.  Members of the Board of Directors have no age limit  or restriction on their term of office.  ", "page_idx": 154, "bbox": [67, 181.48370361328125, 264, 241.63369750976562], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 900, "type": "text", "text": "Curricula vitae (CVs) of all current and former  members (of at least the last five years) of both  bodies and other information (including information  on the years of their first election, additional  positions, memberships and activities) are available  and continuously updated on the Internet. In  addition, the status of the CVs of both bodies at the  relevant reporting date on 31 December (of at least  the last five years) is separately available too. ", "page_idx": 154, "bbox": [67, 253.48370361328125, 264, 361.6336975097656], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 901, "type": "text", "text": "Rules pursuant to article 12 para. 1 point 1 VegüV  on the number of permitted activities of the Board of  Directors and the Corporate Executive Committee  members are outlined in  $\\S22.4$   of the Articles of  Incorporation of Roche Holding Ltd. ", "page_idx": 154, "bbox": [67, 373.48370361328125, 264, 433.6336975097656], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 902, "type": "text", "text": "Since 2014, the Annual General Meeting has elected  all members of the Board of Directors, the Chairman  of the Board of Directors and the members of  the Remuneration Committee on an annual basis  in elections in which each nominee is voted on  separately (see  $\\S\\uparrow8$   of the Articles of Incorporation  of Roche Holding Ltd 4  and the Minutes of the   $103^{\\mathrm{rd}}$   Annual General Meeting of Roche Holding Ltd,  held on 16 March 2021 5 ). ", "page_idx": 154, "bbox": [67, 445.48370361328125, 264, 553.6337280273438], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 903, "type": "text", "text": "With the exception of Dr Severin Schwan none of  the members of the Board of Directors in office  at the end of 2021 has been a member of Roche’s  Corporate Executive Committee or served in an  executive capacity at any Group subsidiary during  the five financial years preceding the current  reporting period and they are for lack of existing  business connections with the Group or any  Group subsidiary independent. Roche’s Board of  ", "page_idx": 154, "bbox": [67, 565.4837036132812, 256, 673.6337280273438], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 904, "type": "text", "text": "Directors’ independence definition is based on the  definition in the Swiss Code of Best Practice for  Corporate Governance of ‘economiesuisse’ and  is complemented by specific preceding criteria  (see  https://www.roche.com/about/governance/ board of directors.htm ). ", "page_idx": 154, "bbox": [278, 181.48370361328125, 471, 253.63369750976562], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 905, "type": "text", "text": "The Principles of Governance (principles of  delegation and competence, reservation of powers  and management of a group of companies) of  the executive bodies of the company include  economic, environmental and social topics. The  principles together with the internal organisation  of the Board of Directors, the division of authority  and responsibilities between the Board and  management, the remits of the Board Committees,  and the information and control mechanisms  available to the Board in its dealings with corporate  management, are governed by the Bylaws. ", "page_idx": 154, "bbox": [278, 265.48370361328125, 471, 409.6336975097656], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 906, "type": "text", "text": "The Board of Directors of Roche Holding Ltd is  organised so as to ensure that the Group conducts  its businesses responsibly and with a focus on  long-term value creation. To this end, the Roche  Board has delegated certain responsibilities  to several committees.  Their composition and  chairpersons as at 31 December 2021 are described  on pages 14 and 146. Each committee’s authorities  and responsibilities are defined in detail in the  Bylaws of the Board of Directors. ", "page_idx": 154, "bbox": [278, 421.48370361328125, 475, 541.6337280273438], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 907, "type": "text", "text": "All the committees are chaired by independent  directors.  ", "page_idx": 154, "bbox": [278, 553.4837036132812, 458, 577.6337280273438], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 908, "type": "text", "text": "According to the Bylaws of the Board of Directors,  a Board meeting may be convened without the  Chairman present at the request of any of its  members. The Roche Board meets once a year to  assess the Chairman’s performance. This meeting,  which is not attended by the Chairman, is chaired  by the Vice-Chairman. ", "page_idx": 154, "bbox": [278, 589.4837036132812, 471, 673.6337280273438], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 909, "type": "text", "text": "Board of Directors\n and Board Committees ", "text_level": 1, "page_idx": 155, "bbox": [34, 127, 148, 159], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 910, "type": "text", "text": "Corporate Executive Committee As part of the Management Information System  (MIS), the Board of Directors is regularly  informed about the most important issues, sales  performance, etc. The Board has access to an  electronic information platform which provides  timely information to the Board of Directors and  the Board Committees as does the system of  controls as set forth below. ", "page_idx": 155, "bbox": [36.850399017333984, 225.97491455078125, 189.0303955078125, 244.87490844726562], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 911, "type": "text", "text": "", "page_idx": 155, "bbox": [120, 325.48370361328125, 309, 421.6336975097656], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 912, "type": "text", "text": "The Board of Directors has established a system  of controls which is continuously monitored by the  Audit Committee, by the Corporate Governance  and Sustainability Committee and by the Board of  Directors and consists of the following elements: • \tReport on operating and financial risks (risk  management system)\n ", "page_idx": 155, "bbox": [120, 433.48370361328125, 309, 517.6337280273438], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 913, "type": "text", "text": "The Roche Group has established a risk  management process covering the entire  company with a system in place to identify and  manage all types of risks potentially affecting  its business (including economic, environmental  and social impacts, risks and opportunities and  stakeholder input). The Board of Directors is  the highest governance body involved. Roche’s  Risk Management Policy sets out the approach  and accompanying responsibilities. The  Pharmaceuticals and Diagnostics Divisions and  global functions conduct a formal risk assessment  process at least once a year and must develop  ", "page_idx": 155, "bbox": [126, 517.4837036132812, 315, 673.6337280273438], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 914, "type": "text", "text": "risk plans for their most material risks. These are  monitored and deviations reviewed in regular  performance dialogues. The consolidated  Group Risk Report including target risk profile is  discussed by the Corporate Executive Committee  and approved together with the Group Business  Plan. All material risks are reviewed by the Board  on a yearly basis. The effectiveness of the risk  management process is monitored by the Group  Risk Advisory team and the overall process is  regularly reviewed by external auditors, with  findings presented to the Audit Committee and  the full Board. For details on risk management,  including risk factors and the Risk Management  Policy, see ‘Risk Management’ on our website.   Financial risk management is specifically described  in the Finance Report. 10\n\n ", "page_idx": 155, "bbox": [334, 325.48370361328125, 529, 529.6337280273438], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 915, "type": "text", "text": "\tSystem of internal controls over financial reporting \n\n (see page 153 of the Finance Report)\n\n \tInternal audit\n ", "page_idx": 155, "bbox": [334, 529.4837036132812, 529, 565.6337280273438], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 916, "type": "text", "text": "Group Audit reports to the General Counsel,  has direct access and gives regular briefings  to the Audit Committee and to the Corporate  Governance and Sustainability Committee about  ongoing activities and audit reports. The Chief  Audit & Risk Advisory Executive attends the Audit  Committee and partly the Corporate Governance  and Sustainability Committee meetings, as do the  external auditors. Group Audit is an independent  ", "page_idx": 155, "bbox": [334, 565.4837036132812, 523, 673.6337280273438], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 917, "type": "text", "text": "appraisal function which evaluates and reviews  the Group’s activities as a service to the Board of  Directors and to management. The annual audit  plan with yearly defined focus areas (eg, market  access, third-party management) is validated by  senior management and approved by the Audit  Committee. The Roche Group is committed to  maintaining a high standard of internal control  throughout its worldwide operations. Management  is responsible for assessing the business risks in  all aspects of its operation and for implementing  effective and efficient processes and controls  whilst ensuring compliance with internal and  external rules and regulations. By conducting  operational audits, Group Audit determines  management’s response to the risks surrounding  business processes and systems, and evaluates  the appropriateness, completeness and efficiency  of the processes and controls. Action plans to  implement necessary changes and enhancements  are developed together with the business/auditee  and are tracked to completion.\n\n •\t  Statutory auditors, see page 158\n\n • \tChief Compliance Officer and Compliance  Officers in subsidiaries, see page 161\n\n • \tSafety, Health and Environmental Protection  Department 11\n\n •\t  Corporate Sustainability Committee 12\n\n • \tScience and Ethics Advisory Group (SEAG), for  issues relating to genetic engineering 13 ", "page_idx": 156, "bbox": [68, 97.4837646484375, 264, 457.6336975097656], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 918, "type": "text", "text": "The members of the Corporate Executive  Committee are invited to attend meetings of the  Board of Directors for, and report in person on,  those agenda items concerning them. When the  situation warrants, members of the Enlarged  Corporate Executive Committee may also be  invited to attend. The Board Committees invite the  Chairman of the Board and Corporate Executive  Committee members to deliver reports at  committee meetings and may elect to commission  independent expert reports and call on the services  of consultants.  ", "page_idx": 156, "bbox": [68, 469.48370361328125, 264, 613.6007080078125], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 919, "type": "text", "text": "Each year several black-out periods are imposed  during which members of the Board of Directors and  senior and certain other employees are prohibited  from trading in company stock.  ", "page_idx": 156, "bbox": [68, 625.4537353515625, 264, 673.5947265625], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 920, "type": "text", "text": "The following black-out periods are/were in effect  for 2022 and 2021, respectively: ", "page_idx": 156, "bbox": [278, 97.44171142578125, 475, 121.5887222290039], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 921, "type": "table", "page_idx": 156, "img_path": "layout_images/roche-holdings_2021_111.jpg", "table_caption": "Black-out periods ", "bbox": [277, 136, 475, 233], "page_size": [595.2760009765625, 793.7009887695312], "ocr_text": "2022\n\n26 December 2021 to\n3 February 2022\n\n1 April to 25 April 2022\n26 June to 21 July 2022\n1 October to\n\n18 October 2022\n\n2021\n\n26 December 2020 to\n4 February 2021\n\n1 Aprilto 21 April 2021\n26 June to 22 July 2021\n1 October to\n\n20 October 2021\n\n", "vlm_text": "The table lists date ranges for the years 2022 and 2021:\n\n**2022:**\n- 26 December 2021 to 3 February 2022\n- 1 April to 25 April 2022\n- 26 June to 21 July 2022\n- 1 October to 18 October 2022\n\n**2021:**\n- 26 December 2020 to 4 February 2021\n- 1 April to 21 April 2021\n- 26 June to 22 July 2021\n- 1 October to 20 October 2021"}
{"layout": 922, "type": "text", "text": "Black-out periods can be changed by the Chairman  of the Board of Directors if circumstances warrant.  ", "page_idx": 156, "bbox": [278, 253.48370361328125, 475, 277.6307067871094], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 923, "type": "text", "text": "Roche employees involved in the preparation of  regular publicity events (in particular annual and  half-year reports and media conferences, quarterly  sales releases) or having otherwise access to such  potentially share price sensitive information of  Roche and all Roche employees who are resident  in the US including US citizens, Green Card  holders, and ‘resident aliens’, as well as terminated  employees and retirees who fall into one of these  US categories are subject to these black-out  periods. Irrespective of whether the relevant  information is share price sensitive for Roche or  not, during the black-out periods these persons  shall keep the relevant information confidential  and must not (i) disclose it to any non-insider within  or outside Roche (including family members), (ii)  buy, sell or otherwise trade in equity securities  of Roche (shares, non-voting equity securities  [NES]) as well as options or similar instruments and  derivatives based thereon, or (iii) provide trading  recommendations thereon. The automatic execution  of predefined periodic purchase orders under the  Roche Connect programme is not subject to these  black-out periods. ", "page_idx": 156, "bbox": [278, 289.48370361328125, 475, 577.5648803710938], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 924, "type": "text", "text": "For addressees, scope and exceptions with regard  to the black-out periods please refer to the Roche  Group Insider Directive ( https://www.roche.com/ dam/jcr:d0fbd427-a2d3-47cc-a13d-aacab92e312b/ en/group insider policy.pdf ). ", "page_idx": 156, "bbox": [278, 589.4178466796875, 475, 649.5558471679688], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 925, "type": "image", "page_idx": 157, "img_path": "layout_images/roche-holdings_2021_112.jpg", "bbox": [0, 67, 318, 382], "page_size": [595.2760009765625, 793.7009887695312], "ocr_text": "", "vlm_text": "This image shows a person sitting at a table indoors, smiling, with their hands folded. They are wearing a white shirt and a smartwatch. In the background, there is a large window with a view of trees and buildings outside."}
{"layout": 926, "type": "text", "text": "Julie Brown, Chairwoman of the Audit Committee. ", "page_idx": 157, "bbox": [331, 98.48370361328125, 471.1627197265625, 109.28370666503906], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 927, "type": "text", "text": "In 2021, the Board of Directors met for 11 meetings:  6 ordinary meetings from 3 to 6 hours in length,  including a full-day meeting, and 5 extraordinary  Board meetings from 1 to 3 hours in length held  in connection with major business transactions.  In addition, the Board went on a 4-day trip to a  European affiliate.\\* ", "page_idx": 157, "bbox": [331, 181.48370361328125, 526, 265.6157531738281], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 928, "type": "text", "text": "The Board Committees met as follows in 2021:\n\n • \tChairman’s/Nomination Committee: 10 meetings \n\n (approx. 2 hours each\\*)\n\n• \tRemuneration Committee: 3 meetings 14  (approx.  2 to 3 hours each\\*)• \tAudit Committee: 6 meetings (approx. 3 to 4 hours  each\\*)• \tCorporate Governance and Sustainability  Committee: 3 meetings (approx. 3 hours each\\*) ", "page_idx": 157, "bbox": [331, 277.46875, 526, 385.6336975097656], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 929, "type": "text", "text": "The Board of Directors regularly conducts an  assessment (self-assessment / assessment by  third parties via electronic survey and personal  interviews) of its performance. ", "page_idx": 157, "bbox": [331, 397.4866943359375, 508.3419494628906, 445.6277160644531], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 930, "type": "text", "text": "Members of the Corporate Executive Committee  have a maximum ordinary notice period of twelve  months. There are no change-of-control clauses  in the employment contracts. ", "page_idx": 157, "bbox": [331, 457.480712890625, 514, 505.6217346191406], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 931, "type": "text", "text": "There are no management contracts which  fall within the scope of Subsection 4.4 (annex)  of the SIX Directive on Information relating to  Corporate Governance. ", "page_idx": 157, "bbox": [331, 517.4747314453125, 504, 565.61572265625], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 932, "type": "table", "page_idx": 158, "img_path": "layout_images/roche-holdings_2021_113.jpg", "table_caption": "Attendance at Board and Board Committee meetings in 2021 ", "table_footnote": "– \t Not a member of that committee ", "bbox": [66, 183, 561, 415], "page_size": [595.2760009765625, 793.7009887695312], "ocr_text": "Corporate\n\nChairman’s/ Governance and\n\nNomination Remuneration Audit Sustainability\n\nBoard Committee Committee Committee Committee\n\nNumber of meetings 11 10 3 6 3\nC. Franz 11 10 3 a =\nA. Hoffmann 7 10 3 3\nJ. Duschmalé 8 = ~ 5 =~\nJ. Brown 10 = S 6 =\nP. Bulcke 10 = = 5 =\nH. Clevers 11 = = eg 3\nP. Frost 11 = = 6 =\nA. Hauser 11 = = eg 3\nR.P. Lifton 10 = 3 a =\nB. Poussot 11 = 3 7 =\nS. Schwan 11 = = a =\n\nC. Suessmuth Dyckerhoff 9 - - S 3\n", "vlm_text": "The table lists the number of meetings attended by various individuals across different committees. Here’s a summary of the information:\n\n- **Columns:**\n  - **Number of meetings**\n  - **Board** (11 meetings)\n  - **Chairman’s/Nomination Committee** (10 meetings)\n  - **Remuneration Committee** (3 meetings)\n  - **Audit Committee** (6 meetings)\n  - **Corporate Governance and Sustainability Committee** (3 meetings)\n\n- **Individuals and their meeting attendance:**\n  - C. Franz: Attended 11 Board, 10 Chairman’s, 3 Remuneration\n  - A. Hoffmann: Attended 7 Board, 10 Chairman’s, 3 Remuneration, 3 Corporate Governance\n  - J. Duschmalé: Attended 8 Board, 5 Audit\n  - J. Brown: Attended 10 Board, 6 Audit\n  - P. Bulcke: Attended 10 Board, 5 Audit\n  - H. Clevers: Attended 11 Board, 3 Corporate Governance\n  - P. Frost: Attended 11 Board, 6 Audit\n  - A. Hauser: Attended 11 Board, 3 Corporate Governance\n  - R.P. Lifton: Attended 10 Board, 3 Remuneration\n  - B. Poussot: Attended 11 Board\n  - S. Schwan: Attended 11 Board\n  - C. Suessmuth Dyckerhoff: Attended 9 Board, 3 Audit\n\nThe table provides an overview of meeting attendance for each person within specified committees."}
{"layout": 933, "type": "text", "text": "Remuneration, shareholdings \n and loans ", "text_level": 1, "page_idx": 159, "bbox": [119, 98, 445, 152], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 934, "type": "text", "text": "All details regarding remuneration, shareholdings  and loans (content and method of determining the  compensation and the shareholding programmes,  basic principles and elements of compensation and  shareholding programmes for serving and former  members of the Board of Directors and Corporate  Executive Committee, together with a description of  the authorities and procedure for determining such)  are set forth in the separate Remuneration Report  on pages 162 to 188 and in the Finance Report,  Notes 22 and 32 to the Roche Group Consolidated  Financial Statements (‘Equity attributable to Roche  shareholders’ and ‘Related parties’, pages 95  and 135), and are listed in Note 6 to the Financial  Statements of Roche Holding Ltd (‘Board and  Executive shareholdings’, page 182). ", "page_idx": 159, "bbox": [120, 181.48370361328125, 316, 373.5888366699219], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 935, "type": "text", "text": "The following rules on remuneration, shareholdings  and loans for the Board of Directors (Board) and the  Corporate Executive Committee (CEC) are set forth  in the Articles of Incorporation (AoI) 15 : ", "page_idx": 159, "bbox": [120, 385.44183349609375, 316, 433.6336975097656], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 936, "type": "text", "text": "Rules in AoI  15  for Content Board CEC Rules on the principles  §25.1–6 §25.1–6 applicable to performance-\n related pay Rules on the principles to the  §25.7 §25.7 allocation of equity securities,  convertible rights and options Additional amount for  §24.5 payments to members of  the Executive Committee  appointed after the vote on  pay at the Annual General  Meeting of Shareholders  Rules on loans, credit facilities  §25.1 and 3 §25.2 and 3  and post-employment benefits Rules on the vote on pay at  §24 §24 the AGM  ", "page_idx": 159, "bbox": [331, 183.7943115234375, 527.3924560546875, 398.4643859863281], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 937, "type": "text", "text": "Participatory rights of shareholders ", "text_level": 1, "page_idx": 160, "bbox": [68, 97, 462, 124], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 938, "type": "text", "text": "The participatory rights of shareholders are  defined in Roche’s Articles of Incorporation. 16   As Roche shares are issued to bearer, there are  no restrictions on admission to Annual General  Meetings, with the exception that shares must be  deposited within a specified period before the  date of a meeting and an admittance card must  be issued in the shareholder’s name, as provided in   $\\S^{12}$   of the Articles of Incorporation. Any shareholder  can elect to be represented by a third party at an  Annual General Meeting. ", "page_idx": 160, "bbox": [67, 157.48370361328125, 263, 289.6336975097656], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 939, "type": "text", "text": "The Articles of Incorporation contain no restrictions  on the exercise of voting rights, and the only  quorum requirements are those stipulated in  $\\S\\uparrow6$  ,  in conformity with the Swiss Code of Obligations. ", "page_idx": 160, "bbox": [67, 301.48370361328125, 263, 349.6336975097656], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 940, "type": "text", "text": "Under  $\\S\\uparrow0.2$   of the Articles of Incorporation,  shareholders representing shares with a nominal  value of at least CHF 1 million can request the  placement of items on the agenda of an Annual  General Meeting. This must be done no later than  28 days before the date of the meeting. ", "page_idx": 160, "bbox": [278, 157.48370361328125, 462, 229.63369750976562], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 941, "type": "text", "text": "The rules on the issue of instructions to the  independent proxy and rules on the electronic  participation in the Annual General Meeting are  laid down in the corresponding invitation to the  Annual General Meeting and are not regulated  in the Articles of Incorporation. ", "page_idx": 160, "bbox": [278, 241.48370361328125, 456, 313.6336975097656], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 942, "type": "text", "text": "Change of control \n and defensive measures ", "text_level": 1, "page_idx": 160, "bbox": [67, 397, 329, 451], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 943, "type": "text", "text": "The Articles of Incorporation contain no provisions  on the mandatory bid rule. Swiss law applies. ", "page_idx": 160, "bbox": [68, 481.48370361328125, 257, 505.6336975097656], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 944, "type": "text", "text": "There are no change-of-control clauses. Those  components of remuneration based on Roche  ", "page_idx": 160, "bbox": [68, 517.4837036132812, 245.06964111328125, 541.6337280273438], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 945, "type": "text", "text": "non-voting equity securities would be terminated  in the event of an acquisition, and vesting period  restrictions on pre-existing awards would be  removed, so that all such options could be  exercised immediately. ", "page_idx": 160, "bbox": [278, 481.48370361328125, 462, 541.6337280273438], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 946, "type": "text", "text": "Relationship to statutory auditors ", "text_level": 1, "page_idx": 161, "bbox": [121, 97, 491, 123], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 947, "type": "text", "text": "At the Annual General Meeting of Roche Holding Ltd  on 16 March 2021, the shareholders voted to  appoint KPMG AG (KPMG) as statutory auditors.  ", "page_idx": 161, "bbox": [120, 157.48370361328125, 315, 193.62771606445312], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 948, "type": "text", "text": "Based on the existing legal requirements of the  Swiss Code of Obligations (Article 730a) concerning  the maximum term of office of seven years of  the auditor in charge, Mark Baillache has been  the auditor in charge since business year 2018  (information on how long the auditor in charge  has been serving in this capacity is provided on  page 147). The statutory auditors participate in  Audit Committee meetings. They prepare written  and oral reports on the results of their audits.  The Audit Committee oversees and assesses  the auditors and makes recommendations to  the Board (for information on the authorities  and responsibilities of the Audit Committee, see  Article 8.1 of the Bylaws 17 ). The statutory auditors  participated in all six meetings of the Audit  Committee in 2021. ", "page_idx": 161, "bbox": [120, 205.480712890625, 315, 409.6277160644531], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 949, "type": "text", "text": "The performance of KPMG is assessed based on  different elements such as affiliate surveys (to  evaluate the service level at the country level),  interviews with Roche key stakeholders and the  self-evaluation of the KPMG internal processes to  ensure compliance with the Federal Audit Oversight  Authority (FAOA) Audit Committee Guide. ", "page_idx": 161, "bbox": [120, 421.480712890625, 315, 505.6127624511719], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 950, "type": "text", "text": "KPMG’s independence is ensured by limiting  KPMG from providing certain non-audit services.  Furthermore, permitted services cannot exceed in  total   $20\\%$   of the audit fee unless they are explicitly  rewieved and approved by the Audit Committee.  The company has a formal policy governing the  engagement of the statutory auditor for non-audit  services of which limits for certain permitted other  services are agreed by the Audit Committee.  ", "page_idx": 161, "bbox": [120, 517.4657592773438, 311, 625.5917358398438], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 951, "type": "text", "text": "Each potential non-audit service engagement is  reviewed against this policy before any authority  to proceed is given. ", "page_idx": 161, "bbox": [331, 157.42974853515625, 518, 193.57376098632812], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 952, "type": "text", "text": "The auditors have direct access to the Audit  Committee and its chair as well as the Head of  Group Audit to discuss relevant issues. ", "page_idx": 161, "bbox": [331, 205.4267578125, 505, 241.57077026367188], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 953, "type": "text", "text": "The reports of the statutory auditor on the  Consolidated Financial Statements and on the  Financial Statements can be found on pages 154  and 186, respectively, of the Finance Report. ", "page_idx": 161, "bbox": [331, 253.42376708984375, 518, 301.5647888183594], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 954, "type": "text", "text": "KPMG received the following remuneration for their  services as statutory auditors of Roche Holding Ltd  and as the auditors of other Roche companies  (including Chugai): ", "page_idx": 161, "bbox": [331, 313.41778564453125, 525, 361.5588073730469], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 955, "type": "table", "page_idx": 161, "img_path": "layout_images/roche-holdings_2021_114.jpg", "bbox": [329, 371, 531, 484], "page_size": [595.2760009765625, 793.7009887695312], "ocr_text": "Auditing services\nAudit-related services\n~ Assurance\n-Non-statutory audits\nTax services\nOther services\nTotal\n\n2021 2020\n(millions of CHF)\n\n19.9 19.8\n0.6 0.9\n2.8 2.9\n0.4 0.1\n\n23.7 23.7\n", "vlm_text": "The table presents financial data for the years 2021 and 2020 in millions of CHF. It includes the following categories:\n\n- **Auditing services**: \n  - 2021: 19.9\n  - 2020: 19.8\n\n- **Audit-related services**: \n  - Assurance: \n    - 2021: 0.6\n    - 2020: 0.9\n  - Non-statutory audits: No data\n\n- **Tax services**: \n  - 2021: 2.8\n  - 2020: 2.9\n\n- **Other services**: \n  - 2021: 0.4\n  - 2020: 0.1\n\n- **Total**: \n  - 2021: 23.7\n  - 2020: 23.7"}
{"layout": 956, "type": "text", "text": "The audit fee is reviewed by the Head of Group Audit  and approved by the Audit Committee every year  and takes into consideration changes in Roche’s  business, as well as changes in financial reporting  and audit standards and regulations. ", "page_idx": 161, "bbox": [331, 505.47418212890625, 528.54296875, 565.6121826171875], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 957, "type": "text", "text": "The statutory auditors are elected each year by the  Annual General Meeting. ", "page_idx": 161, "bbox": [331, 577.4652099609375, 525, 601.6121826171875], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 958, "type": "text", "text": "Auditing services are provided as legally required. ", "page_idx": 161, "bbox": [331, 613.4652099609375, 518, 625.615234375], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 959, "type": "text", "text": "Audit-related services include assurance and  accounting services provided by auditors but  which are not necessarily provided by the statutory  auditor. These services, which go beyond the legal  requirements, could include other attestation  services, comfort letters, and consultations. ", "page_idx": 162, "bbox": [68, 97.48370361328125, 260, 169.63369750976562], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 960, "type": "text", "text": "Tax services include services with respect to  compliance, tax returns and tax advice except  those services related to the audit of tax. ", "page_idx": 162, "bbox": [278, 97.48370361328125, 451.86199951171875, 133.63369750976562], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 961, "type": "text", "text": "Other services include advice relating to process  improvements, regulations and trainings. ", "page_idx": 162, "bbox": [278, 145.48370361328125, 462, 169.63369750976562], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 962, "type": "text", "text": "Relationship to the independent proxy ", "text_level": 1, "page_idx": 162, "bbox": [67, 217, 488, 245], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 963, "type": "text", "text": "Since 2019, Testaris AG has served as the  independent proxy and at the Annual General  Meeting on 16 March 2021, shareholders  elected Testaris AG as the independent proxy  for the period from 2021 until the conclusion  of the 2022 ordinary Annual General Meeting  of Shareholders. Testaris AG was paid for its  services for the Annual General Meeting 2021  and the extraordinary Geneneral Meeting in  November 2021 according to expenditure totalling  CHF 28,288 (2020: CHF 26,429). ", "page_idx": 162, "bbox": [68, 277.48370361328125, 257, 409.6336975097656], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 964, "type": "text", "text": "The Board of Directors nominates Testaris AG for  election as independent proxy by the Annual General  Meeting 2022 for the period from 2022 until the  conclusion of the 2023 ordinary Annual General  Meeting of Shareholders. ", "page_idx": 162, "bbox": [278, 277.48370361328125, 477, 337.6336975097656], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 965, "type": "text", "text": "The rules on the issue of instructions to the independent  proxy and rules on the electronic participation in  the Annual General Meeting are laid down in the  corresponding invitation to the Annual General Meeting  and are not regulated in the Articles of Incorporation. ", "page_idx": 162, "bbox": [278, 349.48370361328125, 484.88287353515625, 409.6336975097656], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 966, "type": "text", "text": "Information policy ", "text_level": 1, "page_idx": 163, "bbox": [120, 98, 328, 124], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 967, "type": "text", "text": "As provided by §34 of the Articles of Incorporation 18 corporate notices are published in the Swiss  Official Gazette of Commerce and in other daily  newspapers designated by the Board of Directors \n\n (‘Basler Zeitung’, ‘Finanz und Wirtschaft’, ‘L’Agefi’, \n\n ‘Le Temps’, ‘Neue Zürcher Zeitung’). ", "page_idx": 163, "bbox": [120, 157.48370361328125, 314, 229.63369750976562], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 968, "type": "text", "text": "Roche reports its half-year and full-year results in  business reports (published in print and/or online  formats) and at media events. In addition, detailed  first-quarter and nine months sales figures are  published each year in April and October. The most  current list of publication dates is available on the  Internet. 19 ", "page_idx": 163, "bbox": [120, 241.48370361328125, 314, 325.6336975097656], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 969, "type": "text", "text": "All relevant information and documents, including  all media releases, investor updates 20  and  ", "page_idx": 163, "bbox": [120, 337.48370361328125, 309, 361.6336975097656], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 970, "type": "text", "text": "presentations to analyst and investor conferences  are available on the Internet. Further publications  are available on \n https://www.roche.com/publications.htm  \n or can be ordered by e-mail: \n basel.warehouse-services@roche.com or fax:   $+41$   (0)61 688 69 02 ", "page_idx": 163, "bbox": [331, 157.48370361328125, 519, 241.63369750976562], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 971, "type": "text", "text": "The contact address for Investor Relations is: F. Hoffmann-La Roche Ltd, Investor Relations, Group Finance, 4070 Basel, Switzerland  Tel.:  $+41$   (0)61 688 88 80 Fax:  $+41$   (0)61 691 00 14 ", "page_idx": 163, "bbox": [331, 253.48370361328125, 501, 313.6336975097656], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 972, "type": "text", "text": "Additional information, including details on  specific contact persons, is available on the  Internet. ", "page_idx": 163, "bbox": [331, 325.48370361328125, 496.57110595703125, 361.6336975097656], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 973, "type": "text", "text": "Chief Compliance Officer  and Compliance Officers network ", "text_level": 1, "page_idx": 164, "bbox": [66, 95, 435, 153], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 974, "type": "text", "text": "The Chief Compliance Officer with the Compliance  Officers network is committed to ensuring that the  Roche Group Code of Conduct 22  is consistently  complied with throughout the Roche Group. The  Chief Compliance Officer also serves as a contact  person for shareholders, employees, business  partners, customers, suppliers and the general  public on issues relating to the implementation of  and compliance with this Code.  ", "page_idx": 164, "bbox": [68, 181.48370361328125, 261, 289.6336975097656], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 975, "type": "text", "text": "Employees and other parties who become aware  of violations of the Roche Group Code of Conduct  can bring them to the attention of their managers  or supervisors, to the local Compliance Officer  or report them to the Chief Compliance Officer 23   (Ms Pascale Schmidt, \n ", "page_idx": 164, "bbox": [68, 301.48370361328125, 261, 373.6336975097656], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 976, "type": "text", "text": "e-mail:  pascale.schmidt@roche.com ", "text_level": 1, "page_idx": 164, "bbox": [67, 374, 206, 381.75], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 977, "type": "text", "text": "tel.:  $+41$   (0)61 688 48 90). Such disclosures will be  treated confidentially. In addition, employees may  anonymously report irregularities or complaints in  their mother tongue via a ‘SpeakUp Line’. In case of  questions or uncertainties about the interpretation  of the Roche Group Code of Conduct and its  reference documents, employees may reach out  to their line managers, the local Compliance Officer  or the Chief Compliance Officer, or contact the  Roche Group Code of Conduct Help & Advice  ", "page_idx": 164, "bbox": [68, 385.48370361328125, 261, 505.6336975097656], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 978, "type": "text", "text": "Line. This compliance tool furthermore serves as  a platform for ideas and suggestions concerning  those documents. ", "page_idx": 164, "bbox": [278, 181.48370361328125, 472, 217.63369750976562], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 979, "type": "text", "text": "In addition, Roche has established a Business Ethics  Incident Reporting (BEIR) system which enables  the Chief Compliance Officer to capture, track and  monitor alleged violations, from initial reports by  local Compliance Officers or the Group Internal  Investigations department through to resolution. ", "page_idx": 164, "bbox": [278, 229.48370361328125, 472, 301.6336975097656], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 980, "type": "text", "text": "Business ethics incidents are recorded in the  system when the Group Internal Investigations  department or the regional/local management  receives specific and concrete information about  an alleged violation of the Roche Group Code of  Conduct in one of certain pre-defined categories. The Corporate Governance and Sustainability  Committee and the Audit Committee of the Board  of Directors are informed of substantial violations  and management’s corrective actions taken. ", "page_idx": 164, "bbox": [278, 313.48370361328125, 472, 433.6336975097656], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 981, "type": "text", "text": "The Chief Compliance Officer reports to the  General Counsel and also submits regular reports  to the Corporate Governance and Sustainability  Committee and as needed to the Audit Committee  of the Board of Directors. ", "page_idx": 164, "bbox": [278, 445.48370361328125, 472, 505.6336975097656], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 982, "type": "text", "text": "Non-applicability/negative disclosure ", "text_level": 1, "page_idx": 164, "bbox": [68, 554, 479, 581], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 983, "type": "text", "text": "It is expressly noted that any information not  contained or mentioned herein is either non- applicable or its omission is to be construed as  a negative declaration (as provided in the SIX Swiss  Exchange Corporate Governance Directive and the  Commentary thereto). ", "page_idx": 164, "bbox": [68, 613.4837036132812, 244, 649.6337280273438], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 984, "type": "text", "text": "", "page_idx": 164, "bbox": [278, 613.4837036132812, 470, 649.6337280273438], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 985, "type": "image", "page_idx": 165, "img_path": "layout_images/roche-holdings_2021_115.jpg", "bbox": [0, 0, 595, 794], "page_size": [595.2760009765625, 793.7009887695312], "ocr_text": "", "vlm_text": "This image shows a collection of glass laboratory stoppers or adapters, some with brown glass tops. They appear to be part of laboratory equipment, typically used to securely close or connect glassware in scientific experiments."}
{"layout": 986, "type": "text", "text": "Remuneration \n Report ", "text_level": 1, "page_idx": 166, "bbox": [130, 470, 442, 586], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 987, "type": "text", "text": "1. Principles ", "text_level": 1, "page_idx": 167, "bbox": [120, 98, 250, 122], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 988, "type": "text", "text": "Roche is an innovative and agile company whose  success depends substantially on the expertise,  motivation and performance of its employees. This  conviction forms the basis of our compensation  policy. ", "page_idx": 167, "bbox": [121, 157.48370361328125, 311, 217.63369750976562], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 989, "type": "text", "text": "Roche aims to remunerate all employees fairly,  transparently and in line with market conditions,  to enable them to participate appropriately in  the company’s success. We pursue this goal by  providing equitable, competitive, performance- based and results-oriented compensation. ", "page_idx": 167, "bbox": [121, 229.48370361328125, 305, 301.6336975097656], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 990, "type": "text", "text": "We strive for a balanced mix of fixed and variable  compensation components geared to each  employee’s position and management responsibility. ", "page_idx": 167, "bbox": [121, 313.48370361328125, 315, 349.6336975097656], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 991, "type": "text", "text": "Firstly, the variable components are intended to  create additional financial incentives to achieve  corporate goals and to keep innovation at a  consistently high level while increasing the value  that the company creates for all stakeholder  groups. Secondly, in order to allow employees and  managers to participate in the company’s business  success, adequate compensation measures are  key. Both objectives are incentivised by annual  bonus payments and long-term securities-based  programmes. ", "page_idx": 167, "bbox": [121, 361.48370361328125, 311, 493.6336975097656], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 992, "type": "text", "text": "For a global company like Roche, market- competitive remuneration plays a key role  ", "page_idx": 167, "bbox": [121, 505.48370361328125, 279, 529.6337280273438], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 993, "type": "text", "text": "along with a performance- and success-based,  transparent compensation structure. To ensure  that compensation packages are competitive,  both the structure and individual components  are regularly benchmarked based on the relevant  Swiss, European and international market criteria.  Our remuneration guidelines and their underlying  principles are also subject to regular outside  comparisons. ", "page_idx": 167, "bbox": [331, 157.48370361328125, 517, 265.6336975097656], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 994, "type": "text", "text": "However, compensation policy is only one factor  in safeguarding Roche’s future success. The  key element is a corporate culture that offers  employees conditions in which they can make their  best possible contribution to the shared corporate  goal of improving healthcare to patients. This  includes a sound and a sustainability-oriented  value system that is based on integrity, courage  and passion. At the same time, our decentralised  management approach plays a major role with  its wide scope for individual decision-making,  respectful interactions, openness to diversity, wide- ranging training and development opportunities and  an attractive working environment. A unidimensional  diminishment to questions on remuneration would  fall by far too short. ", "page_idx": 167, "bbox": [331, 277.48370361328125, 527, 469.6336975097656], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 995, "type": "text", "text": "Roche is committed to a fair, performance-based  and results-oriented compensation policy that links  employees’ interests with those of various other  stakeholder groups. ", "page_idx": 167, "bbox": [331, 481.48370361328125, 527, 529.6337280273438], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 996, "type": "text", "text": "2. Remuneration decision process  and approval framework ", "text_level": 1, "page_idx": 168, "bbox": [67, 98, 433, 154], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 997, "type": "text", "text": "2.1 Overview  ", "text_level": 1, "page_idx": 168, "bbox": [68, 182, 122, 192], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 998, "type": "text", "text": "Each year the Remuneration Committee of Roche’s  Board of Directors decides the remuneration of  Board members and the members of the Group’s  Corporate Executive Committee.  ", "page_idx": 168, "bbox": [68, 193.48370361328125, 259, 241.63369750976562], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 999, "type": "text", "text": "must not be present when the Remuneration  Committee decides their corresponding  compensation and have no right to a say in decisions.  The decision right is reserved to Remuneration  Committee members only. ", "page_idx": 168, "bbox": [278, 181.48370361328125, 475, 241.63369750976562], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 1000, "type": "text", "text": "Chairman, Group CEO and all other members  of the Group’s Corporate Executive Committee  ", "page_idx": 168, "bbox": [68, 253.48370361328125, 245.25570678710938, 277.6336975097656], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 1001, "type": "table", "page_idx": 168, "img_path": "layout_images/roche-holdings_2021_116.jpg", "table_caption": "Remuneration decision process and approval framework as of 2021 ", "bbox": [66, 304, 539, 439], "page_size": [595.2760009765625, 793.7009887695312], "ocr_text": "Remuneration\ncomponents\n\nBase pay / remuneration\nBonus\n\nStock-settled Stock\nAppreciation Rights (S-SARs)\nRestricted Stock Units (RSUs)\nPension\n\nBeneficiary\n\nBoard of Directors (BoD) Corporate Executive\nChairman (C) Committee (CEC) incl.\nCEO Roche Group\nv v\nv(C only) v\n= v\n= v\n\nv(C only) v\n\nDecision by\n\nRemuneration Committee\n\nApproval by\n\nAnnual General Meeting\n", "vlm_text": "The table outlines the different components of remuneration and their beneficiaries. Here's a breakdown of the columns:\n\n1. **Remuneration Components**:\n   - Base pay / remuneration\n   - Bonus\n   - Stock-settled Stock Appreciation Rights (S-SARs)\n   - Restricted Stock Units (RSUs)\n   - Pension\n\n2. **Beneficiary**:\n   - **Board of Directors (BoD) Chairman (C)**:\n     - Base pay, bonus, and pension (for C only)\n   - **Corporate Executive Committee (CEC) incl. CEO Roche Group**:\n     - Base pay, bonus, S-SARs, RSUs, and pension\n\n3. **Decision by**: \n   - Remuneration Committee\n\n4. **Approval by**:\n   - Annual General Meeting"}
{"layout": 1002, "type": "text", "text": "The Remuneration Committee tracks market data  on salaries at other leading global pharmaceutical  companies 1  and at major Swiss companies 2  and  reports its findings to the full Board. The external  consulting firm Price waterhouse Coopers (PwC)  assists the Remuneration Committee of Roche in  performing market comparisons and in advising.  PwC has been awarded additional mandates in the  Roche Group. Information on the Remuneration  Committee’s remit, powers and procedures for  making remuneration decisions can be found in the  Bylaws of the Roche Board of Directors 3  and in the  Articles of Incorporation.  They are also outlined  in the sections below on the principles governing  specific remuneration components (see 3.). ", "page_idx": 168, "bbox": [68, 469.48370361328125, 259, 649.6337280273438], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 1003, "type": "text", "text": "Since 2014, total aggregate amounts that are  based on these decisions have been submitted to  the General Meeting for approval implementing  the ‘Ordinance against excessive compensation at  listed joint-stock companies’ (Verordnung gegen  übermässige Vergütungen bei börsenkotierten  Aktien gesellschaft en [VegüV]). The General Meeting  shall vote annually and with binding effect on the  approval of the remuneration (that the Board of  Directors has resolved) of the Board of Directors  and the Corporate Executive Committee (for details  see 4. and 5.). ", "page_idx": 168, "bbox": [278, 469.48370361328125, 474, 613.6337280273438], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 1004, "type": "image", "page_idx": 169, "img_path": "layout_images/roche-holdings_2021_117.jpg", "bbox": [34, 167, 506, 352.75], "page_size": [595.2760009765625, 793.7009887695312], "ocr_text": "AbbV\n\nie\n\nAmgen\nAstraZeneca\nBristol-Myers Squibb\n\nDanal\nEli Lil\n\nher\ny\n\nGlaxoSmithKline\nJohnson & Johnson\nMedtronic\n\nMerc\n\n& Co.\n\nNovartis\n\nNovo\n\nPfizer\n\nNordisk\n\nSanoi\n\nPy Pee ee a ene tag F\n\nL |\n\nPeer set for 2021\n\nABB\n\nAlcon\n\nCredit Suisse\nHolcim\nLonza\nNestlé\nRichemont\nUBS\n\nZurich\n", "vlm_text": "The image appears to show a visual comparison of companies related to Roche. On the left, there is a list of pharmaceutical and healthcare companies such as AbbVie, Amgen, AstraZeneca, and others. On the right, there is a list labeled \"Peer set for 2021\" which includes companies like ABB, Alcon, and Credit Suisse. The central circle highlights Roche, suggesting it as the focal company among its peers."}
{"layout": 1005, "type": "text", "text": "", "page_idx": 169, "bbox": [35, 353.25, 109, 360], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 1006, "type": "text", "text": "Market comparison companies for salary assessment \n ", "page_idx": 169, "bbox": [34, 387, 212, 397], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 1007, "type": "text", "text": "  Pharma peer set\t   Major Swiss companies ", "page_idx": 169, "bbox": [35, 399, 189, 408], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 1008, "type": "text", "text": "2.2 Procedure for submitting total Board  and Executive remuneration for shareholder  approval at the Annual General Meeting Each year at the Annual General Meeting (AGM)  shareholders approve the total remuneration  for the Board of Directors and for the Corporate  Executive Committee as decided by the Board  of Directors’ Remuneration Committee and the  Board of Directors, respectively. ", "page_idx": 169, "bbox": [120, 469.48370361328125, 306, 577.6337280273438], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 1009, "type": "text", "text": "According to the approval at the AGM 2014,  Roche has committed itself to obtaining separate  and binding shareholder approvals of the total  remuneration paid to the Board of Directors and  to the Corporate Executive Committee as follows: ", "page_idx": 169, "bbox": [120, 589.4837036132812, 306, 649.6337280273438], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 1010, "type": "text", "text": "Retrospective approval  ", "text_level": 1, "page_idx": 169, "bbox": [330, 470, 429, 481], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 1011, "type": "text", "text": "Total aggregate bonus amounts for the Corporate  Executive Committee and the Chairman of the  Board of Directors for the financial year just ended  will be submitted retrospectively at each ordinary  AGM for separate and binding approval. ", "page_idx": 169, "bbox": [331, 481.48370361328125, 521, 541.6337280273438], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 1012, "type": "text", "text": "Prospective approval  ", "text_level": 1, "page_idx": 169, "bbox": [330, 554, 420, 565], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 1013, "type": "text", "text": "All other Board and Executive aggregate  remuneration will be submitted prospectively to  the AGM for separate and binding approval for  the period between two ordinary AGMs. ", "page_idx": 169, "bbox": [331, 565.4837036132812, 510.5377502441406, 613.6337280273438], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 1014, "type": "text", "text": "André Hoffmann, Chairman of the Remuneration Committee. ", "page_idx": 170, "bbox": [68.03150177001953, 99.48370361328125, 248.23104858398438, 108.93370056152344], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 1015, "type": "text", "text": "Approval of total remuneration at the Annual General Meeting (AGM) 2022 ", "page_idx": 170, "bbox": [68, 399.48370361328125, 310.8642883300781, 408.9337158203125], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 1016, "type": "text", "text": "Retrospective:  ", "text_level": 1, "page_idx": 170, "bbox": [67, 432, 147, 445], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 1017, "type": "text", "text": "Chairman (C) of the Board of Directors (BoD): • \tBonus for financial year 2021 (total amount) ", "page_idx": 170, "bbox": [68, 457.48370361328125, 239, 481.6336975097656], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 1018, "type": "text", "text": "Corporate Executive Committee (CEC) including CEO Roche Group: • \tBonus for financial year 2021 (total amount)\n ", "page_idx": 170, "bbox": [68, 493.48370361328125, 318, 517.6337280273438], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 1019, "type": "text", "text": "Prospective: ", "text_level": 1, "page_idx": 170, "bbox": [67, 541, 136, 553], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 1020, "type": "text", "text": "Board of Directors (BoD) including Chairman (C): Aggregate total remuneration (AGM 2022–AGM 2023) • \tBase pay / remuneration ", "page_idx": 170, "bbox": [68, 565.4837036132812, 267, 601.6337280273438], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 1021, "type": "text", "text": "Corporate Executive Committee (CEC) including CEO Roche Group:  Aggregate total remuneration (AGM 2022–AGM 2023)\n\n • \tBase pay \n\n ", "page_idx": 170, "bbox": [68, 613.4837036132812, 318, 649.6337280273438], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 1022, "type": "text", "text": "• \tStock-settled Stock Appreciation Rights (S-SARs)\n\n • \tRestricted Stock Units (RSUs) \n\n\n • \tIndirect benefits ", "page_idx": 170, "bbox": [68, 649.4837036132812, 255.8732147216797, 685.6337280273438], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 1023, "type": "image", "page_idx": 170, "img_path": "layout_images/roche-holdings_2021_118.jpg", "bbox": [326, 395, 551, 709], "page_size": [595.2760009765625, 793.7009887695312], "ocr_text": "Financial year 2021\n\nBonus\n\nBonus\n\nFinancial year 2022\n\nBoD\n\nBase pay / remuneration\n\nCEC\nBase pay\nS-SARs\n\nRSUs\n\nIndirect benefits\n\n11,2023\n", "vlm_text": "The image is a timeline diagram comparing the compensation components for two financial years, 2021 and 2022. It is divided into two main sections—one for each year—and illustrates the compensation structure for different groups or roles within an organization. \n\nFor Financial Year 2021:\n- The diagram shows \"C\" and \"CEC\" as receiving a \"Bonus.\"\n\nFor Financial Year 2022:\n- The Board of Directors (BoD) receives \"Base pay / remuneration.\"\n- The Corporate Executive Committee (CEC) receives \"Base pay,\" \"S-SARs\" (Stock-Settled Appreciation Rights), \"RSUs\" (Restricted Stock Units), and \"Indirect benefits.\"\n\nAnnual General Meetings (AGMs) are marked at the start of each year, respectively, indicating the periods when these compensation packages were probably decided or reviewed."}
{"layout": 1024, "type": "text", "text": "3. Remuneration components ", "text_level": 1, "page_idx": 171, "bbox": [120, 98, 441, 123], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 1025, "type": "text", "text": "3.1 Overview of remuneration elements The remuneration to the members of the Board of  Directors and the Corporate Executive Committee is  composed of the following elements: ", "page_idx": 171, "bbox": [120, 157.48370361328125, 316, 205.63369750976562], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 1026, "type": "text", "text": "The fixed base salary is complemented with the  annual variable bonus as  Short-Term Incentive \n\n (STI)  and with perennial remuneration elements \n\n (S-SARs, RSUs) as  Long-Term Incentive (LTI) . ", "page_idx": 171, "bbox": [120, 217.48370361328125, 303.5104675292969, 265.6336975097656], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 1027, "type": "text", "text": "The remuneration components are linked to the  employees’ performance, the company’s financial  ", "page_idx": 171, "bbox": [120, 277.48370361328125, 308, 301.6336975097656], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 1028, "type": "text", "text": "performance and non-financial success 5  and thus  align the interests of Roche and its employees with  those of shareholders. Societal and environmental  objectives 6  are also taken into account. ", "page_idx": 171, "bbox": [331, 157.48370361328125, 522, 205.63369750976562], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 1029, "type": "text", "text": "The  LTI  remuneration components are intended  to sustainably, homogenously and in a long-term- oriented perspective align management’s interest  with those of shareholders and holders of non- voting equity securities and to give participating  managers an additional incentive to achieve  sustainable shareholder value growth. ", "page_idx": 171, "bbox": [331, 217.48370361328125, 522, 301.6336975097656], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 1030, "type": "table", "page_idx": 171, "img_path": "layout_images/roche-holdings_2021_119.jpg", "table_caption": "Composition of remuneration to the Board of Directors and the Corporate Executive Committee ", "bbox": [54, 338, 529, 595], "page_size": [595.2760009765625, 793.7009887695312], "ocr_text": "Annual\nremuneration elements\n\nBase pay /\nremuneration\nBonus\n\nPensions, etc.\n\nPerennial\nremuneration elements\n\nStock-settled Stock\nAppreciation Rights\n(S-SARs)\n\nRestricted Stock\nUnits (RSUs)\n\nDescription\n\nMonthly payment\n\n(see 3.\nAnnual\n(see 3.\n\n(see 3.\n\n(see 3.\n\n-1be\n\npaym:\n.2 be\n\n0 be\n\now)\nent\now)\n\now)\n\n.3 be\n\now)\n\n(see 3.1.4 below)\n\nBoard of Directors\n\nv For 10 years\nblocked non-voting\nequity securities\nand/or shares\n\nv\n\nBoD\n\nv Quarterly\npayments\n\nCorporate Executive Committee\n\nCEO Roche Group CEG\n\nv v\n\nv For 10 years vCash\nblocked non-voting\nequity securities\nand/or shares\n\nv Vv\n\nv For 4 years v\n\nadditionally\nblocked non-voting\nequity securities\nafter exercise\n\nv For 10 years v\nblocked non-voting\nequity securities\n", "vlm_text": "The table outlines the remuneration elements for different roles, including the Board of Directors and the Corporate Executive Committee. It distinguishes between annual and perennial remuneration elements.\n\n### Annual Remuneration Elements:\n- **Base Pay/Remuneration:**\n  - **Board of Directors (C and BoD):** C receives monthly payments; BoD receives quarterly payments.\n  - **Corporate Executive Committee (CEO Roche Group and CEC):** Both receive monthly payments.\n\n- **Bonus:**\n  - **Board of Directors (C):** Bonus in blocked non-voting equity securities/shares for 10 years.\n  - **Corporate Executive Committee (CEO Roche Group):** Same as C; **CEC:** Cash.\n\n- **Pensions, etc.:**\n  - Available for C and CEO Roche Group, not for BoD and CEC.\n\n### Perennial Remuneration Elements:\n- **Stock-settled Stock Appreciation Rights (S-SARs):**\n  - **CEO Roche Group:** Additional block of non-voting equity securities for 4 years.\n  - **CEC:** Participates.\n\n- **Restricted Stock Units (RSUs):**\n  - **CEO Roche Group:** Blocked for 10 years.\n  - **CEC:** Participates.\n\nEach element in the table references specific subsections (e.g., 3.1.1) for more detailed descriptions."}
{"layout": 1031, "type": "text", "text": "The LTI of the  Corporate Executive Committee  and the Enlarged Corporate Executive  ", "text_level": 1, "page_idx": 172, "bbox": [67, 98, 254, 121], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 1032, "type": "text", "text": "Committee  is composed of   $80\\%$   S-SARs and  $20\\%$    RSUs (based on the already existing individual  target value of the total LTI for Corporate Executive  Committee members of   $135.53\\%$   of a base pay  measured on 1 January of a year). Vesting and  ", "page_idx": 172, "bbox": [68, 121, 262, 181.63369750976562], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 1033, "type": "text", "text": "expiration periods are aligned for any newly  issued S-SARs and RSUs (see below). Unlike all  other participants of the two programmes, members  of the Corporate Executive Committee have no  choice in determining the mix of RSUs and S-SARs,  which as of 2019 have a four-year cliff vesting. ", "page_idx": 172, "bbox": [278, 97.48370361328125, 475, 169.63369750976562], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 1034, "type": "table", "page_idx": 172, "img_path": "layout_images/roche-holdings_2021_120.jpg", "table_caption": "Corporate Executive Committee LTI ", "bbox": [66, 208, 539, 331], "page_size": [595.2760009765625, 793.7009887695312], "ocr_text": "Mix (S-SARs/RSUs) fixed\n\n80% S-SARs\n\n20% RSUs\n\nBase for calculation Vesting period\n\nBased on the individual target\nvalue of the total LTI for\n\n4years\nCorporate Executive\nCommittee members of\n133.33% of a base pay\nmeasured on 1 January of 4 years\n\nayear\n\nCliff vesting\n\n4years\n\n4years\n\nExpiration period\n\n10 years\n\n", "vlm_text": "The table outlines the structure of executive compensation based on S-SARs (Stock-Settled Appreciation Rights) and RSUs (Restricted Stock Units):\n\n- **Mix (S-SARs/RSUs) Fixed:**\n  - 80% S-SARs\n  - 20% RSUs\n\n- **Base for Calculation:**\n  - Based on the individual target value of the total Long-Term Incentive (LTI) for Corporate Executive Committee members, which is 133.33% of a base pay measured on January 1st of a year.\n\n- **Vesting Period:**\n  - 4 years for both S-SARs and RSUs\n\n- **Cliff Vesting:**\n  - 4 years for both S-SARs and RSUs\n\n- **Expiration Period:**\n  - 10 years for S-SARs\n  - No expiration period specified for RSUs"}
{"layout": 1035, "type": "text", "text": "The remaining participants of the S-SARs and  RSUs programmes  are offered on a yearly basis a  choice of three combinations to determine the mix  of Restricted Stock Units (RSUs) and Stock-settled  Stock Appreciation Rights (S-SARs, options are used  instead of S-SARs in some countries). The following  options are available: ", "page_idx": 172, "bbox": [68, 361.48370361328125, 262, 445.6336975097656], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 1036, "type": "table", "page_idx": 172, "img_path": "layout_images/roche-holdings_2021_121.jpg", "bbox": [66, 454, 260, 494], "page_size": [595.2760009765625, 793.7009887695312], "ocr_text": "Choice 1 Choice 2 Choice 3\n\n80% S-SARs 50% S-SARs 20% S-SARs\n20% RSUs 50% RSUs 80% RSUs\n", "vlm_text": "The table shows three options for distribution:\n\n- **Choice 1:** 80% S-SARs, 20% RSUs\n- **Choice 2:** 50% S-SARs, 50% RSUs\n- **Choice 3:** 20% S-SARs, 80% RSUs\n\n\"S-SARs\" likely refers to Stock-Settled Appreciation Rights and \"RSUs\" to Restricted Stock Units."}
{"layout": 1037, "type": "text", "text": "Offering this level of choice empowers participants  to engage more fully in their total rewards, enables  them to better understand a critical element of  their compensation and increases the value of the  programme.  ", "page_idx": 172, "bbox": [277, 361.48370361328125, 471, 421.6336975097656], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 1038, "type": "text", "text": "This attractively designed Roche Long-Term  Incentive programme enables Roche to attract,  motivate and retain the best talent and keep it  aligned with the company’s long-term success.  ", "page_idx": 172, "bbox": [277, 433.48370361328125, 457, 481.6336975097656], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 1039, "type": "image", "page_idx": 173, "img_path": "layout_images/roche-holdings_2021_122.jpg", "bbox": [30, 110, 528, 302], "page_size": [595.2760009765625, 793.7009887695312], "ocr_text": "STI:\n* Bonus\n\nUTI:\n* Stock-settled Stock Appreciation Rights\n* Restricted Stock Units\n\nVariable, long-term\n\ngam,\n\nRoche\nremuneration\n\ncomponents\n\neT\n\nFixed\n\nBase salary\n\nIndirect benefits (employer\ncontribution):\n\n» Pensions and insurance contributions\n* Roche Connect\n\n» Tax consulting services\n\nExpense allowances\n\nOthers:\n\n* Children’s schooling costs\n» Foreign tax obligation\n\n» AHV/IV/ALV*\n\n", "vlm_text": "The image outlines the remuneration components for Roche employees. The components are divided into fixed and variable, long-term elements.\n\n**Fixed:**\n- Base salary\n- Indirect benefits (employer contribution), including:\n  - Pensions and insurance contributions\n  - Roche Connect\n  - Tax consulting services\n- Expense allowances\n- Other benefits, such as:\n  - Children’s schooling costs\n  - Foreign tax obligation\n  - AHV/IV/ALV*\n\n**Variable, long-term:**\n- Short-Term Incentives (STI):\n  - Bonus\n- Long-Term Incentives (LTI):\n  - Stock-settled Stock Appreciation Rights\n  - Restricted Stock Units"}
{"layout": 1040, "type": "text", "text": "3.1.1 Base pay (fixed) ", "text_level": 1, "page_idx": 173, "bbox": [120, 409, 206, 420], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 1041, "type": "text", "text": "Base pay (cash payment) is determined for each  position based on salary market data of other  leading global pharmaceutical companies (see  footnote 1) and of other major Swiss companies  (see footnote 2) and reflects individuals’ abilities,  experience and performance over time. Pay  adjustments are likewise linked to individual  performance and take into account prevailing  market conditions and the company’s overall  financial situation. ", "page_idx": 173, "bbox": [120, 421.48370361328125, 306, 541.6337280273438], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 1042, "type": "text", "text": "The Remuneration Committee makes and reviews  the final decision on the individual base pay paid  to the Chairman of the Board of Directors and  members of the Corporate Executive Committee  and on the remuneration of the other members of  the Board. ", "page_idx": 173, "bbox": [120, 553.4837036132812, 306, 625.6337280273438], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 1043, "type": "text", "text": "3.1.2 Bonuses (variable) ", "text_level": 1, "page_idx": 173, "bbox": [331, 409, 428, 420], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 1044, "type": "text", "text": "Bonuses are annually awarded for individual  contributions of value creation in a business year and  are meant to be an incentive to strive for outstanding  results and to create new business opportunities.  Bonus amounts are linked to Group and divisional  core profits, sales growth at constant exchange  rates, Operating Profit After Capital Charge (OPAC)  based on core operating profit, core earnings per  share and non-voting equity security (NES) growth  at constant exchange rates, product development  pipeline, diversity of employees and managers 7   and  environmental goals 8 . Additionally, they are linked  to the achievement of measurable and qualitative  individual or functional performance objectives. For  competitive reasons, Roche does not disclose the  individual performance objectives of members of its  Corporate Executive Committee and of its Chairman. ", "page_idx": 173, "bbox": [331, 421.48370361328125, 531, 625.6337280273438], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 1045, "type": "text", "text": "In December at the end of a reporting year  or in January following a reporting year, the  Remuneration Committee decides on the bonuses  and their amounts payable to the Chairman of the  Board and the members of the Corporate Executive  Committee in respect of the relevant reporting year,  based on performance against the aforementioned  objectives. At the same time, the Remuneration  Committee also decides in what form bonuses will  be awarded, ie, cash payments and/or blocked  (if applicable) non-voting equity securities and/or  shares.  ", "page_idx": 174, "bbox": [67, 97.48370361328125, 263, 241.63369750976562], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 1046, "type": "text", "text": "The Remuneration Committee uses its discretion  appropriately in the weighting of each criteria and  in the bonus allocation. ", "page_idx": 174, "bbox": [67, 253.48370361328125, 263, 289.6336975097656], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 1047, "type": "text", "text": "In 2021 in total, around 78,900 employees were  eligible for a bonus under the Roche Bonus Program.  ", "page_idx": 174, "bbox": [67, 301.48370361328125, 263, 325.6336975097656], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 1048, "type": "text", "text": "3.1.3 Stock-settled Stock Appreciation Rights  (S-SARs) (long-term) ", "text_level": 1, "page_idx": 174, "bbox": [67, 338, 256, 361], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 1049, "type": "text", "text": "The S-SARs proportion of the LTI of the Corporate  Executive Committee is   $80\\%$   (based on the  individual target value of the total LTI for Corporate  Executive Committee members of   $135.53\\%$   of a  base pay measured on 1 January of a year). ", "page_idx": 174, "bbox": [67, 361.48370361328125, 263, 421.6336975097656], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 1050, "type": "text", "text": "S-SARs entitle holders to benefit financially from  any increase in the value of Roche’s non-voting  equity securities between the grant date and the  exercise date. S-SARs granted all vest together after four years and then have to be exercised within ten years of the grant date. Unexercised  S-SARs lapse without compensation. Since 2012,  the fair value of S-SARs has been calculated at the  grant date using the trinomial model for American  call options (for details see page 182).  ", "page_idx": 174, "bbox": [67, 433.48370361328125, 263, 553.6337280273438], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 1051, "type": "text", "text": "S-SARs to the Corporate Executive Committee  are allocated individually at the Remuneration  Committee’s discretion.  ", "page_idx": 174, "bbox": [67, 565.4837036132812, 263, 601.6337280273438], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 1052, "type": "text", "text": "3.1.4 Restricted Stock Units (RSUs) (long-term) ", "text_level": 1, "page_idx": 174, "bbox": [278, 98, 470, 109], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 1053, "type": "text", "text": "The proportion of Restricted Stock Units (RSUs) of  the members of the Corporate Executive Committee  is   $20\\%$   of the total LTI (based on the individual  target value of the total LTI for Corporate Executive  Committee members of   $135.53\\%$   of a base pay  measured on 1 January of a year).  ", "page_idx": 174, "bbox": [278, 109.48370361328125, 475, 181.63369750976562], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 1054, "type": "text", "text": "RSUs contain rights to receive non-voting equity  securities and/or shares after a four-year vesting  period plus a value adjustment (being the amount  equivalent to the sum of the dividend paid during  the vesting period attributable to the number  of non-voting equity securities and/or shares  for which an individual award has been granted).  They will be all vested to the recipient for the  Corporate Executive Committee after four years  only. Thereafter, resulting non-voting equity  securities and/or shares may remain blocked for  up to ten years. ", "page_idx": 174, "bbox": [278, 193.48370361328125, 475, 337.6336975097656], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 1055, "type": "text", "text": "RSU awards are allocated individually for  the Corporate Executive Committee at the  Remuneration Committee’s discretion. ", "page_idx": 174, "bbox": [278, 349.48370361328125, 438.78399658203125, 385.6336975097656], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 1056, "type": "text", "text": "In 2021, RSUs served as a remuneration component  for 23,106 eligible Roche employees. ", "page_idx": 174, "bbox": [278, 397.48370361328125, 475, 421.6336975097656], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 1057, "type": "text", "text": "3.1.5 Indirect benefits  ", "text_level": 1, "page_idx": 174, "bbox": [278, 434, 368, 444], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 1058, "type": "text", "text": "As shown in 5.8 (5.3 [for the CEO Roche Group]  and 4.3 [for the Chairman], respectively), members  of the Corporate Executive Committee additionally  received indirect benefits (pension funds / insurance  contributions, Roche Connect, payments for foreign  tax obligation and tax consulting services and  annual expense allowances). As shown under 5.9,  individual members of the Corporate Executive  Committee received payments for family, children  and education allowances and for schooling costs  for their children. ", "page_idx": 174, "bbox": [278, 445.48370361328125, 475, 577.6337280273438], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 1059, "type": "text", "text": "In 2021 in total, 22,965 employees received S-SARs. ", "page_idx": 174, "bbox": [68.49109649658203, 613.4837036132812, 263.2025146484375, 625.6337280273438], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 1060, "type": "image", "page_idx": 175, "img_path": "layout_images/roche-holdings_2021_123.jpg", "img_caption": "3.2 Weighting (fixed / variable, long-term) of 2021 remuneration components (at target  and as percentage of total remuneration in 2021) ", "bbox": [102, 98, 531, 244], "page_size": [595.2760009765625, 793.7009887695312], "ocr_text": "Chairman\n\nBoard of Directors\n\nCorporate Executive Committee\n(including CEO Roche Group)\n\n82% 18%\n\n100%\n\n39% 61%\n\n0% 10% 20% 30% 40% 50% 60% 10% 80% 90% 00%\n\n© fixed @ variable, long-term\n", "vlm_text": "The image is a bar chart showing the weighting of remuneration components as a percentage of total remuneration for 2021. It categorizes remuneration into \"fixed\" and \"variable, long-term\" components for different groups:\n\n1. **Chairman**: \n   - Fixed: 82%\n   - Variable, long-term: 18%\n\n2. **Board of Directors**: \n   - Fixed: 100%\n   - Variable, long-term: 0%\n\n3. **Corporate Executive Committee (including CEO Roche Group)**:\n   - Fixed: 39%\n   - Variable, long-term: 61% \n\nThe chart visually compares the proportions of fixed versus variable, long-term components for each group."}
{"layout": 1061, "type": "text", "text": "3.3 Ratio of variable remuneration components relative to fixed base pay of the Corporate  Executive Committee 2021 ", "text_level": 1, "page_idx": 175, "bbox": [120, 301, 491, 325], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 1062, "type": "table", "page_idx": 175, "img_path": "layout_images/roche-holdings_2021_124.jpg", "table_caption": "Ratio of variable remuneration components (bonuses, S-SARs and RSUs) relative to  $\\%$   of value of fixed base pay ", "table_footnote": "n/a – not applicable \\*\t Assessed in consideration of the performance of competitors and the macro-economic development \\*\\*\t \u0007 Based on the already existing individual target value of the total LTI for Corporate Executive Committee members of   $133.53\\%$   of a base pay measured on 1 January of a year ", "bbox": [54, 338, 527, 613], "page_size": [595.2760009765625, 793.7009887695312], "ocr_text": "Criteria\n\nIndividual target value*\nMinimum\n\nMaximum\nPerformance criteria\n\nSplitin %\n\na) Group objectives\n\nb) Individual objectives\nWeighting criteria /\nDecision on objectives\n\nSTI (variable)\n\nBonus\n\n100%\n\n0%\n\n200%\n\nGroup objectives (Group and divisional business\nperformance) and individual objectives considering\ncore profits, sales growth at constant exchange rates,\nOperating Profit After Capital Charge (OPAC) based\non core operating profit, core earnings per share and\nnon-voting equity security (NES) growth at constant\nexchange rates, product development pipeline, diversity\nof employees and managers, environmental goals\n\n70%\n30%\nAt the Remuneration Committee’s discretion\n\nLTI (long-term)\n(total: 133,33%**)\n\nS-SARs (80% of total LTI)\n106.66%**\n\n0%\n\n106.66%\n\nValue development\ndetermined by\nperformance of\n\nNES after grant\n\nn/a\nn/a\n\nRSUs (20% of total LTI)\n26.66%**\n\n0%\n\n26.66%\n\nValue development\ndetermined by\nperformance (plus\navalue adjustment\nfor dividends) of\nNES after grant\n\nn/a\nn/a\n", "vlm_text": "The table presents criteria for performance-related incentives, divided into short-term (STI) and long-term incentives (LTI).\n\n### STI (Variable)\n- **Bonus:**\n  - **Target Value:** 100%\n  - **Minimum:** 0%\n  - **Maximum:** 200%\n- **Performance Criteria:**\n  - Based on group and individual objectives including core profits, sales growth, Operating Profit After Capital Charge (OPAC), core operating profit, core earnings per share, NES growth, product development, diversity, and environmental goals.\n- **Split in %:**\n  - Group objectives: 70%\n  - Individual objectives: 30%\n- **Decision on Objectives:** By the Remuneration Committee.\n\n### LTI (Long-Term Incentives):\nTotal: 133.33%\n\n1. **S-SARs (80% of LTI)**\n   - **Target Value:** 106.66%\n   - **Minimum:** 0%\n   - **Maximum:** 106.66%\n   - **Performance Criteria:** Value determined by NES performance after grant.\n\n2. **RSUs (20% of LTI)**\n   - **Target Value:** 26.66%\n   - **Minimum:** 0%\n   - **Maximum:** 26.66%\n   - **Performance Criteria:** Value based on NES performance and a value adjustment for dividends after grant.\n\nWeighting criteria and decision-making specifics for LTI are not applicable (n/a)."}
{"layout": 1063, "type": "text", "text": "4. Remuneration of the Board of Directors ", "text_level": 1, "page_idx": 176, "bbox": [68, 97, 526, 122], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 1064, "type": "text", "text": "4.1 Resolution and approval ", "text_level": 1, "page_idx": 176, "bbox": [67, 158, 181, 168], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 1065, "type": "text", "text": "Remuneration of the Chairman of the Board of  Directors and of members of the Board of Directors  was decided at the Remuneration Committee’s  discretion, taking into account market comparisons. ", "page_idx": 176, "bbox": [67, 169.48370361328125, 263, 217.63369750976562], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 1066, "type": "text", "text": "The remuneration is in form of cash payments and is  annually tracked against market data on directors’  pay at other leading global pharmaceutical  companies (see footnote 1) and other major Swiss  companies (see footnote 2), and is assisted by the  consultancy of PwC. ", "page_idx": 176, "bbox": [67, 229.48370361328125, 263, 301.6336975097656], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 1067, "type": "text", "text": "As in the previous years, in 2022, the Board of  Directors will separately submit the total aggregate  bonus of the Chairman of the Board of Directors to  the General Meeting for the 2021 financial year, for  retrospective binding approval. ", "page_idx": 176, "bbox": [67, 313.48370361328125, 263, 373.6336975097656], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 1068, "type": "text", "text": "The maximum amounts of the total other aggregate  remuneration of the Board of Directors for the  period between the ordinary General Meeting  2022 and the ordinary General Meeting 2023 will  be separately tabled in 2022 as in the previous  years for the General Meeting’s prospective binding  approval (see 2.2). ", "page_idx": 176, "bbox": [67, 385.48370361328125, 263, 469.6336975097656], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 1069, "type": "text", "text": "4.2 Amount of remuneration to the members  of the Board of Directors ", "text_level": 1, "page_idx": 176, "bbox": [67, 482, 250, 504], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 1070, "type": "text", "text": "In 2021, the members of the Board of Directors 10   received remuneration and additional compensation  in the form of quarterly fixed cash payments as  shown in the ‘Remuneration of members of the  ", "page_idx": 176, "bbox": [67, 505.48370361328125, 263, 553.6337280273438], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 1071, "type": "text", "text": "Board of Directors 2021’ table on page 174 for  their Board activities. Roche paid employer’s  contributions totalling CHF 358,574 to social  security agencies for the members of the Board of  Directors beside the legally required contributions  separately stated for the Chairman of the Board  of Directors. ", "page_idx": 176, "bbox": [277, 157.48370361328125, 468, 241.63369750976562], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 1072, "type": "text", "text": "The basic remuneration of the Board of Directors  (excluding the Chairman) has remained unchanged  since 2001. ", "page_idx": 176, "bbox": [277, 253.48370361328125, 468, 289.6336975097656], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 1073, "type": "text", "text": "With the exception of the Chairman of the Board  of Directors (bonus in form of blocked shares)  and Dr Severin Schwan as an executive member  of the Board, members of the Board of Directors  were not awarded any shares, non-voting equity  securities or S-SARs. ", "page_idx": 176, "bbox": [277, 301.48370361328125, 461, 373.6336975097656], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 1074, "type": "text", "text": "There are no loans or credits granted to the  members of the Board of Directors. ", "page_idx": 176, "bbox": [277, 385.48370361328125, 442.3168640136719, 409.6336975097656], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 1075, "type": "text", "text": "In his capacity as a member of the Chugai  International Council (CIC) of Chugai  Pharmaceutical Co., Ltd. André Hoffmann  received in 2021 honoraria amounting to a  total of USD 20,000 (CHF 18,277). ", "page_idx": 176, "bbox": [277, 421.48370361328125, 438, 481.6336975097656], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 1076, "type": "text", "text": "In 2021, for their advisory service on the  Genentech Scientific Resource Board,  Prof. Dr Richard P. Lifton and Prof. Dr Hans Clevers  received honoraria amounting to a total of  USD 22,000 (CHF 20,105) each. ", "page_idx": 176, "bbox": [277, 493.48370361328125, 468, 553.6337280273438], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 1077, "type": "image", "page_idx": 176, "img_path": "layout_images/roche-holdings_2021_125.jpg", "bbox": [481, 377, 496, 411], "page_size": [595.2760009765625, 793.7009887695312], "ocr_text": "", "vlm_text": "The image contains a grey rectangle with the word \"AUDITED\" written vertically in white letters."}
{"layout": 1078, "type": "table", "page_idx": 177, "img_path": "layout_images/roche-holdings_2021_126.jpg", "table_caption": "Remuneration of members of the Board of Directors 2021  (in CHF) ", "table_footnote": "\\*\t Costs under the provisions of the Swiss Federal Occupational Old Age, Survivors’ and Invalidity Pension Act (BVG). In accordance with the minimum requirements for insurance  benefits under BVG, half of the costs for four members of the Board of Directors who are subject to compulsory insurance are borne by the company. 11\t \u0007 With the exception of members of the Chairman’s Committee (Chairman, Vice-Chairman), Board members receive CHF 30,000/year for each committee they serve on and \n CHF 60,000/year for each committee they chair. 12\t Remuneration for serving as Vice-Chairman of the Board 13\t Additionally, employer contribution to AHV/IV/ALV totalling CHF 997,150 (including the Chairman) was paid that does not form part of remuneration. ", "bbox": [39, 99, 529, 411], "page_size": [595.2760009765625, 793.7009887695312], "ocr_text": "AUDITED\n\nC. Franz, Chairman\nA. Hoffmann, Vice-Chairman\n\nJ. Brown\nP. Bulcke\nH. Clevers\n\nJ. Duschmalé\nP. Frost\n\nA. Hauser\nR.P. Lifton\n\nB. Poussot\n\nS. Schwan\n\nC. Suessmuth Dyckerhoff\nTotal's\n\nBasic remuneration\n\nAdditional\nBVG costs’\n\nAdditional remuneration for\ncommittee members/chairs\"\n\nAdditional special\n\nremuneration Total remuneration\n\n(see ‘4.3 Total remuneration paid to the Chairman of the Board of Directors’)\n\n400,000'? z 18,277 6,904 425,181\nsee page 173\n\n300,000 60,000 = = 360,000\n\n300,000 30,000 a = 330,000\n\n300,000 30,000 20,105 = 350,105\nsee page 173\n\n300,000 30,000 = 4,499 334,499\n\n300,000 30,000 a = 330,000\n\n300,000 30,000 = 6,221 $36,221\n\n300,000 30,000 20,105 = 350,105\nsee page 173\n\n300,000 30,000 a = 330,000\n\n(see ‘5.3 Highest total remuneration paid to Dr Severin Schwan as a member of the Corporate Executive\nCommittee’, remuneration received in his primary function as CEO Roche Group is reflected in total remuneration\nfor the Corporate Executive Committee)\n\n30,000 a 6,176 336,176\n300,000 58,487 23,800 3,482,287\n\n300,000\n3,100,000\n\n", "vlm_text": "The table provides remuneration details for various individuals, specifically board members or executives. Here's a breakdown of the table's structure:\n\n- **Columns**:\n  - Name and Position (e.g., C. Franz, Chairman)\n  - Basic remuneration\n  - Additional remuneration for committee members/chairs\n  - Additional special remuneration\n  - Additional BVG costs\n  - Total remuneration\n\n- **Data example**:\n  - C. Franz, Chairman: \n    - Basic remuneration: 400,000\n    - Additional special remuneration: 18,277\n    - Additional BVG costs: 6,904\n    - Total remuneration: 425,181\n\n- **Totals** at the bottom of the table indicate:\n  - Basic remuneration total: 3,100,000\n  - Additional remuneration for committee members/chairs total: 300,000\n  - Additional special remuneration total: 58,487\n  - Additional BVG costs total: 23,800\n  - Total remuneration: 3,482,287\n\nThere are notes referring to additional information indicated by numbers and asterisks, which provide context or details in a larger document."}
{"layout": 1079, "type": "table", "page_idx": 178, "img_path": "layout_images/roche-holdings_2021_127.jpg", "table_caption": "Remuneration of members of the Board of Directors 2020  (in CHF) ", "table_footnote": "14\t \u0007 With the exception of members of the Chairman’s Committee (Chairman, Vice-Chairman), Board members receive CHF 30,000/year for each committee they serve on and  CHF 60,000/year for each committee they chair. 15\t Remuneration for serving as Vice-Chairman of the Board 16\t Prorated remuneration for the period from March to December 2020 17\t Prorated remuneration for the period from January to March 2020 18\t Additionally, employer contribution to AHV/IV/ALV totalling CHF 354,578 (including the Chairman) was paid that does not form part of remuneration. ", "bbox": [66, 99, 540, 411], "page_size": [595.2760009765625, 793.7009887695312], "ocr_text": "Additional remuneration Additional special\n\nBasic remuneration for committee members/chairs ‘* remuneration Total remuneration\nC. Franz, Chairman (see ‘4.3 Total remuneration paid to the Chairman of the Board of Directors’)\nA. Hoffmann, Vice-Chairman 400,000'® - 37,568 437,568\nJ. Brown 300,000 60,000 - 360,000\nP. Bulcke 300,000 30,000 = 330,000\nH. Clevers 300,000 30,000 24,756 354,756\nJ. Duschmaleé (since March 2020'*) 250,000 22,500 = 272,500\nP. Frost (since March 2020\") 250,000 22,500 - 272,500\nA. Hauser 300,000 30,000 = 330,000\nR.P. Lifton 300,000 30,000 9,392 339,392\nB. Poussot 300,000 30,000 = 330,000\nS. Schwan (see ‘5.3 Highest total remuneration paid to Dr Severin Schwan as a member of the Corporate Executive\n\nCommittee’, remuneration received in his primary function as CEO Roche Group is reflected in total\nremuneration for the Corporate Executive Committee)\n\nC. Suessmuth Dyckerhoff 300,000 30,000 - 330,000\nJ. Bell (until March 2020\") 75,000 = = 75,000\nA. Oeri (until March 2020\") 75,000 15,000 = 90,000\n\nTotal® 3,150,000 300,000 71,716 3,521,716\n\n", "vlm_text": "The table shows the remuneration of various individuals, likely members of a board or committee. It includes:\n\n1. **Names and Positions**: Individuals are listed with their positions, such as Chairman and Vice-Chairman.\n\n2. **Basic Remuneration**: The core salary figures for each person.\n\n3. **Additional Remuneration**:\n   - For committee members/chairs.\n   - Special remuneration in certain cases.\n\n4. **Total Remuneration**: The sum of basic and additional remuneration for each person.\n\n5. **Footnotes** are referenced but not detailed in the image.\n\n**Summary Totals**:\n- Basic Remuneration: 3,150,000\n- Additional for committees: 300,000\n- Additional special remuneration: 71,716\n- Total Remuneration: 3,521,716\n\nSpecific entries note particular conditions, like those starting positions in 2020, or remuneration related to primary functions elsewhere."}
{"layout": 1080, "type": "text", "text": "4.3 Total remuneration paid to the Chairman  of the Board of Directors  ", "text_level": 1, "page_idx": 178, "bbox": [67, 446, 249, 468], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 1081, "type": "text", "text": "As Chairman, Dr Christoph Franz received total  remuneration for 2021 as shown below. The  Remuneration Committee’s bonus proposal  (adopted in late 2021) in respect of the 2021  financial year (in form of shares blocked for  ", "page_idx": 178, "bbox": [67, 469.48370361328125, 242.52842712402344, 529.6337280273438], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 1082, "type": "text", "text": "ten years, payable in March 2022) will be put for  shareholder binding vote at the 2022 ordinary  Annual General Meeting (AGM). ", "page_idx": 178, "bbox": [277, 445.48370361328125, 457, 481.6336975097656], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 1083, "type": "text", "text": "The Chairman’s total remuneration is contained in  the total remuneration of the Board of Directors  in 4.4. ", "page_idx": 178, "bbox": [277, 493.48370361328125, 461, 529.6337280273438], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 1084, "type": "text", "text": "Total remuneration paid to the Chairman of the Board of Directors  (in CHF) ", "text_level": 1, "page_idx": 179, "bbox": [56, 97, 329, 108], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 1085, "type": "image", "page_idx": 179, "img_path": "layout_images/roche-holdings_2021_128.jpg", "bbox": [54, 112, 528, 207], "page_size": [595.2760009765625, 793.7009887695312], "ocr_text": "Base salary (in cash)\n\nTax equalisation for pension fund corrections\n\nBonus (subject to approval of the Annual General Meeting)\n\nPension funds / insurances / annual expense allowances / tax / social\nsecurity (including employer contribution of social securities’ beneficial parts)\n\nTotal”\n\n2021\n3,500,000\n71,534\n949,263*\n676,975\n\n5,197,772\n\n2020\n3,500,000\nnla\n837,585*\n676,710**\n\n5,014,295\n\n2019\n3,500,000\nnla\n558,390*\n1,674,159\n\n5,732,549\n\n", "vlm_text": "The image shows a table displaying financial information for the years 2021, 2020, and 2019. It includes categories such as:\n\n- Base salary (in cash)\n- Tax equalisation for pension fund corrections\n- Bonus (subject to approval of the Annual General Meeting)\n- Pension funds / insurances / annual expense allowances / tax / social security\n\nThe table lists figures for each category and provides total amounts for each year at the bottom."}
{"layout": 1086, "type": "text", "text": "n/a – not applicable\n\n \\*\t In form of shares blocked for 10 years (calculation of number of shares based on the price at the date of transfer in March 2022 and 2021, respectively, after approval at the  AGM 2022 / AGM 2021, respectively), calculation of value in consideration of reduction of value due to blocking period of 10 years (reduced market value:  $55.83\\%$  ) to be submitted  for shareholder approval at the AGM 2022 / as approved at the AGM 2021, respectively\n\n \\*\\*\t \u0007 Agreed reduction of pension fund contributions upon reaching the age of 60 in 2020 19\t \u0007 Additionally, employer contribution to AHV/IV/ALV of CHF 638,576 (2020: CHF 236,732) was paid that does not form part of remuneration. ", "page_idx": 179, "bbox": [56, 213.569580078125, 523.4794921875, 265.51959228515625], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 1087, "type": "text", "text": "4.4 Total remuneration paid to the Board  of Directors  ", "text_level": 1, "page_idx": 179, "bbox": [120, 302, 287, 324], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 1088, "type": "text", "text": "For the 2021 calendar year the members of  the Board of Directors received remuneration  including bonuses and employer contribution  of social securities’ beneficial parts totalling  CHF 8,724,738 (2020: CHF 8,580,399), excluding  additional employer’s contribution paid to  social securities totalling CHF 997,150 (2020:  CHF 354,578). This includes contributions to  foreign authorities amounting to CHF 237,769. ", "page_idx": 179, "bbox": [121, 325.48370361328125, 312, 433.6336975097656], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 1089, "type": "text", "text": "4.5 Remuneration paid to the former members  of the Board of Directors  ", "text_level": 1, "page_idx": 179, "bbox": [119, 446, 310, 468], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 1090, "type": "text", "text": "Former member of the Board of Directors Dr Franz  B. Humer in 2021 received fees amounting to a  total of USD 20,000 (CHF 18,277) for serving as a  member of the Chugai International Council (CIC)  of Chugai Pharmaceutical Co., Ltd. Former member  of the Board of Directors William M. Burns in 2021  received fees amounting to a total of USD 20,000  (CHF 18,277) in his capacity as a member of the  Chugai International Council (CIC) of Chugai  Pharmaceutical Co., Ltd. ", "page_idx": 179, "bbox": [121, 469.48370361328125, 312, 589.6337280273438], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 1091, "type": "text", "text": "In addition, for Sir John Bell, social security  contributions amounting to CHF 204,100 were  paid to a foreign state social security institution. ", "page_idx": 179, "bbox": [331, 301.48370361328125, 511.7713928222656, 337.6336975097656], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 1092, "type": "text", "text": "No additional remuneration was paid. ", "page_idx": 179, "bbox": [331, 349.48370361328125, 470.0242919921875, 361.6336975097656], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 1093, "type": "text", "text": "4.6 Board remuneration subject to approval  at the Annual General Meeting ", "text_level": 1, "page_idx": 179, "bbox": [330, 374, 510, 397], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 1094, "type": "text", "text": "4.6.1 Submission of the Chairman’s total  aggregate bonus for a binding vote at the  Annual General Meeting ", "text_level": 1, "page_idx": 179, "bbox": [330, 410, 501, 445], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 1095, "type": "text", "text": "Remuneration to the Chairman of the Board of  Directors includes a bonus award of CHF 949,263 in  form of shares blocked for ten years as shown in the  table in section ‘4.3 Total remuneration paid to the  Chairman of the Board of Directors’. The Board of  Directors will submit the Remuneration Committee’s  bonus proposal (adopted in late 2021) for the  Chairman of the Board, Dr Christoph Franz, in respect  of the 2021 financial year (payable in March 2022,  excluding legally required employer’s contributions  to AHV/IV/ALV) for the shareholder binding vote to  the 2022 ordinary Annual General Meeting.  ", "page_idx": 179, "bbox": [331, 445.48370361328125, 528, 589.6337280273438], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 1096, "type": "image", "page_idx": 179, "img_path": "layout_images/roche-holdings_2021_129.jpg", "bbox": [535, 302, 548, 359], "page_size": [595.2760009765625, 793.7009887695312], "ocr_text": "aaliany\n", "vlm_text": "The image shows a vertical banner with the word \"AUDITED\" written on it in white text against a gray background."}
{"layout": 1097, "type": "text", "text": "Retrospective approvals of the Chairman’s total aggregate bonus   $(\\mathsf{i}\\cap C\\mathsf{H F})^{*}$  ", "text_level": 1, "page_idx": 180, "bbox": [66, 98, 343, 108], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 1098, "type": "image", "page_idx": 180, "img_path": "layout_images/roche-holdings_2021_130.jpg", "bbox": [81, 113, 540, 183], "page_size": [595.2760009765625, 793.7009887695312], "ocr_text": "Proposal AGM 2022 AGM 2021 AGM 2020\n\nAggregate amount for Aggregate amount for Aggregate amount for\nfinancial year 2021 financial year 2020 financial year 2019\nal aggregate amount proposal for approval /\nroved by the AGM 949,263** 837,585** 558,390**\n", "vlm_text": "The image shows a table with proposals for approval at an AGM over different years. It lists aggregate amounts for the financial years:\n\n- Proposal AGM 2022: 949,263** for financial year 2021\n- AGM 2021: 837,585** for financial year 2020\n- AGM 2020: 558,390** for financial year 2019\n\nThese amounts appear to be financial figures that are proposed or approved annually at the AGM."}
{"layout": 1099, "type": "text", "text": "\\*\t Excluding legally required employer’s contributions to AHV/IV/ALV\n\n \\*\\*\t \u0007 Bonus award (in form of shares blocked for 10 years [calculation of number of shares based on the price at the date of transfer in March 2022 / March 2021 / March 2020,  respectively, after approval at the AGM 2022 / AGM 2021 / AGM 2020, respectively], calculation of value in consideration of reduction of value due to blocking period of 10 years  [reduced market value:  $55.83\\%]$   to be submitted for shareholder approval at the AGM 2022 / as approved at the AGM 2021 and AGM 2020, respectively) ", "page_idx": 180, "bbox": [67, 189.44708251953125, 526.3936767578125, 224.39707946777344], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 1100, "type": "text", "text": "4.6.2 Submission of the Board’s total aggregate  future remuneration for a binding shareholder  vote ", "text_level": 1, "page_idx": 180, "bbox": [67, 254, 263, 288], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 1101, "type": "text", "text": "The Board of Directors proposes that the 2022  ordinary AGM approve Board remuneration totalling  not more than CHF 10,000,000 (excluding legally  required employer’s contributions to AHV/IV/ALV  and excluding bonuses) for the period ending at  the 2023 ordinary AGM. ", "page_idx": 180, "bbox": [67, 289.48370361328125, 263, 361.6336975097656], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 1102, "type": "text", "text": "Dr Severin Schwan’s remuneration as shown  in 5.3 which he receives in his function as CEO  Roche Group and member of the Corporate  Executive Committee is not included here but  is part of the Corporate Executive Committee’s  total remuneration. ", "page_idx": 180, "bbox": [278, 253.48370361328125, 455, 325.6336975097656], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 1103, "type": "image", "page_idx": 180, "img_path": "layout_images/roche-holdings_2021_131.jpg", "img_caption": "Prospective approvals of the Board’s total aggregate future remuneration  (in CHF)\\* ", "bbox": [66, 387, 535, 484], "page_size": [595.2760009765625, 793.7009887695312], "ocr_text": "Proposal AGM 2022\nAggregate amount\nfor the period\nAGM 2022-AGM 2023\nyunt proposal for approval /\nMI 10,000,000\n\nAGM 2021\n\nAggregate amount\nfor the period\nAGM 2021-AGM 2022\n\n10,000,000\n\nAGM 202C\n\nAggregate amount\nfor the period\nAGM 2020-AGM 2021\n\n10,000,000\n", "vlm_text": "The image displays a table containing information on the prospective approvals of the total aggregate future remuneration for a board, presented in Swiss Francs (CHF). The table outlines the proposals and approvals for different Annual General Meetings (AGMs) years. Specifically:\n\n1. Proposal AGM 2022: The aggregate amount proposed for the period from AGM 2022 to AGM 2023 is 10,000,000 CHF.\n2. AGM 2021: The aggregate amount for the period from AGM 2021 to AGM 2022 is 10,000,000 CHF.\n3. AGM 2020: The aggregate amount for the period from AGM 2020 to AGM 2021 is 10,000,000 CHF.\n\nEach column signifies a different AGM year, with consistent proposed or approved remuneration amounts of 10,000,000 CHF for each period mentioned."}
{"layout": 1104, "type": "text", "text": "4.6.3 Reconciliation of the reported  remuneration with the shareholders’  approved remuneration for the members  of the Board of Directors ", "text_level": 1, "page_idx": 180, "bbox": [67, 530, 236, 577], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 1105, "type": "text", "text": "The 2020 ordinary AGM approved Board  remuneration totalling not more than  CHF 10,000,000 (excluding legally required  employer’s contributions to AHV/IV/ALV and  excluding bonuses) for the period ending at the  2021 ordinary AGM.  ", "page_idx": 180, "bbox": [67, 577.4837036132812, 233, 625.6337280273438], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 1106, "type": "text", "text": "", "page_idx": 180, "bbox": [278, 529.4835815429688, 455, 553.6336059570312], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 1107, "type": "text", "text": "For comparison, from the 2020 ordinary AGM  to the 2021 ordinary AGM actual remuneration  amounted to CHF 7,631,377 (excluding legally  required employer’s contributions to AHV/IV/ALV  and excluding bonuses). ", "page_idx": 180, "bbox": [278, 565.4837036132812, 461, 625.6337280273438], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 1108, "type": "table", "page_idx": 181, "img_path": "layout_images/roche-holdings_2021_132.jpg", "table_caption": "Prospectively approved total remuneration for the members of the Board of Directors in comparison to the actual total  payments made  (in  ${\\mathsf{I}}\\;{\\mathsf{C}}{\\mathsf{H}}{\\mathsf{F}})^{*}$  ", "table_footnote": "\\*\t Excluding legally required employer’s contributions to AHV/IV/ALV and excluding bonuses ", "bbox": [55, 98, 522, 211], "page_size": [595.2760009765625, 793.7009887695312], "ocr_text": "juneration approved by the AGM\nation paid\nimit\n\nTotal remuneration\nfor the period\nAGM 2021-AGM 2022\n\n10,000,000\nCalculation at end of period\nCalculation at end of period\n\nTotal remuneration\nfor the period\nAGM 2020-AGM 2021\n\n10,000,000\n7,631,377\nYes\n\nTotal remuneratio:\nfor the perio\nAGM 2019-AGM 202(\n\n10,000,001\n8,597,60'\nYe:\n\n", "vlm_text": "The table appears to display information about the total remuneration over different periods. Here's a breakdown:\n\n- **Periods and Amounts:**\n  - **AGM 2021–AGM 2022:**\n    - Approved remuneration: 10,000,000\n    - Remuneration paid is calculated at the end of the period.\n  - **AGM 2020–AGM 2021:**\n    - Approved remuneration: 10,000,000\n    - Remuneration paid: 7,631,377\n    - Status: Limit reached.\n  - **AGM 2019–AGM 2020:**\n    - Approved remuneration: 10,000,000\n    - Remuneration paid: 8,597,609\n    - Status: Limit reached.\n\nEach column reflects the remuneration details for a specific AGM to AGM period, including the approved amount, the amount paid, and whether the remuneration was within the limit."}
{"layout": 1109, "type": "text", "text": "4.7 Security holdings  ", "text_level": 1, "page_idx": 181, "bbox": [120, 242, 207, 253], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 1110, "type": "text", "text": "Directors André Hoffmann and Dr Jörg Duschmalé  and members of the founder’s families who  are closely associated with them belong to a  contractually bound shareholder group with  pooled voting rights. At the end of 2021 this  group held 72,018,000 shares   $45.01\\%$   of issued  shares). Detailed information about this group  can be found in the Finance Report, Note 32  to the Roche Group Consolidated Financial  ", "page_idx": 181, "bbox": [121, 253.48370361328125, 308, 361.6336975097656], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 1111, "type": "text", "text": "Statements (‘Related parties’, page 135)  and in Note 4 to the Financial Statements of  Roche Holding Ltd (‘Significant shareholders’,  page 181). In addition, as at 31 December 2021  (as at 31 December 2020, respectively) the  members of the Board of Directors and persons  closely associated with them held Roche shares,  non-voting equity securities (NES) and American  Depositary Receipts   $(\\mathsf{A D R S}^{***})$   as shown in the  table ‘Security holdings’ below.  ", "page_idx": 181, "bbox": [331, 241.48370361328125, 511, 361.6336975097656], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 1112, "type": "table", "page_idx": 181, "img_path": "layout_images/roche-holdings_2021_133.jpg", "table_caption": "Security holdings  (shares and NES) ", "table_footnote": "\\*\t Shares held by the shareholder group with pooled voting rights not listed \\*\\*\t Jointly held with close relative \\*\\*\\* \t\u0007 Roche’s ADR (American Depositary Receipt) listed on OTCQX ( https://www.otcmarkets.com/stock/RHHBY/quote ) International Premier under the symbol RHHBY, ISIN US771195104.  Traded in USD, eight (8) ADRs represent one (1) underlying NES. ", "bbox": [53, 387, 529, 694], "page_size": [595.2760009765625, 793.7009887695312], "ocr_text": "Board of Directors\nC. Franz\n\nA. Hoffmann\nJ. Brown\n\nP. Bulcke\n\nH. Clevers\n\nJ. Duschmalé\nP. Frost\n\nA. Hauser\nR.P. Lifton\n\nB. Poussot\n\nS. Schwan\n\nC. Suessmuth Dyckerhoff\nTotal\n\nNon-voting\n\nequity\n\nsecurities\n\nShares (NES)\n(number) (number)\n27,951 4,810\nai 200\n1,000 =\n= 4,000\n\n= 750\n\n_* z\n2,000 =\n3,000 150\n500 500\n\n(as at 31 December 2021)\n\nClose relatives’\nsecurity\nholdings\n\n(number/type)\n\nOthers\n(number/\ntype)\n\n300 ADRs***\n\n(see ‘5.15 Security holdings’\n\nCorporate Executive Committee on page 187)\n\n- 2,100\n34,451 12,510\n\n20 NES\n\n300 ADRs***\n\n(as at 31 December 2020)\n\nClose\nrelatives’\nsecurity\nholdings\n(number/type)\n\nOthers\n(number/\ntype)\n\n300 ADRs***\n\n(see ‘5.15 Security holdings’\n\nCorporate Executive Committee on page 187)\n\nNon-voting\nequity\nsecurities\nShares (NES)\n(number) (number)\n23,210 4,810\n= 200\n729 3\n= 4,000\n= 750\n_* =\n1,000 3\n3,000 150\n500 500\n\n= 2,100**\n28,439 12,510\n\n20NES 300 ADRs***\n", "vlm_text": "The table shows the security holdings of the Board of Directors and a member of the Corporate Executive Committee as of December 31, 2021, and December 31, 2020. It includes:\n\n1. **Shares (number)**: Lists how many shares each director holds.\n2. **Non-voting equity securities (NES) (number)**: Lists non-voting equities held.\n3. **Close relatives’ security holdings (number/type)**: Security holdings of close relatives, if any.\n4. **Others (number/type)**: Additional holdings or types, unspecified here.\n\n### As of December 2021:\n- C. Franz holds 27,951 shares and 4,810 NES.\n- Totals: 34,451 shares, 12,510 NES, 20 NES for close relatives, and 300 ADRs.\n\n### As of December 2020:\n- C. Franz holds 23,210 shares and 4,810 NES.\n- Totals: 28,439 shares, 12,510 NES, 20 NES for close relatives, and 300 ADRs.\n\nThe table compares these holdings across two years, serving to disclose the interests held by corporate insiders."}
{"layout": 1113, "type": "text", "text": "5. Remuneration of the Corporate  Executive Committee ", "text_level": 1, "page_idx": 182, "bbox": [66, 97, 436, 152], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 1114, "type": "text", "text": "5.1 Resolution and approval ", "text_level": 1, "page_idx": 182, "bbox": [67, 182, 182, 193], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 1115, "type": "text", "text": "Remuneration of the members of the Corporate  Executive Committee was decided at the  Remuneration Committee’s discretion, taking into  account market comparisons. ", "page_idx": 182, "bbox": [67, 193.48370361328125, 253, 241.63369750976562], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 1116, "type": "text", "text": "As in the previous years, in 2022, the Board of  Directors will separately submit the total aggregate  bonuses of the Corporate Executive Committee to  the General Meeting for the 2021 financial year for  retrospective binding approval. ", "page_idx": 182, "bbox": [67, 253.48370361328125, 261, 313.6336975097656], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 1117, "type": "text", "text": "The maximum amounts of the total other  aggregate remuneration of the Corporate  Executive Committee for the period between the  ordinary General Meeting 2022 and the ordinary  General Meeting 2023 will be tabled in 2022 as  in the previous years for the General Meeting’s  prospective binding approval (see 2.2). ", "page_idx": 182, "bbox": [67, 325.48370361328125, 253, 409.6336975097656], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 1118, "type": "text", "text": "5.2 Amount of remuneration to members  of the Corporate Executive Committee ", "text_level": 1, "page_idx": 182, "bbox": [277, 182, 446, 205], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 1119, "type": "text", "text": "The general provisions assigning authority for  decisions on Corporate Executive Committee  remuneration to the Remuneration Committee and  to the Board of Directors are outlined on page 165,  ‘2. Remuneration decision process and approval  framework’.  ", "page_idx": 182, "bbox": [277, 205.48370361328125, 468, 277.6336975097656], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 1120, "type": "text", "text": "In 2021, members of the Corporate Executive  Committee received remuneration for their work  as shown in 5.3–5.11. The amount of remuneration  for the CEO Roche Group, Dr Severin Schwan, is  explained in 5.3 in detail.  ", "page_idx": 182, "bbox": [277, 289.48370361328125, 468, 349.6336975097656], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 1121, "type": "text", "text": "5.3 Highest total remuneration paid  to Dr Severin Schwan as a member of  the Corporate Executive Committee ", "text_level": 1, "page_idx": 183, "bbox": [119, 98, 273, 132], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 1122, "type": "text", "text": "Dr Severin Schwan, executive member of the Board  of Directors, received his remuneration in his primary  function as CEO Roche Group. It is reflected as the  ", "page_idx": 183, "bbox": [120, 133.48370361328125, 317, 169.63369750976562], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 1123, "type": "text", "text": "highest total remuneration paid to a member of the  Corporate Executive Committee (see below) and  included in the total amount paid to the Corporate  Executive Committee (see ‘5.11 Total remuneration  paid to the members of the Corporate Executive  Committee’, page 184). ", "page_idx": 183, "bbox": [331, 97.48370361328125, 523, 169.63369750976562], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 1124, "type": "table", "page_idx": 183, "img_path": "layout_images/roche-holdings_2021_134.jpg", "table_caption": "Highest total remuneration paid to Dr Severin Schwan as a member of the Corporate Executive Committee  (in CHF) ", "bbox": [56, 194, 519, 353], "page_size": [595.2760009765625, 793.7009887695312], "ocr_text": "ing)\n\n2021\n4,000,000\n\n27191,9507*\n\n3,379,526\n595,664*\n100,008\n583,789**\n\n43,969\n11,494,906\n\n202070\n3,500,000?\"\n\n2,791,950*\n\n3,379,613\n595,678*\n100,008\n581,106**\n\n85,324\n11,033,679\n\n2019'\n4,000,000\n\n2,791,950\"\n3,379,524\n595,673\n100,008\n580,843\n\n68,856\n11,516,854\n", "vlm_text": "The table appears to show data for the years 2021, 2020, and 2019. Here’s a summary of the numbers for each year:\n\n### 2021\n- Main Value: 4,000,000\n- Other Values: 2,791,950; 3,379,526; 595,664; 100,008; 583,789; 43,969\n- Total: 11,494,906\n\n### 2020\n- Main Value: 3,500,000\n- Other Values: 2,791,950; 3,379,613; 595,678; 100,008; 581,106; 85,324\n- Total: 11,033,679\n\n### 2019\n- Main Value: 4,000,000\n- Other Values: 2,791,950; 3,379,524; 595,673; 100,008; 580,843; 68,856\n- Total: 11,516,854\n\nThe values seem to represent numerical data categories for each year, with a total sum calculated at the bottom of each column."}
{"layout": 1125, "type": "text", "text": "20\t For detailed calculation of the remuneration for 2020 and 2019 see Annual Report 2020, page 156.\n 21\t In light of the overall economic impact of the COVID-19 pandemic, Dr Severin Schwan waived the amount of CHF 500,000 from his contractual base salary in 2020. 22\t Shares blocked for 10 years (calculation of number of shares based on the share price at the date of transfer in March 2022 after approval at the AGM 2022)\n 23\t \u0007 S-SARs 2021:  Number: 100,746, grant value according to the trinomial model for American call options: CHF 42.35. Trinomial model for American call options value as described in  ‘5.6 Stock-settled Stock Appreciation Rights (S-SARs) of the other members of the Corporate Executive Committee’, page 182. S-SARs 2021 are blocked for 4 years and may  thereafter be exercised only, whilst exercising resulting NES are automatically blocked for additional 4 years (calculation of value of non-voting equity securities in consideration  of reduction of value due to additional blocking period of 4 years, reduced market value:  $79.209\\%$  ).\n S-SARs 2020:  Number: 103,260, grant value according to the trinomial model for American call options: CHF 41.32. Trinomial model for American call options value as described in  ‘5.6 Stock-settled Stock Appreciation Rights (S-SARs) of the other members of the Corporate Executive Committee’, page 182. S-SARs 2020 are blocked for 4 years and may  thereafter be exercised only, whilst exercising resulting NES are automatically blocked for additional 4 years (calculation of value of non-voting equity securities in consideration  of reduction of value due to additional blocking period of 4 years, reduced market value:  $79.209\\%$  ). 24\t \u0007 Calculation of RSUs value 2021: number of RSUs (3,481) multiplied by grant value of CHF 306.45 (NES closing price at grant date on 18 March 2021) per RSU; \n calculation of RSUs value 2020: number of RSUs (3,463) multiplied by grant value of CHF 308.05 (NES closing price at grant date on 19 March 2020) per RSU 25\t \u0007 Includes an annual expense allowance (CHF 30,000), payments for tax consulting services (CHF 3,554; 2020: CHF 42,626), family, children and education allowance (CHF 10,415;  2020: CHF 12,698). Additionally, employer contribution to AHV/IV/ALV of CHF 886,295 (2020: CHF 625,415) was paid that does not form part of remuneration.\n\n \\*\t Calculation of value of non-voting equity securities / shares in consideration of reduction of value due to blocking period of 10 years (reduced market value:  $55.83\\%,$   \n\n \\*\\* \t \u0007 Including employer contribution of social securities’ beneficial parts ", "page_idx": 183, "bbox": [56, 358.6087951660156, 522, 504.0588073730469], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 1126, "type": "table", "page_idx": 184, "img_path": "layout_images/roche-holdings_2021_135.jpg", "table_caption": "5.4 Base pay of the other members of the Corporate Executive Committee ", "bbox": [65, 98, 557, 220], "page_size": [595.2760009765625, 793.7009887695312], "ocr_text": "B. Anderson\nA. Hippe\n\nT. Schinecker\nC.A. Wilbur\nTotal\n\n2021\n\n2,245,918\n1,600,000\n1,053,165\n1,015,203\n5,914,286\n\n2020\n\n2,141,652\n1,600,000\n\n879,425\n1,007,256\n5,628,333\n\nAUDITED\n", "vlm_text": "The table contains financial figures for four individuals (B. Anderson, A. Hippe, T. Schinecker, and C.A. Wilbur) across two years, 2021 and 2020. The data appears to represent monetary amounts, possibly salaries or earnings, for each person in each year. Here are the details:\n\n- **B. Anderson**: \n  - 2021: 2,245,918\n  - 2020: 2,141,652\n\n- **A. Hippe**:\n  - 2021: 1,600,000\n  - 2020: 1,600,000\n\n- **T. Schinecker**:\n  - 2021: 1,053,165\n  - 2020: 879,425\n\n- **C.A. Wilbur**:\n  - 2021: 1,015,203\n  - 2020: 1,007,256\n\n- **Total**:\n  - 2021: 5,914,286\n  - 2020: 5,628,333\n\nThe table clearly separates the years, showing a total for each year and has an \"AUDITED\" label along the side."}
{"layout": 1127, "type": "text", "text": "5.5 Bonuses of the other members  of the Corporate Executive Committee  ", "text_level": 1, "page_idx": 184, "bbox": [67, 254, 228, 276.75], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 1128, "type": "text", "text": "The Remuneration Committee of the Board of  Directors determined the Corporate Executive  Committee members’ bonuses based on the  2021 performance against the agreed objectives.  The Remuneration Committee uses its discretion  appropriately in the weighting of each criteria and  in the bonus allocation. The total aggregate amount  of bonuses will be brought forward for a binding  vote by the Annual General Meeting 2022. ", "page_idx": 184, "bbox": [67, 277.48370361328125, 259, 361.6336975097656], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 1129, "type": "text", "text": "", "page_idx": 184, "bbox": [278, 253.48370361328125, 458, 277.6336975097656], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 1130, "type": "text", "text": "Except for Dr Severin Schwan, all members of the  Corporate Executive Committee will receive the  bonus 2021 as a  $100\\%$   cash payment. Dr Severin  Schwan will receive the bonus in form of Roche  shares which are blocked for ten years (see  page 180). Bonus payment is due in March 2022. ", "page_idx": 184, "bbox": [278, 289.48370361328125, 463, 361.6336975097656], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 1131, "type": "table", "page_idx": 184, "img_path": "layout_images/roche-holdings_2021_136.jpg", "table_caption": "Bonus  (in CHF) ", "bbox": [65, 386, 560, 520], "page_size": [595.2760009765625, 793.7009887695312], "ocr_text": "B. Anderson\nA. Hippe\n\nT. Schinecker\nC.A. Wilbur\nTotal\n\n2021\n\n(Subject to approval of the\n\ntotal aggregate bonuses of the\nCorporate Executive Committee by the\nAnnual General Meeting 2022)\n2,600,000\n\n2,300,000\n\n1,500,000\n\n1,300,000\n\n7,700,000\n\n2020\n\n2,400,000\n2,000,000\n1,300,000\n1,200,000\n6,900,000\n\nAUDITED\n", "vlm_text": "The table lists the bonuses for members of the Corporate Executive Committee for the years 2020 and 2021, subject to approval at the Annual General Meeting in 2022. The individuals and their bonuses for each year are as follows:\n\n- **B. Anderson**: \n  - 2021: 2,600,000\n  - 2020: 2,400,000\n\n- **A. Hippe**: \n  - 2021: 2,300,000\n  - 2020: 2,000,000\n\n- **T. Schinecker**: \n  - 2021: 1,500,000\n  - 2020: 1,300,000\n\n- **C.A. Wilbur**: \n  - 2021: 1,300,000\n  - 2020: 1,200,000\n\nThe total bonuses are:\n- 2021: 7,700,000\n- 2020: 6,900,000\n\nThe data for 2020 is marked as audited."}
{"layout": 1132, "type": "text", "text": "5.6 Stock-settled Stock Appreciation  Rights (S-SARs) of the other members  of the Corporate Executive Committee ", "text_level": 1, "page_idx": 185, "bbox": [120, 98, 281, 132], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 1133, "type": "text", "text": "S-SARs to the Corporate Executive Committee  are allocated individually at the Remuneration  Committee’s discretion. The S-SARs shown in the   $5.15.2\\:^{\\circ}\\mathrm{S}$  -SARs’ table on page 188 entitle holders to  benefit financially from any increase in the value of  Roche’s non-voting equity securities (NES) between  the grant date and the exercise date. The strike  price for S-SARs under the terms of this multi-year  plan is the closing price for Roche NES at grant  date. All S-SARs since 2019 vest four (previously  granted S-SARs three) years after the grant date.  Vested S-SARs can be exercised (converted into  NES) within ten (previously granted S-SARs within  seven) years of the grant date. Unexercised S-SARs  lapse without compensation.  ", "page_idx": 185, "bbox": [120, 133.48370361328125, 314, 313.6336975097656], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 1134, "type": "text", "text": "Since 2019, the S-SARs proportion of the LTI  of the Corporate Executive Committee is   $80\\%$  ", "page_idx": 185, "bbox": [120, 325.48370361328125, 306, 349.6336975097656], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 1135, "type": "text", "text": "(based on the already existing individual target  value of the total LTI for Corporate Executive  Committee members of   $135.53\\%$   of a base pay  measured on 1 January of a year). ", "page_idx": 185, "bbox": [330, 97.48370361328125, 509, 145.63369750976562], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 1136, "type": "text", "text": "The fair value of the S-SARs is calculated at the  grant date using the trinomial model for American  call options. The trinomial model is an effective  method for valuation of American call options, as  it considers the possibility of exercising the option  any time prior to maturity (called ‘American’ option,  as compared to a ‘European’ option, which only  allows exercise at its maturity date). ", "page_idx": 185, "bbox": [330, 157.48370361328125, 523, 253.63369750976562], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 1137, "type": "text", "text": "The numbers of S-SARs, the strike prices, expiry  dates and grant values for S-SARs are shown  below and in the 5.15.2 ‘S-SARs’ table on page 188.  The numbers of S-SARs as calculated at the time  of issue have been entered as values in the table  below and on page 180. ", "page_idx": 185, "bbox": [330, 265.48370361328125, 523, 337.6336975097656], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 1138, "type": "image", "page_idx": 185, "img_path": "layout_images/roche-holdings_2021_137.jpg", "bbox": [33, 389, 530, 514], "page_size": [595.2760009765625, 793.7009887695312], "ocr_text": "2021 2020\n\nGrant value per Grant value per\nNumber S-SAR in CHF Value in CHF Number S-SAR in CHF Value in CHF\nB. Anderson 50,374 42.35 2,133,339 46,467 41.32 1,920,016\nA. Hippe 40,300 42.35 1,706,705 41,304 41.32 1,706,681\nT. Schinecker 22,669 42.35 960,032 20,652 41.32 853,341\nC.A. Wilbur 25,187 42.35 1066,669 25,815 41.32 1,066,676\nTotal 138,530 42.35 5,866,745 134,238 41.32 5,546,714\n\nPrice: CHF 306.45, expiry date: 18.3.2031 Price: CHF 308.05, expiry date: 19.3.2030\n", "vlm_text": "The image is a table summarizing grant values for different individuals over two years, 2020 and 2021. It includes the following data:\n\n### For 2021:\n- **B. Anderson**: \n  - Number: 50,374\n  - Grant value per S-SAR in CHF: 42.35\n  - Value in CHF: 2,133,339\n- **A. Hippe**: \n  - Number: 40,300\n  - Grant value per S-SAR in CHF: 42.35\n  - Value in CHF: 1,706,705\n- **T. Schinecker**: \n  - Number: 22,669\n  - Grant value per S-SAR in CHF: 42.35\n  - Value in CHF: 960,032\n- **C.A. Wilbur**: \n  - Number: 25,187\n  - Grant value per S-SAR in CHF: 42.35\n  - Value in CHF: 1,066,669\n- **Total**:\n  - Number: 138,530\n  - Grant value per S-SAR in CHF: 42.35\n  - Value in CHF: 5,866,745\n\nPrice: CHF 306.45, expiry date: 18.3.2031\n\n### For 2020:\n- **B. Anderson**: \n  - Number: 46,467\n  - Grant value per S-SAR in CHF: 41.32\n  - Value in CHF: 1,920,016\n- **A. Hippe**: \n  - Number: 41,304\n  - Grant value per S-SAR in CHF: 41.32\n  - Value in CHF: 1,706,681\n- **T. Schinecker**: \n  - Number: 20,652\n  - Grant value per S-SAR in CHF: 41.32\n  - Value in CHF: 853,341\n- **C.A. Wilbur**: \n  - Number: 25,815\n  - Grant value per S-SAR in CHF: 41.32\n  - Value in CHF: 1,066,676\n- **Total**:\n  - Number: 134,238\n  - Grant value per S-SAR in CHF: 41.32\n  - Value in CHF: 5,546,714\n\nPrice: CHF 308.05, expiry date: 19.3.2030\n\nThe table is labeled \"AUDITED.\""}
{"layout": 1139, "type": "text", "text": "5.7 Restricted Stock Units (RSUs)  of the other members of the Corporate Executive Committee ", "text_level": 1, "page_idx": 185, "bbox": [120, 542, 281, 576], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 1140, "type": "text", "text": "Since 2019, the proportion of Restricted Stock Units  (RSUs) of the members of the Corporate Executive  Committee is  $20\\%$   of the total LTI (based on the  already existing individual target value of the total  LTI for Corporate Executive Committee members  of   $135.53\\%$   of a base pay measured on 1 January  of a year). RSU awards are allocated individually  for the Corporate Executive Committee at the  Remuneration Committee’s discretion. ", "page_idx": 185, "bbox": [121, 577.4837036132812, 316, 685.6337280273438], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 1141, "type": "text", "text": "RSUs contain rights to receive non-voting equity  securities and/or shares after a since 2019 newly  defined four-year vesting period plus a value  adjustment (being the amount equivalent to the  sum of the dividend paid during the vesting period  attributable to the number of non-voting equity  securities and/or shares for which an individual  award has been granted). They will be vested to the  recipient for the Corporate Executive Committee  after four years only. Thereafter, resulting non- voting equity securities and/or shares may remain  blocked for up to ten years. ", "page_idx": 185, "bbox": [331, 541.4837036132812, 524, 685.6337280273438], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 1142, "type": "table", "page_idx": 186, "img_path": "layout_images/roche-holdings_2021_138.jpg", "table_caption": "Restricted Stock Units (RSUs) ", "table_footnote": "\\*\t Calculation of value in consideration of reduction of value due to an additional blocking period of   $10$   years, reduced market value:   $55.83\\%$  \\*\\*\t \u0007 Calculation of value in consideration of reduction of value due to an additional blocking period of 4 years, reduced market value:  $79.209\\%$  ", "bbox": [66, 98, 546, 243], "page_size": [595.2760009765625, 793.7009887695312], "ocr_text": "B. Anderson\nA. Hippe\n\nT. Schinecker\nC.A. Wilbur\nTotal\n\nNumber\n\n1,740\n22\n783\n870\n4,785\n\nValue at grant\nin CHF\n306.45\n306.45\n306.45\n306.45\n306.45\n\n2021\n\nValue in CHF\n\n633,223\n238,197*\n239,950**\n266,612\n1,277,982\n\nNumber\n\n1,558\n1,385\n693\n866\n4,502\n\nValue at grant\nin CHF\n308.05\n308.05\n308.05\n308.05\n308.05\n\n2020\n\nValue in CHF\n\n479,942\n238,237*\n169,094**\n266,771\n1,154,044\n\n", "vlm_text": "The table is likely presenting information about grants or awards given to several individuals in 2020 and 2021, with the values expressed in CHF (Swiss Francs). It includes five columns titled \"Number,\" \"Value at grant in CHF,\" and \"Value in CHF\" for the years 2020 and 2021. \n\nHere’s a breakdown of the data:\n\nFor 2021:\n- B. Anderson received 1,740 units/grants valued at 306.45 CHF each, totaling 533,223 CHF.\n- A. Hippe received 1,392 units/grants valued at 306.45 CHF each, totaling 238,197 CHF (noted with an asterisk *).\n- T. Schinecker received 783 units/grants valued at 306.45 CHF each, totaling 239,950 CHF (noted with a double asterisk **).\n- C.A. Wilbur received 870 units/grants valued at 306.45 CHF each, totaling 266,612 CHF.\n- The total for all individuals in 2021 is 4,785 units/grants, with a total value of 1,277,982 CHF.\n\nFor 2020:\n- B. Anderson received 1,558 units/grants valued at 308.05 CHF each, totaling 479,942 CHF.\n- A. Hippe received 1,385 units/grants valued at 308.05 CHF each, totaling 238,237 CHF (noted with an asterisk *).\n- T. Schinecker received 693 units/grants valued at 308.05 CHF each, totaling 169,094 CHF (noted with a double asterisk **).\n- C.A. Wilbur received 866 units/grants valued at 308.05 CHF each, totaling 266,771 CHF.\n- The total for all individuals in 2020 is 4,502 units/grants, with a total value of 1,154,044 CHF.\n\nThe asterisks next to certain values suggest that these figures might have additional notes or exceptions that are not provided in the table."}
{"layout": 1143, "type": "text", "text": "5.8 Indirect benefits of the other members  of the Corporate Executive Committee ", "text_level": 1, "page_idx": 186, "bbox": [67, 278, 243, 301], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 1144, "type": "text", "text": "Employer contributions made in 2021 to social  security schemes, pension plans and a Group-wide  employee stock purchase plan (Roche Connect)  in respect of members of the Corporate Executive  Committee are shown in the ‘Indirect benefits  (employer contributions)’ table below and in the  table on page 180. ", "page_idx": 186, "bbox": [68, 301.48370361328125, 258, 385.6336975097656], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 1145, "type": "text", "text": "Roche Connect is a voluntary stock purchase  plan offering employees the opportunity to buy  ", "page_idx": 186, "bbox": [68, 397.48370361328125, 248, 421.6336975097656], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 1146, "type": "text", "text": "Roche non-voting equity securities (NES) up to  an amount equal to   $10\\%$   of their annual salary at  a   $20\\%$   discount. NES purchased under this plan  are subject to a holding period, which is four years  in Switzerland. ", "page_idx": 186, "bbox": [278, 277.48370361328125, 466.9447326660156, 337.6336975097656], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 1147, "type": "text", "text": "In addition, members of the Corporate Executive  Committee received annual expense allowances  and some members payments for foreign tax  obligations and tax consulting services as shown  in the table below. ", "page_idx": 186, "bbox": [278, 349.48370361328125, 461, 409.6336975097656], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 1148, "type": "table", "page_idx": 186, "img_path": "layout_images/roche-holdings_2021_139.jpg", "table_caption": "Indirect benefits  (employer contributions) (in CHF) ", "table_footnote": "\\*\t Including employer contribution of social securities’ beneficial parts ", "bbox": [66, 446, 550, 596], "page_size": [595.2760009765625, 793.7009887695312], "ocr_text": "B. Anderson\nA. Hippe\n\nT. Schinecker\nC.A. Wilbur\nTotal\n\nPension funds /\ninsurances*\n\n425,852\n333 789\n333 789\n333 789\n\n1,427,219\n\nAnnual\nexpense\nallowances\n\n30,000\n30,000\n30,000\n30,000\n120,000\n\nRoche\nConnect\n\n39,996\n17,291\n18,744\n76,031\n\n2021\nPayments\nfor tax / tax\nconsulting\nservices\n1,190,848\n7,241\n20,128\n388,067\n\n1,606,284\n\nPension funds /\ninsurances*\n\n331,106\n331,106\n327,928\n331,106\n1,321,246\n\nAnnual\nexpense\n\nallowances\n\n30,000\n30,000\n30,000\n30,000\n120,000\n\nRoche\nConnect\n\n39,996\n\n3,000\n18,744\n61,740\n\n2020\nPayments\nfor tax / tax\nconsulting\nservices\n758,279\n16,535\n25,102\n60,073\n859,989\n\n", "vlm_text": "The table presents financial data for several individuals, detailing pension funds/insurances, annual expense allowances, Roche Connect payments, and payments for tax or tax consulting services for the years 2021 and 2020.\n\n### 2021 Data:\n- **Pension funds / insurances**: Total is 1,427,219.\n- **Annual expense allowances**: Each individual receives 30,000, totaling 120,000.\n- **Roche Connect**: Total payments are 76,031.\n- **Payments for tax / tax consulting services**: Total is 1,606,284.\n\n### 2020 Data:\n- **Pension funds / insurances**: Total is 1,321,246.\n- **Annual expense allowances**: Each individual receives 30,000, totaling 120,000.\n- **Roche Connect**: Total payments are 61,740.\n- **Payments for tax / tax consulting services**: Total is 859,989.\n\nIndividuals listed are B. Anderson, A. Hippe, T. Schinecker, and C.A. Wilbur. Each row includes detailed amounts for each individual."}
{"layout": 1149, "type": "image", "page_idx": 187, "img_path": "layout_images/roche-holdings_2021_140.jpg", "bbox": [99, 99, 114, 288], "page_size": [595.2760009765625, 793.7009887695312], "ocr_text": "daliany\n", "vlm_text": "The image shows a vertical strip with the word \"AUDITED\" written in white on a gray background."}
{"layout": 1150, "type": "image", "page_idx": 187, "img_path": "layout_images/roche-holdings_2021_141.jpg", "bbox": [99, 364, 113, 467], "page_size": [595.2760009765625, 793.7009887695312], "ocr_text": "aaliany\n", "vlm_text": "The image shows a vertical gray strip with the word \"AUDITED\" written in white, oriented vertically."}
{"layout": 1151, "type": "text", "text": "5.9 Other remuneration and loans of members  of the Corporate Executive Committee  (excl. CEO Roche Group) ", "text_level": 1, "page_idx": 187, "bbox": [120, 98, 310, 132], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 1152, "type": "text", "text": "To meet legal and contractual obligations, in 2021  Roche paid a total of CHF 12,451 to individual  members of the Corporate Executive Committee  for family, child and education allowances and  their children’s schooling costs. ", "page_idx": 187, "bbox": [120, 133.48370361328125, 316, 193.63369750976562], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 1153, "type": "text", "text": "All aforementioned additional payments are  included in the total remuneration to members  of the Corporate Executive Committee. ", "page_idx": 187, "bbox": [120, 205.48370361328125, 297, 241.63369750976562], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 1154, "type": "text", "text": "In 2021, there were no loans or credits granted  to the members of the Corporate Executive  Committee. ", "page_idx": 187, "bbox": [120, 253.48370361328125, 297, 289.6336975097656], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 1155, "type": "text", "text": "The maximum regular period of notice for members  of the Corporate Executive Committee is 12 months.  There are no change-of-control clauses in the  employment contracts. ", "page_idx": 187, "bbox": [120, 301.48370361328125, 316, 349.6336975097656], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 1156, "type": "text", "text": "5.10 Remuneration to former members  of the Corporate Executive Committee  A total of CHF 350,000 was paid to Dr Gottlieb Keller. ", "page_idx": 187, "bbox": [120, 361.48370361328125, 316, 397.6336975097656], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 1157, "type": "text", "text": "5.11 Total remuneration paid to the members  of the Corporate Executive Committee For the 2021 calendar year, the members of  the Corporate Executive Committee received  remuneration (including bonuses, employer  ", "page_idx": 187, "bbox": [120, 409.48370361328125, 305, 469.6336975097656], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 1158, "type": "text", "text": "contribution of social securities’ beneficial parts)  totalling CHF 35,495,906 (2020: CHF 33,488,192),  excluding additional employer’s contribution  paid to AHV/IV/ALV totalling CHF 2,637,751  (2020: CHF 2,090,167) that does not form part  of remuneration. ", "page_idx": 187, "bbox": [331, 97.48370361328125, 520, 169.63357543945312], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 1159, "type": "text", "text": "No additional remuneration other than the  above-mentioned payments was paid to current  or former members of the Corporate Executive  Committee. ", "page_idx": 187, "bbox": [331, 181.48358154296875, 520, 229.63357543945312], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 1160, "type": "text", "text": "5.12 The Corporate Executive Committee’s  remuneration subject to approval at the  Annual General Meeting ", "text_level": 1, "page_idx": 187, "bbox": [330, 242, 507, 277], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 1161, "type": "text", "text": "5.12.1 Submission of the Corporate Executive  Committee’s total aggregate bonuses for a  binding vote at the Annual General Meeting The Board of Directors proposes awarding the  members of the Corporate Executive Committee  bonuses (for Dr Severin Schwan in form of Roche  shares which are blocked for ten years, for all  other members of the Corporate Executive  Committee as a   $100\\%$   cash payment, see 5.5)  totalling CHF 10,491,950 in respect of the 2021  financial year (2020: CHF 10,041,950), excluding  legally required employer’s contributions to  social security agencies, and will submit this  proposed total amount to the ordinary Annual  General Meeting (AGM) for a binding vote.  ", "page_idx": 187, "bbox": [331, 289.48358154296875, 520, 469.6335754394531], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 1162, "type": "table", "page_idx": 187, "table_caption": "Retrospective approvals of the members of the Corporate Executive Committee’s total aggregate bonuses  (in CHF) \\* ", "table_footnote": "\\*\t Excluding legally required employer’s contributions to AHV/IV/ALV ", "bbox": [55, 494, 524, 596], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 1163, "type": "text", "text": "5.12.2 Submission of the Corporate Executive  Committee’s total future aggregate  remuneration for a binding shareholder vote The Board of Directors proposes that the 2022  ordinary AGM approve remuneration for the  Corporate Executive Committee totalling not  more than CHF 38,000,000 (excluding legally  required employer’s contributions to AHV/IV/ALV  and excluding bonuses) for the period ending at  the 2023 ordinary AGM. ", "page_idx": 188, "bbox": [68, 97.48370361328125, 253, 217.63369750976562], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 1164, "type": "text", "text": "The amount of the Corporate Executive  Committee’s total future aggregate remuneration  is composed of base pay, long-term incentives  S-SARs (calculated at grant value without  considering reductions of value due to  blocking periods if applicable) and RSUs  (see 3.1.4, calculated at the time of reservation  of non-voting equity securities or shares, without  considering reductions of value due to blocking  periods), pension benefits (excluding legally  required employer’s contributions to AHV/IV/ALV)  as well as contributions for expenses, payments  for foreign tax obligations, tax consulting  services and Roche Connect. ", "page_idx": 188, "bbox": [68, 229.48370361328125, 257, 253.63369750976562], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 1165, "type": "text", "text": "", "page_idx": 188, "bbox": [278, 97.48370361328125, 466, 241.63369750976562], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 1166, "type": "table", "page_idx": 188, "img_path": "layout_images/roche-holdings_2021_142.jpg", "table_caption": "Prospective approvals of the members of the Corporate Executive Committee’s total future aggregate remuneration  (in CHF) \\* ", "table_footnote": "Excluding legally required employer’s contributions to AHV/IV/ALV and excluding bonuses ", "bbox": [65, 278, 541, 404], "page_size": [595.2760009765625, 793.7009887695312], "ocr_text": "Total aggregate amount proposal for approval /\napproved by the AGM\n\nProposal AGM 2022\n\nAggregate amount\nfor the period\nAGM 2022-AGM 2023\n\n38,000,000\n\nAGM 2021\n\nAggregate amount\nfor the period\nAGM 2021-AGM 2022\n\n36,000,000\n\nAGM 2020\n\nAggregate amount\nfor the period\nAGM 2020-AGM 2021\n\n37,000,000\n", "vlm_text": "The table displays proposed aggregate amounts approved by the AGM for different periods:\n\n- **AGM 2022 Proposal**: Aggregate amount for the period AGM 2022–AGM 2023 is 38,000,000.\n- **AGM 2021**: Aggregate amount for the period AGM 2021–AGM 2022 is 36,000,000.\n- **AGM 2020**: Aggregate amount for the period AGM 2020–AGM 2021 is 37,000,000."}
{"layout": 1167, "type": "text", "text": "5.12.3 Reconciliation of the reported  remuneration with the shareholders’  prospectively approved remuneration  for the members of the Corporate Executive  Committee ", "text_level": 1, "page_idx": 188, "bbox": [66, 434, 250, 492], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 1168, "type": "text", "text": "The 2020 ordinary AGM approved remuneration  for the Corporate Executive Committee totalling  not more than CHF 37,000,000 (excluding legally  required employer’s contributions to AHV/IV/ALV  and excluding bonuses) for the period ending at  the 2021 ordinary AGM. ", "page_idx": 188, "bbox": [68, 493.48370361328125, 252, 541.6337280273438], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 1169, "type": "text", "text": "", "page_idx": 188, "bbox": [278, 433.48370361328125, 458, 457.6336975097656], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 1170, "type": "text", "text": "For comparison, from the 2020 ordinary AGM to  the 2021 ordinary AGM remuneration amounted  to CHF 24,635,559 (excluding legally required  employer’s contributions to AHV/IV/ALV and  excluding bonuses). ", "page_idx": 188, "bbox": [278, 469.48370361328125, 458, 529.6337280273438], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 1171, "type": "table", "page_idx": 189, "img_path": "layout_images/roche-holdings_2021_143.jpg", "table_caption": "Prospectively approved total remuneration of the members of the Corporate Executive Committee in comparison to actual  total remuneration effected  (in CHF) \\* ", "table_footnote": "\\*\t Excluding legally required employer’s contributions to AHV/IV/ALV and excluding bonuses ", "bbox": [55, 97, 522, 282], "page_size": [595.2760009765625, 793.7009887695312], "ocr_text": "in prospectively\n\nalised\nat end of\nd)\n\nnembers of the\nafter approval by\noved total amount\n\nAmount for the period\nAGM 2021-AGM 2022\n\n36,000,000\n\nCalculation at the end of\nperiod AGM 2021-AGM 2022\nCalculation at the end of\nperiod AGM 2021-AGM 2022\n\nNo\n\nAmount for the period\nAGM 2020-AGM 2021\n\n37,000,000\n\n24,635,559\n\nYes\n\nNo\n\nAmount for the perio:\nAGM 2019-AGM 2021\n\n38,000,006\n\n26,904,811\n\nYe\n", "vlm_text": "The table displays financial data across three periods, associated with Annual General Meetings (AGM):\n\n1. **AGM 2021–AGM 2022:**\n   - Amount: 36,000,000\n   - Calculation mentioned twice for the end of the period.\n   - Final entry: \"No\"\n\n2. **AGM 2020–AGM 2021:**\n   - Amount: 37,000,000\n   - Calculation: 24,635,559\n   - Final entry: \"Yes\"\n\n3. **AGM 2019–AGM 2020:**\n   - Amount: 38,000,000\n   - Calculation: 26,904,810\n   - Final entry: \"No\""}
{"layout": 1172, "type": "text", "text": "5.13 Clawback  ", "text_level": 1, "page_idx": 189, "bbox": [120, 314, 179, 324], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 1173, "type": "text", "text": "In addition to applicable statutory provisions,  Roche’s long-term incentive plans include the option  to partially reclaim distributed compensation as a  result of special circumstances (clawback). ", "page_idx": 189, "bbox": [120, 325.48370361328125, 318, 373.6336975097656], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 1174, "type": "text", "text": "If the employee voluntarily serves notice of  termination of employment, S-SARs (see 5.15.2) and  RSUs (see 5.15.3) which are unvested at the date  of termination of employment lapse immediately  without any compensation. ", "page_idx": 189, "bbox": [120, 385.48370361328125, 318, 445.6336975097656], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 1175, "type": "text", "text": "Upon termination of employment as a result of  serious misconduct, all S-SARs and RSUs granted  and outstanding, whether vested or unvested,  shall lapse immediately without any compensation.  ", "page_idx": 189, "bbox": [120, 457.48370361328125, 311.9169921875, 505.6336975097656], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 1176, "type": "text", "text": "According to the S-SARs plan rules, serious  misconduct by the participant may include \n\n (inter alia):\n\n ", "page_idx": 189, "bbox": [331, 313.48370361328125, 494, 349.6336975097656], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 1177, "type": "text", "text": "• \tactivity leading to serious disciplinary action\n\n • \trepeated or willful failure to perform such duties  as have been reasonably assigned by Roche\n\n • \tviolation of any law or public regulation\n\n • \tcommission of a crime\n\n • \tgross negligence or willful misconduct in  employment ", "page_idx": 189, "bbox": [331, 361.48370361328125, 518, 445.6336975097656], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 1178, "type": "text", "text": "• \tengaging in conduct bringing disgrace or  disrepute to Roche and/or any of its subsidiaries • \tviolation of any of Roche’s directives and  guidelines relating to business conduct ", "page_idx": 189, "bbox": [331, 445.48370361328125, 518, 493.6336975097656], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 1179, "type": "text", "text": "5.14 Guidelines for security holdings ", "text_level": 1, "page_idx": 190, "bbox": [67, 98, 218, 109], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 1180, "type": "text", "text": "In 2012, the Board of Directors decided that the  CEO Roche Group and other members of the  Corporate Executive Committee must acquire  shares and/or NES equivalent to two annual  base salaries (CEO Roche Group since 2018  equivalent to five annual base salaries) and  one annual base salary, respectively, by the  ", "page_idx": 190, "bbox": [68, 109.48370361328125, 248, 193.63369750976562], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 1181, "type": "text", "text": "end of 2016 and retain these holdings for as  long as they serve on the Corporate Executive  Committee. With the exception of Bill Anderson  and Dr Thomas Schinecker, who joined the  Corporate Executive Committee in 2019 and  who must fulfil the requirement by the end  of 2024, all other members of the Corporate  Executive Committee fulfil this requirement. ", "page_idx": 190, "bbox": [278, 97.48370361328125, 456, 193.63369750976562], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 1182, "type": "image", "page_idx": 190, "img_path": "layout_images/roche-holdings_2021_144.jpg", "bbox": [68, 214, 541, 252], "page_size": [595.2760009765625, 793.7009887695312], "ocr_text": "Type of security Value to be acquired\n\nCEO Roche Group Shares and/or NES 5 x annual base salary\nMembers of the Corporate Executive Committee Shares and/or NES 1x annual base salary\n\n", "vlm_text": "The image shows a table with three columns and two rows. The columns are labeled \"CEO Roche Group,\" \"Type of security,\" and \"Value to be acquired.\" The first row indicates that the CEO should acquire shares and/or NES with a value of 5 times the annual base salary. The second row specifies that members of the Corporate Executive Committee should acquire shares and/or NES with a value of 1 times the annual base salary."}
{"layout": 1183, "type": "text", "text": "5.15 Security holdings ", "text_level": 1, "page_idx": 190, "bbox": [67, 278, 160, 289], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 1184, "type": "text", "text": "As at 31 December 2021 (as at 31 December 2020,  respectively) the members of the Corporate  Executive Committee and persons closely  ", "page_idx": 190, "bbox": [68, 289.48370361328125, 259, 325.6336975097656], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 1185, "type": "text", "text": "associated with them held securities as shown  in the following tables ‘Shares and non-voting  equity securities (NES)’, ‘S-SARs’ and ‘Restricted  Stock Units (RSUs)’. ", "page_idx": 190, "bbox": [278, 277.48370361328125, 460.3055725097656, 325.6336975097656], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 1186, "type": "image", "page_idx": 190, "img_path": "layout_images/roche-holdings_2021_145.jpg", "img_caption": "5.15.1 Shares and non-voting equity securities (NES) ", "bbox": [64, 351, 542, 534], "page_size": [595.2760009765625, 793.7009887695312], "ocr_text": "Corporate\nExecutive\nCommittee\nS. Schwan\n\nB. Anderson\nA. Hippe\n\nT. Schinecker\nC.A. Wilbur\nTotal\n\nShares\n(number)\n\n203,592\n\n6,970\n\n210,562\n\nNES\n(number)\n\n90,342\n7,745\n37,937\n2,093\n14,324\n152,441\n\n(as at 31 December 2021)\n\nShares\n\nClose relatives’\nsecurity holdings\n(number/type)\n\nNES\n\nShares\n(number)\n\n196,789\n\n6,970\n\n203,759\n\nNES\n(number)\n\n50,176\n4,547\n27,579\n737\n8,491\n91,530\n\n(as at 31 December 2020)\n\nShares\n\nClose relatives’\nsecurity holdings\n(number/type)\n\nNES\n", "vlm_text": "The image is a table showing the share and non-voting equity securities (NES) holdings of members of a corporate executive committee as of December 31 for the years 2020 and 2021. The table lists the names of five committee members and the number of shares and NES they hold for each year, along with totals at the bottom. It also includes columns for close relatives' security holdings but shows no entries under these sections. The overall totals for shares and NES for both years are provided, too."}
{"layout": 1187, "type": "image", "page_idx": 191, "img_path": "layout_images/roche-holdings_2021_146.jpg", "img_caption": "5.15.3 Restricted Stock Units (RSUs) ", "bbox": [55, 125, 530, 409], "page_size": [595.2760009765625, 793.7009887695312], "ocr_text": "2021 2020 2019 2018 2017 2016 2015\n\nCorporate Executive Committee\n\nS. Schwan 100,746 103,260 122,322 100,677 85,476 59,517 a\nB. Anderson 50,374 46,467 55,045 19,854 = = =\nA. Hippe 40,300 41,304 48,930 40,275 7,191 ms a\nT. Schinecker 22,669 20,652 3,872 - - - -\nC.A. Wilbur 25,187 25,815 29,052 21,402 16,032 ai =\nTotal 239,276 237,498 259,221 182,208 108,699 59,517 =\nPrice (CHF) 306.45 308.05 271.65 220.80 251.90 251.50 256.10\nMarket price per NES on\n\n31 December 2021 (CHF) 379.10\n\nExpiry date 18.35.2031 19.3.2030 15.3.2029 16.3.2025 16.3.2024 3.3.2023 5.3.2022\nGrant value per S-SAR (CHF) 42.35 41.32* 34.88* 26.49* 31.20* 29.79% 43.34*\n\nSince 1.1.2012:\n\n-  Trinomial model for American\ncall options\n\n* Values according to corresponding\n\nannual reports\n", "vlm_text": "The image displays a table centered on Restricted Stock Units (RSUs) for a Corporate Executive Committee, spanning the years 2015 to 2021. It includes:\n\n- Names of committee members: S. Schwan, B. Anderson, A. Hippe, T. Schinecker, C.A. Wilbur.\n- RSU totals per member annually.\n- Total RSUs for each year.\n- Price in CHF for each year.\n- Market price per NES on December 31, 2021, in CHF.\n- Expiry dates for each year.\n- Grant value per S-SAR in CHF.\n\nAdditional notes mention the use of a trinomial model for American call options since January 1, 2012, with specific values according to annual reports."}
{"layout": 1188, "type": "text", "text": "Corporate Executive Committee S. Schwan B. Anderson A. Hippe T. Schinecker C.  A. Wilbur Total ", "page_idx": 191, "bbox": [56, 446.70098876953125, 176.9281005859375, 529.5009765625], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 1189, "type": "image", "page_idx": 191, "img_path": "layout_images/roche-holdings_2021_147.jpg", "bbox": [190, 426, 530, 568], "page_size": [595.2760009765625, 793.7009887695312], "ocr_text": "2021\n\n3,481\n\n1,740\n\n1,392\n\n783\n\n870\n\n8,266\n\nCHF 306.45\n\n(NES closing price at grant date\non 18 March 2021)\n\n2020\n\n3,463\n\n1,558\n\n1,385\n\n693\n\n866\n\n7,965\n\nCHF 308.05\n\n(NES closing price at grant date\non 19 March 2020)\n\n2019\n\n3,927\n\n1,767\n\n1,571\n\n497\n\n933\n\n8,695\n\nCHF 271.65\n\n(NES closing price at grant date\non 15 March 2019)\n", "vlm_text": "The image is a table comparing numbers from the years 2021, 2020, and 2019. Each column has a list of figures with a total at the bottom in bold. Below each year's total, there is a financial figure labeled as the \"NES closing price at grant date,\" specified in Swiss Francs (CHF) with the respective dates:\n\n- **2021**: Total = 8,266, NES Closing Price = CHF 306.45 (18 March 2021)\n- **2020**: Total = 7,965, NES Closing Price = CHF 308.05 (19 March 2020)\n- **2019**: Total = 8,695, NES Closing Price = CHF 271.65 (15 March 2019)"}
{"layout": 1190, "type": "text", "text": "", "text_level": 1, "page_idx": 192, "bbox": [67, 91, 295, 123], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 1191, "type": "text", "text": "To the General Meeting of Roche Holding Ltd, Basel We have audited the accompanying  Remuneration Report of Roche Holding Ltd  for the year ended 31 December 2021. The  audit was limited to the information according  to articles 14–16 of the Ordinance against  excessive compensation at listed joint-stock  companies (the Ordinance) contained in  the sections marked as ‘audited’ with a grey  line, including the respective footnotes, on  pages 162 to 188 of the Remuneration Report.\n ", "page_idx": 192, "bbox": [68.74019622802734, 134.13360595703125, 293.8105773925781, 144.18829345703125], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 1192, "type": "text", "text": "", "page_idx": 192, "bbox": [68, 170.33624267578125, 260, 288.39093017578125], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 1193, "type": "text", "text": "Responsibility of the Board of Directors\n ", "text_level": 1, "page_idx": 192, "bbox": [67, 302, 243, 312.75], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 1194, "type": "text", "text": "The Board of Directors is responsible for the  preparation and overall fair presentation of  the Remuneration Report in accordance with  Swiss law and the Ordinance. The Board of  Directors is also responsible for designing the  remuneration system and defining individual  remuneration packages. \n ", "page_idx": 192, "bbox": [68, 314.33624267578125, 260, 396.39093017578125], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 1195, "type": "text", "text": "Auditor’s Responsibility\n ", "text_level": 1, "page_idx": 192, "bbox": [67, 410, 174, 420], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 1196, "type": "text", "text": "Our responsibility is to express an opinion on  the accompanying Remuneration Report. We  conducted our audit in accordance with Swiss  Auditing Standards. Those Standards require  that we comply with ethical requirements and  plan and perform the audit to obtain reasonable  ", "page_idx": 192, "bbox": [68, 422.33624267578125, 260, 492.39093017578125], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 1197, "type": "text", "text": "KPMG AG ", "page_idx": 192, "bbox": [68, 530.3362426757812, 110.94329833984375, 540.3909301757812], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 1198, "type": "image", "page_idx": 192, "img_path": "layout_images/roche-holdings_2021_148.jpg", "bbox": [71, 547, 127, 608], "page_size": [595.2760009765625, 793.7009887695312], "ocr_text": "", "vlm_text": "This image shows a handwritten signature."}
{"layout": 1199, "type": "text", "text": "Mark Baillache \t Licensed Audit Expert\t Auditor in Charge ", "page_idx": 192, "bbox": [68, 626.3362426757812, 160.34425354003906, 660.3909301757812], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 1200, "type": "text", "text": "assurance about whether the Remuneration  Report complies with Swiss law and articles  14–16 of the Ordinance. ", "page_idx": 192, "bbox": [278, 170.33624267578125, 460, 204.39093017578125], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 1201, "type": "text", "text": "An audit involves performing procedures to  obtain audit evidence on the disclosures made  in the Remuneration Report with regard to  compensation, loans and credits in accordance  with articles 14–16 of the Ordinance. The  procedures selected depend on the auditor’s  judgement, including the assessment of the risks  of material misstatements in the Remuneration  Report, whether due to fraud or error. This audit  also includes evaluating the reasonableness  of the methods applied to value components of  remuneration, as well as assessing the overall  presentation of the Remuneration Report. ", "page_idx": 192, "bbox": [278, 218.33624267578125, 475, 372.39093017578125], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 1202, "type": "text", "text": "We believe that the audit evidence we have  obtained is sufficient and appropriate to provide  a basis for our opinion. \n ", "page_idx": 192, "bbox": [278, 386.33624267578125, 475, 420.39093017578125], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 1203, "type": "text", "text": "Opinion\n ", "text_level": 1, "page_idx": 192, "bbox": [278, 434, 314, 444], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 1204, "type": "text", "text": "In our opinion, the Remuneration Report for  the year ended 31 December 2021 of Roche  Holding Ltd complies with Swiss law and articles  14–16 of the Ordinance. ", "page_idx": 192, "bbox": [278, 446.33624267578125, 475, 492.39093017578125], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 1205, "type": "image", "page_idx": 192, "img_path": "layout_images/roche-holdings_2021_149.jpg", "bbox": [305, 544, 379, 611], "page_size": [595.2760009765625, 793.7009887695312], "ocr_text": "", "vlm_text": "This image shows a signature, which is a handwritten representation of someone's name or mark used for identification and authorization."}
{"layout": 1206, "type": "text", "text": "Marc Ziegler \n Licensed Audit Expert \n ", "page_idx": 192, "bbox": [306, 626.3362426757812, 400.8440856933594, 648.3909301757812], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 1207, "type": "text", "text": "Basel, 1 February 2022 ", "page_idx": 192, "bbox": [68.74019622802734, 674.3362426757812, 163.53494262695312, 684.3909301757812], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 1208, "type": "text", "text": "Independent Limited Assurance Report ", "text_level": 1, "page_idx": 193, "bbox": [119, 131, 500, 157], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 1209, "type": "text", "text": "on the 2021 non-financial reporting to the Corporate Governance and  Sustainability Committee of Roche Holding Ltd, Basel ", "page_idx": 193, "bbox": [121, 167.47979736328125, 488.9981689453125, 195.51458740234375], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 1210, "type": "text", "text": "We have been engaged by the Corporate  Governance and Sustainability Committee to  perform assurance procedures to provide limited  assurance on the non-financial reporting of Roche  Holding Ltd and its consolidated subsidiaries  (‘Roche’) for the year ended 31 December 2021  disclosed in the Annual Report 2021 (‘Report’)  and prepared in accordance with the suitable  criteria selected by Roche. ", "page_idx": 193, "bbox": [120, 230.78887939453125, 314, 336.28497314453125], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 1211, "type": "text", "text": "Scope and Subject matter ", "text_level": 1, "page_idx": 193, "bbox": [120, 350, 228, 361], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 1212, "type": "text", "text": "Our assurance engagement relates to limited  level of assurance on the specified non-financial  information for the year ended 31 December 2021  disclosed in the Annual Report 2021. ", "page_idx": 193, "bbox": [120, 362.7948913574219, 314, 408.28497314453125], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 1213, "type": "text", "text": "The following specified data and information  published in the Report is within the scope of our  limited assurance engagement:  •  \t\u0007 the materiality determination process of Roche at Group level according to the requirements of the ‘GRI Standards’, as disclosed on pages 24 and 25 of the Report; •  \t\u0007 the design of the sustainability risks and opportunities determination process based on Group level activities, disclosed on page 22 in the paragraph ‘Risk management’ of the Report;  $^\\circ$   \t\u0007 the correctness of the following consolidated key figures:\t\n\n  $^\\circ$  the people key figures in the graphs on page 93 of the Report;\t\n\n  $^\\circ$  the Safety, Security, Health and Environmental protection (‘SHE’) key figures (including greenhouse gas emissions for scope  $1\\ \\&\\ z$   and scope 3 resulting from business flights) in the tables and graphs on page 92 and pages 103 to 105 of the Report; and\t  \t\u0007 the key figures in relation to contributions in Switzerland, disclosed on page 121 of the Report. ", "page_idx": 193, "bbox": [120, 422.7928771972656, 314, 672.2849731445312], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 1214, "type": "text", "text": "", "page_idx": 193, "bbox": [336, 230.78887939453125, 508, 264.28497314453125], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 1215, "type": "text", "text": "Criteria ", "text_level": 1, "page_idx": 193, "bbox": [330, 278, 362, 288], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 1216, "type": "text", "text": "The specified non-financial information was  prepared by the Corporate Governance and  Sustainability Committee of Roche based on  the following criteria (the ‘suitable Criteria’):\n\n •  \t\u0007 the Roche materiality determination process at Group level based on the ‘GRI Standards’ published in October 2016 by the Global Reporting Initiative (GRI);\n\n  $^\\circ$   \t\u0007 the Roche Group internal non-financial reporting guidelines based on the ‘Responsible Care Health, Safety and Environmental Protection reporting guidelines’ published by the European Chemical Industry Council CEFIC and the ‘GRI Standards’ published in October 2016 by the Global Reporting Initiative (GRI);\n\n •  \t\u0007 the defined guidelines, by which Safety, Security, Health and Environmental (‘SHE’), people, contributions key figures, and sustainability risks and opportunities are internally gathered, collated and aggregated; and\n\n •  \t\u0007 the Roche Group guideline ‘Grants, donations and sponsorship (GSD) data collection process’ disclosed on the website  https://www.roche.com/ dam/jcr:f425f9f5-1ead-401b-a912-c9cad93db9cc/ en/grants-donations-sponsorship-process.pdf published in January 2020. ", "page_idx": 193, "bbox": [330, 290.7948913574219, 526, 600.2849731445312], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 1217, "type": "text", "text": "Inherent limitations ", "text_level": 1, "page_idx": 193, "bbox": [330, 614, 412, 624], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 1218, "type": "text", "text": "The accuracy and completeness of the specified  non-financial information are subject to inherent  limitations given their nature and methods for  determining, calculating and estimating such data.  ", "page_idx": 193, "bbox": [330, 626.7948608398438, 526, 672.2969360351562], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 1219, "type": "text", "text": "In addition, the GHG quantification is subject  to inherent uncertainty because of incomplete  scientific knowledge used to determine emission  factors and the values needed to combine  emissions of different gases. Our assurance  report therefore has to be read in connection  with the publicly available individual Roche  Group guidelines used by Roche, its definitions  and procedures as well as on the third-party  guidelines used to present the specified  non-financial information performance.  ", "page_idx": 194, "bbox": [68, 182.78887939453125, 256, 312.28497314453125], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 1220, "type": "text", "text": "Responsibility of the Corporate Governance  and Sustainability Committee ", "text_level": 1, "page_idx": 194, "bbox": [67, 326, 251, 348], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 1221, "type": "text", "text": "The Corporate Governance and Sustainability  Committee of Roche Holding Ltd is responsible  for the selection and application of the suitable  Criteria, as well as for the preparation and  presentation of the specified non-financial  information in accordance with the suitable  Criteria. This responsibility includes adequate  record keeping as well as the design,  implementation and maintenance of an internal  control system as determined necessary  to enable the preparation of the specified  non-financial information that are free from  material misstatement, whether due to fraud  or error.  ", "page_idx": 194, "bbox": [68, 350.78887939453125, 250, 516.2849731445312], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 1222, "type": "text", "text": "Independence and quality control ", "text_level": 1, "page_idx": 194, "bbox": [67, 530, 208, 541], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 1223, "type": "text", "text": "We are independent of Roche Holding Ltd  in accordance with the International Code of  Ethics for Professional Accountants (including  International Independence Standards) issued  by the International Ethics Standards Board for  Accountants (IESBA Code). We have fulfilled our  other ethical responsibilities in accordance with  the IESBA Code, which is founded on fundamental  principles of integrity, objectivity, professional  competence and due care, confidentiality and  professional behaviour.  ", "page_idx": 194, "bbox": [68, 542.7888793945312, 261, 672.2849731445312], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 1224, "type": "text", "text": "Price waterhouse Coopers AG applies International  Standard on Quality Control 1 and accordingly  maintains a comprehensive system of quality  control including documented policies and  procedures regarding compliance with ethical  requirements, professional standards and  applicable legal and regulatory requirements. ", "page_idx": 194, "bbox": [278, 182.78887939453125, 474, 264.28497314453125], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 1225, "type": "text", "text": "Practitioner’s responsibility ", "text_level": 1, "page_idx": 194, "bbox": [277, 278, 394, 288], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 1226, "type": "text", "text": "Our responsibility is to perform an assurance  engagement and to express a limited assurance  conclusion on the 2021 specified non-financial  information of Roche in the Report. We  conducted our engagement in accordance with  International Standard on Assurance Engagements  ISAE 3000 (Revised) ‘Assurance engagements  other than audits or reviews of historical financial  information’ and, in respect of greenhouse gas  emissions, with the International Standard on  Assurance Engagements ISAE 3410 ‘Assurance  Engagements on Greenhouse Gas Statements’,  issued by the International Auditing and  Assurance Standards Board. Those standards  require that we plan and perform our procedures  to obtain limited assurance, on whether the  specified non-financial information was prepared,  in all material aspects, in accordance with the  suitable Criteria.  ", "page_idx": 194, "bbox": [278, 290.78887939453125, 474, 516.2849731445312], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 1227, "type": "text", "text": "Based on risk and materiality considerations, we  performed our procedures to obtain sufficient and  appropriate assurance evidence. The procedures  selected depend on the assurance practitioner’s  judgement. A limited assurance engagement  under ISAE 3000 (Revised) is substantially less in  scope than a reasonable assurance engagement  in relation to both the risk assessment procedures,  including an understanding of internal control,  and the procedures performed in response to the  assessed risks. Consequently, the nature, timing  and extent of procedures for gathering sufficient  appropriate evidence are deliberately limited  relative to a reasonable assurance engagement  and therefore less assurance is obtained with  a limited assurance engagement than for a  reasonable assurance engagement.  ", "page_idx": 194, "bbox": [278, 530.7888793945312, 474, 672.2849731445312], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 1228, "type": "text", "text": "", "page_idx": 195, "bbox": [119, 182.78887939453125, 305, 240.28497314453125], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 1229, "type": "text", "text": "We performed the following assurance procedures,  among others: \n\n • \t\u0007 Review of the application of Roche Group  guidelines\n Reviewing the application of the Roche Group  non-financial reporting and contributions  guidelines;\n\n • \t\u0007 Site visits and management inquiry \n Remotely visiting selected Pharmaceuticals  and Diagnostics sites in the USA, China,  Taiwan and the UK. The selection was based  on quantitative and qualitative criteria; \n Interviewing personnel responsible for internal  non-financial reporting and data collection at  the sites we visited and at the Group level to  determine the understanding and application  of Roche’s non-financial and contributions  guidelines;\n\n • \t\u0007 Assessment of the key figures\n Performing tests on a sample basis of evidence  supporting selected SHE, contributions,  and people key figures (e.g. Roche accident  rate, energy consumption, emissions into the  air, water usage and discharge, number of  employees (full-time equivalents), percentage  of women in total workforce) concerning  completeness, accuracy, adequacy and  consistency;\n\n  $^\\circ$  \t\u0007 Review of documentation and analysis of  relevant policies and principles  \n Reviewing relevant documentation on a sample  basis, including Roche Group non-financial  reporting policies, management of reporting  structures and documentation;\n ", "page_idx": 195, "bbox": [119, 254.78887939453125, 313, 660.2849731445312], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 1230, "type": "text", "text": "Reviewing the principles of the Roche  materiality process providing the definition  for the development of its adherence to GRI’s  environmental, social and economic reporting  requirements addressing the soundness of  the identification process, determination of  impacted stakeholders, peer and competition  review, integration of relevant regulatory  requirements, integration of key organisational  values and objectives and report prioritisation  of material aspects; \n Inspecting the integration of the sustainability  risks and opportunities in the Group risk  management process and its adherence to  the suitable Criteria; \t\u0007 Assessment of the processes and data  consolidation  \n Reviewing the management and non-financial  reporting processes for SHE, people, and  contributions key figures; and\n Assessing the aggregation process of data  at Group level. ", "page_idx": 195, "bbox": [330, 182.78887939453125, 516, 444.28497314453125], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 1231, "type": "text", "text": "We believe that the evidence we have obtained  is sufficient and appropriate to provide a basis  for our conclusion. ", "page_idx": 195, "bbox": [330, 458.78887939453125, 516, 492.28497314453125], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 1232, "type": "text", "text": "Conclusion ", "text_level": 1, "page_idx": 195, "bbox": [330, 506, 379, 516], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 1233, "type": "text", "text": "Based on the procedures we performed and  evidence obtained, nothing has come to  our attention that causes us to believe that  in all material respects, related to the 2021  specified non-financial information in the  Report of Roche Holding Ltd for the year ended  31 December 2021, the following applies:   $^\\circ$  \t the materiality determination process at Group  level disclosed on pages 24 and 25 of the  report does not comply with the principles of  the “GRI Standards”;  ", "page_idx": 195, "bbox": [330, 518.7888793945312, 516, 648.2849731445312], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 1234, "type": "text", "text": "• \t\u0007 the design of the sustainability risks and  opportunities determination process at Group  level is inconsistent with the information  disclosed on page 22 in the paragraph  “Risk Management” of the Report; \n\n  $^\\circ$  \t\u0007 the specified non-financial information  mentioned in the subject matter section  and published in the 2021 Report of Roche  Holding Ltd are not correct in accordance  with the suitable Criteria. ", "page_idx": 196, "bbox": [66, 182.78887939453125, 258, 300.28497314453125], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 1235, "type": "text", "text": "Restriction of use and purpose of the report ", "text_level": 1, "page_idx": 196, "bbox": [67, 314, 251, 321.75], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 1236, "type": "text", "text": "This report is prepared for, and only for, the  Corporate Governance and Sustainability  Committee of Roche Holding Ltd, and solely for  the purpose of reporting to them on the 2021  specified non-financial information in the Report  and no other purpose. We do not, in giving our  conclusion, accept or assume responsibility  (legal or otherwise) or accept liability for, or in  connection with, any other purpose for which  our report including the conclusion may be used,  or to any other person to whom our report is  shown or into whose hands it may come, and  no other persons shall be entitled to rely on  our conclusion. ", "page_idx": 196, "bbox": [66, 326.78887939453125, 258, 492.28497314453125], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 1237, "type": "text", "text": "We permit the disclosure of our report, in full  only and in combination with the suitable Criteria,  to enable the Corporate Governance and  Sustainability Committee of Roche Holding Ltd  to demonstrate that they have discharged their  governance responsibilities by commissioning  an independent assurance report over the specified  non-financial information, without assuming or  accepting any responsibility or liability to any  third parties on our part. To the fullest extent  permitted by law, we do not accept or assume  responsibility to anyone other than the  ", "page_idx": 196, "bbox": [66, 506.78887939453125, 264, 648.2849731445312], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 1238, "type": "text", "text": "Corporate Governance and Sustainability  Committee of Roche Holding Ltd for our work  or this report. ", "page_idx": 196, "bbox": [278, 182.78887939453125, 452.96026611328125, 216.28497314453125], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 1239, "type": "text", "text": "PricewaterhouseCoopers AG ", "page_idx": 196, "bbox": [278, 230.78887939453125, 390.1451416015625, 240.28497314453125], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 1240, "type": "text", "text": "Christophe Bourgoin\t Annina Binder ", "page_idx": 196, "bbox": [278, 290.78887939453125, 441, 300.28497314453125], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 1241, "type": "text", "text": "Zurich, 3 February 2022 ", "page_idx": 196, "bbox": [278, 314.78887939453125, 371.7071533203125, 324.28497314453125], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 1242, "type": "text", "text": "The maintenance and integrity of Roche Holding Ltd’s  website and its content are the responsibility of the  Corporate Governance and Sustainability Committee;  the work carried out by the assurance provider does  not involve consideration of the maintenance and  integrity of Roche Holding Ltd’s website, accordingly,  the assurance provider accepts no responsibility for  any changes that may have occurred to the specified  non-financial information or suitable Criteria since  they were initially presented on the website. ", "page_idx": 196, "bbox": [278, 531.1477661132812, 474, 648.2376098632812], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 1243, "type": "image", "page_idx": 197, "img_path": "layout_images/roche-holdings_2021_150.jpg", "bbox": [0, 68, 316, 407], "page_size": [595.2760009765625, 793.7009887695312], "ocr_text": "", "vlm_text": "This image appears to show an abstract pattern of diagonal lines in various shades of red, brown, and white. The lines are blurred, creating a dynamic and flowing visual effect."}
{"layout": 1244, "type": "text", "text": "Key dates for 2022 ", "text_level": 1, "page_idx": 197, "bbox": [44, 491, 141, 506], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 1245, "type": "text", "text": "Annual General Meeting 15 March 2022 ", "page_idx": 197, "bbox": [44, 529.4837036132812, 147.93092346191406, 553.6337280273438], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 1246, "type": "text", "text": "First-quarter sales 25 April 2022 ", "page_idx": 197, "bbox": [44, 565.4837036132812, 126.75749969482422, 589.6337280273438], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 1247, "type": "text", "text": "Half-year results 21 July 2022 ", "page_idx": 197, "bbox": [44, 601.4837036132812, 120, 625.6337280273438], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 1248, "type": "text", "text": "Nine-month sales 18 October 2022 ", "page_idx": 197, "bbox": [44, 637.4837036132812, 120, 661.6337280273438], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 1249, "type": "text", "text": "Published by F. Hoffmann-La Roche Ltd Group Communications 4070 Basel, Switzerland Tel.:  $+41$   (0)61 688 11 11 www.roche.com  ", "page_idx": 197, "bbox": [328, 421.48370361328125, 426.5759582519531, 493.6336975097656], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 1250, "type": "text", "text": "To order/download publications Internet:  www.roche.com/publications E-mail:  basel.warehouse-services@roche.com Fax:  $+41$   (0)61 688 69 02 ", "page_idx": 197, "bbox": [328, 505.48370361328125, 501.55718994140625, 553.6336059570312], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 1251, "type": "text", "text": "Media Relations Tel.:  $+41$   (0)61 688 88 88 E-mail:  media.relations@roche.com ", "page_idx": 197, "bbox": [328, 565.4835815429688, 461, 601.6336059570312], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 1252, "type": "text", "text": "Investor Relations Tel.: +41 (0)61 688 88 80 E-mail: investor.relations@roche.com", "page_idx": 197, "bbox": [328, 613.4835815429688, 468.2878723144531, 649.6336059570312], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 1253, "type": "text", "text": "Corporate Sustainability Committee Tel.:  $+41$   (0)61 688 40 18 E-mail:  corporate.sustainability@roche.com Cautionary statement regarding forward- looking statements ", "page_idx": 197, "bbox": [328, 661.4835815429688, 493.52557373046875, 697.6337280273438], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 1254, "type": "text", "text": "", "page_idx": 198, "bbox": [66, 265.48370361328125, 244, 289.6336975097656], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 1255, "type": "text", "text": "This Annual Report contains certain forward-looking  statements. These forward-looking statements may  be identified by words such as ‘believes’, ‘expects’, \n\n ‘anticipates’, ‘projects’, ‘intends’, ‘should’, ‘seeks’, \n\n ‘estimates’, ‘future’ or similar expressions or by  discussion of, among other things, strategy, goals,  plans or intentions. Various factors may cause  actual results to differ materially in the future from  those reflected in forward-looking statements  contained in this Annual Report, such as: (1) pricing  and product initiatives of competitors; (2) legislative  and regulatory developments and economic  conditions; (3) delay or inability in obtaining  regulatory approvals or bringing products to market;  (4) fluctuations in currency exchange rates and  general financial market conditions; (5) uncertainties  in the discovery, development or marketing of new  products or new uses of existing products, including  without limitation negative results of clinical trials  or research projects, unexpected side effects  of pipeline or marketed products; (6) increased  government pricing pressures; (7) interruptions  in production; (8) loss of or inability to obtain  adequate protection for intellectual property  rights; (9) litigation; (10) loss of key executives or  other employees; and (11) adverse publicity and  news coverage. ", "page_idx": 198, "bbox": [66, 289.48370361328125, 266, 613.6337280273438], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 1256, "type": "text", "text": "All trademarks are legally protected. ", "page_idx": 198, "bbox": [280, 265.48370361328125, 417.1626281738281, 277.6336975097656], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 1257, "type": "text", "text": "Links to third-party pages are provided for  convenience only. We do not express any opinion on  the content of any third-party pages and expressly  disclaim any liability for all third-party information  and the use thereof. ", "page_idx": 198, "bbox": [280, 289.48370361328125, 475.8128662109375, 349.6336975097656], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 1258, "type": "text", "text": "The Roche Annual Report is published in German  and English. ", "page_idx": 198, "bbox": [280, 361.48370361328125, 463.0579528808594, 385.6336975097656], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 1259, "type": "text", "text": "Our reporting consists of the actual Annual Report  and of the Finance Report and contains the  annual financial statements and the consolidated  financial statements. With regards to content,  the Management Report as per the Articles of  Incorporation consists of both aforementioned  reports with the exception of the Remuneration  Report. ", "page_idx": 198, "bbox": [280, 397.48370361328125, 471, 493.6336975097656], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 1260, "type": "text", "text": "Printed on non-chlorine bleached,  FSC-certified paper. ", "page_idx": 198, "bbox": [280, 505.48370361328125, 409.6800537109375, 529.6337280273438], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 1261, "type": "image", "page_idx": 198, "img_path": "layout_images/roche-holdings_2021_151.jpg", "bbox": [280, 543, 372, 588], "page_size": [595.2760009765625, 793.7009887695312], "ocr_text": "®\n‘3 Paper | Supporting\n\nresponsible forestry\nFoc FSC® C018119\n\n", "vlm_text": "This image shows the FSC (Forest Stewardship Council) label, which indicates that the paper product is made from responsible sources. The label includes the text \"MIX Paper | Supporting responsible forestry\" and \"FSC C018119.\" It is used to certify that the product contributes to environmentally appropriate, socially beneficial, and economically viable management of the world's forests."}
{"layout": 1262, "type": "text", "text": "The statement regarding earnings per share growth  is not a profit forecast and should not be interpreted  to mean that Roche’s earnings or earnings per share  for 2021 or any subsequent period will necessarily  match or exceed the historical published earnings  or earnings per share of Roche. ", "page_idx": 198, "bbox": [67, 625.4837036132812, 266, 697.6337280273438], "page_size": [595.2760009765625, 793.7009887695312]}
{"layout": 1263, "type": "image", "page_idx": 199, "img_path": "layout_images/roche-holdings_2021_152.jpg", "bbox": [0, 0, 596, 794], "page_size": [595.2760009765625, 793.7009887695312], "ocr_text": "", "vlm_text": "The image is a collage featuring various historical and modern photos related to scientific research and laboratory work. It includes:\n\n1. Vintage black and white photos of scientists and laboratory environments.\n2. Modern labs with people working and equipment in use.\n3. Images related to the Roche company, like packaging with the Roche logo.\n4. Pictures of people in lab coats, possibly researchers or scientists.\n5. Scenes from conferences or gatherings.\n6. Diagrams or scientific models being presented or studied.\n\nOverall, the collage highlights the evolution and history of scientific research and pharmaceuticals, focusing on lab environments and people involved in the field."}
{"layout": 1264, "type": "image", "page_idx": 200, "img_path": "layout_images/roche-holdings_2021_153.jpg", "bbox": [0, 0, 596, 794], "page_size": [595.2760009765625, 793.7009887695312], "ocr_text": "//\n\na!\n\naoe sap A a |\nai il i iG a fa\n\n}\n\nme: uE\n\n+ ie a 0s EE”\n’ are\n\n", "vlm_text": "The image is a collage consisting of various scenes:\n\n1. A train with \"HELOPHEPA\" visible on it.\n2. A laboratory or clean room environment with advanced equipment.\n3. A cityscape with a tall, illuminated building.\n4. Medical or scientific activities, such as holding a baby's foot for a procedure.\n5. Modern office buildings with glass facades.\n6. A portrait of a person smiling.\n7. Individuals working in lab environments.\n8. Various laboratory equipment and samples, like test tubes.\n9. An architectural structure, possibly a corporate or research facility.\n10. An aerial view of a building complex.\n\nThe overall theme seems to be related to healthcare, science, and technology."}
{"layout": 1265, "type": "image", "page_idx": 201, "img_path": "layout_images/roche-holdings_2021_154.jpg", "bbox": [0, 0, 596, 794], "page_size": [595.2760009765625, 793.7009887695312], "ocr_text": "| bbded = is\n\n| ,\n1 . te\n\n| 4070 asel, Switzerla'\n\nWhy\nF. Hoffmann-La pea te\nd\n\nAll trademarks are legally protected. —\nI;\nwww.roche.com aki\n\n7001 O44 i yiiifill, ”\n\n", "vlm_text": "The image shows a nighttime view of a cityscape featuring tall, modern skyscrapers. One prominent structure is illuminated with red lighting, possibly indicating aviation lights for aircraft safety. City lights and the glow from the buildings provide a vibrant urban feel. Text in the lower left corner identifies the location as Basel, Switzerland, and references F. Hoffmann-La Roche Ltd, a global healthcare company."}
